Scaling the CERN OpenStack cloud

NASA Astrophysics Data System (ADS)

Bell, T.; Bompastor, B.; Bukowiec, S.; Castro Leon, J.; Denis, M. K.; van Eldik, J.; Fermin Lobo, M.; Fernandez Alvarez, L.; Fernandez Rodriguez, D.; Marino, A.; Moreira, B.; Noel, B.; Oulevey, T.; Takase, W.; Wiebalck, A.; Zilli, S.

2015-12-01

CERN has been running a production OpenStack cloud since July 2013 to support physics computing and infrastructure services for the site. In the past year, CERN Cloud Infrastructure has seen a constant increase in nodes, virtual machines, users and projects. This paper will present what has been done in order to make the CERN cloud infrastructure scale out.

75 FR 58281 - National Farm Safety and Health Week, 2010

Federal Register 2010, 2011, 2012, 2013, 2014

2010-09-23

... National Farm Safety and Health Week, 2010 By the President of the United States of America A Proclamation... and Health Week, we recognize the tremendous contributions of these individuals and rededicate ourselves to ensuring their safety and health at all times. Our farmers, ranchers, farmworkers...

78 FR 20852 - Safety Zones; Marine Week Air Ground Demonstration, Lake Washington; Seattle, WA

Federal Register 2010, 2011, 2012, 2013, 2014

2013-04-08

...-AA00 Safety Zones; Marine Week Air Ground Demonstration, Lake Washington; Seattle, WA AGENCY: Coast... safety zones around vessels and persons involved in the Marine Week Seattle Special Marine Air Ground...: Docket Management Facility (M-30), U.S. Department of Transportation, West Building Ground Floor, Room...

The LHC timeline: a personal recollection (1980-2012)

NASA Astrophysics Data System (ADS)

Maiani, Luciano; Bonolis, Luisa

2017-12-01

The objective of this interview is to study the history of the Large Hadron Collider in the LEP tunnel at CERN, from first ideas to the discovery of the Brout-Englert-Higgs boson, seen from the point of view of a member of CERN scientific committees, of the CERN Council and a former Director General of CERN in the years of machine construction.

"Physics on Stage" Festival Video Now Available

NASA Astrophysics Data System (ADS)

2001-01-01

ESO Video Clip 01/01 is issued on the web in conjunction with the release of an 18-min documentary video from the Science Festival of the "Physics On Stage" programme. This unique event took place during November 6-11, 2000, on the CERN premises at the French-Swiss border near Geneva, and formed part of the European Science and Technology Week 2000, an initiative by the European Commission to raise the public awareness of science in Europe. Physics On Stage and the Science Festival were jointly organised by CERN, ESA and ESO, in collaboration with the European Physical Society (EPS) and the European Association for Astronomy Education (EAAE) and national organisations in about 25 European countries. During this final phase of the yearlong Physics On Stage programme, more than 500 physics teachers, government officials and media representatives gathered at CERN to discuss different aspects of physics education. The meeting was particular timely in view of the current decline of interest in physics and technology by Europe's citizens, especially schoolchildren. It included spectacular demonstrations of new educational materials and methods. An 18-min video is now available that documents this event. It conveys the great enthusiasm of the many participants who spent an extremely fruitful week, meeting and exchanging information with colleagues from all over the continent. It shows the various types of activities that took place, from the central "fair" with national and organisational booths to the exciting performances and other dramatic presentations. Based of the outcome of 13 workshops that focussed on different subject matters, a series of very useful recommendations was passed at the final session. The Science Festival was also visited by several high-ranking officials, including the European Commissioner for Research, Phillipe Busquin. Full reports from the Festival will soon become available from the International Steering Committee..More information is available on the "Physics on Stage" webpages at CERN , ESA and ESO ). Note also the brief account published in the December 2000 issue of the ESO Messenger. The present video clip is available in four versions: two MPEG files and two streamer-versions of different sizes; the latter require RealPlayer software. Video Clip 01/01 may be freely reproduced. Tapes of this video clip and the 18-min video, suitable for transmission and in full professional quality (Betacam, etc.), are available for broadcasters upon request ; please contact the ESO EPR Department for more details. Most of the ESO PR Video Clips at the ESO website provide "animated" illustrations of the ongoing work and events at the European Southern Observatory. The most recent clip was: ESO PR Video Clip 06/00 about Fourth Light at Paranal! (4 September 2000) . General information is available on the web about ESO videos.

Detector Control System for the AFP detector in ATLAS experiment at CERN

NASA Astrophysics Data System (ADS)

Banaś, E.; Caforio, D.; Czekierda, S.; Hajduk, Z.; Olszowska, J.; Seabra, L.; Šícho, P.

2017-10-01

The ATLAS Forward Proton (AFP) detector consists of two forward detectors located at 205 m and 217 m on either side of the ATLAS experiment. The aim is to measure the momenta and angles of diffractively scattered protons. In 2016, two detector stations on one side of the ATLAS interaction point were installed and commissioned. The detector infrastructure and necessary services were installed and are supervised by the Detector Control System (DCS), which is responsible for the coherent and safe operation of the detector. A large variety of used equipment represents a considerable challenge for the AFP DCS design. Industrial Supervisory Control and Data Acquisition (SCADA) product Siemens WinCCOA, together with the CERN Joint Control Project (JCOP) framework and standard industrial and custom developed server applications and protocols are used for reading, processing, monitoring and archiving of the detector parameters. Graphical user interfaces allow for overall detector operation and visualization of the detector status. Parameters, important for the detector safety, are used for alert generation and interlock mechanisms.

Big Bang Day: The Making of CERN (Episode 1)

ScienceCinema

None

2017-12-09

A two-part history of the CERN project. Quentin Cooper explores the fifty-year history of CERN, the European particle physics laboratory in Switzerland. The institution was created to bring scientists together after WW2 .......

Update on CERN Search based on SharePoint 2013

NASA Astrophysics Data System (ADS)

Alvarez, E.; Fernandez, S.; Lossent, A.; Posada, I.; Silva, B.; Wagner, A.

2017-10-01

CERN’s enterprise Search solution “CERN Search” provides a central search solution for users and CERN service providers. A total of about 20 million public and protected documents from a wide range of document collections is indexed, including Indico, TWiki, Drupal, SharePoint, JACOW, E-group archives, EDMS, and CERN Web pages. In spring 2015, CERN Search was migrated to a new infrastructure based on SharePoint 2013. In the context of this upgrade, the document pre-processing and indexing process was redesigned and generalised. The new data feeding framework allows to profit from new functionality and it facilitates the long term maintenance of the system.

Big Bang Day: The Making of CERN (Episode 1)

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2009-10-06

A two-part history of the CERN project. Quentin Cooper explores the fifty-year history of CERN, the European particle physics laboratory in Switzerland. The institution was created to bring scientists together after WW2 .......

CERN welcomes new members

NASA Astrophysics Data System (ADS)

2017-08-01

Lithuania is on course to become an associate member of CERN, pending final approval by the Lithuanian parliament. Associate membership will allow representatives of the Baltic nation to take part in meetings of the CERN Council, which oversees the Geneva-based physics lab.

CERN and high energy physics, the grand picture

ScienceCinema

Heuer, Rolf-Dieter

2018-05-24

The lecture will touch on several topics, to illustrate the role of CERN in the present and future of high-energy physics: how does CERN work? What is the role of the scientific community, of bodies like Council and SPC, and of international cooperation, in the definition of CERN's scientific programme? What are the plans for the future of the LHC and of the non-LHC physics programme? What is the role of R&D; and technology transfer at CERN?

Got Questions About the Higgs Boson? Ask a Scientist

DOE Office of Scientific and Technical Information (OSTI.GOV)

Hinchliffe, Ian

Ask a scientist about the Higgs boson. There's a lot of buzz this week over new data from CERN's Large Hadron Collider (LHC) and the final data from Fermilab's Tevatron about the Higgs boson. It raises questions about what scientists have found and what still remains to be found -- and what it all means. Berkeley Lab's Ian Hinchliffe invites you to send in questions about the Higgs. He'll answer a few of your questions in a follow-up video later this week. Hinchliffe is a theoretical physicist who heads Berkeley Lab's sizable contingent with the ATLAS experiment at CERN. •more » Post your questions in the comment box • E-mail your questions to askascientist@lbl.gov • Tweet to @BerkeleyLab • Or post on our facebook page: facebook/berkeleylab Update on July 5: Ian responds to several of your questions in this video: http://youtu.be/1BkpD1IS62g. Update on 7/04: Here's CERN's press release from earlier today on the latest preliminary results in the search for the long sought Higgs particle: http://press.web.cern.ch/press/PressReleases/Releases2012/PR17.12E.htm. And here's a Q&A on what the news tells us: http://cdsweb.cern.ch/journal/CERNBulletin/2012/28/News%20Articles/1459460?ln=en. CERN will present the new LHC data at a seminar July 4th at 9:00 in the morning Geneva time (3:00 in the morning Eastern Daylight Time, midnight on the Pacific Coast), where the ATLAS collaboration and their rivals in the CMS experiment will announce their results. Tevatron results were announced by Fermilab on Monday morning. For more background on the LHC's search for the Higgs boson, visit http://newscenter.lbl.gov/feature-stories/2012/06/28/higgs-2012/.« less

Got Questions About the Higgs Boson? Ask a Scientist

ScienceCinema

Hinchliffe, Ian

2017-12-12

Ask a scientist about the Higgs boson. There's a lot of buzz this week over new data from CERN's Large Hadron Collider (LHC) and the final data from Fermilab's Tevatron about the Higgs boson. It raises questions about what scientists have found and what still remains to be found -- and what it all means. Berkeley Lab's Ian Hinchliffe invites you to send in questions about the Higgs. He'll answer a few of your questions in a follow-up video later this week. Hinchliffe is a theoretical physicist who heads Berkeley Lab's sizable contingent with the ATLAS experiment at CERN. • Post your questions in the comment box • E-mail your questions to askascientist@lbl.gov • Tweet to @BerkeleyLab • Or post on our facebook page: facebook/berkeleylab Update on July 5: Ian responds to several of your questions in this video: http://youtu.be/1BkpD1IS62g. Update on 7/04: Here's CERN's press release from earlier today on the latest preliminary results in the search for the long sought Higgs particle: http://press.web.cern.ch/press/PressReleases/Releases2012/PR17.12E.htm. And here's a Q&A on what the news tells us: http://cdsweb.cern.ch/journal/CERNBulletin/2012/28/News%20Articles/1459460?ln=en. CERN will present the new LHC data at a seminar July 4th at 9:00 in the morning Geneva time (3:00 in the morning Eastern Daylight Time, midnight on the Pacific Coast), where the ATLAS collaboration and their rivals in the CMS experiment will announce their results. Tevatron results were announced by Fermilab on Monday morning. For more background on the LHC's search for the Higgs boson, visit http://newscenter.lbl.gov/feature-stories/2012/06/28/higgs-2012/.

75 FR 34927 - Safety Zone; Parade of Ships, Seattle SeaFair Fleet Week, Pier 66, Elliott Bay, WA

Federal Register 2010, 2011, 2012, 2013, 2014

2010-06-21

...-AA00 Safety Zone; Parade of Ships, Seattle SeaFair Fleet Week, Pier 66, Elliott Bay, WA AGENCY: Coast... Seattle SeaFair Fleet Week. This action is intended to restrict vessel traffic movement and entry into... of Ships for the annual Seattle SeaFair Fleet Week. For the purposes of this rule the Parade of Ships...

Learning with the ATLAS Experiment at CERN

ERIC Educational Resources Information Center

Barnett, R. M.; Johansson, K. E.; Kourkoumelis, C.; Long, L.; Pequenao, J.; Reimers, C.; Watkins, P.

2012-01-01

With the start of the LHC, the new particle collider at CERN, the ATLAS experiment is also providing high-energy particle collisions for educational purposes. Several education projects--education scenarios--have been developed and tested on students and teachers in several European countries within the Learning with ATLAS@CERN project. These…

EFQPSK Versus CERN: A Comparative Study

NASA Technical Reports Server (NTRS)

Borah, Deva K.; Horan, Stephen

2001-01-01

This report presents a comparative study on Enhanced Feher's Quadrature Phase Shift Keying (EFQPSK) and Constrained Envelope Root Nyquist (CERN) techniques. These two techniques have been developed in recent times to provide high spectral and power efficiencies under nonlinear amplifier environment. The purpose of this study is to gain insights into these techniques and to help system planners and designers with an appropriate set of guidelines for using these techniques. The comparative study presented in this report relies on effective simulation models and procedures. Therefore, a significant part of this report is devoted to understanding the mathematical and simulation models of the techniques and their set-up procedures. In particular, mathematical models of EFQPSK and CERN, effects of the sampling rate in discrete time signal representation, and modeling of nonlinear amplifiers and predistorters have been considered in detail. The results of this study show that both EFQPSK and CERN signals provide spectrally efficient communications compared to filtered conventional linear modulation techniques when a nonlinear power amplifier is used. However, there are important differences. The spectral efficiency of CERN signals, with a small amount of input backoff, is significantly better than that of EFQPSK signals if the nonlinear amplifier is an ideal clipper. However, to achieve such spectral efficiencies with a practical nonlinear amplifier, CERN processing requires a predistorter which effectively translates the amplifier's characteristics close to those of an ideal clipper. Thus, the spectral performance of CERN signals strongly depends on the predistorter. EFQPSK signals, on the other hand, do not need such predistorters since their spectra are almost unaffected by the nonlinear amplifier, Ibis report discusses several receiver structures for EFQPSK signals. It is observed that optimal receiver structures can be realized for both coded and uncoded EFQPSK signals with not too much increase in computational complexity. When a nonlinear amplifier is used, the bit error rate (BER) performance of the CERN signals with a matched filter receiver is found to be more than one decibel (dB) worse compared to the bit error performance of EFQPSK signals. Although channel coding is found to provide BER performance improvement for both EFQPSK and CERN signals, the performance of EFQPSK signals remains better than that of CERN. Optimal receiver structures for CERN signals with nonlinear equalization is left as a possible future work. Based on the numerical results, it is concluded that, in nonlinear channels, CERN processing leads towards better bandwidth efficiency with a compromise in power efficiency. Hence for bandwidth efficient communications needs, CERN is a good solution provided effective adaptive predistorters can be realized. On the other hand, EFQPSK signals provide a good power efficient solution with a compromise in band width efficiency.

Sharing scientific discovery globally: toward a CERN virtual visit service

NASA Astrophysics Data System (ADS)

Goldfarb, S.; Hatzifotiadou, D.; Lapka, M.; Papanestis, A.

2017-10-01

The installation of virtual visit services by the LHC collaborations began shortly after the first high-energy collisions were provided by the CERN accelerator in 2010. The experiments: ATLAS [1], CMS [2], LHCb [3], and ALICE [4] have all joined in this popular and effective method to bring the excitement of scientific exploration and discovery into classrooms and other public venues around the world. Their programmes, which use a combination of video conference, webcast, and video recording to communicate with remote audiences have already reached tens of thousands of viewers, and the demand only continues to grow. Other venues, such as the CERN Control Centre, are also considering similar permanent installations. We present a summary of the development of the various systems in use around CERN today, including the technology deployed and a variety of use cases. We then lay down the arguments for the creation of a CERN-wide service that would support these programmes in a more coherent and effective manner. Potential services include a central booking system and operational management similar to what is currently provided for the common CERN video conference facilities. Certain choices in technology could be made to support programmes based on popular tools including (but not limited to) Skype™ [5], Google Hangouts [6], Facebook Live [7], and Periscope [8]. Successful implementation of the project, which relies on close partnership between the experiments, CERN IT CDA [9], and CERN IR ECO [10], has the potential to reach an even larger, global audience, more effectively than ever before.

Signature CERN-URSS

ScienceCinema

None

2017-12-09

Le DG W.Jentschke souhaite la bienvenue à l'assemblée et aux invités pour la signature du protocole entre le Cern et l'URSS qui est un événement important. C'est en 1955 que 55 visiteurs soviétiques ont visité le Cern pour la première fois. Le premier DG au Cern, F.Bloch, et Mons.Amaldi sont aussi présents. Tandis que le discours anglais de W.Jentschke est traduit en russe, le discours russe de Mons.Morozov est traduit en anglais.

Hangout with CERN: a direct conversation with the public

NASA Astrophysics Data System (ADS)

Rao, Achintya; Goldfarb, Steven; Kahle, Kate

2016-04-01

Hangout with CERN refers to a weekly, half-hour-long, topical webcast hosted at CERN. The aim of the programme is threefold: (i) to provide a virtual tour of various locations and facilities at CERN, (ii) to discuss the latest scientific results from the laboratory, and, most importantly, (iii) to engage in conversation with the public and answer their questions. For each ;episode;, scientists gather around webcam-enabled computers at CERN and partner institutes/universities, connecting to one another using the Google+ social network's ;Hangouts; tool. The show is structured as a conversation mediated by a host, usually a scientist, and viewers can ask questions to the experts in real time through a Twitter hashtag or YouTube comments. The history of Hangout with CERN can be traced back to ICHEP 2012, where several physicists crowded in front of a laptop connected to Google+, using a ;Hangout On Air; webcast to explain to the world the importance of the discovery of the Higgs-like boson, announced just two days before at the same conference. Hangout with CERN has also drawn inspiration from two existing outreach endeavours: (i) ATLAS Virtual Visits, which connected remote visitors with scientists in the ATLAS Control Room via video conference, and (ii) the Large Hangout Collider, in which CMS scientists gave underground tours via Hangouts to groups of schools and members of the public around the world. In this paper, we discuss the role of Hangout with CERN as a bi-directional outreach medium and an opportunity to train scientists in effective communication.

News Particle Physics: ATLAS unveils mural at CERN Prize: Corti Trust invites essay entries Astrophysics: CERN holds cosmic-ray conference Researchers in Residence: Lord Winston returns to school Music: ATLAS scientists record physics music Conference: Champagne flows at Reims event Competition: Students triumph at physics olympiad Teaching: Physics proves popular in Japanese schools Forthcoming Events

NASA Astrophysics Data System (ADS)

2011-01-01

Particle Physics: ATLAS unveils mural at CERN Prize: Corti Trust invites essay entries Astrophysics: CERN holds cosmic-ray conference Researchers in Residence: Lord Winston returns to school Music: ATLAS scientists record physics music Conference: Champagne flows at Reims event Competition: Students triumph at physics olympiad Teaching: Physics proves popular in Japanese schools Forthcoming Events

Hands on CERN: A Well-Used Physics Education Project

ERIC Educational Resources Information Center

Johansson, K. E.

2006-01-01

The "Hands on CERN" education project makes it possible for students and teachers to get close to the forefront of scientific research. The project confronts the students with contemporary physics at its most fundamental level with the help of particle collisions from the DELPHI particle physics experiment at CERN. It now exists in 14 languages…

CERN@school: bringing CERN into the classroom

NASA Astrophysics Data System (ADS)

Whyntie, T.; Cook, J.; Coupe, A.; Fickling, R. L.; Parker, B.; Shearer, N.

2016-04-01

CERN@school brings technology from CERN into the classroom to aid with the teaching of particle physics. It also aims to inspire the next generation of physicists and engineers by giving participants the opportunity to be part of a national collaboration of students, teachers and academics, analysing data obtained from detectors based on the ground and in space to make new, curiosity-driven discoveries at school. CERN@school is based around the Timepix hybrid silicon pixel detector developed by the Medipix 2 Collaboration, which features a 300 μm thick silicon sensor bump-bonded to a Timepix readout ASIC. This defines a 256-by-256 grid of pixels with a pitch of 55 μm, the data from which can be used to visualise ionising radiation in a very accessible way. Broadly speaking, CERN@school consists of a web portal that allows access to data collected by the Langton Ultimate Cosmic ray Intensity Detector (LUCID) experiment in space and the student-operated Timepix detectors on the ground; a number of Timepix detector kits for ground-based experiments, to be made available to schools for both teaching and research purposes; and educational resources for teachers to use with LUCID data and detector kits in the classroom. By providing access to cutting-edge research equipment, raw data from ground and space-based experiments, CERN@school hopes to provide the foundation for a programme that meets the many of the aims and objectives of CERN and the project's supporting academic and industrial partners. The work presented here provides an update on the status of the programme as supported by the UK Science and Technology Facilities Council (STFC) and the Royal Commission for the Exhibition of 1851. This includes recent results from work with the GridPP Collaboration on using grid resources with schools to run GEANT4 simulations of CERN@school experiments.

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

PubMed Central

Mendelsohn, Alan M.; Kim, Lilianne; Xu, Zhenhua; Leu, Jocelyn; Han, Chenglong; Lo, Kim Hung; Westhovens, Rene; Weinblatt, Michael E.

2015-01-01

Objective To evaluate the safety, efficacy, pharmacokinetics, immunogenicity, and radiographic progression through 2 years of treatment with intravenous (IV) golimumab plus methotrexate (MTX) in an open‐label extension of a phase III trial of patients with active rheumatoid arthritis (RA) despite MTX therapy. Methods In the phase III, double‐blind, randomized, placebo‐controlled GO‐FURTHER trial, 592 patients with active RA were randomized (2:1) to intravenous golimumab 2 mg/kg plus MTX (Group 1) or placebo plus MTX (Group 2) at weeks 0 and 4, then every 8 weeks thereafter; placebo patients crossed over to golimumab at week 16 (early escape) or week 24 (crossover). The final golimumab infusion was at week 100. Assessments included American College of Rheumatology 20%, 50%, 70% (ACR20, ACR50, ACR70) response criteria, 28‐joint count disease activity score using the C‐reactive protein level (DAS28‐CRP), physical function and quality of life measures, and changes in the modified Sharp/van der Heijde scores (SHS). Safety was monitored through week 112. Results In total, 486 patients (82.1%) continued treatment through week 100, and 68.1%, 43.8%, and 23.5% had an ACR20/50/70 response, respectively, at week 100. Clinical response and improvements in physical function and quality of life were generally maintained from week 24 through 2 years. Mean change from baseline to week 100 in SHS score was 0.74 in Group 1 and 2.10 in Group 2 (P = 0.005); progression from week 52 to week 100 was clinically insignificant in both groups. A total of 481 patients completed the safety followup through week 112; 79.1% had an adverse event, and 18.2% had a serious adverse event. Conclusion Clinical response to IV golimumab plus MTX was maintained through week 100. Radiographic progression following golimumab treatment was clinically insignificant between week 52 and week 100. No unexpected adverse events occurred through week 112, and the safety profile was consistent with anti–tumor necrosis factor therapy. PMID:25623393

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-05-15

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network Constituents, Fundamental Forces and Symmetries of the Universe. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva.

News Conference: Serbia hosts teachers' seminar Resources: Teachers TV website closes for business Festival: Science takes to the stage in Denmark Research: How noise affects learning in secondary schools CERN: CERN visit inspires new teaching ideas Education: PLS aims to improve perception of science for school students Conference: Scientix conference discusses challenges in science education

NASA Astrophysics Data System (ADS)

2011-07-01

Conference: Serbia hosts teachers' seminar Resources: Teachers TV website closes for business Festival: Science takes to the stage in Denmark Research: How noise affects learning in secondary schools CERN: CERN visit inspires new teaching ideas Education: PLS aims to improve perception of science for school students Conference: Scientix conference discusses challenges in science education

PREFACE: International Conference on Computing in High Energy and Nuclear Physics (CHEP 2010)

NASA Astrophysics Data System (ADS)

Lin, Simon C.; Shen, Stella; Neufeld, Niko; Gutsche, Oliver; Cattaneo, Marco; Fisk, Ian; Panzer-Steindel, Bernd; Di Meglio, Alberto; Lokajicek, Milos

2011-12-01

The International Conference on Computing in High Energy and Nuclear Physics (CHEP) was held at Academia Sinica in Taipei from 18-22 October 2010. CHEP is a major series of international conferences for physicists and computing professionals from the worldwide High Energy and Nuclear Physics community, Computer Science, and Information Technology. The CHEP conference provides an international forum to exchange information on computing progress and needs for the community, and to review recent, ongoing and future activities. CHEP conferences are held at roughly 18 month intervals, alternating between Europe, Asia, America and other parts of the world. Recent CHEP conferences have been held in Prauge, Czech Republic (2009); Victoria, Canada (2007); Mumbai, India (2006); Interlaken, Switzerland (2004); San Diego, California(2003); Beijing, China (2001); Padova, Italy (2000) CHEP 2010 was organized by Academia Sinica Grid Computing Centre. There was an International Advisory Committee (IAC) setting the overall themes of the conference, a Programme Committee (PC) responsible for the content, as well as Conference Secretariat responsible for the conference infrastructure. There were over 500 attendees with a program that included plenary sessions of invited speakers, a number of parallel sessions comprising around 260 oral and 200 poster presentations, and industrial exhibitions. We thank all the presenters, for the excellent scientific content of their contributions to the conference. Conference tracks covered topics on Online Computing, Event Processing, Software Engineering, Data Stores, and Databases, Distributed Processing and Analysis, Computing Fabrics and Networking Technologies, Grid and Cloud Middleware, and Collaborative Tools. The conference included excursions to various attractions in Northern Taiwan, including Sanhsia Tsu Shih Temple, Yingko, Chiufen Village, the Northeast Coast National Scenic Area, Keelung, Yehliu Geopark, and Wulai Aboriginal Village, as well as two banquets held at the Grand Hotel and Grand Formosa Regent in Taipei. The next CHEP conference will be held in New York, the United States on 21-25 May 2012. We would like to thank the National Science Council of Taiwan, the EU ACEOLE project, commercial sponsors, and the International Advisory Committee and the Programme Committee members for all their support and help. Special thanks to the Programme Committee members for their careful choice of conference contributions and enormous effort in reviewing and editing about 340 post conference proceedings papers. Simon C Lin CHEP 2010 Conference Chair and Proceedings Editor Taipei, Taiwan November 2011 Track Editors/ Programme Committee Chair Simon C Lin, Academia Sinica, Taiwan Online Computing Track Y H Chang, National Central University, Taiwan Harry Cheung, Fermilab, USA Niko Neufeld, CERN, Switzerland Event Processing Track Fabio Cossutti, INFN Trieste, Italy Oliver Gutsche, Fermilab, USA Ryosuke Itoh, KEK, Japan Software Engineering, Data Stores, and Databases Track Marco Cattaneo, CERN, Switzerland Gang Chen, Chinese Academy of Sciences, China Stefan Roiser, CERN, Switzerland Distributed Processing and Analysis Track Kai-Feng Chen, National Taiwan University, Taiwan Ulrik Egede, Imperial College London, UK Ian Fisk, Fermilab, USA Fons Rademakers, CERN, Switzerland Torre Wenaus, BNL, USA Computing Fabrics and Networking Technologies Track Harvey Newman, Caltech, USA Bernd Panzer-Steindel, CERN, Switzerland Antonio Wong, BNL, USA Ian Fisk, Fermilab, USA Niko Neufeld, CERN, Switzerland Grid and Cloud Middleware Track Alberto Di Meglio, CERN, Switzerland Markus Schulz, CERN, Switzerland Collaborative Tools Track Joao Correia Fernandes, CERN, Switzerland Philippe Galvez, Caltech, USA Milos Lokajicek, FZU Prague, Czech Republic International Advisory Committee Chair: Simon C. Lin , Academia Sinica, Taiwan Members: Mohammad Al-Turany , FAIR, Germany Sunanda Banerjee, Fermilab, USA Dario Barberis, CERN & Genoa University/INFN, Switzerland Lothar Bauerdick, Fermilab, USA Ian Bird, CERN, Switzerland Amber Boehnlein, US Department of Energy, USA Kors Bos, CERN, Switzerland Federico Carminati, CERN, Switzerland Philippe Charpentier, CERN, Switzerland Gang Chen, Institute of High Energy Physics, China Peter Clarke, University of Edinburgh, UK Michael Ernst, Brookhaven National Laboratory, USA David Foster, CERN, Switzerland Merino Gonzalo, CIEMAT, Spain John Gordon, STFC-RAL, UK Volker Guelzow, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany John Harvey, CERN, Switzerland Frederic Hemmer, CERN, Switzerland Hafeez Hoorani, NCP, Pakistan Viatcheslav Ilyin, Moscow State University, Russia Matthias Kasemann, DESY, Germany Nobuhiko Katayama, KEK, Japan Milos Lokajícek, FZU Prague, Czech Republic David Malon, ANL, USA Pere Mato Vila, CERN, Switzerland Mirco Mazzucato, INFN CNAF, Italy Richard Mount, SLAC, USA Harvey Newman, Caltech, USA Mitsuaki Nozaki, KEK, Japan Farid Ould-Saada, University of Oslo, Norway Ruth Pordes, Fermilab, USA Hiroshi Sakamoto, The University of Tokyo, Japan Alberto Santoro, UERJ, Brazil Jim Shank, Boston University, USA Alan Silverman, CERN, Switzerland Randy Sobie , University of Victoria, Canada Dongchul Son, Kyungpook National University, South Korea Reda Tafirout , TRIUMF, Canada Victoria White, Fermilab, USA Guy Wormser, LAL, France Frank Wuerthwein, UCSD, USA Charles Young, SLAC, USA

"Life in the Universe" Final Event Video Now Available

NASA Astrophysics Data System (ADS)

2002-02-01

ESO Video Clip 01/02 is issued on the web in conjunction with the release of a 20-min documentary video from the Final Event of the "Life in the Universe" programme. This unique event took place in November 2001 at CERN in Geneva, as part of the 2001 European Science and Technology Week, an initiative by the European Commission to raise the public awareness of science in Europe. The "Life in the Universe" programme comprised competitions in 23 European countries to identify the best projects from school students. The projects could be scientific or a piece of art, a theatrical performance, poetry or even a musical performance. The only restriction was that the final work must be based on scientific evidence. Winning teams from each country were invited to a "Final Event" at CERN on 8-11 November, 2001 to present their projects to a panel of International Experts during a special three-day event devoted to understanding the possibility of other life forms existing in our Universe. This Final Event also included a spectacular 90-min webcast from CERN with the highlights of the programme. The video describes the Final Event and the enthusiastic atmosphere when more than 200 young students and teachers from all over Europe met with some of the world's leading scientific experts of the field. The present video clip, with excerpts from the film, is available in four versions: two MPEG files and two streamer-versions of different sizes; the latter require RealPlayer software. Video Clip 01/02 may be freely reproduced. The 20-min video is available on request from ESO, for viewing in VHS and, for broadcasters, in Betacam-SP format. Please contact the ESO EPR Department for more details. Life in the Universe was jointly organised by the European Organisation for Nuclear Research (CERN) , the European Space Agency (ESA) and the European Southern Observatory (ESO) , in co-operation with the European Association for Astronomy Education (EAAE). Other research organisations were associated with the programme, e.g., the European Molecular Biology Laboratory (EMBL) and the European Synchrotron Radiation Facility (ESRF). Detailed information about the "Life in the Universe" programme can be found at the website b>http://www.lifeinuniverse.org and a webcast of this 90-min closing session in one of the large experimental halls at CERN is available on the web via that page. Most of the ESO PR Video Clips at the ESO website provide "animated" illustrations of the ongoing work and events at the European Southern Observatory. The most recent clip was: ESO PR Video Clips 08a-b/01 about The Eagle's EGGs (20 December 2001) . General information is available on the web about ESO videos.

25th Birthday Cern- Amphi

ScienceCinema

None

2017-12-09

Cérémonie du 25ème anniversaire du Cern avec 2 orateurs: le Prof.Weisskopf parle de la signification et le rôle du Cern et le Prof.Casimir(?) fait un exposé sur les rélations entre la science pure et la science appliquée et la "big science" (science légère)

The trigger system for K0→2 π0 decays of the NA48 experiment at CERN

NASA Astrophysics Data System (ADS)

Mikulec, I.

1998-02-01

A fully pipelined 40 MHz "dead-time-free" trigger system for neutral K0 decays for the NA48 experiment at CERN is described. The NA48 experiment studies CP-violation using the high intensity beam of the CERN SPS accelerator. The trigger system sums, digitises, filters and processes signals from 13 340 channels of the liquid krypton electro-magnetic calorimeter. In 1996 the calorimeter and part of the trigger electronics were installed and tested. In 1997 the system was completed and prepared to be used in the first NA48 physics data taking period. Cagliari, Cambridge, CERN, Dubna, Edinburgh, Ferrara, Firenze, Mainz, Orsay, Perugia, Pisa, Saclay, Siegen, Torino, Warszawa, Wien Collaboration.

Introduction to CERN

ScienceCinema

Heuer, R.-D.

2018-02-19

Summer Student Lecture Programme Introduction. The mission of CERN; push back the frontiers of knowledge, e.g. the secrets of the Big Bang...what was the matter like within the first moments of the Universe's existence? You have to develop new technologies for accelerators and detectors (also information technology--the Web and the GRID and medicine--diagnosis and therapy). There are three key technology areas at CERN; accelerating, particle detection, large-scale computing.

45 CFR 2543.84 - Contract Work Hours and Safety Standards Act.

Code of Federal Regulations, 2010 CFR

2010-10-01

... 45 Public Welfare 4 2010-10-01 2010-10-01 false Contract Work Hours and Safety Standards Act. 2543... laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work week is... pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable...

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

PubMed Central

Emery, P; Deodhar, A; Rigby, W F; Isaacs, J D; Combe, B; Racewicz, A J; Latinis, K; Abud-Mendoza, C; Szczepański, L J; Roschmann, R A; Chen, A; Armstrong, G K; Douglass, W; Tyrrell, H

2010-01-01

Objectives This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment. Methods Patients with active disease on stable MTX (10–25 mg/week) were randomised to rituximab 2×500 mg (n=168), rituximab 2×1000 mg (n=172), or placebo (n=172). From week 24, patients not in remission (Disease Activity Score (28 joints) ≥2.6) received a second course of rituximab; patients initially assigned to placebo switched to rituximab 2×500 mg. The primary end point was American College of Rheumatology 20 (ACR20) response at week 24. All patients were followed until week 48. Results At week 24, both doses of rituximab showed statistically superior efficacy (p<0.0001) to placebo (ACR20: 54%, 51% and 23%; rituximab (2×500 mg) + MTX, rituximab (2×1000 mg) + MTX and placebo + MTX, respectively). Secondary end points were also significantly improved for both rituximab groups compared with placebo. Further improvements in both rituximab arms were observed from week 24 to week 48. Rituximab + MTX was well tolerated, demonstrating comparable safety to placebo + MTX through to week 24, and between rituximab doses through to week 48. Conclusions Rituximab (at 2×500 mg and 2×1000 mg) plus MTX significantly improved clinical outcomes at week 24, which were further improved by week 48. No significant differences in either clinical or safety outcomes were apparent between the rituximab doses. PMID:20488885

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.

PubMed

Cohen, Stanley B; Alonso-Ruiz, Alberto; Klimiuk, Piotr A; Lee, Eric C; Peter, Nuala; Sonderegger, Ivo; Assudani, Deepak

2018-06-01

To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. Patients with active rheumatoid arthritis on stable methotrexate were randomised to BI 695501 or Humira in a double-blind, parallel-group, equivalence study. At week 24, patients were rerandomised to continue BI 695501 or Humira, or switch from Humira to BI 695501. The coprimary endpoints were the percentage of patients achieving the American College of Rheumatology 20% response criteria (ACR20) at weeks 12 and 24. Further efficacy and safety endpoints and immunogenicity were assessed up to week 58. 645 patients were randomised. At week 12, 67.0% and 61.1% (90% CI -0.9 to 12.7) of patients receiving BI 695501 (n=324) and Humira (n=321), respectively, achieved ACR20; at week 24 the corresponding values were 69.0% and 64.5% (95% CI -3.4 to 12.5). These differences were within prespecified margins (week 12: 90% CI (-12% to 15%); week 24: 95% CI (-15% to 15%)), demonstrating therapeutic bioequivalence. 593 patients were rerandomised at week 24. Up to week 48, mean change from baseline in Disease Activity Score 28-erythrocyte sedimentation rate and ACR20/ACR50/ACR70 response rates were similar across the switched (n=147), continuous BI 695501 (n=298) and continuous Humira (n=148) groups. Similar immunogenicity (antidrug antibodies (ADAs), ADA titres and neutralising antibodies) was seen between BI 695501 and Humira (to week 24) and across rerandomised groups (to week 48). Safety and tolerability profiles were similar between groups. BI 695501 demonstrated similar efficacy, safety and immunogenicity to Humira; switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity. NCT02137226, Results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

McAllister, Liam

2018-05-14

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-05-22

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons.Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).

PubMed

Emery, P; Deodhar, A; Rigby, W F; Isaacs, J D; Combe, B; Racewicz, A J; Latinis, K; Abud-Mendoza, C; Szczepanski, L J; Roschmann, R A; Chen, A; Armstrong, G K; Douglass, W; Tyrrell, H

2010-09-01

This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment. Patients with active disease on stable MTX (10-25 mg/week) were randomised to rituximab 2 x 500 mg (n=168), rituximab 2 x 1000 mg (n=172), or placebo (n=172). From week 24, patients not in remission (Disease Activity Score (28 joints) > or =2.6) received a second course of rituximab; patients initially assigned to placebo switched to rituximab 2 x 500 mg. The primary end point was American College of Rheumatology 20 (ACR20) response at week 24. All patients were followed until week 48. At week 24, both doses of rituximab showed statistically superior efficacy (p<0.0001) to placebo (ACR20: 54%, 51% and 23%; rituximab (2 x 500 mg) + MTX, rituximab (2 x 1000 mg) + MTX and placebo + MTX, respectively). Secondary end points were also significantly improved for both rituximab groups compared with placebo. Further improvements in both rituximab arms were observed from week 24 to week 48. Rituximab + MTX was well tolerated, demonstrating comparable safety to placebo + MTX through to week 24, and between rituximab doses through to week 48. Rituximab (at 2 x 500 mg and 2 x 1000 mg) plus MTX significantly improved clinical outcomes at week 24, which were further improved by week 48. No significant differences in either clinical or safety outcomes were apparent between the rituximab doses.

77 FR 35862 - Safety Zone; Fleet Week Maritime Festival, Pier 66 Elliott Bay, Seattle, WA

Federal Register 2010, 2011, 2012, 2013, 2014

2012-06-15

... Zone; Fleet Week Maritime Festival, Pier 66 Elliott Bay, Seattle, WA AGENCY: Coast Guard, DHS. ACTION... Festival's Pier 66 Safety Zone in Elliott Bay, WA from 8 a.m. until 8 p.m. on August 1, 2012, however, it... Fleet Week Maritime Festival in 33 CFR 165.1330 on August 1, 2012, from 8 a.m. until 8 p.m.; however, it...

33 CFR 165.163 - Safety Zones; Port of New York/New Jersey Fleet Week.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 33 Navigation and Navigable Waters 2 2010-07-01 2010-07-01 false Safety Zones; Port of New York... § 165.163 Safety Zones; Port of New York/New Jersey Fleet Week. (a) The following areas are established... parade vessels as it transits the Port of New York and New Jersey from the Verrazano Narrows Bridge to...

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-02-09

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental InteractionS". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2017-12-09

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

Meeting Jentschke

ScienceCinema

None

2018-05-18

After an introduction about the latest research and news at CERN, the DG W. Jentschke speaks about future management of CERN with two new general managers, who will be in charge for the next 5 years: Dr. J.B. Adams who will focus on the administration of CERN and also the construction of buildings and equipment, and Dr. L. Van Hove who will be responsible for research activities. The DG speaks about expected changes, shared services, different divisions and their leaders, etc.

Global EOS: exploring the 300-ms-latency region

NASA Astrophysics Data System (ADS)

Mascetti, L.; Jericho, D.; Hsu, C.-Y.

2017-10-01

EOS, the CERN open-source distributed disk storage system, provides the highperformance storage solution for HEP analysis and the back-end for various work-flows. Recently EOS became the back-end of CERNBox, the cloud synchronisation service for CERN users. EOS can be used to take advantage of wide-area distributed installations: for the last few years CERN EOS uses a common deployment across two computer centres (Geneva-Meyrin and Budapest-Wigner) about 1,000 km apart (∼20-ms latency) with about 200 PB of disk (JBOD). In late 2015, the CERN-IT Storage group and AARNET (Australia) set-up a challenging R&D project: a single EOS instance between CERN and AARNET with more than 300ms latency (16,500 km apart). This paper will report about the success in deploy and run a distributed storage system between Europe (Geneva, Budapest), Australia (Melbourne) and later in Asia (ASGC Taipei), allowing different type of data placement and data access across these four sites.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.

PubMed

Sands, Bruce E; Sandborn, William J; Feagan, Brian G; Lichtenstein, Gary R; Zhang, Hongyan; Strauss, Richard; Szapary, Philippe; Johanns, Jewel; Panes, Julian; Vermeire, Severine; O'Brien, Christopher D; Yang, Zijiang; Bertelsen, Kirk; Marano, Colleen

2018-06-15

Janus kinase (JAK) inhibitors have shown efficacy in ulcerative colitis (UC). We studied the dose-response, efficacy, and safety of peficitinib, an oral JAK inhibitor, in patients with moderate-to-severe UC. In this Phase 2b, dose-ranging trial, we evaluated peficitinib at 25mg once daily (qd), 75mg qd, 150mg qd, and 75mg twice daily versus placebo for efficacy and safety in 219 patients with moderate-to-severe UC. The primary outcome was peficitinib dose-response at Week 8 with response assessed using Mayo score change from baseline. Secondary endpoints were clinical response, clinical remission, mucosal healing, change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ), and normalization of inflammatory biomarkers at Week 8; other secondary endpoints were treatment response through Week 16 and through Week 32 for patients in clinical response at Week 8. Safety was assessed through Week 36 or 4 weeks after the last dose. A statistically significant peficitinib dose-response was not demonstrated at Week 8, although a numerically greater proportion of patients receiving peficitinib ≥75mg qd achieved clinical response, remission, and mucosal healing at Week 8, supported by IBDQ improvement and inflammatory biomarker normalization. Treatment-emergent adverse event (TEAE) rates reported through Week 8 and the final safety visit were higher in the combined peficitinib group than placebo; patients receiving doses of ≥75mg qd peficitinib reported TEAEs more frequently. While no dose-response in patients with moderate-to-severe UC was demonstrated with peficitinib, evidence of efficacy was suggested at doses ≥75mg qd. The safety profile of peficitinib was consistent with current information. ClinicalTrials.gov NCT01959282.

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-05-23

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-05-23

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe";. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

McAllister, Liam

2018-05-24

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe";. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions".This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde. Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

None

2018-06-28

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

Sen, Ashoke

2018-04-27

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network". The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher.

Public Lecture

ScienceCinema

None

2017-12-09

An outreach activity is being organized by the Turkish community at CERN, on 5 June 2010 at CERN Main Auditorium. The activity consists of several talks that will take 1.5h in total. The main goal of the activity will be describing the CERN based activities and experiments as well as stimulating the public's attention to the science related topics. We believe the wide communication of the event has certain advantages especially for the proceeding membership process of Turkey.

Service management at CERN with Service-Now

NASA Astrophysics Data System (ADS)

Toteva, Z.; Alvarez Alonso, R.; Alvarez Granda, E.; Cheimariou, M.-E.; Fedorko, I.; Hefferman, J.; Lemaitre, S.; Clavo, D. Martin; Martinez Pedreira, P.; Pera Mira, O.

2012-12-01

The Information Technology (IT) and the General Services (GS) departments at CERN have decided to combine their extensive experience in support for IT and non-IT services towards a common goal - to bring the services closer to the end user based on Information Technology Infrastructure Library (ITIL) best practice. The collaborative efforts have so far produced definitions for the incident and the request fulfilment processes which are based on a unique two-dimensional service catalogue that combines both the user and the support team views of all services. After an extensive evaluation of the available industrial solutions, Service-now was selected as the tool to implement the CERN Service-Management processes. The initial release of the tool provided an attractive web portal for the users and successfully implemented two basic ITIL processes; the incident management and the request fulfilment processes. It also integrated with the CERN personnel databases and the LHC GRID ticketing system. Subsequent releases continued to integrate with other third-party tools like the facility management systems of CERN as well as to implement new processes such as change management. Independently from those new development activities it was decided to simplify the request fulfilment process in order to achieve easier acceptance by the CERN user community. We believe that due to the high modularity of the Service-now tool, the parallel design of ITIL processes e.g., event management and non-ITIL processes, e.g., computer centre hardware management, will be easily achieved. This presentation will describe the experience that we have acquired and the techniques that were followed to achieve the CERN customization of the Service-Now tool.

Prospects for observation at CERN in NA62

NASA Astrophysics Data System (ADS)

Hahn, F.; NA62 Collaboration; Aglieri Rinella, G.; Aliberti, R.; Ambrosino, F.; Angelucci, B.; Antonelli, A.; Anzivino, G.; Arcidiacono, R.; Azhinenko, I.; Balev, S.; Bendotti, J.; Biagioni, A.; Biino, C.; Bizzeti, A.; Blazek, T.; Blik, A.; Bloch-Devaux, B.; Bolotov, V.; Bonaiuto, V.; Bragadireanu, M.; Britton, D.; Britvich, G.; Brook, N.; Bucci, F.; Butin, F.; Capitolo, E.; Capoccia, C.; Capussela, T.; Carassiti, V.; Cartiglia, N.; Cassese, A.; Catinaccio, A.; Cecchetti, A.; Ceccucci, A.; Cenci, P.; Cerny, V.; Cerri, C.; Chikilev, O.; Ciaranfi, R.; Collazuol, G.; Cooke, P.; Cooper, P.; Corradi, G.; Cortina Gil, E.; Costantini, F.; Cotta Ramusino, A.; Coward, D.; D'Agostini, G.; Dainton, J.; Dalpiaz, P.; Danielsson, H.; Degrange, J.; De Simone, N.; Di Filippo, D.; Di Lella, L.; Dixon, N.; Doble, N.; Duk, V.; Elsha, V.; Engelfried, J.; Enik, T.; Falaleev, V.; Fantechi, R.; Federici, L.; Fiorini, M.; Fry, J.; Fucci, A.; Fulton, L.; Gallorini, S.; Gatignon, L.; Gianoli, A.; Giudici, S.; Glonti, L.; Goncalves Martins, A.; Gonnella, F.; Goudzovski, E.; Guida, R.; Gushchin, E.; Hahn, F.; Hallgren, B.; Heath, H.; Herman, F.; Hutchcroft, D.; Iacopini, E.; Jamet, O.; Jarron, P.; Kampf, K.; Kaplon, J.; Karjavin, V.; Kekelidze, V.; Kholodenko, S.; Khoriauli, G.; Khudyakov, A.; Kiryushin, Yu; Kleinknecht, K.; Kluge, A.; Koval, M.; Kozhuharov, V.; Krivda, M.; Kudenko, Y.; Kunze, J.; Lamanna, G.; Lazzeroni, C.; Leitner, R.; Lenci, R.; Lenti, M.; Leonardi, E.; Lichard, P.; Lietava, R.; Litov, L.; Lomidze, D.; Lonardo, A.; Lurkin, N.; Madigozhin, D.; Maire, G.; Makarov, A.; Mannelli, I.; Mannocchi, G.; Mapelli, A.; Marchetto, F.; Massarotti, P.; Massri, K.; Matak, P.; Mazza, G.; Menichetti, E.; Mirra, M.; Misheva, M.; Molokanova, N.; Morant, J.; Morel, M.; Moulson, M.; Movchan, S.; Munday, D.; Napolitano, M.; Newson, F.; Norton, A.; Noy, M.; Nuessle, G.; Obraztsov, V.; Padolski, S.; Page, R.; Palladino, V.; Pardons, A.; Pedreschi, E.; Pepe, M.; Perez Gomez, F.; Perrin-Terrin, M.; Petrov, P.; Petrucci, F.; Piandani, R.; Piccini, M.; Pietreanu, D.; Pinzino, J.; Pivanti, M.; Polenkevich, I.; Popov, I.; Potrebenikov, Yu; Protopopescu, D.; Raffaelli, F.; Raggi, M.; Riedler, P.; Romano, A.; Rubin, P.; Ruggiero, G.; Russo, V.; Ryjov, V.; Salamon, A.; Salina, G.; Samsonov, V.; Santovetti, E.; Saracino, G.; Sargeni, F.; Schifano, S.; Semenov, V.; Sergi, A.; Serra, M.; Shkarovskiy, S.; Sotnikov, A.; Sougonyaev, V.; Sozzi, M.; Spadaro, T.; Spinella, F.; Staley, R.; Statera, M.; Sutcliffe, P.; Szilasi, N.; Tagnani, D.; Valdata-Nappi, M.; Valente, P.; Vasile, M.; Vassilieva, V.; Velghe, B.; Veltri, M.; Venditti, S.; Vormstein, M.; Wahl, H.; Wanke, R.; Wertelaers, P.; Winhart, A.; Winston, R.; Wrona, B.; Yushchenko, O.; Zamkovsky, M.; Zinchenko, A.

2015-07-01

The rare decays are excellent processes to probe the Standard Model and indirectly search for new physics complementary to the direct LHC searches. The NA62 experiment at CERN SPS aims to collect and analyse O(1013) kaon decays before the CERN long-shutdown 2 (in 2018). This will allow to measure the branching ratio to a level of 10% accuracy. The experimental apparatus has been commissioned during a first run in autumn 2014.

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.

PubMed

Inoue, Nagamu; Kobayashi, Kiyonori; Naganuma, Makoto; Hirai, Fumihito; Ozawa, Morio; Arikan, Dilek; Huang, Bidan; Robinson, Anne M; Thakkar, Roopal B; Hibi, Toshifumi

2017-07-01

Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671). Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, followed by 40 mg every other week until the end of the study. Long-term safety and all adverse events (AEs) were examined. The efficacy was assessed on the basis of marked improvement (MI) and complete remission (CR) using a composite efficacy index, which combined global gastrointestinal symptoms and endoscopic assessments. Twenty patients were enrolled in this study; 15 patients received adalimumab treatment until study completion. The incidence of AEs through week 100 was 544.4 events/100 person-years, which was comparable to the incidence through week 52 (560.4 events/100 person-years). No unexpected trend was observed and adalimumab was well tolerated. At weeks 52 and 100, 60.0% and 40.0% of patients showed MI, respectively, and 20.0% and 15.0% of patients showed CR, respectively. This report demonstrates 2 years safety and effectiveness of adalimumab in intestinal BD patients. Patients with intestinal BD refractory to conventional treatment receiving up to 2 years of adalimumab treatment demonstrated safety outcomes consistent with the known profile of adalimumab, and the treatment led to sustained reduction of clinical and endoscopic disease activity.

CERN Collider, France-Switzerland

NASA Image and Video Library

2013-08-23

This image, acquired by NASA Terra spacecraft, is of the CERN Large Hadron Collider, the world largest and highest-energy particle accelerator laying beneath the French-Swiss border northwest of Geneva yellow circle.

CERN and 60 years of science for peace

DOE Office of Scientific and Technical Information (OSTI.GOV)

Heuer, Rolf-Dieter, E-mail: Rolf.Heuer@cern.ch

2015-02-24

This paper presents CERN as it celebrates its 60{sup th} Anniversary since its founding. The presentation first discusses the mission of CERN and its role as an inter-governmental Organization. The paper also reviews aspects of the particle physics research programme, looking at both current and future accelerator-based facilities at the high-energy and intensity frontiers. Finally, the paper considers issues beyond fundamental research, such as capacity-building and the interface between Art and Science.

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network Constituents, Fundamental Forces and Symmetries of the Universe. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva.« less

Review of CERN Data Centre Infrastructure

NASA Astrophysics Data System (ADS)

Andrade, P.; Bell, T.; van Eldik, J.; McCance, G.; Panzer-Steindel, B.; Coelho dos Santos, M.; Traylen and, S.; Schwickerath, U.

2012-12-01

The CERN Data Centre is reviewing strategies for optimizing the use of the existing infrastructure and expanding to a new data centre by studying how other large sites are being operated. Over the past six months, CERN has been investigating modern and widely-used tools and procedures used for virtualisation, clouds and fabric management in order to reduce operational effort, increase agility and support unattended remote data centres. This paper gives the details on the project's motivations, current status and areas for future investigation.

Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.

PubMed

Seino, Yutaka; Sasaki, Takashi; Fukatsu, Atsushi; Imazeki, Hisae; Ochiai, Hidekazu; Sakai, Soichi

2018-06-01

To evaluate the efficacy and safety of luseogliflozin in Japanese patients with type 2 diabetes (T2D) inadequately controlled with insulin monotherapy. This 52-week multicenter study entailed a 16-week, double-blind period followed by a 36-week, open-label period. Patients were randomized to receive either luseogliflozin 2.5 mg (n = 159) or placebo (n = 74) during the double-blind period. All patients who entered the open-label period received luseogliflozin. Major efficacy endpoints included the changes from baseline in HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and bodyweight. Safety assessments included adverse events, laboratory tests and vital signs. In the double-blind period, luseogliflozin significantly decreased HbA1c (-1.18%), FPG (-42.4 mg/dL), 2 hour PPG (-68.7 mg/dL) and bodyweight (-1.27 kg) compared with placebo (all p < .001); these reductions were maintained over 52 weeks. The changes from baseline at Week 52 were -1.00%, -35.1 mg/dL, -68.8 mg/dL and -1.81 kg, respectively (all p < .001). In the placebo group, favorable glycemic control and bodyweight reduction were also observed after switching to luseogliflozin. Most adverse events were mild in severity. During the double-blind period, the incidences of hypoglycemia were 20.8% and 13.5% in the luseogliflozin and placebo groups, respectively. During the 52 weeks of luseogliflozin treatment, the frequency of hypoglycemia was 33.3%, but no serious hypoglycemia occurred. The safety profile other than hypoglycemia was also acceptable. There were no new safety concerns about luseogliflozin added to insulin. Luseogliflozin added to insulin therapy significantly improved glycemic control with bodyweight reduction and was well tolerated in Japanese patients with T2D. Japan Pharmaceutical Information Center (JapicCTI-142582).

Revised LHC deal quiets congress

DOE Office of Scientific and Technical Information (OSTI.GOV)

Lawler, A.

The roughest part of the ride may be over for U.S. physicists who want to participate in the Large Hadron Collider (LHC), the $5 billion accelerator planned for CERN in Geneva. They have found themselves on a political roller coaster for the past few months. This week, U.S. and European negotiators were putting the final touches on a revamped agreement that should pave the way for the United States to help pay for construction of the accelerator and its two main detectors, and guarantee U.S. scientists a role in research on the machine. The trouble began in March, when Representativemore » Joe Barton (R-TX) declared war on a proposed $530 million U.S. contribution to the new facility, slated for completion in 2005. Barton and many other members of Congress were still smarting from what they said was a lack of European support for the canceled Superconducting Super Collider that was being built in Barton`s backyard. Representative James Sensenbrenner (R-WI), who chairs the House Science Committee, led the charge to alter a draft agreement initialed this winter by Department of Energy (DOE) and CERN officials that spelled out the details of U.S. participation. After hurried negotiations, both sides have sharpened the agreement to address the lawmakers` concerns. The new deal, says Energy Secretary Federico Pena, {open_quotes}has made that project even better.{close_quotes}« less

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

ScienceCinema

Sen, Ashoke

2017-12-18

Part 7.The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher

CERN Winter School on Supergravity, Strings, and Gauge Theory 2010

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2010-01-22

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

CERN alerter—RSS based system for information broadcast to all CERN offices

NASA Astrophysics Data System (ADS)

Otto, R.

2008-07-01

Nearly every large organization uses a tool to broadcast messages and information across the internal campus (messages like alerts announcing interruption in services or just information about upcoming events). These tools typically allow administrators (operators) to send 'targeted' messages which are sent only to specific groups of users or computers, e/g only those located in a specified building or connected to a particular computing service. CERN has a long history of such tools: CERNVMS's SPM_quotMESSAGE command, Zephyr [2] and the most recent the NICE Alerter based on the NNTP protocol. The NICE Alerter used on all Windows-based computers had to be phased out as a consequence of phasing out NNTP at CERN. The new solution to broadcast information messages on the CERN campus continues to provide the service based on cross-platform technologies, hence minimizing custom developments and relying on commercial software as much as possible. The new system, called CERN Alerter, is based on RSS (Really Simple Syndication) [9] for the transport protocol and uses Microsoft SharePoint as the backend for database and posting interface. The windows-based client relies on Internet Explorer 7.0 with custom code to trigger the window pop-ups and the notifications for new events. Linux and Mac OS X clients could also rely on any RSS readers to subscribe to targeted notifications. The paper covers the architecture and implementation aspects of the new system.

NA61/SHINE facility at the CERN SPS: beams and detector system

NASA Astrophysics Data System (ADS)

Abgrall, N.; Andreeva, O.; Aduszkiewicz, A.; Ali, Y.; Anticic, T.; Antoniou, N.; Baatar, B.; Bay, F.; Blondel, A.; Blumer, J.; Bogomilov, M.; Bogusz, M.; Bravar, A.; Brzychczyk, J.; Bunyatov, S. A.; Christakoglou, P.; Cirkovic, M.; Czopowicz, T.; Davis, N.; Debieux, S.; Dembinski, H.; Diakonos, F.; Di Luise, S.; Dominik, W.; Drozhzhova, T.; Dumarchez, J.; Dynowski, K.; Engel, R.; Efthymiopoulos, I.; Ereditato, A.; Fabich, A.; Feofilov, G. A.; Fodor, Z.; Fulop, A.; Gaździcki, M.; Golubeva, M.; Grebieszkow, K.; Grzeszczuk, A.; Guber, F.; Haesler, A.; Hasegawa, T.; Hierholzer, M.; Idczak, R.; Igolkin, S.; Ivashkin, A.; Jokovic, D.; Kadija, K.; Kapoyannis, A.; Kaptur, E.; Kielczewska, D.; Kirejczyk, M.; Kisiel, J.; Kiss, T.; Kleinfelder, S.; Kobayashi, T.; Kolesnikov, V. I.; Kolev, D.; Kondratiev, V. P.; Korzenev, A.; Koversarski, P.; Kowalski, S.; Krasnoperov, A.; Kurepin, A.; Larsen, D.; Laszlo, A.; Lyubushkin, V. V.; Maćkowiak-Pawłowska, M.; Majka, Z.; Maksiak, B.; Malakhov, A. I.; Maletic, D.; Manglunki, D.; Manic, D.; Marchionni, A.; Marcinek, A.; Marin, V.; Marton, K.; Mathes, H.-J.; Matulewicz, T.; Matveev, V.; Melkumov, G. L.; Messina, M.; Mrówczyński, St.; Murphy, S.; Nakadaira, T.; Nirkko, M.; Nishikawa, K.; Palczewski, T.; Palla, G.; Panagiotou, A. D.; Paul, T.; Peryt, W.; Petukhov, O.; Pistillo, C.; Płaneta, R.; Pluta, J.; Popov, B. A.; Posiadala, M.; Puławski, S.; Puzovic, J.; Rauch, W.; Ravonel, M.; Redij, A.; Renfordt, R.; Richter-Was, E.; Robert, A.; Röhrich, D.; Rondio, E.; Rossi, B.; Roth, M.; Rubbia, A.; Rustamov, A.; Rybczyński, M.; Sadovsky, A.; Sakashita, K.; Savic, M.; Schmidt, K.; Sekiguchi, T.; Seyboth, P.; Sgalaberna, D.; Shibata, M.; Sipos, R.; Skrzypczak, E.; Słodkowski, M.; Sosin, Z.; Staszel, P.; Stefanek, G.; Stepaniak, J.; Stroebele, H.; Susa, T.; Szuba, M.; Tada, M.; Tereshchenko, V.; Tolyhi, T.; Tsenov, R.; Turko, L.; Ulrich, R.; Unger, M.; Vassiliou, M.; Veberic, D.; Vechernin, V. V.; Vesztergombi, G.; Vinogradov, L.; Wilczek, A.; Włodarczyk, Z.; Wojtaszek-Szwarz, A.; Wyszyński, O.; Zambelli, L.; Zipper, W.

2014-06-01

NA61/SHINE (SPS Heavy Ion and Neutrino Experiment) is a multi-purpose experimental facility to study hadron production in hadron-proton, hadron-nucleus and nucleus-nucleus collisions at the CERN Super Proton Synchrotron. It recorded the first physics data with hadron beams in 2009 and with ion beams (secondary 7Be beams) in 2011. NA61/SHINE has greatly profited from the long development of the CERN proton and ion sources and the accelerator chain as well as the H2 beamline of the CERN North Area. The latter has recently been modified to also serve as a fragment separator as needed to produce the Be beams for NA61/SHINE. Numerous components of the NA61/SHINE set-up were inherited from its predecessors, in particular, the last one, the NA49 experiment. Important new detectors and upgrades of the legacy equipment were introduced by the NA61/SHINE Collaboration. This paper describes the state of the NA61/SHINE facility — the beams and the detector system — before the CERN Long Shutdown I, which started in March 2013.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

PubMed

Bagella, Paola; De Socio, Giuseppe Vl; Ricci, Elena; Menzaghi, Barbara; Martinelli, Canio; Squillace, Nicola; Maggi, Paolo; Orofino, Giancarlo; Calza, Leonardo; Carenzi, Laura; Celesia, Benedetto Maurizio; Penco, Giovanni; Di Biagio, Antonio; Valsecchi, Laura; Vichi, Francesca; Colombo, Valeria; Parruti, Giustino; Dentone, Chiara; Falasca, Katia; Bonfanti, Paolo; Madeddu, Giordano

2018-01-01

Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log 10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 ( p =0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 ( p =0.0008) and 72 ( p =0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 ( p =0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

PubMed Central

Bagella, Paola; De Socio, Giuseppe VL; Ricci, Elena; Menzaghi, Barbara; Martinelli, Canio; Squillace, Nicola; Maggi, Paolo; Orofino, Giancarlo; Calza, Leonardo; Carenzi, Laura; Celesia, Benedetto Maurizio; Penco, Giovanni; Di Biagio, Antonio; Valsecchi, Laura; Vichi, Francesca; Colombo, Valeria; Parruti, Giustino; Dentone, Chiara; Falasca, Katia; Bonfanti, Paolo; Madeddu, Giordano

2018-01-01

Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored. PMID:29731650

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.

PubMed

Ryan, Caitriona; Sobell, Jeffrey M; Leonardi, Craig L; Lynde, Charles W; Karunaratne, Mahinda; Valdecantos, Wendell C; Hendrickson, Barbara A

2018-06-01

Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions. Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications. The safety of adalimumab 40-mg EOW versus EW dosing was examined during placebo-controlled and open-label study periods in patients with HS (three studies), psoriasis (two studies), Crohn's disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study). No new safety risks or increased rates of particular adverse events (AEs) were identified with EW dosing. In patients with HS or psoriasis, the overall safety of adalimumab 40-mg EOW and EW was generally comparable. In studies of adalimumab for non-dermatologic indications, including Crohn's disease, ulcerative colitis, and rheumatoid arthritis, the overall AE rates were similar for EW and EOW dosing. In patients with HS or psoriasis, the safety of adalimumab EW and EOW was comparable and consistent with the expected adalimumab AE profile. The safety of adalimumab EW dosing in patients with dermatologic conditions is supported by data comparing adalimumab EW and EOW dosing for Crohn's disease, ulcerative colitis, and rheumatoid arthritis. ClinicalTrials.gov NCT00918255, NCT01468207, NCT01468233, NCT00645814, NCT00077779, NCT00055497, NCT01070303, NCT00195715, NCT00348283, NCT00385736, NCT00408629, and NCT00573794.

PARTICLE PHYSICS: CERN Gives Higgs Hunters Extra Month to Collect Data.

PubMed

Morton, O

2000-09-22

After 11 years of banging electrons and positrons together at higher energies than any other machine in the world, CERN, the European laboratory for particle physics, had decided to shut down the Large Electron-Positron collider (LEP) and install a new machine, the Large Hadron Collider (LHC), in its 27-kilometer tunnel. In 2005, the LHC will start bashing protons together at even higher energies. But tantalizing hints of a long-sought fundamental particle have forced CERN managers to grant LEP a month's reprieve.

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.

PubMed

Sano, Shigetoshi; Kubo, Hiroshi; Morishima, Hitomi; Goto, Ryosuke; Zheng, Richuan; Nakagawa, Hidemi

2018-05-01

Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis, which are often difficult to treat. The aim of this phase 3, open-label study was to evaluate efficacy and safety of guselkumab, a human interleukin-23 monoclonal antibody, in Japanese patients with GPP and EP. Guselkumab 50 mg was administrated to GPP (n = 10) and EP (n = 11) patients at weeks 0, 4 and thereafter every 8 weeks (q8w). Beginning at week 20, patients were escalated to 100 mg q8w if they met the dose escalation criteria. The primary end-point was the proportion of patients achieving treatment success (Clinical Global Impression score of "very much improved", "much improved" or "minimally improved") at week 16. Safety evaluations included assessment of treatment-emergent adverse events (TEAE) through week 52. At week 16, the proportions of GPP and EP patients achieving treatment success were 77.8% (7/9) and 90.9% (10/11), respectively. Furthermore, guselkumab treatment consistently showed improvement in responses of secondary end-points such as Psoriasis Area and Severity Index, Investigator's Global Assessment, Japanese Dermatological Association severity index and improvement in body surface area involvement. Improvements in quality of life, as assessed by the Dermatology Life Quality Index, were also observed through week 52. The most commonly reported TEAE was nasopharyngitis (28.6%, 6/21). Safety findings were consistent with those observed previously in other studies. In conclusion, guselkumab treatment demonstrated efficacy and showed no safety concerns in Japanese patients with GPP and EP through week 52. © 2018 Janssen Pharmaceutical K.K. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.

CERN launches high-school internship programme

NASA Astrophysics Data System (ADS)

Johnston, Hamish

2017-07-01

The CERN particle-physics lab has hosted 22 high-school students from Hungary in a pilot programme designed to show teenagers how science, technology, engineering and mathematics is used at the particle-physics lab.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

PubMed Central

Emery, Paul; Vencovský, Jiří; Sylwestrzak, Anna; Leszczyński, Piotr; Porawska, Wieslawa; Baranauskaite, Asta; Tseluyko, Vira; Zhdan, Vyacheslav M.; Stasiuk, Barbara; Milasiene, Roma; Barrera Rodriguez, Aaron Alejandro; Cheong, Soo Yeon; Ghil, Jeehoon

2017-01-01

Abstract Objective To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. Methods In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive 50 mg/week of s.c. SB4 or ETN up to week 52. Efficacy assessments included ACR response rates, 28-joint DAS, Simplified and Clinical Disease Activity Indices and changes in the modified total Sharp score (mTSS). Safety and immunogenicity were also evaluated. Results A total of 596 patients were randomized to receive either SB4 (n = 299) or ETN (n = 297) and 505 (84.7%) patients completed 52 weeks of the study. At week 52, the ACR20 response rates in the per-protocol set were comparable between SB4 (80.8%) and ETN (81.5%). All efficacy results were comparable between the two groups and they were maintained up to week 52. Radiographic progression was also comparable and the change from baseline in the mTSS was 0.45 for SB4 and 0.74 for ETN. The safety profile of SB4 was similar to that of ETN and the incidence of anti-drug antibody development up to week 52 was 1.0 and 13.2% in the SB4 and ETN groups, respectively. Conclusion Efficacy including radiographic progression was comparable between SB4 and ETN up to week 52. SB4 was well tolerated and had a similar safety profile to that of ETN. Trial registration number ClinicalTrials.gov NCT01895309, EudraCT 2012-005026-30 PMID:28968793

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

PubMed

Griesshammer, Martin; Saydam, Guray; Palandri, Francesca; Benevolo, Giulia; Egyed, Miklos; Callum, Jeannie; Devos, Timothy; Sivgin, Serdar; Guglielmelli, Paola; Bensasson, Caroline; Khan, Mahmudul; Ronco, Julian Perez; Passamonti, Francesco

2018-05-27

RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients without palpable splenomegaly. This analysis evaluated the durability of the efficacy and safety of ruxolitinib after patients completed the visit at week 80 or discontinued the study. Endpoints included proportion of patients achieving hematocrit control (< 45%), proportion of patients achieving complete hematologic remission (CHR) at week 28, and the durability of hematocrit control and CHR. At the time of analysis, 93% (69/74) of patients randomized to ruxolitinib were receiving ruxolitinib; while in the BAT arm, 77% (58/75) of patients crossed over to ruxolitinib after week 28. No patient remained on BAT by week 80. Among patients who achieved a hematocrit response at week 28, the probability of maintaining response up to week 80 was 78% in the ruxolitinib arm. At week 80, durable CHR was achieved in 18 patients (24%) in the ruxolitinib arm versus 2 patients (3%) in the BAT arm. The safety profile of ruxolitinib was consistent with previous reports. These data support that ruxolitinib treatment should be considered also as a standard of care for hydroxyurea-resistant/hydroxyurea-intolerant PV patients without palpable splenomegaly.

Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.

PubMed

Mimori, Tsuneyo; Harigai, Masayoshi; Atsumi, Tatsuya; Fujii, Takao; Kuwana, Masataka; Matsuno, Hiroaki; Momohara, Shigeki; Takei, Syuji; Tamura, Naoto; Takasaki, Yoshinari; Ikeuchi, Satoshi; Kushimoto, Satoru; Koike, Takao

2017-09-01

To determine the real-world safety and effectiveness of iguratimod (IGU) for rheumatoid arthritis (RA), a 52-week, Japanese, post-marketing surveillance study was conducted. An interim analysis at week 24 was performed. This study included all RA patients who received IGU following its introduction to the market. All adverse events (AEs) and adverse drug reactions (ADRs) were collected. Effectiveness was evaluated by the change in Disease Activity Score 28-C-reactive protein (DAS28-CRP) from baseline to week 24. Safety was analyzed in 2679 patients. The overall incidences of AEs, ADRs, and serious ADRs were 38.41, 31.65, and 3.21%, respectively; the most commonly reported serious ADRs were pneumonia/bacterial pneumonia, interstitial lung disease, and Pneumocystis jiroveci pneumonia. Concomitant glucocorticoid use and comorbid conditions associated with respiratory disease were identified as risk factors for serious infections. Pulmonary alveolar hemorrhage and increased international normalized ratio of prothrombin time were observed with concomitant use of IGU and warfarin. The DAS28-CRP decreased from baseline to week 24. Although a safety concern was identified with concomitant use of IGU and warfarin, this real-world study showed no other new safety concerns and similar effectiveness to clinical trials. IGU is a new therapeutic option for RA patients.

Commissioning of a CERN Production and Analysis Facility Based on xrootd

NASA Astrophysics Data System (ADS)

Campana, Simone; van der Ster, Daniel C.; Di Girolamo, Alessandro; Peters, Andreas J.; Duellmann, Dirk; Coelho Dos Santos, Miguel; Iven, Jan; Bell, Tim

2011-12-01

The CERN facility hosts the Tier-0 of the four LHC experiments, but as part of WLCG it also offers a platform for production activities and user analysis. The CERN CASTOR storage technology has been extensively tested and utilized for LHC data recording and exporting to external sites according to experiments computing model. On the other hand, to accommodate Grid data processing activities and, more importantly, chaotic user analysis, it was realized that additional functionality was needed including a different throttling mechanism for file access. This paper will describe the xroot-based CERN production and analysis facility for the ATLAS experiment and in particular the experiment use case and data access scenario, the xrootd redirector setup on top of the CASTOR storage system, the commissioning of the system and real life experience for data processing and data analysis.

First experience with the new .cern Top Level Domain

NASA Astrophysics Data System (ADS)

Alvarez, E.; Malo de Molina, M.; Salwerowicz, M.; Silva De Sousa, B.; Smith, T.; Wagner, A.

2017-10-01

In October 2015, CERN’s core website has been moved to a new address, http://home.cern, marking the launch of the brand new top-level domain .cern. In combination with a formal governance and registration policy, the IT infrastructure needed to be extended to accommodate the hosting of Web sites in this new top level domain. We will present the technical implementation in the framework of the CERN Web Services that allows to provide virtual hosting, a reverse proxy solution and that also includes the provisioning of SSL server certificates for secure communications.

OPERA - First Beam Results

DOE Office of Scientific and Technical Information (OSTI.GOV)

Nakamura, M.

2008-02-21

OPERA is a long base-line neutrino oscillation experiment to detect tau-neutrino appearance and to prove that the origin of the atmospheric muon neutrino deficit observed by Kamiokande is the neutrino oscillation. A Hybrid emulsion detector, of which weight is about 1.3 kton, has been installed in Gran Sasso laboratory. New muon neutrino beam line, CNGS, has been constructed at CERN to send neutrinos to Gran Sasso, 730 km apart from CERN. In 2006, first neutrinos were sent from CERN to LNGS and were detected by the OPERA detector successfully as planned.

Measurements and FLUKA simulations of bismuth and aluminium activation at the CERN Shielding Benchmark Facility (CSBF)

NASA Astrophysics Data System (ADS)

Iliopoulou, E.; Bamidis, P.; Brugger, M.; Froeschl, R.; Infantino, A.; Kajimoto, T.; Nakao, N.; Roesler, S.; Sanami, T.; Siountas, A.

2018-03-01

The CERN High Energy AcceleRator Mixed field facility (CHARM) is located in the CERN Proton Synchrotron (PS) East Experimental Area. The facility receives a pulsed proton beam from the CERN PS with a beam momentum of 24 GeV/c with 5 ṡ1011 protons per pulse with a pulse length of 350 ms and with a maximum average beam intensity of 6.7 ṡ1010 p/s that then impacts on the CHARM target. The shielding of the CHARM facility also includes the CERN Shielding Benchmark Facility (CSBF) situated laterally above the target. This facility consists of 80 cm of cast iron and 360 cm of concrete with barite concrete in some places. Activation samples of bismuth and aluminium were placed in the CSBF and in the CHARM access corridor in July 2015. Monte Carlo simulations with the FLUKA code have been performed to estimate the specific production yields for these samples. The results estimated by FLUKA Monte Carlo simulations are compared to activation measurements of these samples. The comparison between FLUKA simulations and the measured values from γ-spectrometry gives an agreement better than a factor of 2.

Visit CD

ScienceCinema

None

2017-12-09

Le DG H.Schopper souhaite la bienvenue aux ambassadeurs des pays membres et aux représentants des pays avec lesquels le Cern entretient des relations proches et fait un exposé sur les activités au Cern

Membership Finland

ScienceCinema

None

2018-05-18

The DG C. Rubbia and the vice president of the council of CERN gives a warm welcome to the membership of Finland, as the 15th member of CERN since January 1 1991 in the presence of the Secretary-General and the ambassador.

Memorial W.Gentner

ScienceCinema

None

2018-05-25

The DG H. Schopper gives an introduction for the commemoration and ceremony of the life and work of Professor Wolfgang Gentner. W. Gentner, German physicist, born in 1906 in Frankfurt and died in September 1980 in Heidelberg, was director of CERN from 1955 to 1960, president of the Scientific Policy Committee from 1968 to 1971 and president of the Council of CERN from 1972 to 1974. He was one of the founders of CERN and four people who knew him well pay tribute to him, among others one of his students, as well as J.B. Adams and O. Sheffard.

Self-service for software development projects and HPC activities

NASA Astrophysics Data System (ADS)

Husejko, M.; Høimyr, N.; Gonzalez, A.; Koloventzos, G.; Asbury, D.; Trzcinska, A.; Agtzidis, I.; Botrel, G.; Otto, J.

2014-05-01

This contribution describes how CERN has implemented several essential tools for agile software development processes, ranging from version control (Git) to issue tracking (Jira) and documentation (Wikis). Running such services in a large organisation like CERN requires many administrative actions both by users and service providers, such as creating software projects, managing access rights, users and groups, and performing tool-specific customisation. Dealing with these requests manually would be a time-consuming task. Another area of our CERN computing services that has required dedicated manual support has been clusters for specific user communities with special needs. Our aim is to move all our services to a layered approach, with server infrastructure running on the internal cloud computing infrastructure at CERN. This contribution illustrates how we plan to optimise the management of our of services by means of an end-user facing platform acting as a portal into all the related services for software projects, inspired by popular portals for open-source developments such as Sourceforge, GitHub and others. Furthermore, the contribution will discuss recent activities with tests and evaluations of High Performance Computing (HPC) applications on different hardware and software stacks, and plans to offer a dynamically scalable HPC service at CERN, based on affordable hardware.

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial

PubMed Central

Tanaka, Yoshiya; Harigai, Masayoshi; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Yamamoto, Kazuhiko; Miyasaka, Nobuyuki; Koike, Takao; Baker, Daniel; Ishii, Yutaka; Yoshinari, Toru

2016-01-01

Abstract Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with <20% improvement in swollen/tender joint counts entered early escape at week 16. At week 24, all remaining placebo patients crossed over to golimumab 50 mg. Efficacy assessments included ACR20, DAS28-ESR, and HAQ-DI. Radiographic progression was assessed with the van der Heijde-modified Sharp (vdH-S) score. Results: ACR20 response rates in Group 1, Group 2, and Group 3 were 67.9, 86.1, and 82.4%, respectively, at week 52 and were maintained through week 104 (87.1, 94.0, and 88.7%) and week 156 (97.1, 94.1, and 89.5%). Proportions of patients with good/moderate DAS28-ESR response or clinically meaningful improvement in HAQ-DI were also maintained through week 156. The majority of patients did not experience radiographic progression through week 156. Among 257 golimumab-treated patients, 251 (97.7%) had ≥1 AE; 54 (21.0%) had ≥1 serious AE through week 156. Infections were the most common type of AE. Conclusions: Response to golimumab + MTX was maintained over 3 years in Japanese patients with active RA despite MTX. Safety results were consistent with the known safety profile of golimumab. PMID:26474192

Cryogenic Control System Migration and Developments towards the UNICOS CERN Standard at INFN

NASA Astrophysics Data System (ADS)

Modanese, Paolo; Calore, Andrea; Contran, Tiziano; Friso, Alessandro; Pengo, Marco; Canella, Stefania; Burioli, Sergio; Gallese, Benedetto; Inglese, Vitaliano; Pezzetti, Marco; Pengo, Ruggero

The cryogenic control systems at Laboratori Nazionali di Legnaro (LNL) are undergoing an important and radical modernization, allowing all the plants controls and supervision systems to be renewed in a homogeneous way towards the CERN-UNICOS standard. Before the UNICOS migration project started there were as many as 7 different types of PLC and 7 different types of SCADA, each one requiring its own particular programming language. In these conditions, even a simple modification and/or integration on the program or on the supervision, required the intervention of a system integrator company, specialized in its specific control system. Furthermore it implied that the operators have to be trained to learn the different types of control systems. The CERN-UNICOS invented for LHC [1] has been chosen due to its reliability and planned to run and be maintained for decades on. The complete migration is part of an agreement between CERN and INFN.

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The DG H. Schopper gives an introduction for the commemoration and ceremony of the life and work of Professor Wolfgang Gentner. W. Gentner, German physicist, born in 1906 in Frankfurt and died in September 1980 in Heidelberg, was director of CERN from 1955 to 1960, president of the Scientific Policy Committee from 1968 to 1971 and president of the Council of CERN from 1972 to 1974. He was one of the founders of CERN and four people who knew him well pay tribute to him, among others one of his students, as well as J.B. Adams and O. Sheffard.

Ageing Studies on the First Resistive-MicroMeGaS Quadruplet at GIF++ Preliminary Results

NASA Astrophysics Data System (ADS)

Alvarez Gonzalez, B.; Bianco, M.; Farina, E.; Iengo, P.; Kuger, F.; Lin, T.; Longo, L.; Sekhniaidze, G.; Sidiropoulou, O.; Schott, M.; Valderanis, C.; Wotschack, J.

2018-02-01

A resistive-MicroMeGaS quadruplet built at CERN has been installed at the new CERN Gamma Irradiation Facility (GIF++) with the aim of carrying out a long-term ageing study. Two smaller resistive bulk-MicroMeGaS produced at the CERN PCB workshop have also been installed at GIF++ in order to provide a comparison of the ageing behavior with the MicroMeGaS quadruplet. We give an overview of the ongoing tests at GIF++ in terms of particle rate, integrated charge and spatial resolution of the MicroMeGaS detectors.

CERN openlab: Engaging industry for innovation in the LHC Run 3-4 R&D programme

NASA Astrophysics Data System (ADS)

Girone, M.; Purcell, A.; Di Meglio, A.; Rademakers, F.; Gunne, K.; Pachou, M.; Pavlou, S.

2017-10-01

LHC Run3 and Run4 represent an unprecedented challenge for HEP computing in terms of both data volume and complexity. New approaches are needed for how data is collected and filtered, processed, moved, stored and analysed if these challenges are to be met with a realistic budget. To develop innovative techniques we are fostering relationships with industry leaders. CERN openlab is a unique resource for public-private partnership between CERN and leading Information Communication and Technology (ICT) companies. Its mission is to accelerate the development of cutting-edge solutions to be used by the worldwide HEP community. In 2015, CERN openlab started its phase V with a strong focus on tackling the upcoming LHC challenges. Several R&D programs are ongoing in the areas of data acquisition, networks and connectivity, data storage architectures, computing provisioning, computing platforms and code optimisation and data analytics. This paper gives an overview of the various innovative technologies that are currently being explored by CERN openlab V and discusses the long-term strategies that are pursued by the LHC communities with the help of industry in closing the technological gap in processing and storage needs expected in Run3 and Run4.

Wi-Fi Service enhancement at CERN

NASA Astrophysics Data System (ADS)

Ducret, V.; Sosnowski, A.; Gonzalez Caballero, B.; Barrand, Q.

2017-10-01

Since the early 2000’s, the number of mobile devices connected to CERN’s internal network has increased from just a handful to well over 10,000. Wireless access is no longer simply “nice to have” or just for conference and meeting rooms; support for mobility is expected by most, if not all, of the CERN community. In this context, a full renewal of the CERN Wi-Fi network has been launched to deliver a state-of-the-art campus-wide Wi-Fi Infrastructure. We aim to deliver, in more than 200 office buildings with a surface area of over 400,000m2 and including many high-priority and high-occupation zones, an end-user experience comparable, for most applications, to a wired connection and with seamless mobility support. We describe here the studies and tests performed at CERN to ensure the solution we are deploying can meet these goals as well as delivering a single, simple, flexible and open management platform.

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

PubMed

Papp, Kim; Bachelez, Herve; Costanzo, Antonio; Foley, Peter; Gooderham, Melinda; Kaur, Primal; Narbutt, Joanna; Philipp, Sandra; Spelman, Lynda; Weglowska, Jolanta; Zhang, Nan; Strober, Bruce

2017-06-01

ABP 501 is a biosimilar of adalimumab. We sought to compare the efficacy and safety of ABP 501 with adalimumab. This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 or adalimumab. At week 16, those with 50% or more improvement in Psoriasis Area and Severity Index score from baseline on ABP 501 continued the same treatment, whereas adalimumab-treated patients were rerandomized to adalimumab or ABP 501. Clinical similarity in Psoriasis Area and Severity Index percent improvement from baseline to week 16 (primary end point) was established if the point estimate of treatment difference and its 2-sided 95% confidence interval between groups was within equivalence margin of ±15. Patients, including those undergoing a single transition at week 16, were evaluated for safety and immunogenicity. Psoriasis Area and Severity Index percent improvement at week 16 was 80.9 for ABP 501 and 83.1 for adalimumab (least-square mean difference -2.18 [95% confidence interval -7.39 to 3.02]). Adverse events (67.2% [117/174] vs 63.6% [110/173]) and antidrug antibody incidence (55.2% [96/174] vs 63.6% [110/173]) for ABP 501 vs adalimumab were similar. Safety, including immunogenicity, was similar among groups after single transition (week 20). The 52-week data are not reported here. ABP 501 was shown to be clinically similar to adalimumab. Safety and immunogenicity were not impacted immediately after single transition (adalimumab to ABP 501). Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

CERN IRRADIATION FACILITIES.

PubMed

Pozzi, Fabio; Garcia Alia, Ruben; Brugger, Markus; Carbonez, Pierre; Danzeca, Salvatore; Gkotse, Blerina; Richard Jaekel, Martin; Ravotti, Federico; Silari, Marco; Tali, Maris

2017-09-28

CERN provides unique irradiation facilities for applications in dosimetry, metrology, intercomparison of radiation protection devices, benchmark of Monte Carlo codes and radiation damage studies to electronics. © The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

LHC@Home: a BOINC-based volunteer computing infrastructure for physics studies at CERN

NASA Astrophysics Data System (ADS)

Barranco, Javier; Cai, Yunhai; Cameron, David; Crouch, Matthew; Maria, Riccardo De; Field, Laurence; Giovannozzi, Massimo; Hermes, Pascal; Høimyr, Nils; Kaltchev, Dobrin; Karastathis, Nikos; Luzzi, Cinzia; Maclean, Ewen; McIntosh, Eric; Mereghetti, Alessio; Molson, James; Nosochkov, Yuri; Pieloni, Tatiana; Reid, Ivan D.; Rivkin, Lenny; Segal, Ben; Sjobak, Kyrre; Skands, Peter; Tambasco, Claudia; Veken, Frederik Van der; Zacharov, Igor

2017-12-01

The LHC@Home BOINC project has provided computing capacity for numerical simulations to researchers at CERN since 2004, and has since 2011 been expanded with a wider range of applications. The traditional CERN accelerator physics simulation code SixTrack enjoys continuing volunteers support, and thanks to virtualisation a number of applications from the LHC experiment collaborations and particle theory groups have joined the consolidated LHC@Home BOINC project. This paper addresses the challenges related to traditional and virtualized applications in the BOINC environment, and how volunteer computing has been integrated into the overall computing strategy of the laboratory through the consolidated LHC@Home service. Thanks to the computing power provided by volunteers joining LHC@Home, numerous accelerator beam physics studies have been carried out, yielding an improved understanding of charged particle dynamics in the CERN Large Hadron Collider (LHC) and its future upgrades. The main results are highlighted in this paper.

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED

NASA Astrophysics Data System (ADS)

Cavaier, R. Formento; Haddad, F.; Sounalet, T.; Stora, T.; Zahi, I.

A new facility, named CERN-MEDICIS, is under construction at CERN to produce radionuclides for medical applications. In parallel, the MEDICIS-PROMED, a Marie Sklodowska-Curie innovative training network of the Horizon 2020 European Commission's program, is being coordinated by CERN to train young scientists on the production and use of innovative radionuclides and develop a network of experts within Europe. One program within MEDICIS-PROMED is to determine the feasibility of producing innovative radioisotopes for theranostics using a commercial middle-sized high-current cyclotron and the mass separation technology developed at CERN-MEDICIS. This will allow the production of high specific activity radioisotopes not achievable with the common post-processing by chemical separation. Radioisotopes of scandium, copper, arsenic and terbium have been identified. Preliminary studies of activation yield and irradiation parameters optimization for the production of Tb-149 will be described.

76 FR 30495 - National Safe Boating Week, 2011

Federal Register 2010, 2011, 2012, 2013, 2014

2011-05-25

... Safe Boating Week, 2011 By the President of the United States of America A Proclamation As Americans... to watergoers. National Safe Boating Week is an opportunity to highlight the importance of safety... can save lives. Each year for National Safe Boating Week, the United States Coast Guard partners with...

Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study.

PubMed

Olde Rikkert, Marcel G M; Verhey, Frans R; Blesa, Rafael; von Arnim, Christine A F; Bongers, Anke; Harrison, John; Sijben, John; Scarpini, Elio; Vandewoude, Maurits F J; Vellas, Bruno; Witkamp, Renger; Kamphuis, Patrick J G H; Scheltens, Philip

2015-01-01

The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to improve synapse formation and function in patients with Alzheimer's disease (AD). Two double-blind randomized controlled trials (RCT) with Souvenaid of 12 and 24 week duration (Souvenir I and Souvenir II) showed that memory performance was improved in drug-naïve mild AD patients, whereas no effects on cognition were observed in a 24-week RCT (S-Connect) in mild to moderate AD patients using AD medication. Souvenaid was well-tolerated in all RCTs. In this 24-week open-label extension (OLE) study to the 24-week Souvenir II RCT, long-term safety and intake adherence of the medical food Souvenaid was evaluated. Patients with mild AD (n = 201) received Souvenaid once-daily during the OLE. Main outcome parameters were safety and product intake adherence. The memory domain z-score from a revised neuropsychological test battery was continued as exploratory parameter. Compared to the RCT, a similar (low) incidence and type of adverse events was observed, being mainly (68.3%) of mild intensity. Pooled data (RCT and OLE) showed that 48-week use of Souvenaid was well tolerated with high intake adherence (96.1%). Furthermore, a significant increase in the exploratory memory outcome was observed in both the active-active and control-active groups during Souvenaid intervention. Souvenaid use for up to 48-weeks was well tolerated with a favorable safety profile and high intake adherence. The findings in this OLE study warrant further investigation toward the long-term safety and efficacy of Souvenaid in a well-controlled, double-blind RCT.

Hurricane Safety and Information - Central Pacific Hurricane Center -

Science.gov Websites

NOAA NWS United States Department of Commerce Central Pacific Hurricane Center National Oceanic and Distance Calculator Blank Tracking Maps ▾ Educational Resources Be Prepared! NWS Hurricane Prep Week Search For Go NWS All NOAA ▾ Hurricane Safety Hurricane Awareness Week Information from CPHC Red Cross

75 FR 62307 - Fire Prevention Week, 2010

Federal Register 2010, 2011, 2012, 2013, 2014

2010-10-08

... Prevention Week, 2010 By the President of the United States of America A Proclamation During Fire Prevention Week, we reaffirm the importance of fire safety and awareness, and we pay tribute to our firefighters..., injuries, and lives lost to fire and its consequences. Fire Prevention Week also calls our attention to the...

The ATLAS Experiment at the CERN Large Hadron Collider

NASA Astrophysics Data System (ADS)

ATLAS Collaboration; Aad, G.; Abat, E.; Abdallah, J.; Abdelalim, A. A.; Abdesselam, A.; Abdinov, O.; Abi, B. A.; Abolins, M.; Abramowicz, H.; Acerbi, E.; Acharya, B. S.; Achenbach, R.; Ackers, M.; Adams, D. L.; Adamyan, F.; Addy, T. N.; Aderholz, M.; Adorisio, C.; Adragna, P.; Aharrouche, M.; Ahlen, S. P.; Ahles, F.; Ahmad, A.; Ahmed, H.; Aielli, G.; Åkesson, P. F.; Åkesson, T. P. A.; Akimov, A. V.; Alam, S. M.; Albert, J.; Albrand, S.; Aleksa, M.; Aleksandrov, I. N.; Aleppo, M.; Alessandria, F.; Alexa, C.; Alexander, G.; Alexopoulos, T.; Alimonti, G.; Aliyev, M.; Allport, P. P.; Allwood-Spiers, S. E.; Aloisio, A.; Alonso, J.; Alves, R.; Alviggi, M. G.; Amako, K.; Amaral, P.; Amaral, S. P.; Ambrosini, G.; Ambrosio, G.; Amelung, C.; Ammosov, V. V.; Amorim, A.; Amram, N.; Anastopoulos, C.; Anderson, B.; Anderson, K. J.; Anderssen, E. C.; Andreazza, A.; Andrei, V.; Andricek, L.; Andrieux, M.-L.; Anduaga, X. S.; Anghinolfi, F.; Antonaki, A.; Antonelli, M.; Antonelli, S.; Apsimon, R.; Arabidze, G.; Aracena, I.; Arai, Y.; Arce, A. T. H.; Archambault, J. P.; Arguin, J.-F.; Arik, E.; Arik, M.; Arms, K. E.; Armstrong, S. R.; Arnaud, M.; Arnault, C.; Artamonov, A.; Asai, S.; Ask, S.; Åsman, B.; Asner, D.; Asquith, L.; Assamagan, K.; Astbury, A.; Athar, B.; Atkinson, T.; Aubert, B.; Auerbach, B.; Auge, E.; Augsten, K.; Aulchenko, V. M.; Austin, N.; Avolio, G.; Avramidou, R.; Axen, A.; Ay, C.; Azuelos, G.; Baccaglioni, G.; Bacci, C.; Bachacou, H.; Bachas, K.; Bachy, G.; Badescu, E.; Bagnaia, P.; Bailey, D. C.; Baines, J. T.; Baker, O. K.; Ballester, F.; Baltasar Dos Santos Pedrosa, F.; Banas, E.; Banfi, D.; Bangert, A.; Bansal, V.; Baranov, S. P.; Baranov, S.; Barashkou, A.; Barberio, E. L.; Barberis, D.; Barbier, G.; Barclay, P.; Bardin, D. Y.; Bargassa, P.; Barillari, T.; Barisonzi, M.; Barnett, B. M.; Barnett, R. M.; Baron, S.; Baroncelli, A.; Barone, M.; Barr, A. J.; Barreiro, F.; Barreiro Guimarães da Costa, J.; Barrillon, P.; Barriuso Poy, A.; Barros, N.; Bartheld, V.; Bartko, H.; Bartoldus, R.; Basiladze, S.; Bastos, J.; Batchelor, L. E.; Bates, R. L.; Batley, J. R.; Batraneanu, S.; Battistin, M.; Battistoni, G.; Batusov, V.; Bauer, F.; Bauss, B.; Baynham, D. E.; Bazalova, M.; Bazan, A.; Beauchemin, P. H.; Beaugiraud, B.; Beccherle, R. B.; Beck, G. A.; Beck, H. P.; Becks, K. H.; Bedajanek, I.; Beddall, A. J.; Beddall, A.; Bednár, P.; Bednyakov, V. A.; Bee, C.; Behar Harpaz, S.; Belanger, G. A. N.; Belanger-Champagne, C.; Belhorma, B.; Bell, P. J.; Bell, W. H.; Bella, G.; Bellachia, F.; Bellagamba, L.; Bellina, F.; Bellomo, G.; Bellomo, M.; Beltramello, O.; Belymam, A.; Ben Ami, S.; Ben Moshe, M.; Benary, O.; Benchekroun, D.; Benchouk, C.; Bendel, M.; Benedict, B. H.; Benekos, N.; Benes, J.; Benhammou, Y.; Benincasa, G. P.; Benjamin, D. P.; Bensinger, J. R.; Benslama, K.; Bentvelsen, S.; Beretta, M.; Berge, D.; Bergeaas, E.; Berger, N.; Berghaus, F.; Berglund, S.; Bergsma, F.; Beringer, J.; Bernabéu, J.; Bernardet, K.; Berriaud, C.; Berry, T.; Bertelsen, H.; Bertin, A.; Bertinelli, F.; Bertolucci, S.; Besson, N.; Beteille, A.; Bethke, S.; Bialas, W.; Bianchi, R. M.; Bianco, M.; Biebel, O.; Bieri, M.; Biglietti, M.; Bilokon, H.; Binder, M.; Binet, S.; Bingefors, N.; Bingul, A.; Bini, C.; Biscarat, C.; Bischof, R.; Bischofberger, M.; Bitadze, A.; Bizzell, J. P.; Black, K. M.; Blair, R. E.; Blaising, J. J.; Blanch, O.; Blanchot, G.; Blocker, C.; Blocki, J.; Blondel, A.; Blum, W.; Blumenschein, U.; Boaretto, C.; Bobbink, G. J.; Bocci, A.; Bocian, D.; Bock, R.; Boehm, M.; Boek, J.; Bogaerts, J. A.; Bogouch, A.; Bohm, C.; Bohm, J.; Boisvert, V.; Bold, T.; Boldea, V.; Bondarenko, V. G.; Bonino, R.; Bonis, J.; Bonivento, W.; Bonneau, P.; Boonekamp, M.; Boorman, G.; Boosten, M.; Booth, C. N.; Booth, P. S. L.; Booth, P.; Booth, J. R. A.; Borer, K.; Borisov, A.; Borjanovic, I.; Bos, K.; Boscherini, D.; Bosi, F.; Bosman, M.; Bosteels, M.; Botchev, B.; Boterenbrood, H.; Botterill, D.; Boudreau, J.; Bouhova-Thacker, E. V.; Boulahouache, C.; Bourdarios, C.; Boutemeur, M.; Bouzakis, K.; Boyd, G. R.; Boyd, J.; Boyer, B. H.; Boyko, I. R.; Bozhko, N. I.; Braccini, S.; Braem, A.; Branchini, P.; Brandenburg, G. W.; Brandt, A.; Brandt, O.; Bratzler, U.; Braun, H. M.; Bravo, S.; Brawn, I. P.; Brelier, B.; Bremer, J.; Brenner, R.; Bressler, S.; Breton, D.; Brett, N. D.; Breugnon, P.; Bright-Thomas, P. G.; Brochu, F. M.; Brock, I.; Brock, R.; Brodbeck, T. J.; Brodet, E.; Broggi, F.; Broklova, Z.; Bromberg, C.; Brooijmans, G.; Brouwer, G.; Broz, J.; Brubaker, E.; Bruckman de Renstrom, P. A.; Bruncko, D.; Bruni, A.; Bruni, G.; Bruschi, M.; Buanes, T.; Buchanan, N. J.; Buchholz, P.; Budagov, I. A.; Büscher, V.; Bugge, L.; Buira-Clark, D.; Buis, E. J.; Bujor, F.; Buran, T.; Burckhart, H.; Burckhart-Chromek, D.; Burdin, S.; Burns, R.; Busato, E.; Buskop, J. J. F.; Buszello, K. P.; Butin, F.; Butler, J. M.; Buttar, C. M.; Butterworth, J.; Butterworth, J. M.; Byatt, T.; Cabrera Urbán, S.; Cabruja Casas, E.; Caccia, M.; Caforio, D.; Cakir, O.; Calafiura, P.; Calderini, G.; Calderón Terol, D.; Callahan, J.; Caloba, L. P.; Caloi, R.; Calvet, D.; Camard, A.; Camarena, F.; Camarri, P.; Cambiaghi, M.; Cameron, D.; Cammin, J.; Campabadal Segura, F.; Campana, S.; Canale, V.; Cantero, J.; Capeans Garrido, M. D. M.; Caprini, I.; Caprini, M.; Caprio, M.; Caracinha, D.; Caramarcu, C.; Carcagno, Y.; Cardarelli, R.; Cardeira, C.; Cardiel Sas, L.; Cardini, A.; Carli, T.; Carlino, G.; Carminati, L.; Caron, B.; Caron, S.; Carpentieri, C.; Carr, F. S.; Carter, A. A.; Carter, J. R.; Carvalho, J.; Casadei, D.; Casado, M. P.; Cascella, M.; Caso, C.; Castelo, J.; Castillo Gimenez, V.; Castro, N.; Castrovillari, F.; Cataldi, G.; Cataneo, F.; Catinaccio, A.; Catmore, J. R.; Cattai, A.; Caughron, S.; Cauz, D.; Cavallari, A.; Cavalleri, P.; Cavalli, D.; Cavalli-Sforza, M.; Cavasinni, V.; Ceradini, F.; Cerna, C.; Cernoch, C.; Cerqueira, A. S.; Cerri, A.; Cerutti, F.; Cervetto, M.; Cetin, S. A.; Cevenini, F.; Chalifour, M.; Chamizo llatas, M.; Chan, A.; Chapman, J. W.; Charlton, D. G.; Charron, S.; Chekulaev, S. V.; Chelkov, G. A.; Chen, H.; Chen, L.; Chen, T.; Chen, X.; Cheng, S.; Cheng, T. L.; Cheplakov, A.; Chepurnov, V. F.; Cherkaoui El Moursli, R.; Chesneanu, D.; Cheu, E.; Chevalier, L.; Chevalley, J. L.; Chevallier, F.; Chiarella, V.; Chiefari, G.; Chikovani, L.; Chilingarov, A.; Chiodini, G.; Chouridou, S.; Chren, D.; Christiansen, T.; Christidi, I. A.; Christov, A.; Chu, M. L.; Chudoba, J.; Chuguev, A. G.; Ciapetti, G.; Cicalini, E.; Ciftci, A. K.; Cindro, V.; Ciobotaru, M. D.; Ciocio, A.; Cirilli, M.; Citterio, M.; Ciubancan, M.; Civera, J. V.; Clark, A.; Cleland, W.; Clemens, J. C.; Clement, B. C.; Clément, C.; Clements, D.; Clifft, R. W.; Cobal, M.; Coccaro, A.; Cochran, J.; Coco, R.; Coe, P.; Coelli, S.; Cogneras, E.; Cojocaru, C. D.; Colas, J.; Colijn, A. P.; Collard, C.; Collins-Tooth, C.; Collot, J.; Coluccia, R.; Comune, G.; Conde Muiño, P.; Coniavitis, E.; Consonni, M.; Constantinescu, S.; Conta, C.; Conventi, F. A.; Cook, J.; Cooke, M.; Cooper-Smith, N. J.; Cornelissen, T.; Corradi, M.; Correard, S.; Corso-Radu, A.; Coss, J.; Costa, G.; Costa, M. J.; Costanzo, D.; Costin, T.; Coura Torres, R.; Courneyea, L.; Couyoumtzelis, C.; Cowan, G.; Cox, B. E.; Cox, J.; Cragg, D. A.; Cranmer, K.; Cranshaw, J.; Cristinziani, M.; Crosetti, G.; Cuenca Almenar, C.; Cuneo, S.; Cunha, A.; Curatolo, M.; Curtis, C. J.; Cwetanski, P.; Czyczula, Z.; D'Auria, S.; D'Onofrio, M.; Da Rocha Gesualdi Mello, A.; Da Silva, P. V. M.; Da Silva, R.; Dabrowski, W.; Dael, A.; Dahlhoff, A.; Dai, T.; Dallapiccola, C.; Dallison, S. J.; Dalmau, J.; Daly, C. H.; Dam, M.; Damazio, D.; Dameri, M.; Danielsen, K. M.; Danielsson, H. O.; Dankers, R.; Dannheim, D.; Darbo, G.; Dargent, P.; Daum, C.; Dauvergne, J. P.; David, M.; Davidek, T.; Davidson, N.; Davidson, R.; Dawson, I.; Dawson, J. W.; Daya, R. K.; De, K.; de Asmundis, R.; de Boer, R.; DeCastro, S.; DeGroot, N.; de Jong, P.; de La Broise, X.; DeLa Cruz-Burelo, E.; DeLa Taille, C.; DeLotto, B.; DeOliveira Branco, M.; DePedis, D.; de Saintignon, P.; DeSalvo, A.; DeSanctis, U.; DeSanto, A.; DeVivie DeRegie, J. B.; DeZorzi, G.; Dean, S.; Dedes, G.; Dedovich, D. V.; Defay, P. O.; Degele, R.; Dehchar, M.; Deile, M.; DelPapa, C.; DelPeso, J.; DelPrete, T.; Delagnes, E.; Delebecque, P.; Dell'Acqua, A.; Della Pietra, M.; della Volpe, D.; Delmastro, M.; Delpierre, P.; Delruelle, N.; Delsart, P. A.; Deluca Silberberg, C.; Demers, S.; Demichev, M.; Demierre, P.; Demirköz, B.; Deng, W.; Denisov, S. P.; Dennis, C.; Densham, C. J.; Dentan, M.; Derkaoui, J. E.; Derue, F.; Dervan, P.; Desch, K. K.; Dewhurst, A.; Di Ciaccio, A.; Di Ciaccio, L.; Di Domenico, A.; Di Girolamo, A.; Di Girolamo, B.; Di Luise, S.; Di Mattia, A.; Di Simone, A.; Diaz Gomez, M. M.; Diehl, E. B.; Dietl, H.; Dietrich, J.; Dietsche, W.; Diglio, S.; Dima, M.; Dindar, K.; Dinkespiler, B.; Dionisi, C.; Dipanjan, R.; Dita, P.; Dita, S.; Dittus, F.; Dixon, S. D.; Djama, F.; Djilkibaev, R.; Djobava, T.; do Vale, M. A. B.; Dobbs, M.; Dobinson, R.; Dobos, D.; Dobson, E.; Dobson, M.; Dodd, J.; Dogan, O. B.; Doherty, T.; Doi, Y.; Dolejsi, J.; Dolenc, I.; Dolezal, Z.; Dolgoshein, B. A.; Domingo, E.; Donega, M.; Dopke, J.; Dorfan, D. E.; Dorholt, O.; Doria, A.; Dos Anjos, A.; Dosil, M.; Dotti, A.; Dova, M. T.; Dowell, J. D.; Doyle, A. T.; Drake, G.; Drakoulakos, D.; Drasal, Z.; Drees, J.; Dressnandt, N.; Drevermann, H.; Driouichi, C.; Dris, M.; Drohan, J. G.; Dubbert, J.; Dubbs, T.; Duchovni, E.; Duckeck, G.; Dudarev, A.; Dührssen, M.; Dür, H.; Duerdoth, I. P.; Duffin, S.; Duflot, L.; Dufour, M.-A.; Dumont Dayot, N.; Duran Yildiz, H.; Durand, D.; Dushkin, A.; Duxfield, R.; Dwuznik, M.; Dydak, F.; Dzahini, D.; Díez Cornell, S.; Düren, M.; Ebenstein, W. L.; Eckert, S.; Eckweiler, S.; Eerola, P.; Efthymiopoulos, I.; Egede, U.; Egorov, K.; Ehrenfeld, W.; Eifert, T.; Eigen, G.; Einsweiler, K.; Eisenhandler, E.; Ekelof, T.; Eklund, L. M.; El Kacimi, M.; Ellert, M.; Elles, S.; Ellis, N.; Elmsheuser, J.; Elsing, M.; Ely, R.; Emeliyanov, D.; Engelmann, R.; Engström, M.; Ennes, P.; Epp, B.; Eppig, A.; Epshteyn, V. S.; Ereditato, A.; Eremin, V.; Eriksson, D.; Ermoline, I.; Ernwein, J.; Errede, D.; Errede, S.; Escalier, M.; Escobar, C.; Espinal Curull, X.; Esposito, B.; Esteves, F.; Etienne, F.; Etienvre, A. I.; Etzion, E.; Evans, H.; Evdokimov, V. N.; Evtoukhovitch, P.; Eyring, A.; Fabbri, L.; Fabjan, C. W.; Fabre, C.; Faccioli, P.; Facius, K.; Fadeyev, V.; Fakhrutdinov, R. M.; Falciano, S.; Falleau, I.; Falou, A. C.; Fang, Y.; Fanti, M.; Farbin, A.; Farilla, A.; Farrell, J.; Farthouat, P.; Fasching, D.; Fassi, F.; Fassnacht, P.; Fassouliotis, D.; Fawzi, F.; Fayard, L.; Fayette, F.; Febbraro, R.; Fedin, O. L.; Fedorko, I.; Feld, L.; Feldman, G.; Feligioni, L.; Feng, C.; Feng, E. J.; Fent, J.; Fenyuk, A. B.; Ferencei, J.; Ferguson, D.; Ferland, J.; Fernando, W.; Ferrag, S.; Ferrari, A.; Ferrari, P.; Ferrari, R.; Ferrer, A.; Ferrer, M. L.; Ferrere, D.; Ferretti, C.; Ferro, F.; Fiascaris, M.; Fichet, S.; Fiedler, F.; Filimonov, V.; Filipčič, A.; Filippas, A.; Filthaut, F.; Fincke-Keeler, M.; Finocchiaro, G.; Fiorini, L.; Firan, A.; Fischer, P.; Fisher, M. J.; Fisher, S. M.; Flaminio, V.; Flammer, J.; Flechl, M.; Fleck, I.; Flegel, W.; Fleischmann, P.; Fleischmann, S.; Fleta Corral, C. M.; Fleuret, F.; Flick, T.; Flix, J.; Flores Castillo, L. R.; Flowerdew, M. J.; Föhlisch, F.; Fokitis, M.; Fonseca Martin, T. M.; Fopma, J.; Forbush, D. A.; Formica, A.; Foster, J. M.; Fournier, D.; Foussat, A.; Fowler, A. J.; Fox, H.; Francavilla, P.; Francis, D.; Franz, S.; Fraser, J. T.; Fraternali, M.; Fratianni, S.; Freestone, J.; French, R. S.; Fritsch, K.; Froidevaux, D.; Frost, J. A.; Fukunaga, C.; Fulachier, J.; Fullana Torregrosa, E.; Fuster, J.; Gabaldon, C.; Gadomski, S.; Gagliardi, G.; Gagnon, P.; Gallas, E. J.; Gallas, M. V.; Gallop, B. J.; Gan, K. K.; Gannaway, F. C.; Gao, Y. S.; Gapienko, V. A.; Gaponenko, A.; Garciá, C.; Garcia-Sciveres, M.; Garcìa Navarro, J. E.; Garde, V.; Gardner, R. W.; Garelli, N.; Garitaonandia, H.; Garonne, V. G.; Garvey, J.; Gatti, C.; Gaudio, G.; Gaumer, O.; Gautard, V.; Gauzzi, P.; Gavrilenko, I. L.; Gay, C.; Gayde, J.-C.; Gazis, E. N.; Gazo, E.; Gee, C. N. P.; Geich-Gimbel, C.; Gellerstedt, K.; Gemme, C.; Genest, M. H.; Gentile, S.; George, M. A.; George, S.; Gerlach, P.; Gernizky, Y.; Geweniger, C.; Ghazlane, H.; Ghete, V. M.; Ghez, P.; Ghodbane, N.; Giacobbe, B.; Giagu, S.; Giakoumopoulou, V.; Giangiobbe, V.; Gianotti, F.; Gibbard, B.; Gibson, A.; Gibson, M. D.; Gibson, S. M.; Gieraltowski, G. F.; Gil Botella, I.; Gilbert, L. M.; Gilchriese, M.; Gildemeister, O.; Gilewsky, V.; Gillman, A. R.; Gingrich, D. M.; Ginzburg, J.; Giokaris, N.; Giordani, M. P.; Girard, C. G.; Giraud, P. F.; Girtler, P.; Giugni, D.; Giusti, P.; Gjelsten, B. K.; Glasman, C.; Glazov, A.; Glitza, K. W.; Glonti, G. L.; Gnanvo, K. G.; Godlewski, J.; Göpfert, T.; Gössling, C.; Göttfert, T.; Goldfarb, S.; Goldin, D.; Goldschmidt, N.; Golling, T.; Gollub, N. P.; Golonka, P. J.; Golovnia, S. N.; Gomes, A.; Gomes, J.; Gonçalo, R.; Gongadze, A.; Gonidec, A.; Gonzalez, S.; González de la Hoz, S.; González Millán, V.; Gonzalez Silva, M. L.; Gonzalez-Pineiro, B.; González-Sevilla, S.; Goodrick, M. J.; Goodson, J. J.; Goossens, L.; Gorbounov, P. A.; Gordeev, A.; Gordon, H.; Gorelov, I.; Gorfine, G.; Gorini, B.; Gorini, E.; Gorišek, A.; Gornicki, E.; Gorokhov, S. A.; Gorski, B. T.; Goryachev, S. V.; Goryachev, V. N.; Gosselink, M.; Gostkin, M. I.; Gouanère, M.; Gough Eschrich, I.; Goujdami, D.; Goulette, M.; Gousakov, I.; Gouveia, J.; Gowdy, S.; Goy, C.; Grabowska-Bold, I.; Grabski, V.; Grafström, P.; Grah, C.; Grahn, K.-J.; Grancagnolo, F.; Grancagnolo, S.; Grassmann, H.; Gratchev, V.; Gray, H. M.; Graziani, E.; Green, B.; Greenall, A.; Greenfield, D.; Greenwood, D.; Gregor, I. M.; Grewal, A.; Griesmayer, E.; Grigalashvili, N.; Grigson, C.; Grillo, A. A.; Grimaldi, F.; Grimm, K.; Gris, P. L. Y.; Grishkevich, Y.; Groenstege, H.; Groer, L. S.; Grognuz, J.; Groh, M.; Gross, E.; Grosse-Knetter, J.; Grothe, M. E. M.; Grudzinski, J.; Gruse, C.; Gruwe, M.; Grybel, K.; Grybos, P.; Gschwendtner, E. M.; Guarino, V. J.; Guicheney, C. J.; Guilhem, G.; Guillemin, T.; Gunther, J.; Guo, B.; Gupta, A.; Gurriana, L.; Gushchin, V. N.; Gutierrez, P.; Guy, L.; Guyot, C.; Gwenlan, C.; Gwilliam, C. B.; Haas, A.; Haas, S.; Haber, C.; Haboubi, G.; Hackenburg, R.; Hadash, E.; Hadavand, H. K.; Haeberli, C.; Härtel, R.; Haggerty, R.; Hahn, F.; Haider, S.; Hajduk, Z.; Hakimi, M.; Hakobyan, H.; Hakobyan, H.; Haller, J.; Hallewell, G. D.; Hallgren, B.; Hamacher, K.; Hamilton, A.; Han, H.; Han, L.; Hanagaki, K.; Hance, M.; Hanke, P.; Hansen, C. J.; Hansen, F. H.; Hansen, J. R.; Hansen, J. B.; Hansen, J. D.; Hansen, P. H.; Hansl-Kozanecka, T.; Hanson, G.; Hansson, P.; Hara, K.; Harder, S.; Harel, A.; Harenberg, T.; Harper, R.; Hart, J. C.; Hart, R. G. G.; Hartjes, F.; Hartman, N.; Haruyama, T.; Harvey, A.; Hasegawa, Y.; Hashemi, K.; Hassani, S.; Hatch, M.; Hatley, R. W.; Haubold, T. G.; Hauff, D.; Haug, F.; Haug, S.; Hauschild, M.; Hauser, R.; Hauviller, C.; Havranek, M.; Hawes, B. M.; Hawkings, R. J.; Hawkins, D.; Hayler, T.; Hayward, H. S.; Haywood, S. J.; Hazen, E.; He, M.; He, Y. P.; Head, S. J.; Hedberg, V.; Heelan, L.; Heinemann, F. E. W.; Heldmann, M.; Hellman, S.; Helsens, C.; Henderson, R. C. W.; Hendriks, P. J.; Henriques Correia, A. M.; Henrot-Versille, S.; Henry-Couannier, F.; Henß, T.; Herten, G.; Hertenberger, R.; Hervas, L.; Hess, M.; Hessey, N. P.; Hicheur, A.; Hidvegi, A.; Higón-Rodriguez, E.; Hill, D.; Hill, J.; Hill, J. C.; Hill, N.; Hillier, S. J.; Hinchliffe, I.; Hindson, D.; Hinkelbein, C.; Hodges, T. A.; Hodgkinson, M. C.; Hodgson, P.; Hoecker, A.; Hoeferkamp, M. R.; Hoffman, J.; Hoffmann, A. E.; Hoffmann, D.; Hoffmann, H. F.; Holder, M.; Hollins, T. I.; Hollyman, G.; Holmes, A.; Holmgren, S. O.; Holt, R.; Holtom, E.; Holy, T.; Homer, R. J.; Homma, Y.; Homola, P.; Honerbach, W.; Honma, A.; Hooton, I.; Horazdovsky, T.; Horn, C.; Horvat, S.; Hostachy, J.-Y.; Hott, T.; Hou, S.; Houlden, M. A.; Hoummada, A.; Hover, J.; Howell, D. F.; Hrivnac, J.; Hruska, I.; Hryn'ova, T.; Huang, G. S.; Hubacek, Z.; Hubaut, F.; Huegging, F.; Huffman, B. T.; Hughes, E.; Hughes, G.; Hughes-Jones, R. E.; Hulsbergen, W.; Hurst, P.; Hurwitz, M.; Huse, T.; Huseynov, N.; Huston, J.; Huth, J.; Iacobucci, G.; Ibbotson, M.; Ibragimov, I.; Ichimiya, R.; Iconomidou-Fayard, L.; Idarraga, J.; Idzik, M.; Iengo, P.; Iglesias Escudero, M. C.; Igonkina, O.; Ikegami, Y.; Ikeno, M.; Ilchenko, Y.; Ilyushenka, Y.; Imbault, D.; Imbert, P.; Imhaeuser, M.; Imori, M.; Ince, T.; Inigo-Golfin, J.; Inoue, K.; Ioannou, P.; Iodice, M.; Ionescu, G.; Ishii, K.; Ishino, M.; Ishizawa, Y.; Ishmukhametov, R.; Issever, C.; Ito, H.; Ivashin, A. V.; Iwanski, W.; Iwasaki, H.; Izen, J. M.; Izzo, V.; Jackson, J.; Jackson, J. N.; Jaekel, M.; Jagielski, S.; Jahoda, M.; Jain, V.; Jakobs, K.; Jakubek, J.; Jansen, E.; Jansweijer, P. P. M.; Jared, R. C.; Jarlskog, G.; Jarp, S.; Jarron, P.; Jelen, K.; Jen-La Plante, I.; Jenni, P.; Jeremie, A.; Jez, P.; Jézéquel, S.; Jiang, Y.; Jin, G.; Jin, S.; Jinnouchi, O.; Joffe, D.; Johansen, L. G.; Johansen, M.; Johansson, K. E.; Johansson, P.; Johns, K. A.; Jon-And, K.; Jones, M.; Jones, R.; Jones, R. W. L.; Jones, T. W.; Jones, T. J.; Jones, A.; Jonsson, O.; Joo, K. K.; Joos, D.; Joos, M.; Joram, C.; Jorgensen, S.; Joseph, J.; Jovanovic, P.; Junnarkar, S. S.; Juranek, V.; Jussel, P.; Kabachenko, V. V.; Kabana, S.; Kaci, M.; Kaczmarska, A.; Kado, M.; Kagan, H.; Kagawa, S.; Kaiser, S.; Kajomovitz, E.; Kakurin, S.; Kalinovskaya, L. V.; Kama, S.; Kambara, H.; Kanaya, N.; Kandasamy, A.; Kandasamy, S.; Kaneda, M.; Kantserov, V. A.; Kanzaki, J.; Kaplan, B.; Kapliy, A.; Kaplon, J.; Karagounis, M.; Karagoz Unel, M.; Karr, K.; Karst, P.; Kartvelishvili, V.; Karyukhin, A. N.; Kashif, L.; Kasmi, A.; Kass, R. D.; Kastanas, A.; Kataoka, M.; Kataoka, Y.; Katsoufis, E.; Katunin, S.; Kawagoe, K.; Kawai, M.; Kawamoto, T.; Kayumov, F.; Kazanin, V. A.; Kazarinov, M. Y.; Kazarov, A.; Kazi, S. I.; Keates, J. R.; Keeler, R.; Keener, P. T.; Kehoe, R.; Keil, M.; Kekelidze, G. D.; Kelly, M.; Kennedy, J.; Kenyon, M.; Kepka, O.; Kerschen, N.; Kerševan, B. P.; Kersten, S.; Ketterer, C.; Khakzad, M.; Khalilzade, F.; Khandanyan, H.; Khanov, A.; Kharchenko, D.; Khodinov, A.; Kholodenko, A. G.; Khomich, A.; Khomutnikov, V. P.; Khoriauli, G.; Khovanskiy, N.; Khovanskiy, V.; Khramov, E.; Khubua, J.; Kieft, G.; Kierstead, J. A.; Kilvington, G.; Kim, H.; Kim, H.; Kim, S. H.; Kind, P.; King, B. T.; Kirk, J.; Kirsch, G. P.; Kirsch, L. E.; Kiryunin, A. E.; Kisielewska, D.; Kisielewski, B.; Kittelmann, T.; Kiver, A. M.; Kiyamura, H.; Kladiva, E.; Klaiber-Lodewigs, J.; Kleinknecht, K.; Klier, A.; Klimentov, A.; Kline, C. R.; Klingenberg, R.; Klinkby, E. B.; Klioutchnikova, T.; Klok, P. F.; Klous, S.; Kluge, E.-E.; Kluit, P.; Klute, M.; Kluth, S.; Knecht, N. K.; Kneringer, E.; Knezo, E.; Knobloch, J.; Ko, B. R.; Kobayashi, T.; Kobel, M.; Kodys, P.; König, A. C.; König, S.; Köpke, L.; Koetsveld, F.; Koffas, T.; Koffeman, E.; Kohout, Z.; Kohriki, T.; Kokott, T.; Kolachev, G. M.; Kolanoski, H.; Kolesnikov, V.; Koletsou, I.; Kollefrath, M.; Kolos, S.; Kolya, S. D.; Komar, A. A.; Komaragiri, J. R.; Kondo, T.; Kondo, Y.; Kondratyeva, N. V.; Kono, T.; Kononov, A. I.; Konoplich, R.; Konovalov, S. P.; Konstantinidis, N.; Kootz, A.; Koperny, S.; Kopikov, S. V.; Korcyl, K.; Kordas, K.; Koreshev, V.; Korn, A.; Korolkov, I.; Korotkov, V. A.; Korsmo, H.; Kortner, O.; Kostrikov, M. E.; Kostyukhin, V. V.; Kotamäki, M. J.; Kotchetkov, D.; Kotov, S.; Kotov, V. M.; Kotov, K. Y.; Kourkoumelis, C.; Koutsman, A.; Kovalenko, S.; Kowalewski, R.; Kowalski, H.; Kowalski, T. Z.; Kozanecki, W.; Kozhin, A. S.; Kral, V.; Kramarenko, V.; Kramberger, G.; Kramer, A.; Krasel, O.; Krasny, M. W.; Krasznahorkay, A.; Krepouri, A.; Krieger, P.; Krivkova, P.; Krobath, G.; Kroha, H.; Krstic, J.; Kruchonak, U.; Krüger, H.; Kruger, K.; Krumshteyn, Z. V.; Kubik, P.; Kubischta, W.; Kubota, T.; Kudin, L. G.; Kudlaty, J.; Kugel, A.; Kuhl, T.; Kuhn, D.; Kukhtin, V.; Kulchitsky, Y.; Kundu, N.; Kupco, A.; Kupper, M.; Kurashige, H.; Kurchaninov, L. L.; Kurochkin, Y. A.; Kus, V.; Kuykendall, W.; Kuzhir, P.; Kuznetsova, E. K.; Kvasnicka, O.; Kwee, R.; La Marra, D.; La Rosa, M.; La Rotonda, L.; Labarga, L.; Labbe, J. A.; Lacasta, C.; Lacava, F.; Lacker, H.; Lacour, D.; Lacuesta, V. R.; Ladygin, E.; Lafaye, R.; Laforge, B.; Lagouri, T.; Lai, S.; Lamanna, E.; Lambacher, M.; Lambert, F.; Lampl, W.; Lancon, E.; Landgraf, U.; Landon, M. P. J.; Landsman, H.; Langstaff, R. R.; Lankford, A. J.; Lanni, F.; Lantzsch, K.; Lanza, A.; Lapin, V. V.; Laplace, S.; Laporte, J. F.; Lara, V.; Lari, T.; Larionov, A. V.; Lasseur, C.; Lau, W.; Laurelli, P.; Lavorato, A.; Lavrijsen, W.; Lazarev, A. B.; LeBihan, A.-C.; LeDortz, O.; LeManer, C.; LeVine, M.; Leahu, L.; Leahu, M.; Lebel, C.; Lechowski, M.; LeCompte, T.; Ledroit-Guillon, F.; Lee, H.; Lee, J. S. H.; Lee, S. C.; Lefebvre, M.; Lefevre, R. P.; Legendre, M.; Leger, A.; LeGeyt, B. C.; Leggett, C.; Lehmacher, M.; Lehmann Miotto, G.; Lehto, M.; Leitner, R.; Lelas, D.; Lellouch, D.; Leltchouk, M.; Lendermann, V.; Leney, K. J. C.; Lenz, T.; Lenzen, G.; Lepidis, J.; Leroy, C.; Lessard, J.-R.; Lesser, J.; Lester, C. G.; Letheren, M.; Fook Cheong, A. Leung; Levêque, J.; Levin, D.; Levinson, L. J.; Levitski, M. S.; Lewandowska, M.; Leyton, M.; Li, J.; Li, W.; Liabline, M.; Liang, Z.; Liang, Z.; Liberti, B.; Lichard, P.; Liebig, W.; Lifshitz, R.; Liko, D.; Lim, H.; Limper, M.; Lin, S. C.; Lindahl, A.; Linde, F.; Lindquist, L.; Lindsay, S. W.; Linhart, V.; Lintern, A. J.; Liolios, A.; Lipniacka, A.; Liss, T. M.; Lissauer, A.; List, J.; Litke, A. M.; Liu, S.; Liu, T.; Liu, Y.; Livan, M.; Lleres, A.; Llosá Llácer, G.; Lloyd, S. L.; Lobkowicz, F.; Loch, P.; Lockman, W. S.; Loddenkoetter, T.; Loebinger, F. K.; Loginov, A.; Loh, C. W.; Lohse, T.; Lohwasser, K.; Lokajicek, M.; Loken, J.; Lokwitz, S.; Long, M. C.; Lopes, L.; Lopez Mateos, D.; Losty, M. J.; Lou, X.; Loureiro, K. F.; Lovas, L.; Love, J.; Lowe, A.; Lozano Fantoba, M.; Lu, F.; Lu, J.; Lu, L.; Lubatti, H. J.; Lucas, S.; Luci, C.; Lucotte, A.; Ludwig, A.; Ludwig, I.; Ludwig, J.; Luehring, F.; Lüke, D.; Luijckx, G.; Luisa, L.; Lumb, D.; Luminari, L.; Lund, E.; Lund-Jensen, B.; Lundberg, B.; Lundquist, J.; Lupi, A.; Lupu, N.; Lutz, G.; Lynn, D.; Lynn, J.; Lys, J.; Lysan, V.; Lytken, E.; López-Amengual, J. M.; Ma, H.; Ma, L. L.; Maaß en, M.; Maccarrone, G.; Mace, G. G. R.; Macina, D.; Mackeprang, R.; Macpherson, A.; MacQueen, D.; Macwaters, C.; Madaras, R. J.; Mader, W. F.; Maenner, R.; Maeno, T.; Mättig, P.; Mättig, S.; Magrath, C. A.; Mahalalel, Y.; Mahboubi, K.; Mahout, G.; Maidantchik, C.; Maio, A.; Mair, G. M.; Mair, K.; Makida, Y.; Makowiecki, D.; Malecki, P.; Maleev, V. P.; Malek, F.; Malon, D.; Maltezos, S.; Malychev, V.; Malyukov, S.; Mambelli, M.; Mameghani, R.; Mamuzic, J.; Manabe, A.; Manara, A.; Manca, G.; Mandelli, L.; Mandić, I.; Mandl, M.; Maneira, J.; Maneira, M.; Mangeard, P. S.; Mangin-Brinet, M.; Manjavidze, I. D.; Mann, W. A.; Manolopoulos, S.; Manousakis-Katsikakis, A.; Mansoulie, B.; Manz, A.; Mapelli, A.; Mapelli, L.; March, L.; Marchand, J. F.; Marchesotti, M.; Marcisovsky, M.; Marin, A.; Marques, C. N.; Marroquim, F.; Marshall, R.; Marshall, Z.; Martens, F. K.; Garcia, S. Marti i.; Martin, A. J.; Martin, B.; Martin, B.; Martin, F. F.; Martin, J. P.; Martin, Ph; Martinez, G.; Martínez Lacambra, C.; Martinez Outschoorn, V.; Martini, A.; Martins, J.; Maruyama, T.; Marzano, F.; Mashimo, T.; Mashinistov, R.; Masik, J.; Maslennikov, A. L.; Maß, M.; Massa, I.; Massaro, G.; Massol, N.; Mathes, M.; Matheson, J.; Matricon, P.; Matsumoto, H.; Matsunaga, H.; Maugain, J. M.; Maxfield, S. J.; May, E. N.; Mayer, J. K.; Mayri, C.; Mazini, R.; Mazzanti, M.; Mazzanti, P.; Mazzoni, E.; Mazzucato, F.; McKee, S. P.; McCarthy, R. L.; McCormick, C.; McCubbin, N. A.; McDonald, J.; McFarlane, K. W.; McGarvie, S.; McGlone, H.; McLaren, R. A.; McMahon, S. J.; McMahon, T. R.; McMahon, T. J.; McPherson, R. A.; Mechtel, M.; Meder-Marouelli, D.; Medinnis, M.; Meera-Lebbai, R.; Meessen, C.; Mehdiyev, R.; Mehta, A.; Meier, K.; Meinhard, H.; Meinhardt, J.; Meirosu, C.; Meisel, F.; Melamed-Katz, A.; Mellado Garcia, B. R.; Mendes Jorge, P.; Mendez, P.; Menke, S.; Menot, C.; Meoni, E.; Merkl, D.; Merola, L.; Meroni, C.; Merritt, F. S.; Messmer, I.; Metcalfe, J.; Meuser, S.; Meyer, J.-P.; Meyer, T. C.; Meyer, W. T.; Mialkovski, V.; Michelotto, M.; Micu, L.; Middleton, R.; Miele, P.; Migliaccio, A.; Mijović, L.; Mikenberg, G.; Mikestikova, M.; Mikestikova, M.; Mikulec, B.; Mikuž, M.; Miller, D. W.; Miller, R. J.; Miller, W.; Milosavljevic, M.; Milstead, D. A.; Mima, S.; Minaenko, A. A.; Minano, M.; Minashvili, I. A.; Mincer, A. I.; Mindur, B.; Mineev, M.; Mir, L. M.; Mirabelli, G.; Miralles Verge, L.; Misawa, S.; Miscetti, S.; Misiejuk, A.; Mitra, A.; Mitrofanov, G. Y.; Mitsou, V. A.; Miyagawa, P. S.; Miyazaki, Y.; Mjörnmark, J. U.; Mkrtchyan, S.; Mladenov, D.; Moa, T.; Moch, M.; Mochizuki, A.; Mockett, P.; Modesto, P.; Moed, S.; Mönig, K.; Möser, N.; Mohn, B.; Mohr, W.; Mohrdieck-Möck, S.; Moisseev, A. M.; Moles Valls, R. M.; Molina-Perez, J.; Moll, A.; Moloney, G.; Mommsen, R.; Moneta, L.; Monnier, E.; Montarou, G.; Montesano, S.; Monticelli, F.; Moore, R. W.; Moore, T. B.; Moorhead, G. F.; Moraes, A.; Morel, J.; Moreno, A.; Moreno, D.; Morettini, P.; Morgan, D.; Morii, M.; Morin, J.; Morley, A. K.; Mornacchi, G.; Morone, M.-C.; Morozov, S. V.; Morris, E. J.; Morris, J.; Morrissey, M. C.; Moser, H. G.; Mosidze, M.; Moszczynski, A.; Mouraviev, S. V.; Mouthuy, T.; Moye, T. H.; Moyse, E. J. W.; Mueller, J.; Müller, M.; Muijs, A.; Muller, T. R.; Munar, A.; Munday, D. J.; Murakami, K.; Murillo Garcia, R.; Murray, W. J.; Myagkov, A. G.; Myska, M.; Nagai, K.; Nagai, Y.; Nagano, K.; Nagasaka, Y.; Nairz, A. M.; Naito, D.; Nakamura, K.; Nakamura, Y.; Nakano, I.; Nanava, G.; Napier, A.; Nassiakou, M.; Nasteva, I.; Nation, N. R.; Naumann, T.; Nauyock, F.; Nderitu, S. K.; Neal, H. A.; Nebot, E.; Nechaeva, P.; Neganov, A.; Negri, A.; Negroni, S.; Nelson, C.; Nemecek, S.; Nemethy, P.; Nepomuceno, A. A.; Nessi, M.; Nesterov, S. Y.; Neukermans, L.; Nevski, P.; Newcomer, F. M.; Nichols, A.; Nicholson, C.; Nicholson, R.; Nickerson, R. B.; Nicolaidou, R.; Nicoletti, G.; Nicquevert, B.; Niculescu, M.; Nielsen, J.; Niinikoski, T.; Niinimaki, M. J.; Nikitin, N.; Nikolaev, K.; Nikolic-Audit, I.; Nikolopoulos, K.; Nilsen, H.; Nilsson, B. S.; Nilsson, P.; Nisati, A.; Nisius, R.; Nodulman, L. J.; Nomachi, M.; Nomoto, H.; Noppe, J.-M.; Nordberg, M.; Norniella Francisco, O.; Norton, P. R.; Novakova, J.; Nowak, M.; Nozaki, M.; Nunes, R.; Nunes Hanninger, G.; Nunnemann, T.; Nyman, T.; O'Connor, P.; O'Neale, S. W.; O'Neil, D. C.; O'Neill, M.; O'Shea, V.; Oakham, F. G.; Oberlack, H.; Obermaier, M.; Oberson, P.; Ochi, A.; Ockenfels, W.; Odaka, S.; Odenthal, I.; Odino, G. A.; Ogren, H.; Oh, S. H.; Ohshima, T.; Ohshita, H.; Okawa, H.; Olcese, M.; Olchevski, A. G.; Oliver, C.; Oliver, J.; Olivo Gomez, M.; Olszewski, A.; Olszowska, J.; Omachi, C.; Onea, A.; Onofre, A.; Oram, C. J.; Ordonez, G.; Oreglia, M. J.; Orellana, F.; Oren, Y.; Orestano, D.; Orlov, I. O.; Orr, R. S.; Orsini, F.; Osborne, L. S.; Osculati, B.; Osuna, C.; Otec, R.; Othegraven, R.; Ottewell, B.; Ould-Saada, F.; Ouraou, A.; Ouyang, Q.; Øye, O. K.; Ozcan, V. E.; Ozone, K.; Ozturk, N.; Pacheco Pages, A.; Padhi, S.; Padilla Aranda, C.; Paganis, E.; Paige, F.; Pailler, P. M.; Pajchel, K.; Palestini, S.; Palla, J.; Pallin, D.; Palmer, M. J.; Pan, Y. B.; Panikashvili, N.; Panin, V. N.; Panitkin, S.; Pantea, D.; Panuskova, M.; Paolone, V.; Paoloni, A.; Papadopoulos, I.; Papadopoulou, T.; Park, I.; Park, W.; Parker, M. A.; Parker, S.; Parkman, C.; Parodi, F.; Parsons, J. A.; Parzefall, U.; Pasqualucci, E.; Passardi, G.; Passeri, A.; Passmore, M. S.; Pastore, F.; Pastore, Fr; Pataraia, S.; Pate, D.; Pater, J. R.; Patricelli, S.; Pauly, T.; Pauna, E.; Peak, L. S.; Peeters, S. J. M.; Peez, M.; Pei, E.; Peleganchuk, S. V.; Pellegrini, G.; Pengo, R.; Pequenao, J.; Perantoni, M.; Perazzo, A.; Pereira, A.; Perepelkin, E.; Perera, V. J. O.; Perez Codina, E.; Perez Reale, V.; Peric, I.; Perini, L.; Pernegger, H.; Perrin, E.; Perrino, R.; Perrodo, P.; Perrot, G.; Perus, P.; Peshekhonov, V. D.; Petereit, E.; Petersen, J.; Petersen, T. C.; Petit, P. J. F.; Petridou, C.; Petrolo, E.; Petrucci, F.; Petti, R.; Pezzetti, M.; Pfeifer, B.; Phan, A.; Phillips, A. W.; Phillips, P. W.; Piacquadio, G.; Piccinini, M.; Pickford, A.; Piegaia, R.; Pier, S.; Pilcher, J. E.; Pilkington, A. D.; Pimenta Dos Santos, M. A.; Pina, J.; Pinfold, J. L.; Ping, J.; Pinhão, J.; Pinto, B.; Pirotte, O.; Placakyte, R.; Placci, A.; Plamondon, M.; Plano, W. G.; Pleier, M.-A.; Pleskach, A. V.; Podkladkin, S.; Podlyski, F.; Poffenberger, P.; Poggioli, L.; Pohl, M.; Polak, I.; Polesello, G.; Policicchio, A.; Polini, A.; Polychronakos, V.; Pomarede, D. M.; Pommès, K.; Ponsot, P.; Pontecorvo, L.; Pope, B. G.; Popescu, R.; Popovic, D. S.; Poppleton, A.; Popule, J.; Portell Bueso, X.; Posch, C.; Pospelov, G. E.; Pospichal, P.; Pospisil, S.; Postranecky, M.; Potrap, I. N.; Potter, C. J.; Poulard, G.; Pousada, A.; Poveda, J.; Prabhu, R.; Pralavorio, P.; Prasad, S.; Prast, J.; Prat, S.; Prata, M.; Pravahan, R.; Preda, T.; Pretzl, K.; Pribyl, L.; Price, D.; Price, L. E.; Price, M. J.; Prichard, P. M.; Prieur, D.; Primavera, M.; Primor, D.; Prokofiev, K.; Prosso, E.; Proudfoot, J.; Przysiezniak, H.; Puigdengoles, C.; Purdham, J.; Purohit, M.; Puzo, P.; Pylaev, A. N.; Pylypchenko, Y.; Qi, M.; Qian, J.; Qian, W.; Qian, Z.; Qing, D.; Quadt, A.; Quarrie, D. R.; Quayle, W. B.; Rabbers, J. J.; Radeka, V.; Rafi, J. M.; Ragusa, F.; Rahimi, A. M.; Rahm, D.; Raine, C.; Raith, B.; Rajagopalan, S.; Rajek, S.; Rammer, H.; Ramstedt, M.; Rangod, S.; Ratoff, P. N.; Raufer, T.; Rauscher, F.; Rauter, E.; Raymond, M.; Reads, A. L.; Rebuzzi, D.; Redlinger, G. R.; Reeves, K.; Rehak, M.; Reichold, A.; Reinherz-Aronis, E.; Reisinger, I.; Reljic, D.; Rembser, C.; Ren, Z.; Renaudin-Crepe, S. R. C.; Renkel, P.; Rensch, B.; Rescia, S.; Rescigno, M.; Resconi, S.; Resende, B.; Rewiersma, P.; Rey, J.; Rey-Campagnolle, M.; Rezaie, E.; Reznicek, P.; Richards, R. A.; Richer, J.-P.; Richter, R. H.; Richter, R.; Richter-Was, E.; Ridel, M.; Riegler, W.; Rieke, S.; Rijpstra, M.; Rijssenbeek, M.; Rimoldi, A.; Rios, R. R.; Riu Dachs, I.; Rivline, M.; Rivoltella, G.; Rizatdinova, F.; Robertson, S. H.; Robichaud-Veronneau, A.; Robins, S.; Robinson, D.; Robson, A.; Rochford, J. H.; Roda, C.; Rodier, S.; Roe, S.; Røhne, O.; Rohrbach, F.; Roldán, J.; Rolli, S.; Romance, J. B.; Romaniouk, A.; Romanov, V. M.; Romeo, G.; Roos, L.; Ros, E.; Rosati, S.; Rosenbaum, F.; Rosenbaum, G. A.; Rosenberg, E. I.; Rosselet, L.; Rossi, L. P.; Rossi, L.; Rotaru, M.; Rothberg, J.; Rottländer, I.; Rousseau, D.; Rozanov, A.; Rozen, Y.; Ruber, R.; Ruckert, B.; Rudolph, G.; Rühr, F.; Ruggieri, F.; Ruggiero, G.; Ruiz, H.; Ruiz-Martinez, A.; Rulikowska-Zarebska, E.; Rumiantsev, V.; Rumyantsev, L.; Runge, K.; Runolfsson, O.; Rusakovich, N. A.; Rust, D. R.; Rutherfoord, J. P.; Ruwiedel, C.; Ryabov, Y. F.; Ryadovikov, V.; Ryan, P.; Rybkine, G.; da Costa, J. Sá; Saavedra, A. F.; Saboumazrag, S.; F-W Sadrozinski, H.; Sadykov, R.; Sakamoto, H.; Sala, P.; Salamon, A.; Saleem, M.; Salihagic, D.; Salt, J.; Saltó Bauza, O.; Salvachúa Ferrando, B. M.; Salvatore, D.; Salzburger, A.; Sampsonidis, D.; Samset, B. H.; Sánchez Sánchez, C. A.; Sanchis Lozano, M. A.; Sanchis Peris, E.; Sandaker, H.; Sander, H. G.; Sandhoff, M.; Sandvoss, S.; Sankey, D. P. C.; Sanny, B.; Sansone, S.; Sansoni, A.; Santamarina Rios, C.; Santander, J.; Santi, L.; Santoni, C.; Santonico, R.; Santos, J.; Sapinski, M.; Saraiva, J. G.; Sarri, F.; Sasaki, O.; Sasaki, T.; Sasao, N.; Satsounkevitch, I.; Sauvage, D.; Sauvage, G.; Savard, P.; Savine, A. Y.; Savinov, V.; Savoy-Navarro, A.; Savva, P.; Saxon, D. H.; Says, L. P.; Sbarra, C.; Sbrissa, E.; Sbrizzi, A.; Scannicchio, D. A.; Schaarschmidt, J.; Schacht, P.; Schäfer, U.; Schaffer, A. C.; Schaile, D.; Schaller, M.; Schamov, A. G.; Schegelsky, V. A.; Scheirich, D.; Schernau, M.; Scherzer, M. I.; Schiavi, C.; Schick, H.; Schieck, J.; Schieferdecker, P.; Schioppa, M.; Schlager, G.; Schlenker, S.; Schlereth, J. L.; Schmid, P.; Schmidt, M. P.; Schmitt, C.; Schmitt, K.; Schmitz, M.; Schmücker, H.; Schoerner, T.; Scholte, R. C.; Schott, M.; Schouten, D.; Schram, M.; Schricker, A.; Schroff, D.; Schuh, S.; Schuijlenburg, H. W.; Schuler, G.; Schultes, J.; Schultz-Coulon, H.-C.; Schumacher, J.; Schumacher, M.; Schune, Ph; Schwartzman, A.; Schweiger, D.; Schwemling, Ph; Schwick, C.; Schwienhorst, R.; Schwierz, R.; Schwindling, J.; Scott, W. G.; Secker, H.; Sedykh, E.; Seguin-Moreau, N.; Segura, E.; Seidel, S. C.; Seiden, A.; Seixas, J. M.; Sekhniaidze, G.; Seliverstov, D. M.; Selldén, B.; Seman, M.; Semprini-Cesari, N.; Serfon, C.; Serin, L.; Seuster, R.; Severini, H.; Sevior, M. E.; Sexton, K. A.; Sfyrla, A.; Shah, T. P.; Shan, L.; Shank, J. T.; Shapiro, M.; Shatalov, P. B.; Shaver, L.; Shaw, C.; Shears, T. G.; Sherwood, P.; Shibata, A.; Shield, P.; Shilov, S.; Shimojima, M.; Shin, T.; Shiyakova, M.; Shmeleva, A.; Shoa, M.; Shochet, M. J.; Shupe, M. A.; Sicho, P.; Sidoti, A.; Siebel, A.; Siebel, M.; Siegrist, J.; Sijacki, D.; Silva, J.; Silverstein, S. B.; Simak, V.; Simic, Lj; Simion, S.; Simmons, B.; Simonyan, M.; Sinervo, P.; Sipica, V.; Siragusa, G.; Sisakyan, A. N.; Sivoklokov, S.; Sjölin, J.; Skubic, P.; Skvorodnev, N.; Slattery, P.; Slavicek, T.; Sliwa, K.; Sloan, T. J.; Sloper, J.; Smakhtin, V.; Small, A.; Smirnov, S. Yu; Smirnov, Y.; Smirnova, L.; Smirnova, O.; Smith, N. A.; Smith, B. C.; Smith, D. S.; Smith, J.; Smith, K. M.; Smith, B.; Smizanska, M.; Smolek, K.; Snesarev, A. A.; Snow, S. W.; Snow, J.; Snuverink, J.; Snyder, S.; Soares, M.; Soares, S.; Sobie, R.; Sodomka, J.; Söderberg, M.; Soffer, A.; Solans, C. A.; Solar, M.; Sole, D.; Solfaroli Camillocci, E.; Solodkov, A. A.; Solov'yanov, O. V.; Soloviev, I.; Soluk, R.; Sondericker, J.; Sopko, V.; Sopko, B.; Sorbi, M.; Soret Medel, J.; Sosebee, M.; Sosnovtsev, V. V.; Sospedra Suay, L.; Soukharev, A.; Soukup, J.; Spagnolo, S.; Spano, F.; Speckmayer, P.; Spegel, M.; Spencer, E.; Spighi, R.; Spigo, G.; Spila, F.; Spiriti, E.; Spiwoks, R.; Spogli, L.; Spousta, M.; Sprachmann, G.; Spurlock, B.; St. Denis, R. D.; Stahl, T.; Staley, R. J.; Stamen, R.; Stancu, S. N.; Stanecka, E.; Stanek, R. W.; Stanescu, C.; Stapnes, S.; Starchenko, E. A.; Staroba, P.; Stastny, J.; Staude, A.; Stavina, P.; Stavrianakou, M.; Stavropoulos, G.; Stefanidis, E.; Steffens, J. L.; Stekl, I.; Stelzer, H. J.; Stenzel, H.; Stewart, G.; Stewart, T. D.; Stiller, W.; Stockmanns, T.; Stodulski, M.; Stonjek, S.; Stradling, A.; Straessner, A.; Strandberg, J.; Strandlie, A.; Strauss, M.; Strickland, V.; Striegel, D.; Strizenec, P.; Ströhmer, R.; Strom, D. M.; Strong, J. A.; Stroynowski, R.; Stugu, B.; Stumer, I.; Su, D.; Subramania, S.; Suchkov, S. I.; Sugaya, Y.; Sugimoto, T.; Suk, M.; Sulin, V. V.; Sultanov, S.; Sun, Z.; Sundal, B.; Sushkov, S.; Susinno, G.; Sutcliffe, P.; Sutton, M. R.; Sviridov, Yu M.; Sykora, I.; Szczygiel, R. R.; Szeless, B.; Szymocha, T.; Sánchez, J.; Ta, D.; Taboada Gameiro, S.; Tadel, M.; Tafirout, R.; Taga, A.; Takai, H.; Takashima, R.; Takeda, H.; Takeshita, T.; Talby, M.; Talyshev, A.; Tamsett, M. C.; Tanaka, J.; Tanaka, K.; Tanaka, R.; Tanaka, S.; Tanaka, S.; Tanaka, Y.; Tappern, G. P.; Tapprogge, S.; Tarem, S.; Tarrade, F.; Tarrant, J.; Tartarelli, G.; Tas, P.; Tasevsky, M.; Tayalati, Y.; Taylor, F. E.; Taylor, G.; Taylor, G. N.; Taylor, R. P.; Tcherniatine, V.; Tegenfeldt, F.; Teixeira-Dias, P.; Ten Kate, H.; Teng, P. K.; Ter-Antonyan, R.; Terada, S.; Terron, J.; Terwort, M.; Teuscher, R. J.; Tevlin, C. M.; Thadome, J.; Thion, J.; Thioye, M.; Thomas, A.; Thomas, J. P.; Thomas, T. L.; Thomas, E.; Thompson, R. J.; Thompson, A. S.; Thun, R. P.; Tic, T.; Tikhomirov, V. O.; Tikhonov, Y. A.; Timm, S.; Timmermans, C. J. W. P.; Tipton, P.; Tique Aires Viegas, F. J.; Tisserant, S.; Titov, M.; Tobias, J.; Tocut, V. M.; Toczek, B.; Todorova-Nova, S.; Tojo, J.; Tokár, S.; Tokushuku, K.; Tomasek, L.; Tomasek, M.; Tomasz, F.; Tomoto, M.; Tompkins, D.; Tompkins, L.; Toms, K.; Tonazzo, A.; Tong, G.; Tonoyan, A.; Topfel, C.; Topilin, N. D.; Torrence, E.; Torres Pais, J. G.; Toth, J.; Touchard, F.; Tovey, D. R.; Tovey, S. N.; Towndrow, E. F.; Trefzger, T.; Treichel, M.; Treis, J.; Tremblet, L.; Tribanek, W.; Tricoli, A.; Trigger, I. M.; Trilling, G.; Trincaz-Duvoid, S.; Tripiana, M. F.; Trischuk, W.; Trka, Z.; Trocmé, B.; Troncon, C.; C-L Tseng, J.; Tsiafis, I.; Tsiareshka, P. V.; Tsipolitis, G.; Tskhadadze, E. G.; Tsukerman, I. I.; Tsulaia, V.; Tsuno, S.; Turala, M.; Turk Cakir, I.; Turlay, E.; Tuts, P. M.; Twomey, M. S.; Tyndel, M.; Typaldos, D.; Tyrvainen, H.; Tzamarioudaki, E.; Tzanakos, G.; Ueda, I.; Uhrmacher, M.; Ukegawa, F.; Ullán Comes, M.; Unal, G.; Underwood, D. G.; Undrus, A.; Unel, G.; Unno, Y.; Urkovsky, E.; Usai, G.; Usov, Y.; Vacavant, L.; Vacek, V.; Vachon, B.; Vahsen, S.; Valderanis, C.; Valenta, J.; Valente, P.; Valero, A.; Valkar, S.; Valls Ferrer, J. A.; Van der Bij, H.; van der Graaf, H.; van der Kraaij, E.; Van Eijk, B.; van Eldik, N.; van Gemmeren, P.; van Kesteren, Z.; van Vulpen, I.; Van Berg, R.; Vandelli, W.; Vandoni, G.; Vaniachine, A.; Vannucci, F.; Varanda, M.; Varela Rodriguez, F.; Vari, R.; Varnes, E. W.; Varouchas, D.; Vartapetian, A.; Varvell, K. E.; Vassilakopoulos, V. I.; Vassilieva, L.; Vataga, E.; Vaz, L.; Vazeille, F.; Vedrine, P.; Vegni, G.; Veillet, J. J.; Vellidis, C.; Veloso, F.; Veness, R.; Veneziano, S.; Ventura, A.; Ventura, S.; Vercesi, V.; Verducci, M.; Verkerke, W.; Vermeulen, J. C.; Vertogardov, L.; Vetterli, M. C.; Vichou, I.; Vickey, T.; Viehhauser, G. H. A.; Vigeolas, E.; Villa, M.; Villani, E. G.; Villate, J.; Villella, I.; Vilucchi, E.; Vincent, P.; Vincke, H.; Vincter, M. G.; Vinogradov, V. B.; Virchaux, M.; Viret, S.; Virzi, J.; Vitale, A.; Vivarelli, I.; Vives, R.; Vives Vaques, F.; Vlachos, S.; Vogt, H.; Vokac, P.; Vollmer, C. F.; Volpi, M.; Volpini, G.; von Boehn-Buchholz, R.; von der Schmitt, H.; von Toerne, E.; Vorobel, V.; Vorobiev, A. P.; Vorozhtsov, A. S.; Vorozhtsov, S. B.; Vos, M.; Voss, K. C.; Voss, R.; Vossebeld, J. H.; Vovenko, A. S.; Vranjes, N.; Vrba, V.; Vreeswijk, M.; Anh, T. Vu; Vuaridel, B.; Vudragovic, M.; Vuillemin, V.; Vuillermet, R.; Wänanen, A.; Wahlen, H.; Walbersloh, J.; Walker, R.; Walkowiak, W.; Wall, R.; Wallny, R. S.; Walsh, S.; Wang, C.; Wang, J. C.; Wappler, F.; Warburton, A.; Ward, C. P.; Warner, G. P.; Warren, M.; Warsinsky, M.; Wastie, R.; Watkins, P. M.; Watson, A. T.; Watts, G.; Waugh, A. T.; Waugh, B. M.; Weaverdyck, C.; Webel, M.; Weber, G.; Weber, J.; Weber, M.; Weber, P.; Weidberg, A. R.; Weilhammer, P. M.; Weingarten, J.; Weiser, C.; Wellenstein, H.; Wellisch, H. P.; Wells, P. S.; Wemans, A.; Wen, M.; Wenaus, T.; Wendler, S.; Wengler, T.; Wenig, S.; Wermes, N.; Werneke, P.; Werner, P.; Werthenbach, U.; Wheeler-Ellis, S. J.; Whitaker, S. P.; White, A.; White, M. J.; White, S.; Whittington, D.; Wicek, F.; Wicke, D.; Wickens, F. J.; Wiedenmann, W.; Wielers, M.; Wienemann, P.; Wiesmann, M.; Wiesmann, M.; Wijnen, T.; Wildauer, A.; Wilhelm, I.; Wilkens, H. G.; Williams, H. H.; Willis, W.; Willocq, S.; Wilmut, I.; Wilson, J. A.; Wilson, A.; Wingerter-Seez, I.; Winton, L.; Witzeling, W.; Wlodek, T.; Woehrling, E.; Wolter, M. W.; Wolters, H.; Wosiek, B.; Wotschack, J.; Woudstra, M. J.; Wright, C.; Wu, S. L.; Wu, X.; Wuestenfeld, J.; Wunstorf, R.; Xella-Hansen, S.; Xiang, A.; Xie, S.; Xie, Y.; Xu, G.; Xu, N.; Yamamoto, A.; Yamamoto, S.; Yamaoka, H.; Yamazaki, Y.; Yan, Z.; Yang, H.; Yang, J. C.; Yang, S.; Yang, U. K.; Yang, Y.; Yang, Z.; Yao, W.-M.; Yao, Y.; Yarradoddi, K.; Yasu, Y.; Ye, J.; Yilmaz, M.; Yoosoofmiya, R.; Yorita, K.; Yoshida, H.; Yoshida, R.; Young, C.; Youssef, S. P.; Yu, D.; Yu, J.; Yu, M.; Yu, X.; Yuan, J.; Yurkewicz, A.; Zaets, V. G.; Zaidan, R.; Zaitsev, A. M.; Zajac, J.; Zajacova, Z.; Zalite, A. Yu; Zalite, Yo K.; Zanello, L.; Zarzhitsky, P.; Zaytsev, A.; Zdrazil, M.; Zeitnitz, C.; Zeller, M.; Zema, P. F.; Zendler, C.; Zenin, A. V.; Zenis, T.; Zenonos, Z.; Zenz, S.; Zerwas, D.; Zhang, H.; Zhang, J.; Zheng, W.; Zhang, X.; Zhao, L.; Zhao, T.; Zhao, X.; Zhao, Z.; Zhelezko, A.; Zhemchugov, A.; Zheng, S.; Zhichao, L.; Zhou, B.; Zhou, N.; Zhou, S.; Zhou, Y.; Zhu, C. G.; Zhu, H. Z.; Zhuang, X. A.; Zhuravlov, V.; Zilka, B.; Zimin, N. I.; Zimmermann, S.; Ziolkowski, M.; Zitoun, R.; Zivkovic, L.; Zmouchko, V. V.; Zobernig, G.; Zoccoli, A.; Zoeller, M. M.; Zolnierowski, Y.; Zsenei, A.; zur Nedden, M.; Zychacek, V.

2008-08-01

The ATLAS detector as installed in its experimental cavern at point 1 at CERN is described in this paper. A brief overview of the expected performance of the detector when the Large Hadron Collider begins operation is also presented.

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).

PubMed

Tanaka, Yoshiya; Takeuchi, Tsutomu; Harigai, Masayoshi; Yamanaka, Hisashi; Nakano, Toshikazu; Akagi, Koshiro; Ukyo, Yoshifumi; Hsu, Benjamin

2018-04-13

To evaluate the efficacy and safety of sirukumab, a human anti-interleukin six monoclonal antibody, in Japanese patients with rheumatoid arthritis who were refractory to anti-tumor necrosis factor therapy. This subgroup analysis, based on a double-blind, placebo-controlled, 52-week phase 3, global study (SIRROUND-T) assessed the American College of Rheumatology (ACR) 20 response at week 16 (primary endpoint). Secondary endpoints: ACR 50, Disease Activity Score in 28 joints-C reactive protein, Health Assessment Questionnaire-Disability Index and safety were assessed. Results 116/878 patients received sirukumab 50 mg/4 weeks (q4w, n = 35), 100 mg/2 weeks (q2w, n = 44) or placebo (n = 37) subcutaneously. Significantly more patients achieved ACR 20 response at week 16 with sirukumab (50 mg q4w:20 [57.1%]; p < .001, 100 mg q2w:24 [54.5%]; p = .001) versus placebo (7 [18.9%]); consistent significant improvement in secondary endpoints at week 24 and 52 was observed. At week 24, incidence of treatment-emergent adverse events (TEAEs) was numerically higher with sirukumab groups (50 mg q4w:29 [82.9%]; 100 mg q2w:38 [86.4%] versus placebo (28 [75.7%]); however, at week 52, sirukumab combined groups had comparable incidence of TEAEs. Efficacy findings through 52 weeks were comparable between sirukumab doses in Japanese patients and consistent with primary SIRROUND-T study results. No new safety signals were observed.

Vidyo@CERN: A Service Update

NASA Astrophysics Data System (ADS)

Fernandes, J.; Baron, T.

2015-12-01

We will present an overview of the current real-time video service offering for the LHC, in particular the operation of the CERN Vidyo service will be described in terms of consolidated performance and scale: The service is an increasingly critical part of the daily activity of the LHC collaborations, topping recently more than 50 million minutes of communication in one year, with peaks of up to 852 simultaneous connections. We will elaborate on the improvement of some front-end key features such as the integration with CERN Indico, or the enhancements of the Unified Client and also on new ones, released or in the pipeline, such as a new WebRTC client and CERN SSO/Federated SSO integration. An overview of future infrastructure improvements, such as virtualization techniques of Vidyo routers and geo-location mechanisms for load-balancing and optimum user distribution across the service infrastructure will also be discussed. The work done by CERN to improve the monitoring of its Vidyo network will also be presented and demoed. As a last point, we will touch the roadmap and strategy established by CERN and Vidyo with a clear objective of optimizing the service both on the end client and backend infrastructure to make it truly universal, to serve Global Science. To achieve those actions, the introduction of the multitenant concept to serve different communities is needed. This is one of the consequences of CERN's decision to offer the Vidyo service currently operated for the LHC, to other Sciences, Institutions and Virtual Organizations beyond HEP that might express interest for it.

Building an organic block storage service at CERN with Ceph

NASA Astrophysics Data System (ADS)

van der Ster, Daniel; Wiebalck, Arne

2014-06-01

Emerging storage requirements, such as the need for block storage for both OpenStack VMs and file services like AFS and NFS, have motivated the development of a generic backend storage service for CERN IT. The goals for such a service include (a) vendor neutrality, (b) horizontal scalability with commodity hardware, (c) fault tolerance at the disk, host, and network levels, and (d) support for geo-replication. Ceph is an attractive option due to its native block device layer RBD which is built upon its scalable, reliable, and performant object storage system, RADOS. It can be considered an "organic" storage solution because of its ability to balance and heal itself while living on an ever-changing set of heterogeneous disk servers. This work will present the outcome of a petabyte-scale test deployment of Ceph by CERN IT. We will first present the architecture and configuration of our cluster, including a summary of best practices learned from the community and discovered internally. Next the results of various functionality and performance tests will be shown: the cluster has been used as a backend block storage system for AFS and NFS servers as well as a large OpenStack cluster at CERN. Finally, we will discuss the next steps and future possibilities for Ceph at CERN.

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental InteractionS". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

McAllister, Liam

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

Sen, Ashoke

Part 7.The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five seriesmore » of pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons.Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

PREFACE: Lectures from the CERN Winter School on Strings, Supergravity and Gauge Theories, CERN, 9-13 February 2009 Lectures from the CERN Winter School on Strings, Supergravity and Gauge Theories, CERN, 9-13 February 2009

NASA Astrophysics Data System (ADS)

Uranga, A. M.

2009-11-01

This special section is devoted to the proceedings of the conference `Winter School on Strings, Supergravity and Gauge Theories', which took place at CERN, the European Centre for Nuclear Research, in Geneva, Switzerland 9-13 February 2009. This event is part of a yearly series of scientific schools, which represents a well established tradition. Previous events have been held at SISSA, in Trieste, Italy, in February 2005 and at CERN in January 2006, January 2007 and January 2008, and were funded by the European Mobility Research and Training Network `Constituents, Fundamental Forces and Symmetries of the Universe'. The next event will take place again at CERN, in January 2010. The school was primarily meant for young doctoral students and postdoctoral researchers working in the area of string theory. It consisted of several general lectures of four hours each, whose notes are published in this special section, and six working group discussion sessions, focused on specific topics of the network research program. It was well attended by over 200 participants. The topics of the lectures were chosen to provide an introduction to some of the areas of recent progress, and to the open problems, in string theory. One of the most active areas in string theory in recent years has been the AdS/CFT or gauge/gravity correspondence, which proposes the complete equivalence of string theory on (asymptotically) anti de Sitter spacetimes with certain quantum (gauge) field theories. The duality has recently been applied to understanding the hydrodynamical properties of a hot plasma in gauge theories (like the quark-gluon plasma created in heavy ion collisions at the RHIC experiment at Brookhaven, and soon at the LHC at CERN) in terms of a dual gravitational AdS theory in the presence of a black hole. These developments were reviewed in the lecture notes by M Rangamani. In addition, the AdS/CFT duality has been proposed as a tool to study interesting physical properties in other physical systems described by quantum field theory, for instance in the context of a condensed matter system. The lectures by S Hartnoll provided an introduction to this recent development with an emphasis on the dual holographic description of superconductivity. Finally, ideas inspired by the AdS/CFT correspondence are yielding deep insights into fundamental questions of quantum gravity, like the entropy of black holes and its interpretation in terms of microstates. The lectures by S Mathur reviewed the black hole entropy and information paradox, and the proposal for its resolution in terms of `fuzzball' microstates. Further sets of lectures, not included in this special section, by F Zwirner and V Mukhanov, covered phenomenological aspects of high energy physics beyond the Standard Model and of cosmology. The coming experimental data in these two fields are expected to foster new developments in connecting string theory to the real world. The conference was financially supported by CERN and partially by the Arnold Sommerfeld Center for Theoretical Physics of the Ludwig Maximilians University of Munich. It is a great pleasure for us to warmly thank the Theory Unit of CERN for its very kind hospitality and for the high quality of the assistance and the infrastructures that it has provided. A M Uranga CERN, Switzerland Guest Editor

Dissemination of data measured at the CERN n_TOF facility

NASA Astrophysics Data System (ADS)

Dupont, E.; Otuka, N.; Cabellos, O.; Aberle, O.; Aerts, G.; Altstadt, S.; Alvarez, H.; Alvarez-Velarde, F.; Andriamonje, S.; Andrzejewski, J.; Audouin, L.; Bacak, M.; Badurek, G.; Balibrea, J.; Barbagallo, M.; Barros, S.; Baumann, P.; Bécares, V.; Bečvář, F.; Beinrucker, C.; Belloni, F.; Berthier, B.; Berthoumieux, E.; Billowes, J.; Boccone, V.; Bosnar, D.; Brown, A.; Brugger, M.; Caamaño, M.; Calviani, M.; Calviño, F.; Cano-Ott, D.; Capote, R.; Cardella, R.; Carrapiço, C.; Casanovas, A.; Castelluccio, D. M.; Cennini, P.; Cerutti, F.; Chen, Y. H.; Chiaveri, E.; Chin, M.; Colonna, N.; Cortés, G.; Cortés-Giraldo, M. A.; Cosentino, L.; Couture, A.; Cox, J.; Damone, L. A.; David, S.; Deo, K.; Diakaki, M.; Dillmann, I.; Domingo-Pardo, C.; Dressler, R.; Dridi, W.; Duran, I.; Eleftheriadis, C.; Embid-Segura, M.; Fernández-Domínguez, B.; Ferrant, L.; Ferrari, A.; Ferreira, P.; Finocchiaro, P.; Fraval, K.; Frost, R. J. W.; Fujii, K.; Furman, W.; Ganesan, S.; Garcia, A. R.; Gawlik, A.; Gheorghe, I.; Gilardoni, S.; Giubrone, G.; Glodariu, T.; Göbel, K.; Gomez-Hornillos, M. B.; Goncalves, I. F.; Gonzalez-Romero, E.; Goverdovski, A.; Gramegna, F.; Griesmayer, E.; Guerrero, C.; Gunsing, F.; Gurusamy, P.; Haight, R.; Harada, H.; Heftrich, T.; Heil, M.; Heinitz, S.; Hernández-Prieto, A.; Heyse, J.; Igashira, M.; Isaev, S.; Jenkins, D. G.; Jericha, E.; Kadi, Y.; Kaeppeler, F.; Kalamara, A.; Karadimos, D.; Karamanis, D.; Katabuchi, T.; Kavrigin, P.; Kerveno, M.; Ketlerov, V.; Khryachkov, V.; Kimura, A.; Kivel, N.; Kokkoris, M.; Konovalov, V.; Krtička, M.; Kroll, J.; Kurtulgil, D.; Lampoudis, C.; Langer, C.; Leal-Cidoncha, E.; Lederer, C.; Leeb, H.; Naour, C. Le; Lerendegui-Marco, J.; Leong, L. S.; Licata, M.; Meo, S. Lo; Lonsdale, S. J.; Losito, R.; Lozano, M.; Macina, D.; Manousos, A.; Marganiec, J.; Martinez, T.; Marrone, S.; Masi, A.; Massimi, C.; Mastinu, P.; Mastromarco, M.; Matteucci, F.; Maugeri, E. A.; Mazzone, A.; Mendoza, E.; Mengoni, A.; Milazzo, P. M.; Mingrone, F.; Mirea, M.; Mondelaers, W.; Montesano, S.; Moreau, C.; Mosconi, M.; Musumarra, A.; Negret, A.; Nolte, R.; O'Brien, S.; Oprea, A.; Palomo-Pinto, F. R.; Pancin, J.; Paradela, C.; Patronis, N.; Pavlik, A.; Pavlopoulos, P.; Perkowski, J.; Perrot, L.; Pigni, M. T.; Plag, R.; Plompen, A.; Plukis, L.; Poch, A.; Porras, I.; Praena, J.; Pretel, C.; Quesada, J. M.; Radeck, D.; Rajeev, K.; Rauscher, T.; Reifarth, R.; Riego, A.; Robles, M.; Roman, F.; Rout, P. C.; Rudolf, G.; Rubbia, C.; Rullhusen, P.; Ryan, J. A.; Sabaté-Gilarte, M.; Salgado, J.; Santos, C.; Sarchiapone, L.; Sarmento, R.; Saxena, A.; Schillebeeckx, P.; Schmidt, S.; Schumann, D.; Sedyshev, P.; Smith, A. G.; Sosnin, N. V.; Stamatopoulos, A.; Stephan, C.; Suryanarayana, S. V.; Tagliente, G.; Tain, J. L.; Tarifeño-Saldivia, A.; Tarrío, D.; Tassan-Got, L.; Tavora, L.; Terlizzi, R.; Tsinganis, A.; Valenta, S.; Vannini, G.; Variale, V.; Vaz, P.; Ventura, A.; Versaci, R.; Vermeulen, M. J.; Villamarin, D.; Vicente, M. C.; Vlachoudis, V.; Vlastou, R.; Voss, F.; Wallner, A.; Walter, S.; Ware, T.; Warren, S.; Weigand, M.; Weiß, C.; Wolf, C.; Wiesher, M.; Wisshak, K.; Woods, P. J.; Wright, T.; Žugec, P.

2017-09-01

The n_TOF neutron time-of-flight facility at CERN is used for high quality nuclear data measurements from thermal energy up to hundreds of MeV. In line with the CERN open data policy, the n_TOF Collaboration takes actions to preserve its unique data, facilitate access to them in standardised format, and allow their re-use by a wide community in the fields of nuclear physics, nuclear astrophysics and various nuclear technologies. The present contribution briefly describes the n_TOF outcomes, as well as the status of dissemination and preservation of n_TOF final data in the international EXFOR library.

QM2017: Status and Key open Questions in Ultra-Relativistic Heavy-Ion Physics

NASA Astrophysics Data System (ADS)

Schukraft, Jurgen

2017-11-01

Almost exactly 3 decades ago, in the fall of 1986, the era of experimental ultra-relativistic E / m ≫ 1) heavy ion physics started simultaneously at the SPS at CERN and the AGS at Brookhaven with first beams of light Oxygen ions at fixed target energies of 200 GeV/A and 14.6 GeV/A, respectively. The event was announced by CERN [CERN's subatomic particle accelerators: Set up world-record in energy and break new ground for physics (CERN-PR-86-11-EN) (1986) 4 p, issued on 29 September 1986. URL (http://cds.cern.ch/record/855571)

The significance of Cern

ScienceCinema

None

2017-12-09

Le Prof. V.Weisskopf, DG du Cern de 1961 à 1965, est né à Vienne, a fait ses études à Göttingen et a une carrière académique particulièrement riche. Il a travaillé à Berlin, Copenhague et Berlin et est parti aux Etats Unis pour participer au projet Manhattan et était Prof. au MTT jusqu'à 1960. Revenu en Europe, il a été DG du Cern et lui a donné l'impulsion que l'on sait.

PREFACE: International Conference on Computing in High Energy and Nuclear Physics (CHEP 2012)

NASA Astrophysics Data System (ADS)

Ernst, Michael; Düllmann, Dirk; Rind, Ofer; Wong, Tony

2012-12-01

The International Conference on Computing in High Energy and Nuclear Physics (CHEP) was held at New York University on 21- 25 May 2012. CHEP is a major series of international conferences for physicists and computing professionals from the High Energy and Nuclear Physics community and related scientific and technical fields. The CHEP conference provides a forum to exchange information on computing progress and needs for the community, and to review recent, ongoing and future activities. CHEP conferences are held at roughly 18-month intervals, alternating between Europe, Asia, the Americas and other parts of the world. Recent CHEP conferences have been held in Taipei, Taiwan (2010); Prague, Czech Republic (2009); Victoria, Canada (2007); Mumbai, India (2006); Interlaken, Switzerland (2004); San Diego, United States (2003); Beijing, China (2001); Padova, Italy (2000). CHEP 2012 was organized by Brookhaven National Laboratory (BNL) and co-sponsored by New York University. The organizational structure for CHEP consists of an International Advisory Committee (IAC) which sets the overall themes of the conference, a Program Organizing Committee (POC) that oversees the program content, and a Local Organizing Committee (LOC) that is responsible for local arrangements (lodging, transportation and social events) and conference logistics (registration, program scheduling, conference site selection and conference proceedings). There were over 500 attendees with a program that included plenary sessions of invited speakers, a number of parallel sessions comprising around 125 oral and 425 poster presentations and industrial exhibitions. We thank all the presenters for the excellent scientific content of their contributions to the conference. Conference tracks covered topics on Online Computing, Event Processing, Distributed Processing and Analysis on Grids and Clouds, Computer Facilities, Production Grids and Networking, Software Engineering, Data Stores and Databases and Collaborative Tools. We would like to thank Brookhaven Science Associates, New York University, Blue Nest Events, the International Advisory Committee, the Program Committee and the Local Organizing Committee members for all their support and assistance. We also would like to acknowledge the support provided by the following sponsors: ACEOLE, Data Direct Networks, Dell, the European Middleware Initiative and Nexsan. Special thanks to the Program Committee members for their careful choice of conference contributions and enormous effort in reviewing and editing the conference proceedings. The next CHEP conference will be held in Amsterdam, the Netherlands on 14-18 October 2013. Conference Chair Michael Ernst (BNL) Program Committee Daniele Bonacorsi, University of Bologna, Italy Simone Campana, CERN, Switzerland Philippe Canal, Fermilab, United States Sylvain Chapeland, CERN, Switzerland Dirk Düllmann, CERN, Switzerland Johannes Elmsheuser, Ludwig Maximilian University of Munich, Germany Maria Girone, CERN, Switzerland Steven Goldfarb, University of Michigan, United States Oliver Gutsche, Fermilab, United States Benedikt Hegner, CERN, Switzerland Andreas Heiss, Karlsruhe Institute of Technology, Germany Peter Hristov, CERN, Switzerland Tony Johnson, SLAC, United States David Lange, LLNL, United States Adam Lyon, Fermilab, United States Remigius Mommsen, Fermilab, United States Axel Naumann, CERN, Switzerland Niko Neufeld, CERN, Switzerland Rolf Seuster, TRIUMF, Canada Local Organizing Committee Maureen Anderson, John De Stefano, Mariette Faulkner, Ognian Novakov, Ofer Rind, Tony Wong (BNL) Kyle Cranmer (NYU) International Advisory Committee Mohammad Al-Turany, GSI, Germany Lothar Bauerdick, Fermilab, United States Ian Bird, CERN, Switzerland Dominique Boutigny, IN2P3, France Federico Carminati, CERN, Switzerland Marco Cattaneo, CERN, Switzerland Gang Chen, Institute of High Energy Physics, China Peter Clarke, University of Edinburgh, United Kingdom Sridhara Dasu, University of Wisconsin-Madison, United States Günter Duckeck, Ludwig Maximilian University of Munich, Germany Richard Dubois, SLAC, United States Michael Ernst, BNL, United States Ian Fisk, Fermilab, United States Gonzalo Merino, PIC, Spain John Gordon, STFC-RAL, United Kingdom Volker Gülzow, DESY, Germany Frederic Hemmer, CERN, Switzerland Viatcheslav Ilyin, Moscow State University, Russia Nobuhiko Katayama, KEK, Japan Alexei Klimentov, BNL, United States Simon C. Lin, Academia Sinica, Taiwan Milos Lokajícek, FZU Prague, Czech Republic David Malon, ANL, United States Pere Mato Vila, CERN, Switzerland Mauro Morandin, INFN CNAF, Italy Harvey Newman, Caltech, United States Farid Ould-Saada, University of Oslo, Norway Ruth Pordes, Fermilab, United States Hiroshi Sakamoto, University of Tokyo, Japan Alberto Santoro, UERJ, Brazil Jim Shank, Boston University, United States Dongchul Son, Kyungpook National University, South Korea Reda Tafirout, TRIUMF, Canada Stephen Wolbers, Fermilab, United States Frank Wuerthwein, UCSD, United States

Towards a 21st century telephone exchange at CERN

NASA Astrophysics Data System (ADS)

Valentín, F.; Hesnaux, A.; Sierra, R.; Chapron, F.

2015-12-01

The advent of mobile telephony and Voice over IP (VoIP) has significantly impacted the traditional telephone exchange industry—to such an extent that private branch exchanges are likely to disappear completely in the near future. For large organisations, such as CERN, it is important to be able to smooth this transition by implementing new multimedia platforms that can protect past investments and the flexibility needed to securely interconnect emerging VoIP solutions and forthcoming developments such as Voice over LTE (VoLTE). We present the results of ongoing studies and tests at CERN of the latest technologies in this area.

NEWS: A trip to CERN

NASA Astrophysics Data System (ADS)

Ellison, A. D.

2000-07-01

Two years ago John Kinchin and myself were lucky enough to attend the Goldsmith's particle physics course. As well as many interesting lectures and activities, this course included a visit to CERN. To most physics teachers CERN is Mecca, a hallowed place where gods manipulate and manufacture matter. The experience of being there was even better. Alison Wright was an enthusiastic and very knowledgeable host who ensured the visit went smoothly and we all learned a lot. While we were there, John and I discussed the possibility of bringing a party of A-level students to see real physics in action. In February of this year we managed it. 33 students from two schools, Boston Grammar School and Northampton School for Boys, and four staff left England and caught the 2 am ferry to France. Many hours and a few `short cuts' later we arrived at our hotel in St Genis, not far from CERN. The first day was spent sight-seeing in Lausanne and Geneva. The Olympic museum in Lausanne is well worth a visit. Unfortunately, the famous fountain in Geneva was turned off, but then you can't have everything. The following morning we turned up at CERN late due to the coach's brakes being iced up! We were met once again by Alison Wright who forgave us and introduced the visit by giving an excellent talk on CERN, its background and its reason for existing. At this point we met another member of our Goldsmith's course and his students so we joined forces once again. We then piled back into the coach to re-cross the border and visit ALEPH. ALEPH is a monster of a detector 150 m below ground. We divided into four groups, each with a very able and knowledgeable guide, and toured the site. The size and scale of the detector are awesome and the students were suitably impressed. We repeated the speed of sound experiment of two years ago at the bottom of a 150 m concrete shaft (320 m s-1), posed for a group photo in front of the detector (figure 1) and returned to the main site for lunch in the canteen. Over lunch we mixed with physicists of many different nationalities and backgrounds. Figure 1 Figure 1. In the afternoon we visited Microcosm, the CERN visitors centre, and the LEP control room and also the SPS. Here the students learned new applications for much of the physics of standing waves and resonance that they had been taught in the classroom. Later that night, we visited a bowling alley where momentum and collision theory were put into practice. The following morning we returned to CERN and visited the large magnet testing facility. Here again physics was brought to life. We saw superconducting magnets being assembled and tested and the students gained a real appreciation of the problems and principles involved. The afternoon was rounded off by a visit to a science museum in Geneva - well worth a visit, as some of us still use some of the apparatus on display. Friday was our last full day so we visited Chamonix in the northern Alps. In the morning, we ascended the Aiguille de Midi - by cable car. Twenty minutes and 3842 m later we emerged into 50 km h-1 winds and -10 °C temperature, not counting the -10 °C wind chill factor. A crisp packet provided an unusual demonstration of the effects of air pressure (figure 2). Figure 2 Figure 2. The views from the summit were very spectacular though a few people experienced mild altitude sickness. That afternoon the party went to the Mer de Glace. Being inside a 3 million year-old structure moving down a mountain at 3 cm per day was an interesting experience, as was a tot of whisky with 3 million year-old water. Once again the local scenery was very photogenic and the click and whirr of cameras was a constant background noise. Saturday morning saw an early start for the long drive home. Most students - and some staff - took the opportunity to catch up on their sleep. Thanks are due to many people without whom the trip would never have taken place. Anne Craige, Stuart Williams, Christine Sutton and Andrew Morrison of PPARC, but most especially Alison Wright of CERN and John Kinchin of Boston Grammar School who did all the hard work and organization. The week gave students a unique chance to see the principles of physics being applied in many different ways and I am sure this has reinforced their knowledge and understanding. Some students also took the opportunity to practise their language skills. The only remaining question is: what next? I'll have to think about it in the summer when I have some slack time. Hmm, SLAC, that gives me an idea....

Safety and Tolerability of Methylphenidate in Preschool Children with ADHD

ERIC Educational Resources Information Center

Wigal, Tim; Greenhill, Laurence; Chuang, Shirley; McGough, James; Vitiello, Benedetto; Skrobala, Anne; Swanson, James; Wigal, Sharon; Abikoff, Howard; Kollins, Scott; McCracken, James; Riddle, Mark; Posner, Kelly; Ghuman, Jaswinder; Davies, Mark; Thorp, Ben; Stehli, Annamarie

2006-01-01

Objective: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. Method: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled,…

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe";. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

McAllister, Liam

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe";. The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions".This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde. Local organizers: A. Uranga, J. Walcher« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

Sen, Ashoke

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network". The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde Local organizers: A. Uranga, J. Walcher.« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions";. This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde. Local organizers: A. Uranga, J. Walcher« less

Phase 3 randomised study of the proposed biosimilar adalimumab GP2017 in psoriasis - impact of multiple switches.

PubMed

Blauvelt, A; Lacour, J-P; Fowler, J F; Weinberg, J M; Gospodinov, D; Schuck, E; Jauch-Lembach, J; Balfour, A; Leonardi, C L

2018-06-19

The impact of multiple switches between GP2017 and reference adalimumab (ref-ADMB) was assessed following the demonstration of equivalent efficacy and similar safety and immunogenicity, in adult patients with active, clinically stable, moderate-to-severe plaque psoriasis. This 51-week double-blinded, phase 3 study randomly assigned patients to GP2017 (N=231) or ref-ADMB (N=234) 80 mg subcutaneously at Week 0, then 40 mg biweekly from Week 1. At Week 17, patients were re-randomised to switch (n=126) or continue (n=253) treatment. Primary endpoint: patients achieving Psoriasis Area and Severity Index (PASI)75 at Week 16 (equivalence confirmed if the 95% confidence interval [CI] for the difference in PASI75 between treatments was ±18%). Key secondary endpoint: change from baseline to Week 16 in continuous PASI. Other endpoints: PASI over time, PASI 50/75/90/100, pharmacokinetics, safety, tolerability and immunogenicity for the switched and continued treatment groups. Equivalent efficacy between GP2017 and ref-ADMB was confirmed for the primary (66.8% and 65.0%, respectively; 95% CI, -7.46, 11.15) and key secondary (-60.7% and -61.5%, respectively; 95% CI, -3.15, 4.84) endpoints. PASI improved over time and was similar between treatment groups at Week 16, and the switched/continued groups from Weeks 17-51. There were no relevant safety or immunogenicity differences between GP2017 and ref-ADMB at Week 16, or the switched/continued groups from Weeks 17-51. No hypersensitivity to adalimumab was reported upon switching. Following the demonstration of GP2017 biosimilarity to ref-ADMB, switching up to four times between GP2017 and ref-ADMB had no detectable impact on efficacy, safety or immunogenicity. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

PubMed

van der Heijde, Désirée; Deodhar, Atul; Wei, James C; Drescher, Edit; Fleishaker, Dona; Hendrikx, Thijs; Li, David; Menon, Sujatha; Kanik, Keith S

2017-08-01

To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12. Secondary endpoints included objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was monitored. Emax model analysis of the primary endpoint predicted a tofacitinib 10 mg twice daily ASAS20 response rate of 67.4%, 27.3% higher than placebo. Supportive normal approximation analysis demonstrated tofacitinib 5 mg twice daily ASAS20 response rate significantly higher than placebo (80.8% vs 41.2%; p<0.001); tofacitinib 2 and 10 mg twice daily demonstrated greater response rate than placebo (51.9% and 55.8%, respectively; not significant). Secondary endpoints generally demonstrated greater improvements with tofacitinib 5 and 10 mg twice daily than placebo. Objective (including MRI) endpoints demonstrated clear dose response. Adverse events were similar across treatment groups with no unexpected safety findings. Dose-dependent laboratory outcome changes returned close to baseline by week 16. Tofacitinib 5 and 10 mg twice daily demonstrated greater clinical efficacy versus placebo in reducing signs, symptoms and objective endpoints of active AS in adult patients with a similar 12-week safety profile as reported in other indications. NCT01786668. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

PubMed

Amiot, A; Serrero, M; Peyrin-Biroulet, L; Filippi, J; Pariente, B; Roblin, X; Buisson, A; Stefanescu, C; Trang-Poisson, C; Altwegg, R; Marteau, P; Vaysse, T; Bourrier, A; Nancey, S; Laharie, D; Allez, M; Savoye, G; Moreau, J; Vuitton, L; Viennot, S; Aubourg, A; Pelletier, A-L; Bouguen, G; Abitbol, V; Gagniere, C; Bouhnik, Y

2017-08-01

We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with vedolizumab induction therapy. Among those 294 patients, 272 completed the induction period and were evaluated at the week 14 visit (161 patients with CD and 111 with UC). Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. The primary outcome was steroid-free clinical remission at week 54. At week 54, steroid-free clinical remission rates at week 54 were 27.2% and 40.5% in patients with CD and UC respectively. In addition, the sustained steroid-free clinical remission (from week 14 to week 54) rates were 8.1% and 19.0% respectively. No deaths were observed. Severe adverse events occurred in 17 (7.2%) patients, including six (2.5%) leading to vedolizumab discontinuation. Vedolizumab is able to maintain steroid-free clinical remission in up to one-third of patients with UC and CD at week 54 with a reasonable safety profile. A significant number of patients experienced loss of response during the first year of treatment, particularly in patients with CD. © 2017 John Wiley & Sons Ltd.

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.

PubMed

Kadowaki, Takashi; Muto, Satsuki; Ouchi, Yoshiumi; Shimazaki, Ryutaro; Seino, Yutaka

2017-12-01

We examined the efficacy and safety of saxagliptin as an add-on to insulin in Japanese patients with type 2 diabetes mellitus. We randomized 240 patients with type 2 diabetes mellitus on insulin monotherapy to 5-mg saxagliptin or placebo as add-on therapy for a 16-week, double-blind period. All patients received 5-mg saxagliptin and insulin for an additional 36 weeks (open-label extension). Change in hemoglobin A1c (HbA1c) at Week 16 was the main endpoint. At Week 16, the adjusted change in HbA1c from baseline increased by 0.51% with placebo and decreased by 0.40% with saxagliptin (difference -0.92% [95% confidence interval -1.07%, -0.76%; p < 0.001]). In patients receiving saxagliptin, reductions in HbA1c at Week 16 were maintained to Week 52, while switching from placebo to saxagliptin resulted in a similar reduction in HbA1c. The incidence of hypoglycemia was not markedly increased with saxagliptin versus placebo in the double-blind period and did not increase substantially during the open-label extension period. The efficacy and safety of saxagliptin was similar between the elderly and non-elderly patient groups. Adding saxagliptin to ongoing insulin therapy improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes.

OBITUARY: Maurice Jacob (1933 2007)

NASA Astrophysics Data System (ADS)

Quercigh, Emanuele; Šándor, Ladislav

2008-04-01

Maurice Jacob passed away on 2 May 2007. With his death, we have lost one of the founding fathers of the ultra-relativistic heavy ion programme. His interest in high-energy nuclear physics started in 1981 when alpha alpha collisions could first be studied in the CERN ISR. An enthusiastic supporter of ion beam experiments at CERN, Maurice was at the origin of the 1982 Quark Matter meeting in Bielefeld [1] which brought together more than 100 participants from both sides of the Atlantic, showing a good enthusiastic constituency for such research. There were twice as many the following year at Brookhaven. Finally in the mid-eighties, a heavy ion programme was approved both at CERN and at Brookhaven involving as many nuclear as particle physicists. It was the start of a fruitful interdisciplinary collaboration which is nowadays continuing both at RHIC and at LHC. Maurice followed actively the development of this field, reporting at a number of conferences and meetings (Les Arcs, Bielefeld, Beijing, Brookhaven, Lenox, Singapore, Taormina,...). This activity culminated in 2000, when Maurice, together with Ulrich Heinz, summarized the main results of the CERN SPS heavy-ion experiments and the evidence was obtained for a new state of matter [2]. Maurice was a brilliant theoretical physicist. His many contributions have been summarized in a recent article in the CERN Courier by two leading CERN theorists, John Ellis and Andre Martin [3]. The following is an excerpt from their article: `He began his research career at Saclay and, while still a PhD student, he continued brilliantly during a stay at Brookhaven. It was there in 1959 that Maurice, together with Giancarlo Wick, developed the helicity amplitude formalism that is the basis of many modern theoretical calculations. Maurice obtained his PhD in 1961 and, after a stay at Caltech, returned to Saclay. A second American foray was to SLAC, where he and Sam Berman made the crucial observation that the point-like structures (partons) seen in deep-inelastic scattering implied the existence of high-transverse-momentum processes in proton proton collisions, as the ISR at CERN subsequently discovered. In 1967 Maurice joined CERN, where he remained, apart from influential visits to Yale, Fermilab and elsewhere, until his retirement in 1998. He became one of the most respected international experts on the phenomenology of strong interactions, including diffraction, scaling, high-transverse-momentum processes and the formation of quark gluon plasma. In particular, he pioneered the studies of inclusive hadron-production processes, including scaling and its violations. Also, working with Ron Horgan, he made detailed predictions for the production of jets at CERN's proton antiproton collider. The UA2 and UA1 experiments subsequently discovered these. He was also interested in electron positron colliders, making pioneering calculations, together with Tai Wu, of radiation in high-energy collisions. Maurice was one of the scientific pillars of CERN, working closely with experimental colleagues in predicting and interpreting results from successive CERN colliders. He was indefatigable in organizing regular meetings on ISR physics, bringing together theorists and experimentalists to debate the meaning of new results and propose new measurements. He was one of the strongest advocates of Carlo Rubbia's proposal for a proton antiproton collider at CERN, and was influential in preparing and advertising its physics. In 1978 he organized the Les Houches workshop that brought the LEP project to the attention of the wider European particle physics community. He also organized the ECFA workshop at Lausanne in 1984 that made the first exploration of the possible physics of the LHC. It is a tragedy that Maurice has not lived to enjoy data from the LHC.' References [1] Maurice Jacob and Helmut Satz (eds) 1982 Proc. Workshop on Quark Matter Formation and Heavy Ion Collisions, Bielefeld, 10 14 May 1982 (Singapore: World Scientific Publishing) [2] Heinz Ulrich W and Jacob Maurice 2000 Evidence for a new state of matter: An assessment of the results from the CERN lead beam program. Preprint nucl-th/0002042 [3] Ellis J and Martin A 2007 CERN Courier 47 issue 6

WorldWide Web: Hypertext from CERN.

ERIC Educational Resources Information Center

Nickerson, Gord

1992-01-01

Discussion of software tools for accessing information on the Internet focuses on the WorldWideWeb (WWW) system, which was developed at the European Particle Physics Laboratory (CERN) in Switzerland to build a worldwide network of hypertext links using available networking technology. Its potential for use with multimedia documents is also…

Neutrino Factory Plans at CERN

NASA Astrophysics Data System (ADS)

Riche, J. A.

2002-10-01

The considerable interest raised by the discovery of neutrino oscillations and recent progress in studies of muon colliders has triggered interest in considering a neutrino factory at CERN. This paper explains the reference scenario, indicates the other possible choices and mentions the R&D that are foreseen.

CERN goes iconic

NASA Astrophysics Data System (ADS)

2017-06-01

There are more than 1800 emoji that can be sent and received in text messages and e-mails. Now, the CERN particle-physics lab near Geneva has got in on the act and released its own collection of 35 images that can be used by anyone with an Apple device.

An Open-Label Pilot Study to Assess the Efficacy and Safety of Virgin Coconut Oil in Reducing Visceral Adiposity

PubMed Central

Liau, Kai Ming; Lee, Yeong Yeh; Chen, Chee Keong; Rasool, Aida Hanum G.

2011-01-01

Introduction. This is an open-label pilot study on four weeks of virgin coconut oil (VCO) to investigate its efficacy in weight reduction and its safety of use in 20 obese but healthy Malay volunteers. Methodology. Efficacy was assessed by measuring weight and associated anthropometric parameters and lipid profile one week before and one week after VCO intake. Safety was assessed by comparing organ function tests one week before and one week after intake of VCO. Paired t-test was used to analyse any differences in all the measurable variables. Results. Only waist circumference (WC) was significantly reduced with a mean reduction of 2.86 cm or 0.97% from initial measurement (P = .02). WC reduction was only seen in males (P < .05). There was no change in the lipid profile. There was a small reduction in creatinine and alanine transferase levels. Conclusion. VCO is efficacious for WC reduction especially in males and it is safe for use in humans. PMID:22164340

Medical Applications at CERN and the ENLIGHT Network.

PubMed

Dosanjh, Manjit; Cirilli, Manuela; Myers, Steve; Navin, Sparsh

2016-01-01

State-of-the-art techniques derived from particle accelerators, detectors, and physics computing are routinely used in clinical practice and medical research centers: from imaging technologies to dedicated accelerators for cancer therapy and nuclear medicine, simulations, and data analytics. Principles of particle physics themselves are the foundation of a cutting edge radiotherapy technique for cancer treatment: hadron therapy. This article is an overview of the involvement of CERN, the European Organization for Nuclear Research, in medical applications, with specific focus on hadron therapy. It also presents the history, achievements, and future scientific goals of the European Network for Light Ion Hadron Therapy, whose co-ordination office is at CERN.

Thermostructural characterization and structural elastic property optimization of novel high luminosity LHC collimation materials at CERN

NASA Astrophysics Data System (ADS)

Borg, M.; Bertarelli, A.; Carra, F.; Gradassi, P.; Guardia-Valenzuela, J.; Guinchard, M.; Izquierdo, G. Arnau; Mollicone, P.; Sacristan-de-Frutos, O.; Sammut, N.

2018-03-01

The CERN Large Hadron Collider is currently being upgraded to operate at a stored beam energy of 680 MJ through the High Luminosity upgrade. The LHC performance is dependent on the functionality of beam collimation systems, essential for safe beam cleaning and machine protection. A dedicated beam experiment at the CERN High Radiation to Materials facility is created under the HRMT-23 experimental campaign. This experiment investigates the behavior of three collimation jaws having novel composite absorbers made of copper diamond, molybdenum carbide graphite, and carbon fiber carbon, experiencing accidental scenarios involving the direct beam impact on the material. Material characterization is imperative for the design, execution, and analysis of such experiments. This paper presents new data and analysis of the thermostructural characteristics of some of the absorber materials commissioned within CERN facilities. In turn, characterized elastic properties are optimized through the development and implementation of a mixed numerical-experimental optimization technique.

An open-label pilot study to assess the efficacy and safety of virgin coconut oil in reducing visceral adiposity.

PubMed

Liau, Kai Ming; Lee, Yeong Yeh; Chen, Chee Keong; Rasool, Aida Hanum G

2011-01-01

Introduction. This is an open-label pilot study on four weeks of virgin coconut oil (VCO) to investigate its efficacy in weight reduction and its safety of use in 20 obese but healthy Malay volunteers. Methodology. Efficacy was assessed by measuring weight and associated anthropometric parameters and lipid profile one week before and one week after VCO intake. Safety was assessed by comparing organ function tests one week before and one week after intake of VCO. Paired t-test was used to analyse any differences in all the measurable variables. Results. Only waist circumference (WC) was significantly reduced with a mean reduction of 2.86 cm or 0.97% from initial measurement (P = .02). WC reduction was only seen in males (P < .05). There was no change in the lipid profile. There was a small reduction in creatinine and alanine transferase levels. Conclusion. VCO is efficacious for WC reduction especially in males and it is safe for use in humans.

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

The CERN Winter School on Supergravity, Strings, and Gauge Theory is the analytic continuation of the yearly training school of the former EC-RTN string network "Constituents, Fundamental Forces and Symmetries of the Universe". The 2010 edition of the school is supported and organized by the CERN Theory Divison, and will take place from Monday January 25 to Friday January 29, at CERN. As its predecessors, this school is meant primarily for training of doctoral students and young postdoctoral researchers in recent developments in theoretical high-energy physics and string theory. The programme of the school will consist of five series ofmore » pedagogical lectures, complemented by tutorial discussion sessions in the afternoons. Previous schools in this series were organized in 2005 at SISSA in Trieste, and in 2006, 2007, 2008, and 2009 at CERN, Geneva. Other similar schools have been organized in the past by the former related RTN network "The Quantum Structure of Spacetime and the Geometric Nature of Fundamental Interactions". This edition of the school is not funded by the European Union. The school is funded by the CERN Theory Division, and the Arnold Sommerfeld Center at Ludwig-Maximilians University of Munich. Scientific committee: M. Gaberdiel, D. Luest, A. Sevrin, J. Simon, K. Stelle, S. Theisen, A. Uranga, A. Van Proeyen, E. Verlinde. Local organizers: A. Uranga, J. Walcher. This video is Part 11 in the series.« less

A possible biomedical facility at the European Organization for Nuclear Research (CERN).

PubMed

Dosanjh, M; Jones, B; Myers, S

2013-05-01

A well-attended meeting, called "Brainstorming discussion for a possible biomedical facility at CERN", was held by the European Organization for Nuclear Research (CERN) at the European Laboratory for Particle Physics on 25 June 2012. This was concerned with adapting an existing, but little used, 78-m circumference CERN synchrotron to deliver a wide range of ion species, preferably from protons to at least neon ions, with beam specifications that match existing clinical facilities. The potential extensive research portfolio discussed included beam ballistics in humanoid phantoms, advanced dosimetry, remote imaging techniques and technical developments in beam delivery, including gantry design. In addition, a modern laboratory for biomedical characterisation of these beams would allow important radiobiological studies, such as relative biological effectiveness, in a dedicated facility with standardisation of experimental conditions and biological end points. A control photon and electron beam would be required nearby for relative biological effectiveness comparisons. Research beam time availability would far exceed that at other facilities throughout the world. This would allow more rapid progress in several biomedical areas, such as in charged hadron therapy of cancer, radioisotope production and radioprotection. The ethos of CERN, in terms of open access, peer-reviewed projects and governance has been so successful for High Energy Physics that application of the same to biomedicine would attract high-quality research, with possible contributions from Europe and beyond, along with potential new funding streams.

Highlights from the CERN/ESO/NordForsk ''Gender in Physics Day''

NASA Astrophysics Data System (ADS)

Primas, F.; Guinot, G.; Strandberg, L.

2017-03-01

In their role as observers on the EU Gender Equality Network in the European Research Area (GENERA) project, funded under the Horizon 2020 framework, CERN, ESO and NordForsk joined forces and organised a Gender in Physics Day at the CERN Globe of Science and Innovation. The one-day conference aimed to examine innovative activities promoting gender equality, and to discuss gender-oriented policies and best practice in the European Research Area (with special emphasis on intergovernmental organisations), as well as the importance of building solid networks. The event was very well attended and was declared a success. The main highlights of the meeting are reported.

Medical Applications at CERN and the ENLIGHT Network

PubMed Central

Dosanjh, Manjit; Cirilli, Manuela; Myers, Steve; Navin, Sparsh

2016-01-01

State-of-the-art techniques derived from particle accelerators, detectors, and physics computing are routinely used in clinical practice and medical research centers: from imaging technologies to dedicated accelerators for cancer therapy and nuclear medicine, simulations, and data analytics. Principles of particle physics themselves are the foundation of a cutting edge radiotherapy technique for cancer treatment: hadron therapy. This article is an overview of the involvement of CERN, the European Organization for Nuclear Research, in medical applications, with specific focus on hadron therapy. It also presents the history, achievements, and future scientific goals of the European Network for Light Ion Hadron Therapy, whose co-ordination office is at CERN. PMID:26835422

Knowledge and Technology: Sharing With Society

NASA Astrophysics Data System (ADS)

Benvenuti, Cristoforo; Sutton, Christine; Wenninger, Horst

The following sections are included: * A Core Mission of CERN * Medical Accelerators: A Tool for Tumour Therapy * Medipix: The Image is the Message * Crystal Clear: From Higgs to PET * Solar Collectors: When Nothing is Better * The TARC Experiment at CERN: Modern Alchemy * A CLOUD Chamber with a Silvery Lining * References

Contextualized Magnetism in Secondary School: Learning from the LHC (CERN)

ERIC Educational Resources Information Center

Cid, Ramon

2005-01-01

Physics teachers in secondary schools usually mention the world's largest particle physics laboratory--CERN (European Organization for Nuclear Research)--only because of the enormous size of the accelerators and detectors used there, the number of scientists involved in their activities and also the necessary international scientific…

33 CFR 165.163 - Safety Zones; Port of New York/New Jersey Fleet Week.

Code of Federal Regulations, 2011 CFR

2011-07-01

... as safety zones: (1) Safety Zone A—(i) Location. A moving safety zone for the Parade of Ships... Wednesday before Memorial Day. (2) Safety Zone B—(i) Location. A safety zone including all waters of the.... (ii) Enforcement period. Paragraph (a)(2)(i) of this section is enforced annually from 8 a.m. until 5...

History of Cern

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2007-12-20

Cérémonie à l'occasion de l'apparition du premier volume du livre sur l'histoire du Cern, avec plusieurs personnes présentes qui jouaient un rôle important dans cette organisation européenne couronnée de succès grâce à l'esprit des membres fondateurs qui est et restera essentiel

DG's New Year's presentation

ScienceCinema

Heuer, R.-D.

2018-05-22

CERN general staff meeting. Looking back at key messages: Highest priority: LHC physics in 2009; Increase diversity of the scientific program; Prepare for future projects; Establish open and direct communication; Prepare CERN towards a global laboratory; Increase consolidation efforts; Financial situation--tight; Knowledge and technology transfer--proactive; Contract policy and internal mobility--lessons learned.

Mapping Remote and Multidisciplinary Learning Barriers: Lessons from "Challenge-Based Innovation" at CERN

ERIC Educational Resources Information Center

Jensen, Matilde Bisballe; Utriainen, Tuuli Maria; Steinert, Martin

2018-01-01

This paper presents the experienced difficulties of students participating in the multidisciplinary, remote collaborating engineering design course challenge-based innovation at CERN. This is with the aim to identify learning barriers and improve future learning experiences. We statistically analyse the rated differences between distinct design…

The keys to CERN conference rooms - Managing local collaboration facilities in large organisations

NASA Astrophysics Data System (ADS)

Baron, T.; Domaracky, M.; Duran, G.; Fernandes, J.; Ferreira, P.; Gonzalez Lopez, J. B.; Jouberjean, F.; Lavrut, L.; Tarocco, N.

2014-06-01

For a long time HEP has been ahead of the curve in its usage of remote collaboration tools, like videoconference and webcast, while the local CERN collaboration facilities were somewhat behind the expected quality standards for various reasons. This time is now over with the creation by the CERN IT department in 2012 of an integrated conference room service which provides guidance and installation services for new rooms (either equipped for videoconference or not), as well as maintenance and local support. Managing now nearly half of the 246 meeting rooms available on the CERN sites, this service has been built to cope with the management of all CERN rooms with limited human resources. This has been made possible by the intensive use of professional software to manage and monitor all the room equipment, maintenance and activity. This paper focuses on presenting these packages, either off-the-shelf commercial products (asset and maintenance management tool, remote audio-visual equipment monitoring systems, local automation devices, new generation touch screen interfaces for interacting with the room) when available or locally developed integration and operational layers (generic audio-visual control and monitoring framework) and how they help overcoming the challenges presented by such a service. The aim is to minimise local human interventions while preserving the highest service quality and placing the end user back in the centre of this collaboration platform.

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.

PubMed

Zhang, JianZhong; Tsai, Tsen-Fang; Lee, Min-Geol; Zheng, Min; Wang, Gang; Jin, HongZhong; Gu, Jun; Li, RuoYu; Liu, QuanZhong; Chen, Jin; Tu, CaiXia; Qi, ChunMei; Zhu, Hua; Ports, William C; Crook, Tim

2017-10-01

Tofacitinib is an oral Janus kinase inhibitor. This study assessed tofacitinib efficacy and safety vs placebo in Asian patients with moderate to severe chronic plaque psoriasis. Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5mg (N=88), tofacitinib 10mg (N=90), placebo→5mg (N=44), or placebo→10mg (N=44), twice daily (BID) for 52 weeks. Placebo-treated patients advanced to tofacitinib at Week 16. Co-primary efficacy endpoints: proportions of patients achieving Physician's Global Assessment (PGA) response ('clear' or 'almost clear') and proportion achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI75) at Week 16. At Week 16, more patients achieved PGA and PASI75 responses with tofacitinib 5mg (52.3%; 54.6%) and 10mg (75.6%; 81.1%) BID vs placebo (19.3%; 12.5%; all p<0.0001). Of patients with a Week 16 response, 73.6% and 75.0% maintained PGA response, and 76.8% and 84.9% maintained PASI75 to Week 52 with tofacitinib 5mg and 10mg BID, respectively. Over 52 weeks, 2.2-4.5% of patients across treatment groups experienced serious adverse events, and 1.1-6.8% discontinued due to adverse events. Tofacitinib demonstrated efficacy vs placebo at Week 16 in Asian patients with moderate to severe plaque psoriasis; efficacy was maintained through Week 52. No unexpected safety findings were observed. [NCT01815424]. Copyright © 2017 The Authors and Pfizer Inc. Published by Elsevier B.V. All rights reserved.

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial

PubMed Central

Puig, Lluís; Gottlieb, Alice B.; Ritchlin, Christopher; Li, Shu; Wang, Yuhua; Mendelsohn, Alan M.; Song, Michael; Zhu, Yaowei; Rahman, Proton; McInnes, Iain B.

2015-01-01

Objective To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active psoriatic arthritis (PsA). Methods A total of 615 adult patients with active PsA were randomized to placebo, ustekinumab 45 mg, or ustekinumab 90 mg, at weeks 0, 4, and every 12 weeks through week 88 (last dose). At week 16, patients with <5% improvement in both tender and swollen joint counts entered blinded early escape (placebo to 45 mg, 45 mg to 90 mg, and 90 mg to 90 mg). All remaining placebo patients crossed over to ustekinumab 45 mg at week 24. Clinical efficacy measures included American College of Rheumatology criteria for 20% improvement (ACR20), Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP), and ≥75% improvement in the Psoriasis Area and Severity Index (PASI75). Radiographic progression was evaluated using the modified Sharp/van der Heijde score (SHS). Results At week 100, ACR20, DAS28‐CRP moderate/good response, and PASI75 rates ranged from 56.7–63.6%, 71.9–76.7%, and 63.9–72.5%, respectively, across the 3 treatment groups. In both ustekinumab groups, the median percent improvement in dactylitis and enthesitis was 100% at week 100. The mean changes in SHS score from week 52 to week 100 were similar to those observed from week 0 to week 52 in the ustekinumab groups. Through week 108, 70.7% and 9.7% of patients had an adverse event (AE) or serious AE, respectively. The rates and type of AEs were similar between the dose groups. Conclusion Clinical and radiographic benefits from ustekinumab treatment were maintained through week 100 in the PSUMMIT 1 study. No unexpected safety events were observed; the safety profile of ustekinumab in this population was similar to that previously observed in psoriasis patients treated with ustekinumab. PMID:26097039

Of people, particles and prejudice

NASA Astrophysics Data System (ADS)

Jackson, Penny; Greene, Anne; Mears, Matt; Spacecadet1; Green, Christian; Hunt, Devin J.; Berglyd Olsen, Veronica K.; Ilya, Komarov; Pierpont, Elaine; Gillman, Matthew

2016-05-01

In reply to Louise Mayor's feature article “Where people and particles collide”, about the experiences of researchers at CERN who are lesbian, gay, bisexual or transgender (LGBT), efforts to make LGBT CERN an officially recognized club, and incidents where posters advertising the club have been torn down or defaced (March pp31-36, http://ow.ly/YVP2Z).

CERN - Six Decades of Science, Innovation, Cooperation, and Inspiration

DOE Office of Scientific and Technical Information (OSTI.GOV)

Quigg, Chris

The European Laboratory for Particle Physics, which straddles the Swiss-French border northwest of Geneva, celebrates its sixtieth birthday in 2014 CERN is the preeminent particle-physics institution in the world, currently emphasizing the study of collisions of protons and heavy nuclei at very high energies and the exploration of physics on the electroweak scale (energies where electromagnetism and the weak nuclear force merge). With brilliant accomplishments in research, innovation, and education, and a sustained history of cooperation among people from different countries and cultures, CERN ranks as one of the signal achievements of the postwar European Project. For physicists the worldmore » over, the laboratory is a source of pride and inspiration.« less

33 CFR 165.943 - Annual events requiring safety zones in the Captain of the Port Duluth zone.

Code of Federal Regulations, 2014 CFR

2014-07-01

.... (ii) Enforcement date and time. This event historically occurs during the 4th of July week. The... historically occurs the week before, after or during 4th of July week. The Captain of the Port Duluth, will... 4th of July week. The Captain of the Port Duluth, will establish enforcement dates that will be...

Determination and Fabrication of New Shield Super Alloys Materials for Nuclear Reactor Safety by Experiments and Cern-Fluka Monte Carlo Simulation Code, Geant4 and WinXCom

NASA Astrophysics Data System (ADS)

Aygun, Bünyamin; Korkut, Turgay; Karabulut, Abdulhalik

2016-05-01

Despite the possibility of depletion of fossil fuels increasing energy needs the use of radiation tends to increase. Recently the security-focused debate about planned nuclear power plants still continues. The objective of this thesis is to prevent the radiation spread from nuclear reactors into the environment. In order to do this, we produced higher performanced of new shielding materials which are high radiation holders in reactors operation. Some additives used in new shielding materials; some of iron (Fe), rhenium (Re), nickel (Ni), chromium (Cr), boron (B), copper (Cu), tungsten (W), tantalum (Ta), boron carbide (B4C). The results of this experiments indicated that these materials are good shields against gamma and neutrons. The powder metallurgy technique was used to produce new shielding materials. CERN - FLUKA Geant4 Monte Carlo simulation code and WinXCom were used for determination of the percentages of high temperature resistant and high-level fast neutron and gamma shielding materials participated components. Super alloys was produced and then the experimental fast neutron dose equivalent measurements and gamma radiation absorpsion of the new shielding materials were carried out. The produced products to be used safely reactors not only in nuclear medicine, in the treatment room, for the storage of nuclear waste, nuclear research laboratories, against cosmic radiation in space vehicles and has the qualities.

More "Hands-On" Particle Physics: Learning with ATLAS at CERN

ERIC Educational Resources Information Center

Long, Lynne

2011-01-01

This article introduces teachers and students to a new portal of resources called Learning with ATLAS at CERN (http://learningwithatlas-portal.eu/), which has been developed by a European consortium of academic researchers and schools' liaison and outreach providers from countries across Europe. It includes the use of some of the mind-boggling…

Comittees

NASA Astrophysics Data System (ADS)

2004-10-01

Fritz Caspers (CERN, Switzerland), Michel Chanel (CERN, Switzerland), Håkan Danared (MSL, Sweden), Bernhard Franzke (GSI, Germany), Manfred Grieser (MPI für Kernphysik, Germany), Dieter Habs (LMU München, Germany), Jeffrey Hangst (University of Aarhus, Denmark), Takeshi Katayama (RIKEN/Univ. Tokyo, Japan), H.-Jürgen Kluge (GSI, Germany), Shyh-Yuan Lee (Indiana University, USA), Rudolf Maier (FZ Jülich, Germany), John Marriner (FNAL, USA), Igor Meshkov (JINR, Russia), Dieter Möhl (CERN, Switzerland), Vasily Parkhomchuk (BINP, Russia), Robert Pollock (Indiana University), Dieter Prasuhn (FZ Jülich, Germany), Dag Reistad (TSL, Sweden), John Schiffer (ANL, USA), Andrew Sessler (LBNL, USA), Alexander Skrinsky (BINP, Russia), Markus Steck (GSI, Germany), Jie Wei (BNL, USA), Andreas Wolf (MPI für Kernphysik, Germany), Hongwei Zhao (IMP, People's Rep. of China).

Dissemination of CERN's Technology Transfer: Added Value from Regional Transfer Agents

ERIC Educational Resources Information Center

Hofer, Franz

2005-01-01

Technologies developed at CERN, the European Organization for Nuclear Research, are disseminated via a network of external technology transfer officers. Each of CERN's 20 member states has appointed at least one technology transfer officer to help establish links with CERN. This network has been in place since 2001 and early experiences indicate…

Software Aspects of IEEE Floating-Point Computations for Numerical Applications in High Energy Physics

ScienceCinema

Arnold, Jeffrey

2018-05-14

Floating-point computations are at the heart of much of the computing done in high energy physics. The correctness, speed and accuracy of these computations are of paramount importance. The lack of any of these characteristics can mean the difference between new, exciting physics and an embarrassing correction. This talk will examine practical aspects of IEEE 754-2008 floating-point arithmetic as encountered in HEP applications. After describing the basic features of IEEE floating-point arithmetic, the presentation will cover: common hardware implementations (SSE, x87) techniques for improving the accuracy of summation, multiplication and data interchange compiler options for gcc and icc affecting floating-point operations hazards to be avoided. About the speaker: Jeffrey M Arnold is a Senior Software Engineer in the Intel Compiler and Languages group at Intel Corporation. He has been part of the Digital->Compaq->Intel compiler organization for nearly 20 years; part of that time, he worked on both low- and high-level math libraries. Prior to that, he was in the VMS Engineering organization at Digital Equipment Corporation. In the late 1980s, Jeff spent 2½ years at CERN as part of the CERN/Digital Joint Project. In 2008, he returned to CERN to spent 10 weeks working with CERN/openlab. Since that time, he has returned to CERN multiple times to teach at openlab workshops and consult with various LHC experiments. Jeff received his Ph.D. in physics from Case Western Reserve University.

TOWARDS A NOVEL MODULAR ARCHITECTURE FOR CERN RADIATION MONITORING.

PubMed

Boukabache, Hamza; Pangallo, Michel; Ducos, Gael; Cardines, Nicola; Bellotta, Antonio; Toner, Ciarán; Perrin, Daniel; Forkel-Wirth, Doris

2017-04-01

The European Organization for Nuclear Research (CERN) has the legal obligation to protect the public and the people working on its premises from any unjustified exposure to ionising radiation. In this context, radiation monitoring is one of the main concerns of the Radiation Protection Group. After 30 y of reliable service, the ARea CONtroller (ARCON) system is approaching the end of its lifecycle, which raises the need for new, more efficient radiation monitors with a high level of modularity to ensure better maintainability. Based on these two main principles, new detectors are currently being developed that will be capable of measuring very low dose rates down to 50 nSv h-1, whilst being able to measure radiation over an extensive range of 8 decades without any auto scaling. To reach these performances, CERN Radiation MOnitoring Electronics (CROME), the new generation of CERN radiation monitors, is based on the versatile architecture that includes new read-out electronics developed by the Instrumentation and Logistics section of the CERN Radiation Protection Group as well as a reconfigurable system on chip capable of performing complex processing calculations. Beside the capabilities of CROME to continuously measure the ambient dose rate, the system generates radiation alarms, provides interlock signals, drives alarm display units through a fieldbus and provides long-term, permanent and reliable data logging. The measurement tests performed during the first phase of the development show very promising results that pave the way to the second phase: the certification. © The Author 2016. Published by Oxford University Press.

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.

PubMed

Stein Gold, Linda; Bagel, Jerry; Lebwohl, Mark; Jackson, J Mark; Chen, Rongdean; Goncalves, Joana; Levi, Eugenia; Duffin, Kristina Callis

2018-02-01

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL.

METHODS: Patients with moderate plaque psoriasis (BSA 5%-10%; static Physician's Global Assessment [sPGA] score of 3 [moderate]) and naive to systemic therapies for psoriasis were randomized (2:1) to receive apremilast 30 mg twice daily or placebo for 16 weeks. At week 16, patients continued on apremilast (apremilast/apremilast) or were switched from placebo to apremilast (placebo/apremilast) through week 52 (open-label apremilast treatment phase). Efficacy assessments included the product of sPGA and BSA (PGAxBSA) (mean percentage change from baseline; ≥75% reduction from baseline [PGAxBSA-75]), sPGA response (achievement of score of 0 [clear] or 1 [almost clear]), and the Dermatology Life Quality Index (DLQI; mean change from baseline).

RESULTS: A total of 136 patients completed the 52-week analysis period (placebo/apremilast, n=50/64; apremilast/apremilast, n=86/121). At week 52, improvements in all efficacy end points observed at week 16 were maintained in the apremilast/apremilast group (mean percentage change from baseline in PGAxBSA: -55.5%; PGAxBSA-75: 42.1%; sPGA response: 33.1%; mean change from baseline in DLQI score: -4.4); similar improvements emerged in the placebo/apremilast group after switching to apremilast. The most common adverse events (≥5% of patients) through week 52 were diarrhea (28.0%), nausea (19.0%), headache (15.2%), nasopharyngitis (10.4%), upper respiratory tract infection (7.1%), vomiting (5.7%), and decreased appetite (5.2%).

CONCLUSIONS: Apremilast was effective in systemic-naive patients with moderate plaque psoriasis with BSA 5%-10%; efficacy was sustained through week 52. No new safety signals emerged with continued apremilast exposure.

ClinicalTrials.gov: NCT02425826

J Drugs Dermatol. 2018;17(2):221-228.

THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE.

PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN.

NO PURCHASE NECESSARY.

Réunion publique HR

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2010-04-30

Chers Collègues,Je me permets de vous rappeler qu'une réunion publique organisée par le Département HR se tiendra aujourd'hui:Vendredi 30 avril 2010 à 9h30 dans l'Amphithéâtre principal (café offert dès 9h00).Durant cette réunion, des informations générales seront données sur:le CERN Admin e-guide, qui est un nouveau guide des procédures administratives du CERN ayant pour but de faciliter la recherche d'informations pratiques et d'offrir un format de lecture convivial;le régime d'Assurance Maladie de l'Organisation (présentation effectuée par Philippe Charpentier, Président du CHIS Board) et;la Caisse de Pensions (présentation effectuée par Théodore Economou, Administrateur de la Caisse de Pensions du CERN).Une transmission simultanéemore » de cette réunion sera assurée dans l'Amphithéâtre BE de Prévessin et également disponible à l'adresse suivante: http://webcast.cern.chJe me réjouis de votre participation!Meilleures salutations,Anne-Sylvie CatherinChef du Département des Ressources humaines__________________________________________________________________________________Dear Colleagues,I should like to remind you that a plublic meeting organised by HR Department will be held today:Friday 30 April 2010 at 9:30 am in the Main Auditorium (coffee from 9:00 am).During this meeting, general information will be given about:the CERN Admin e-guide which is a new guide to the Organization's administrative procedures, drawn up to facilitate the retrieval of practical information and to offer a user-friendly format;the CERN Health Insurance System (presentation by Philippe Charpentier, President of the CHIS Board) and;the Pension Fund (presentation by Theodore Economou, Administrator of the CERN Pension Fund).A simultaneous transmission of this meeting will be broadcast in the BE Auditorium at Prévessin and will also be available at the following address. http://webcast.cern.chI look forward to your participation!Best regards,Anne-Sylvie CatherinHead, Human Resources Department« less

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.

PubMed

Ogata, Atsushi; Amano, Koichi; Dobashi, Hiroaki; Inoo, Masayuki; Ishii, Tomonori; Kasama, Tsuyoshi; Kawai, Shinichi; Kawakami, Atsushi; Koike, Tatsuya; Miyahara, Hisaaki; Miyamoto, Toshiaki; Munakata, Yasuhiko; Murasawa, Akira; Nishimoto, Norihiro; Ogawa, Noriyoshi; Ojima, Tomohiro; Sano, Hajime; Shi, Kenrin; Shono, Eisuke; Suematsu, Eiichi; Takahashi, Hiroki; Tanaka, Yoshiya; Tsukamoto, Hiroshi; Nomura, Akira

2015-05-01

To evaluate the longterm safety and efficacy of subcutaneous tocilizumab (TCZ-SC) as monotherapy in patients with rheumatoid arthritis (RA). Of 346 patients who received 24 weeks of double-blind treatment with either TCZ-SC monotherapy, 162 mg every 2 weeks (q2w); or intravenous TCZ (TCZ-IV) monotherapy, 8 mg/kg every 4 weeks; 319 patients continued to receive TCZ-SC q2w in the 84-week open-label extension (OLE) of the MUSASHI study (JAPICCTI-101117). Efficacy, safety, and immunogenicity were evaluated for all patients treated with TCZ during 108 weeks. The proportions of patients who achieved American College of Rheumatology 20/50/70 responses, low disease activity [28-joint Disease Activity Score (DAS28) ≤ 3.2], or remission (DAS28 < 2.6) at Week 24 were maintained until Week 108. The incidences of adverse events and serious adverse events were 498.3 and 16.9 per 100 patient-years (PY), respectively. The overall safety of TCZ-SC monotherapy was similar to that of TCZ-IV monotherapy. Rates of injection site reactions (ISR) through 108 weeks remained similar to rates through 24 weeks. ISR were mild and did not cause any patient withdrawals. No serious hypersensitivity events (including anaphylactic reactions) occurred. Anti-TCZ antibodies were present in 2.1% of patients treated with TCZ-SC monotherapy. TCZ-SC monotherapy maintained a favorable safety profile and consistent efficacy throughout the 108-week study. Like TCZ-IV, TCZ-SC could provide an additional treatment option for patients with RA.

TOWARDS A NOVEL MODULAR ARCHITECTURE FOR CERN RADIATION MONITORING

PubMed Central

Boukabache, Hamza; Pangallo, Michel; Ducos, Gael; Cardines, Nicola; Bellotta, Antonio; Toner, Ciarán; Perrin, Daniel; Forkel-Wirth, Doris

2017-01-01

Abstract The European Organization for Nuclear Research (CERN) has the legal obligation to protect the public and the people working on its premises from any unjustified exposure to ionising radiation. In this context, radiation monitoring is one of the main concerns of the Radiation Protection Group. After 30 y of reliable service, the ARea CONtroller (ARCON) system is approaching the end of its lifecycle, which raises the need for new, more efficient radiation monitors with a high level of modularity to ensure better maintainability. Based on these two main principles, new detectors are currently being developed that will be capable of measuring very low dose rates down to 50 nSv h−1, whilst being able to measure radiation over an extensive range of 8 decades without any auto scaling. To reach these performances, CERN Radiation MOnitoring Electronics (CROME), the new generation of CERN radiation monitors, is based on the versatile architecture that includes new read-out electronics developed by the Instrumentation and Logistics section of the CERN Radiation Protection Group as well as a reconfigurable system on chip capable of performing complex processing calculations. Beside the capabilities of CROME to continuously measure the ambient dose rate, the system generates radiation alarms, provides interlock signals, drives alarm display units through a fieldbus and provides long-term, permanent and reliable data logging. The measurement tests performed during the first phase of the development show very promising results that pave the way to the second phase: the certification. PMID:27909154

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.

PubMed

Weinblatt, Michael E; Baranauskaite, Asta; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Baek, Inyoung; Ghil, Jeehoon

2018-06-01

The 24-week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate-to-severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluate patients who switched from ADA to SB5 or who continued to receive SB5 or ADA up to 52 weeks. In this phase III study, patients were initially randomized 1:1 to receive SB5 or ADA (40 mg subcutaneously every other week). At 24 weeks, patients receiving ADA were rerandomized 1:1 to continue with ADA (ADA/ADA group) or to switch to SB5 (ADA/SB5 group) up to week 52; patients receiving SB5 continued with SB5 for 52 weeks (SB5 group). Efficacy, safety, and immunogenicity were evaluated up to 52 weeks. The full analysis set population consisted of 542 patients (269 in the SB5 group, 273 in the ADA overall group [patients who were randomized to receive ADA at week 0], 125 in the ADA/SB5 group, and 129 in the ADA/ADA group). The percentages of patients meeting the American College of Rheumatology 20%, 50%, or 70% improvement criteria (achieving an ACR20, ACR50, or ACR70 response) at week 24 were maintained after the transition from ADA to SB5, and these response rates were comparable across treatment groups throughout the study. ACR20 response rates ranged from 73.4% to 78.8% at week 52. Radiographic progression was minimal and comparable across treatment groups. The safety profile and the incidence of antidrug antibodies were comparable across treatment groups after transition. SB5 was well tolerated over 1 year in patients with RA, with efficacy, safety, and immunogenicity comparable to those of ADA. Switching from ADA to SB5 had no treatment-emergent issues such as increased adverse events, increased immunogenicity, or loss of efficacy. © 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

PubMed Central

Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieslawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Lee, Younju; Rho, Young Hee

2018-01-01

Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those in patients who maintained treatment with INF or SB2. Methods Patients with moderate to severe RA despite methotrexate treatment were randomised (1:1) to receive SB2 or INF at weeks 0, 2 and 6 and every 8 weeks thereafter until week 46. At week 54, patients previously receiving INF were rerandomised (1:1) to switch to SB2 (INF/SB2 (n=94)) or to continue on INF (INF/INF (n=101)) up to week 70. Patients previously receiving SB2 continued on SB2 (SB2/SB2 (n=201)) up to week 70. Efficacy, safety and immunogenicity were assessed up to week 78. Results Efficacy was sustained and comparable across treatment groups. American College of Rheumatology (ACR) 20 responses between weeks 54 and 78 ranged from 63.5% to 72.3% with INF/SB2, 66.3%%–69.4% with INF/INF and 65.6%–68.3% with SB2/SB2. Treatment-emergent adverse events during this time occurred in 36.2%, 35.6% and 40.3%, respectively, and infusion-related reactions in 3.2%, 2.0% and 3.5%. Among patients who were negative for antidrug antibodies (ADA) up to week 54, newly developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and SB2/SB2 groups, respectively. Conclusions The efficacy, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2. Trial registration number NCT01936181; EudraCT number: 2012-005733-37. PMID:29042358

Lead Ions and Coulomb's Law at the LHC (CERN)

ERIC Educational Resources Information Center

Cid-Vidal, Xabier; Cid, Ramon

2018-01-01

Although for most of the time the Large Hadron Collider (LHC) at CERN collides protons, for around one month every year lead ions are collided, to expand the diversity of the LHC research programme. Furthermore, in an effort not originally foreseen, proton-lead collisions are also taking place, with results of high interest to the physics…

Across Europe to CERN: Taking students on the ultimate physics experience

NASA Astrophysics Data System (ADS)

Wheeler, Sam

2018-05-01

In 2013, I was an Einstein Fellow with the U.S. Department of Energy and I was asked by a colleague, working in a senator's office, if I would join him in a meeting with a physicist to "translate" the science into something more understandable. That meeting turned out to be a wonderful opportunity I would never have otherwise had. During the meeting I met Michael Tuts, a physicist who was working on project ATLAS at CERN. Afterwards, I walked with him out of the Senate office building to Union Station and, in parting, he gave me his card and told me that if I were in Geneva that he could help me get a tour of CERN and the LHC.

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

PubMed

Panaccione, Remo; Sandborn, William J; D'Haens, Geert; Wolf, Douglas C; Berg, Sofie; Maa, Jen-Fue; Petersson, Joel; Robinson, Anne M

2018-04-25

In the 4-week GAIN clinical trial, adalimumab was efficacious in inducing remission in patients with moderate to severe Crohn's disease (CD) who had prior loss of response/intolerance to infliximab. The efficacy and safety of adalimumab in these patients are reported here up to 96 weeks or for 3 years, respectively, in ADHERE open-label extension study. Patients who completed GAIN could enrol in ADHERE and receive open-label adalimumab 40 mg every other week. Efficacy variables included clinical response (Crohn's Disease Activity Index [CDAI] decrease from baseline ≥70/≥100 points [CR-70/CR-100]) and remission (CDAI<150), steroid discontinuation and fistula remission (absence of drainage). Data were reported using hybrid non-responder imputation (hNRI), last observation carried forward and as-observed analysis. Subgroup analyses were performed by randomised group in GAIN and by Week 4 efficacy in GAIN. Safety was also assessed. A total of 310 patients from GAIN enrolled in ADHERE. CR-70, CR-100 and remission rates at Week 96 were 39.0%, 35.5% and 26.5% (hNRI), respectively. Of the patients with CR-70 response or remission at Week 4 of GAIN, 45.5% and 44.4% (hNRI), respectively, maintained effect at Week 96. Steroid discontinuation and steroid-free remission rates increased from Week 12 to 96 in patients using corticosteroids at GAIN baseline. Long-term adalimumab maintenance therapy led to sustained clinical remission and response, and steroid discontinuation in a considerable proportion of patients with CD previously treated with infliximab. No new safety signals were observed in this patient population.

The Secret Chambers in the Chephren Pyramid

ERIC Educational Resources Information Center

Gutowski, Bartosz; Józwiak, Witold; Joos, Markus; Kempa, Janusz; Komorowska, Kamila; Krakowski, Kamil; Pijus, Ewa; Szymczak, Kamil; Trojanowska, Malgorzata

2018-01-01

In 2016, we (seven high school students from a school in Plock, Poland) participated in the CERN Beamline for Schools competition. Together with our team coach, Mr. Janusz Kempa, we submitted a proposal to CERN that was selected as one of two winning proposals that year. This paper describes our experiment from the early days of brainstorming to…

Réunion publique HR

ScienceCinema

None

2017-12-09

Chers Collègues,Je me permets de vous rappeler qu'une réunion publique organisée par le Département HR se tiendra aujourd'hui:Vendredi 30 avril 2010 à 9h30 dans l'Amphithéâtre principal (café offert dès 9h00).Durant cette réunion, des informations générales seront données sur:le CERN Admin e-guide, qui est un nouveau guide des procédures administratives du CERN ayant pour but de faciliter la recherche d'informations pratiques et d'offrir un format de lecture convivial;le régime d'Assurance Maladie de l'Organisation (présentation effectuée par Philippe Charpentier, Président du CHIS Board) et;la Caisse de Pensions (présentation effectuée par Théodore Economou, Administrateur de la Caisse de Pensions du CERN).Une transmission simultanée de cette réunion sera assurée dans l'Amphithéâtre BE de Prévessin et également disponible à l'adresse suivante: http://webcast.cern.chJe me réjouis de votre participation!Meilleures salutations,Anne-Sylvie CatherinChef du Département des Ressources humaines__________________________________________________________________________________Dear Colleagues,I should like to remind you that a plublic meeting organised by HR Department will be held today:Friday 30 April 2010 at 9:30 am in the Main Auditorium (coffee from 9:00 am).During this meeting, general information will be given about:the CERN Admin e-guide which is a new guide to the Organization's administrative procedures, drawn up to facilitate the retrieval of practical information and to offer a user-friendly format;the CERN Health Insurance System (presentation by Philippe Charpentier, President of the CHIS Board) and;the Pension Fund (presentation by Theodore Economou, Administrator of the CERN Pension Fund).A simultaneous transmission of this meeting will be broadcast in the BE Auditorium at Prévessin and will also be available at the following address. http://webcast.cern.chI look forward to your participation!Best regards,Anne-Sylvie CatherinHead, Human Resources Department

From strangeness enhancement to quark-gluon plasma discovery

NASA Astrophysics Data System (ADS)

Koch, Peter; Müller, Berndt; Rafelski, Johann

2017-11-01

This is a short survey of signatures and characteristics of the quark-gluon plasma in the light of experimental results that have been obtained over the past three decades. In particular, we present an in-depth discussion of the strangeness observable, including a chronology of the experimental effort to detect QGP at CERN-SPS, BNL-RHIC, and CERN-LHC.

History of Cern

ScienceCinema

None

2017-12-09

Cérémonie à l'occasion de l'apparition du premier volume du livre sur l'histoire du Cern, avec plusieurs personnes présentes qui jouaient un rôle important dans cette organisation européenne couronnée de succès grâce à l'esprit des membres fondateurs qui est et restera essentiel

40 CFR Appendix to Part 30 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

.... 4. Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where applicable, all contracts... week of 40 hours. Work in excess of the standard work week is permissible provided that the worker is... hours in the work week. Section 107 of the Act is applicable to construction work and provides that no...

User and group storage management the CMS CERN T2 centre

NASA Astrophysics Data System (ADS)

Cerminara, G.; Franzoni, G.; Pfeiffer, A.

2015-12-01

A wide range of detector commissioning, calibration and data analysis tasks is carried out by CMS using dedicated storage resources available at the CMS CERN Tier-2 centre. Relying on the functionalities of the EOS disk-only storage technology, the optimal exploitation of the CMS user/group resources has required the introduction of policies for data access management, data protection, cleanup campaigns based on access pattern, and long term tape archival. The resource management has been organised around the definition of working groups and the delegation to an identified responsible of each group composition. In this paper we illustrate the user/group storage management, and the development and operational experience at the CMS CERN Tier-2 centre in the 2012-2015 period.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

PubMed

Dean, Emma; Banerji, Udai; Schellens, Jan H M; Krebs, Matthew G; Jimenez, Begona; van Brummelen, Emilie; Bailey, Chris; Casson, Ed; Cripps, Diana; Cullberg, Marie; Evans, Stephen; Foxley, Andrew; Lindemann, Justin; Rugman, Paul; Taylor, Nigel; Turner, Guy; Yates, James; Lawrence, Peter

2018-05-01

AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet. Adults with advanced solid tumours received AZD5363 480 mg bid in a partially fasted state by tablet (Week 1) and capsule (Week 2) in a '4-days-on/3-days-off' schedule (Part A). PK parameters were evaluated using pre-defined 90% CIs for AUCτ and C max ratios of 0.75-1.33 to assess comparability. In Part B, AZD5363 tablet was given to a new cohort of patients under the same conditions as Part A, except on the morning of PK assessment days, when it was administered after an overnight fast (Week 1) and standard meal (Week 2). In evaluable patients (N = 11), the geometric least-squares mean ratios (tablet:capsule) for AUCτ and C max were 0.90 (0.77-1.06) and 1.02 (0.86-1.20), respectively, demonstrating comparable PK in the partially fasted state. Tablet and capsule safety data were also comparable. Tablet PK profiles indicated later t max and lower C max after food versus overnight fast. Fed and fasted AUCτ and C max ratios were 0.89 (0.76-1.05) and 0.67 (0.55-0.82), respectively (N = 9). The safety/tolerability profile of the tablet was comparable between fed and fasted states. PK and safety/tolerability of AZD5363 tablet and capsule were comparable. Food did not affect the bioavailability of AZD5363, but reduced the absorption rate without discernibly affecting safety/tolerability.

[CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): a new facility].

PubMed

Viertl, David; Buchegger, Franz; Prior, John O; Forni, Michel; Morel, Philippe; Ratib, Osman; Bühler Léo H; Stora, Thierry

2015-06-17

CERN-MEDICIS is a facility dedicated to research and development in life science and medical applications. The research platform was inaugurated in October 2014 and will produce an increasing range of innovative isotopes using the proton beam of ISOLDE for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for preclinical trials, possibly extended to specific early phase clinical studies (phase 0) up to phase I trials. CERN, the University Hospital of Geneva (HUG), the University Hospital of Lausanne (CHUV), the Swiss Institute for Experimental Cancer (ISREC) at Swiss Federal Institutes of Technology (EPFL) that currently support the project will benefit of the initial production that will then be extended to other centers.

DataBase on Demand

NASA Astrophysics Data System (ADS)

Gaspar Aparicio, R.; Gomez, D.; Coterillo Coz, I.; Wojcik, D.

2012-12-01

At CERN a number of key database applications are running on user-managed MySQL database services. The database on demand project was born out of an idea to provide the CERN user community with an environment to develop and run database services outside of the actual centralised Oracle based database services. The Database on Demand (DBoD) empowers the user to perform certain actions that had been traditionally done by database administrators, DBA's, providing an enterprise platform for database applications. It also allows the CERN user community to run different database engines, e.g. presently open community version of MySQL and single instance Oracle database server. This article describes a technology approach to face this challenge, a service level agreement, the SLA that the project provides, and an evolution of possible scenarios.

Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.

PubMed

Mimori, Tsuneyo; Harigai, Masayoshi; Atsumi, Tatsuya; Fujii, Takao; Kuwana, Masataka; Matsuno, Hiroaki; Momohara, Shigeki; Takei, Syuji; Tamura, Naoto; Takasaki, Yoshinari; Yamamoto, Kazuhiko; Ikeuchi, Satoshi; Kushimoto, Satoru; Koike, Takao

2018-04-27

We evaluated the long-term (52 weeks) safety and effectiveness of iguratimod (IGU) in patients with rheumatoid arthritis (RA). This multicenter, prospective, observational study included all evaluable RA patients who received IGU since its market launch in 2012. We evaluated adverse events (AEs); adverse drug reactions (ADRs); ADRs of special interest, including liver and renal dysfunctions, interstitial lung disease, gastrointestinal and blood disorders, and infection; and change in Disease Activity Score 28-C-reactive protein (DAS28-CRP) at week 52. Safety and effectiveness were analyzed in 2666 and 1614 patients, respectively. The incidences of AEs, serious AEs, ADRs, and serious ADRs were 46.92, 7.35, 38.26, and 4.58%, respectively. The incidence of ADRs peaked at approximately 4 weeks of treatment. Subsequently, the ADR incidence did not increase over time. Improvement of RA activity was shown up to week 52. Long-term treatment with IGU in patients with RA resulted in a tolerable safety profile and an improvement in RA activity. IGU could be considered a useful treatment option for patients with RA.

Live Webcasts from CERN and ESO for European Science and Technology Week

NASA Astrophysics Data System (ADS)

2002-10-01

Visit http://www.cern.ch/sci-tech on 7 - 8 November to find out what modern Europeans can't live without. Seven of Europe's leading Research Organizations [1] are presenting three live Webcasts from CERN in a joint outreach programme for the European Science and Technology Week . The aim of Sci-Tech... couldn't be without it! is to show how today's society couldn't be without cutting-edge scientific research. See also ESO Press Release 05/02. Northern Europeans can't imagine their households without ovens, whereas Southern Europeans identify the refrigerator as the most essential household appliance. In the area of communications, cars and motorbikes are clearly the technologies of choice in Italy, but are regarded as less important in countries like Norway and Germany. For entertainment, the personal computer is a clear winner as the device is considered most essential by all Europeans, followed by the TV and the Internet. This hit parade of technological marvels is the result of a phone and online survey conducted by the Sci-Tech... couldn't be without it! team for this year's European Science and Technology Week on 4-10 November. The technologies Europeans could not be without, form the starting point of three entertaining and informative Webcast shows in Italian (Thursday 7 November at 10:00 CET), French (Thursday 7 November at 15:00 CET) and English (Friday 8 November at 15:00 CET), broadcast live on the Internet from a studio at CERN. During these Webcasts scientists from the seven research Organizations and their industrial partners Sun Microsystems, Siemens, L'Oreal and Luminex will engage - from the CERN studio or from remote locations through teleconference links - an audience of Internauts all over the world. The public will be taken inside their most popular gadgets to discover the science that made them possible and how vital fundamental research has been in the creation of modern technology. Fundamental science will be brought as close as possible to people's daily lives by showing in an entertaining way how the behaviour of electrons in silicon was essential to the development of transistors and thus to computers, for example. How new medicines are developed by looking at the genome of malaria-carrying mosquitoes, and how cancer can be diagnosed and treated with particle beams. People will be amazed to discover how everyday products such as cosmetics are developed using advanced scientific instruments like synchrotron radiation sources. And how fashion and design will be soon revolutionised by a new fabric made of the same optical fibre used for advanced computer networks. The excitement of the Internet audience will be maintained thanks to live quiz shows for 15 to 19 year-old Europeans in the studio and online, with top-tech prizes to win. Sci-tech... couldn't be without it! will show the next generation of technology users how fundamental research is relevant to everyday life, and draw attention to the fascinating opportunities that lie ahead in the world of research and development. WATCH THE LIVE WEBCASTS and take part in the Online quizzes: * Thursday 7 November at 10:00 hrs CET in Italian * Thursday 7 November at 15:00 hrs CET in French * Friday 8 November at 15:00 hrs CET in English on http://www.cern.ch/sci-tech For more information on the webcasts and the Sci-tech... couldn't be without it! project, contact: paola.catapano@cern.ch Catch A Star! Go to the Catch a Star! educational programme Another interesting webcast can be followed on Friday, November 8, 2002, from 13:00 hrs CET (in English) at: http://www.eso.org/public/outreach/eduoff/cas/cas2002/cas-webcast.html Earlier this year, the European Southern Observatory (ESO) and the European Association for Astronomy Education (EAAE) invited all students in Europe's schools to the exciting Catch A Star! web-based educational programme with a competition. It takes place within the context of the EC-sponsored European Week of Science and Technology (EWST) - 2002 . See also ESO Press Release 08/02. This project revolves around a web-based competition and is centred on astronomy. It is specifically conceived to stimulate the interest of young people in various aspects of this well-known field of science, but will also be of interest to the broad public. Three hundred groups of up to four persons (e.g., three students and one teacher) have selected an astronomical object of their choice - a bright star, a distant galaxy, a beautiful comet, a planet or a moon in the solar system, or some other celestial body. They come from 25 countries. Until tomorrow, November 1, 2002, they have to deliver a comprehensive report about their chosen object. All reports have to conform with certain rules and are judged by a jury. Those fulfilling the criteria (explained at the Catch A Star! website) will participate in a lottery with exciting prizes, the first prize being a free trip in early 2003 for the members of the group to the ESO Paranal Observatory in Chile, the site of the ESO Very Large Telescope (VLT) . The lottery drawing will take place at the end of the European Week of Science and Technology, on November 8th, 2002, beginning at 13:00 hrs CET (12:00 UT) . This event will be broadcast by webcast and the outcome will be displayed via a dedicated webpage. All accepted reports (that fulfill the criteria) will be published on the Catch A Star! website soon thereafter.

Water safety training as a potential means of reducing risk of young children's drowning.

PubMed Central

Asher, K. N.; Rivara, F. P.; Felix, D.; Vance, L.; Dunne, R.

1995-01-01

OBJECTIVES: To determine the effects of training in swimming and water safety on young preschool-children's ability to recover safely from a simulated episode of falling into a swimming pool. DESIGN: Randomized trial of 12 or eight weeks' duration water safety and swimming lessons for children 24 to 42 months old. OUTCOME MEASURES: Swimming ability, deck behavior, water recovery, and swimming to side after jumping into pool were measured before, during, and after the training program. RESULTS: 109 children completed the study (61 in the 12 week group, 48 in the eight week group). The average age was 34.2 months, 54% were male. Swimming ability, deck behavior, water recovery, and jump and swim skills improved over baseline levels in both groups. By the end of training, the 12 week group improved more than the eight week group only in swimming ability. Improvements in water recovery and jump and swim skills were associated positively with changes in swimming ability. CONCLUSIONS: Swimming ability and safety skills of young preschool children can be improved through training. Such programs may offer some protection for children at risk of drowning and there was no indication that this program increased the risk of drowning. However, pool fencing, other barriers around water, and parental supervision still remain the most important prevention strategies to reduce drowning in young children. PMID:9346036

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

This year's edition of the annual Cosmo International Conference on Particle Physics and Cosmology -- Cosmo09 -- will be hosted by the CERN Theory Group from Monday September 7 till Friday September 11, 2009. The conference will take place at CERN, Geneva (Switzerland). The Cosmo series is one of the major venues of interaction between cosmologists and particle physicists. In the exciting LHC era, the Conference will be devoted to the modern interfaces between Fundamental and Phenomenological Particle Physics and Physical Cosmology and Astronomy. The Conference will be followed by the CERN TH Institute Particle Cosmology which will take placemore » from Monday September 14 till Friday September 18, 2009. The CERN-TH Institutes are visitor programs intended to bring together scientists with similar interests and to promote scientific collaborations. If you wish to participate, please register on the Institute web page. Link to last editions: COSMO 07 (U. of Sussex), COSMO 08 (U. of Wisconsin) List of plenary speakers: Gianfranco Bertone, Pierre Binetruy, Francois Bouchet, Juerg Diemand, Jonathan Feng, Gregory Gabadadze, Francis Halzen, Steen Hannestad, Will Kinney, Johannes Knapp, Hiranya Peiris, Will Percival, Syksy Rasanen, Alexandre Refregier, Pierre Salati, Roman Scoccimarro, Michael Schubnell, Christian Spiering, Neil Spooner, Andrew Tolley, Matteo Viel. The plenary program is available on-line.« less

CERN automatic audio-conference service

NASA Astrophysics Data System (ADS)

Sierra Moral, Rodrigo

2010-04-01

Scientists from all over the world need to collaborate with CERN on a daily basis. They must be able to communicate effectively on their joint projects at any time; as a result telephone conferences have become indispensable and widely used. Managed by 6 operators, CERN already has more than 20000 hours and 5700 audio-conferences per year. However, the traditional telephone based audio-conference system needed to be modernized in three ways. Firstly, to provide the participants with more autonomy in the organization of their conferences; secondly, to eliminate the constraints of manual intervention by operators; and thirdly, to integrate the audio-conferences into a collaborative working framework. The large number, and hence cost, of the conferences prohibited externalization and so the CERN telecommunications team drew up a specification to implement a new system. It was decided to use a new commercial collaborative audio-conference solution based on the SIP protocol. The system was tested as the first European pilot and several improvements (such as billing, security, redundancy...) were implemented based on CERN's recommendations. The new automatic conference system has been operational since the second half of 2006. It is very popular for the users and has doubled the number of conferences in the past two years.

Taking Energy to the Physics Classroom from the Large Hadron Collider at CERN

ERIC Educational Resources Information Center

Cid, Xabier; Cid, Ramon

2009-01-01

In 2008, the greatest experiment in history began. When in full operation, the Large Hadron Collider (LHC) at CERN will generate the greatest amount of information that has ever been produced in an experiment before. It will also reveal some of the most fundamental secrets of nature. Despite the enormous amount of information available on this…

Asymmetric B-factory note

DOE Office of Scientific and Technical Information (OSTI.GOV)

Calderon, M.

Three main issues giving purpose to our visit to CERN, ESRF and DESY were to: assess the current thinking at CERN on whether Eta, the gas desorption coefficient, would continue to decrease with continued with continued beam cleaning, determine if the time between NEG reconditioning could be expanded, and acquire a knowledge of the basic fabrication processes and techniques for producing beam vacuum chambers of copper.

65th birthday Jack Steinberger

ScienceCinema

None

2017-12-09

Laudatio pour Jack Steinberger né le 25 mai 1921, à l'occasion de son 65me anniversaire et sa retraite officielle, pour sa précieuse collaboration au Cern. Néanmoins son principal activité continuera comme avant dans sa recherche au Cern. Plusieurs orateurs prennent la parole (p.ex. E.Picasso) pour le féliciter et lui rendre hommage

The Proton Synchrotron (PS): At the Core of the CERN Accelerators

NASA Astrophysics Data System (ADS)

Cundy, Donald; Gilardoni, Simone

The following sections are included: * Introduction * Extraction: Getting the Beam to Leave the Accelerator * Acceleration and Bunch Gymnastics * Boosting PS Beam Intensity * Capacitive Energy Storage Replaces Flywheel * Taking the Neutrinos by the Horns * OMEGA: Towards the Electronic Bubble Chamber * ISOLDE: Targeting a New Era in Nuclear Physics * The CERN n_TOF Facility: Catching Neutrons on the Fly * References

38 CFR Appendix A to Part 49 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

... Federal awarding agency. 4. Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where... the basis of a standard work week of 40 hours. Work in excess of the standard work week is permissible... hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable to...

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.

PubMed

Ohtsuki, Mamitaro; Kubo, Hiroshi; Morishima, Hitomi; Goto, Ryosuke; Zheng, Richuan; Nakagawa, Hidemi

2018-06-15

Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52-week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque-type psoriasis. Patients randomly received guselkumab 50 mg or 100 mg at weeks 0, 4 and every 8 weeks, or placebo with cross-over to guselkumab 50 mg or 100 mg at week 16. Co-primary end-points were the proportion of patients achieving Investigator's Global Assessment (IGA) cleared/minimal (0/1) and 90% or more improvement in Psoriasis Area and Severity Index (PASI-90) at week 16. Overall, 192 patients were randomized to placebo, guselkumab 50 mg or 100 mg. At week 16, patients in the placebo group were crossed over to guselkumab 50 mg or 100 mg. At week 16, a significantly (P < 0.001) higher proportion of patients receiving guselkumab 50 mg and 100 mg versus placebo achieved IGA 0/1 (92.3% and 88.9% vs 7.8%) and PASI-90 (70.8% and 69.8% vs 0%). Patients in guselkumab 50 mg and 100 mg groups achieved significant improvement versus placebo in PASI-75 (89.2% and 84.1% vs 6.3%, P < 0.001) at week 16; improvement was maintained through week 52. Incidences of treatment-emergent adverse events were comparable among the groups through week 16; the most commonly reported was nasopharyngitis. No new safety concerns were observed until week 52. In conclusion, guselkumab treatment demonstrated superior efficacy over placebo and was well tolerated in Japanese patients with moderate to severe plaque-type psoriasis. © 2018 Janssen Pharmaceutical K.K. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.

Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.

PubMed

Nakajima, Atsushi; Seki, Mitsunori; Taniguchi, Shinya; Ohta, Akira; Gillberg, Per-Göran; Mattsson, Jan P; Camilleri, Michael

2018-05-24

A subset of patients with constipation has reduced colonic bile acid concentrations, which are associated with slow colonic transit. In a previous study, elobixibat, a locally acting ileal bile acid transporter inhibitor, accelerated colonic transit in Japanese patients with functional constipation. In this study, we aimed to determine the efficacy of elobixibat for short-term treatment of chronic constipation, and safety, patient satisfaction, and quality of life with long-term treatment. We did two phase 3 studies of patients aged 20-80 years in Japan with at least 6 months of chronic constipation, who satisfied Rome III criteria for functional constipation, including fewer than three spontaneous bowel movements per week. The first trial, including patients enrolled at 16 clinics, was a 2-week, randomised, double-blind, placebo-controlled study in which (after a 2-week run-in period) patients were randomly assigned (1:1) to either elobixibat 10 mg/day for 2 weeks or placebo. Randomisation was done with permuted block method (block size six) without stratification. Masking to treatment allocation was achieved with identical appearances of elobixibat and placebo, which were supplied in sealed, opaque containers. Group assignment was concealed from patients, investigators, and analysts. The second trial, including patients enrolled at 34 clinics or hospitals, was an open-label, 1-year study in which all patients received elobixibat; participants could titrate the dose to 5 mg/day or 15 mg/day, or maintain the 10 mg/day dose. In both studies, participants took the study drug as an oral tablet once per day before breakfast. The primary outcome of the 2-week randomised trial was the change from baseline (ie, last week of the 2-week run-in) in the frequency of spontaneous bowel movements during week 1 of treatment. The primary outcome of the 52-week open-label trial was safety (type, severity, and incidence of adverse drug reactions) at all times from treatment initiation. All efficacy analyses were based on the modified intention-to-treat (ITT) population without imputation for any missing data. Safety analyses included all patients who received at least one dose of study drug. These trials are registered with the Japan Pharmaceutical Information Center (numbers JapicCTI-153061 and JapicCTI-153062) and have been completed. Between Nov 4, 2015, and June 11, 2016, we assigned 133 patients to treatment in the 2-week randomised trial: 70 to elobixibat (69 included in the modified ITT and safety populations) and 63 to placebo. The frequency of spontaneous bowel movements per week during week 1 of treatment was greater with elobixibat (least-squares mean 6·4, 95% CI 5·3-7·6) than with placebo (1·7, 1·2-2·2), p<0·0001). Between Oct 31, 2015, and March 15, 2017, we allocated 341 patients to 52 weeks of elobixibat (340 included in the modified ITT and safety populations). 163 (48%) patients in the 52-week trial had an adverse drug reaction, the most common of which were mild gastrointestinal disorders (in 135 [40%] patients). Inguinal hernia was reported in one patient with elobixibat in the 52-week study as a moderate adverse drug reaction. The most common adverse drug reactions in both trials were mild abdominal pain (13 [19%] patients with elobixibat and one [2%] with placebo in the 2-week randomised trial, and 82 [24%] patients in the 52-week trial) and diarrhoea (nine [13%] patients with elobixibat and none with placebo in the 2-week randomised trial and 50 [15%] in the 52-week trial). Elobixibat resolved constipation in the short-term, and was well tolerated with both short-term and long-term treatment. The evidence supports the use of this novel approach to increase intracolonic concentrations of endogenous bile acid for the treatment of chronic constipation. EA Pharma and Mochida Pharmaceutical. Copyright © 2018 Elsevier Ltd. All rights reserved.

Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.

PubMed

Seino, Yutaka; Yabe, Daisuke; Takami, Akane; Niemoeller, Elisabeth; Takagi, Hiroki

2015-01-01

This 76-week, open-label, parallel-group study assessed the long-term safety of once-daily lixisenatide monotherapy in Japanese patients with type 2 diabetes mellitus. Patients were randomized to receive lixisenatide in a 2-step or a 1-step dose-increase regimen. The primary objective was to assess the safety of lixisenatide at week 24 by a descriptive comparison of the 2- and 1-step groups. As expected with treatment with a glucagon-like peptide-1 agonist, nausea was the most common treatment-emergent adverse event (2-step group: n=12/33 [36.4%] vs 1-step group: n=18/36 [50.0%] up to week 24). In total, 5/33 patients (15.2%; 2-step group) and 2/36 patients (5.6%; 1-step group) prematurely discontinued treatment up to week 24, mainly due to adverse events. Serious treatment-emergent adverse events occurred in 2/33 patients (6.1%; 2-step group) versus 0/36 patients (0%; 1-step group) up to week 24. Symptomatic hypoglycemia occurred in 2/33 patients (6.1%; 2-step group) versus 1/36 patients (2.8%; 1-step group) up to week 24, with no severe events reported. Glycated hemoglobin, fasting plasma glucose, and body weight were reduced from baseline at weeks 24 and 76. In Japanese patients with type 2 diabetes mellitus, once-daily lixisenatide monotherapy was well tolerated, with less nausea with the 2-step regimen. Copyright © 2015. Published by Elsevier Inc.

28 CFR Appendix A to Part 70 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

... Department. 4. Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where applicable, all... standard work week of forty hours. Work in excess of the standard work week is permissible provided that... all hours worked in excess of forty hours in the work week. Section 107 of the Act is applicable to...

HPC in a HEP lab: lessons learned from setting up cost-effective HPC clusters

NASA Astrophysics Data System (ADS)

Husejko, Michal; Agtzidis, Ioannis; Baehler, Pierre; Dul, Tadeusz; Evans, John; Himyr, Nils; Meinhard, Helge

2015-12-01

In this paper we present our findings gathered during the evaluation and testing of Windows Server High-Performance Computing (Windows HPC) in view of potentially using it as a production HPC system for engineering applications. The Windows HPC package, an extension of Microsofts Windows Server product, provides all essential interfaces, utilities and management functionality for creating, operating and monitoring a Windows-based HPC cluster infrastructure. The evaluation and test phase was focused on verifying the functionalities of Windows HPC, its performance, support of commercial tools and the integration with the users work environment. We describe constraints imposed by the way the CERN Data Centre is operated, licensing for engineering tools and scalability and behaviour of the HPC engineering applications used at CERN. We will present an initial set of requirements, which were created based on the above constraints and requests from the CERN engineering user community. We will explain how we have configured Windows HPC clusters to provide job scheduling functionalities required to support the CERN engineering user community, quality of service, user- and project-based priorities, and fair access to limited resources. Finally, we will present several performance tests we carried out to verify Windows HPC performance and scalability.

Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a Phase 3 randomized placebo-controlled trial.

PubMed

Tanaka, Yoshiya; Bass, Damon; Chu, Myron; Egginton, Sally; Ji, Beulah; Struemper, Herbert; Roth, David

2018-05-24

To assess the efficacy and safety of intravenous belimumab plus standard systemic lupus erythematosus (SLE) therapy (SoC) in Japanese patients with SLE. A Phase 3, multicenter, double-blind, placebo-controlled, 52-week study (BEL 113750; NCT01345253) in patients with SLE, randomized 2:1 to belimumab 10 mg/kg plus SoC or placebo plus SoC to Week 48. Sixty of 707 randomized patients were enrolled from study centers in Japan (belimumab, n = 39; placebo, n = 21). In this cohort, more patients achieved SLE Responder Index 4 response at Week 52 in the belimumab group compared with placebo (46.2% [18/39] vs 25.0% [5/20]; odds ratio, 2.57 [95% confidence interval: 0.78, 8.47]; p = 0.1204). Fewer patients receiving belimumab experienced a severe flare through Week 52, with longer median time to flare compared with placebo. More patients with baseline prednisone dose >7.5 mg/day receiving belimumab had a dose reduction of ≥25% from baseline to ≤7.5 mg/day during Weeks 40 to 52, compared with placebo. No new safety issues were identified within the Japanese cohort. In Japanese patients with SLE, belimumab improved disease activity, with efficacy and safety results similar and consistent to the pivotal Phase 3 trials, suggesting that belimumab is a potential treatment option in this population.

Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated With Dementia With Lewy Bodies: A Pilot Study

PubMed Central

Lapid, Maria I.; Kuntz, Karen M.; Mason, Sara S.; Aakre, Jeremiah A.; Lundt, Emily S.; Kremers, Walter; Allen, Laura A.; Drubach, Daniel A.; Boeve, Bradley F.

2017-01-01

Background/Aims Hypersomnia is common in dementia with Lewy bodies (DLB). We assessed the efficacy, safety, and tolerability of armodafinil for hypersomnia associated with DLB. Methods We performed a 12-week pilot trial of armodafinil therapy (125–250 mg orally daily) in DLB outpatients with hypersomnia. Patients underwent neurologic examinations, neuropsychological battery, laboratory testing, electrocardiography, and polysomnography. Efficacy was assessed at 2, 4, 8, and 12 weeks. Safety assessment included laboratory examinations, QTc interval, and heart rate. Tolerability was assessed by analysis of adverse events. Data were analyzed using the last-observation-carried-forward method. Results Of 20 participants, 17 completed the protocol. Median age was 72 years, most were men (80%), and most had spouses as caregivers. Epworth Sleepiness Scale (P<.001), Maintenance of Wakefulness Test (P=.003), and Clinical Global Impression of Change (P<.001) scores improved at week 12. Neuropsychiatric Inventory total score (P=.003), visual hallucinations (P=.003), and agitation (P=.02) improved at week 4. Caregiver overall quality of life improved at week 12 (P=.004). No adverse events occurred. Conclusion These pilot data suggest improvements in hypersomnia and wakefulness and reasonable safety and tolerability of armodafinil therapy in hypersomnolent patients with DLB. Our findings inform the use of pharmacologic strategies to manage hypersomnolence in these patients. PMID:28448998

The kaon identification system in the NA62 experiment at CERN

DOE Office of Scientific and Technical Information (OSTI.GOV)

Romano, A.

2015-07-01

The main goal of the NA62 experiment at CERN is to measure the branching ratio of the ultra-rare K{sup +} → π{sup +} ν ν-bar decay with 10% accuracy. NA62 will use a 750 MHz high-energy un-separated charged hadron beam, with kaons corresponding to ∼6% of the beam, and a kaon decay-in-flight technique. The positive identification of kaons is performed with a differential Cherenkov detector (CEDAR), filled with Nitrogen gas and placed in the incoming beam. To stand the kaon rate (45 MHz average) and meet the performances required in NA62, the Cherenkov detector has been upgraded (KTAG) with newmore » photon detectors, readout, mechanics and cooling systems. The KTAG provides a fast identification of kaons with an efficiency of at least 95% and precise time information with a resolution below 100 ps. A half-equipped KTAG detector has been commissioned during a technical run at CERN in 2012, while the fully equipped detector, its readout and front-end have been commissioned during a pilot run at CERN in October 2014. The measured time resolution and efficiency are within the required performances. (authors)« less

COSMO 09

ScienceCinema

None

2018-02-13

This year's edition of the annual Cosmo International Conference on Particle Physics and Cosmology -- Cosmo09 -- will be hosted by the CERN Theory Group from Monday September 7 till Friday September 11, 2009. The conference will take place at CERN, Geneva (Switzerland). The Cosmo series is one of the major venues of interaction between cosmologists and particle physicists. In the exciting LHC era, the Conference will be devoted to the modern interfaces between Fundamental and Phenomenological Particle Physics and Physical Cosmology and Astronomy. The Conference will be followed by the CERN TH Institute Particle Cosmology which will take place from Monday September 14 till Friday September 18, 2009. The CERN-TH Institutes are visitor programs intended to bring together scientists with similar interests and to promote scientific collaborations. If you wish to participate, please register on the Institute web page. Link to last editions: COSMO 07 (U. of Sussex), COSMO 08 (U. of Wisconsin) List of plenary speakers: Gianfranco Bertone, Pierre Binetruy, Francois Bouchet, Juerg Diemand, Jonathan Feng, Gregory Gabadadze, Francis Halzen, Steen Hannestad, Will Kinney, Johannes Knapp, Hiranya Peiris, Will Percival, Syksy Rasanen, Alexandre Refregier, Pierre Salati, Roman Scoccimarro, Michael Schubnell, Christian Spiering, Neil Spooner, Andrew Tolley, Matteo Viel. The plenary program is available on-line.

A New Approach to Logging.

ERIC Educational Resources Information Center

Miles, Donna

2001-01-01

In response to high numbers of preventable fatal accidents in the logging industry, the Occupational Safety and Health Administration (OSHA) developed a week-long logger safety training program that includes hands-on learning of safety techniques in the woods. Reaching small operators has been challenging; outreach initiatives in Maine, North…

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

PubMed Central

Li, Huafang; Li, Yan; Feng, Yu; Zhuo, Jianmin; Turkoz, Ibrahim; Mathews, Maju; Tan, Wilson

2018-01-01

Purpose To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. Patients and methods PREVAIL was a multicenter, single-arm, open-label, prospective Phase IV study in hospitalized Asian patients (either sex, aged 18–65 years) diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition). Change from baseline to week 13 in primary (Positive and Negative Syndrome Scale [PANSS] total score), secondary endpoints (PANSS responder rate, PANSS subscale, PANSS Marder factor, Clinical Global Impression-Severity, and Personal and Social Performance scale scores, readiness for hospital discharge questionnaire) and safety were assessed in this post hoc analysis. Results Significant mean reduction from baseline to week 13 in the PANSS total score, 30% PANSS responder rates (P≤0.01), PANSS subscales (positive and general psychopathology; all P≤0.01), PANSS Marder factor (positive symptoms, uncontrolled hostility, and excitement and anxiety/depression; all P≤0.01), Personal and Social Performance scale scores (P≤0.05) and Clinical Global Impression-Severity categorical summary (P≤0.05) were significantly greater in the ≤1 week subgroup versus >1 week subgroup (P≤0.05). The readiness for hospital discharge questionnaire improved over time for the overall study population, but remained similar between subgroups at all-time points. Treatment-emergent adverse events were similar between the subgroups. Conclusion Early initiation of once-monthly paliperidone palmitate in hospitalized patients with acute exacerbation of schizophrenia led to greater improvements in psychotic symptoms with comparable safety than treatment initiation following 1 week of hospitalization. PMID:29731633

The beam test of muon detector parameters for the SHiP experiment at CERN

NASA Astrophysics Data System (ADS)

Likhacheva, V. L.; Kudenko, Yu. G.; Mefodiev, A. V.; Mineev, O. V.; Khotyantsev, A. N.

2018-01-01

Scintillation detectors based on extruded plastics have been tested in a 10 GeV/c beam at CERN. The scintillation signal readout was provided using optical wavelength shifting fibers Y11 Kuraray and Hamamatsu MPPC micropixel avalanche photodiodes. The light yield was scanned along and across the detectors. Time resolution was found by fitting the MPPC digitized pulse rise and other methods.

Investigating the Inverse Square Law with the Timepix Hybrid Silicon Pixel Detector: A CERN [at] School Demonstration Experiment

ERIC Educational Resources Information Center

Whyntie, T.; Parker, B.

2013-01-01

The Timepix hybrid silicon pixel detector has been used to investigate the inverse square law of radiation from a point source as a demonstration of the CERN [at] school detector kit capabilities. The experiment described uses a Timepix detector to detect the gamma rays emitted by an [superscript 241]Am radioactive source at a number of different…

Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.

PubMed

Spierings, Egilius L H; Drossman, Douglas A; Cryer, Byron; Mazen Jamal, M; Losch-Beridon, Taryn; Mareya, Shadreck M; Wang, Martin

2018-06-01

The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response. In the primary study, adults with OIC (fewer than three spontaneous bowel movements [SBMs] per week) were randomized to receive lubiprostone 24 mcg or placebo twice daily for 12 weeks. The primary end point was a change from baseline in the frequency of SBMs at week 8 in patients without a prior dose reduction. For the pooled analysis, the efficacy of lubiprostone was compared with placebo in patients receiving methadone or nonmethadone opioids. Responders were defined as patients with nine or more weeks of nonmissing SBM data who had one or more additional SBMs per week from baseline for each week that data were available and three or more SBMs per week for nine or more weeks. In the primary study, the change from baseline at week 8 in SBM frequency was similar in the lubiprostone and placebo groups (P = 0.842). In the pooled analysis, the response rate was significantly higher with lubiprostone treatment vs placebo for patients receiving nonmethadone opioids (P = 0.002) but was similar between lubiprostone treatment and placebo in patients receiving methadone (P = 0.692). The safety profile of lubiprostone was unaffected by methadone use. The phase 3 study did not meet its primary efficacy end point. However, analysis of pooled data from all phase 3 studies in the OIC clinical development program, stratified by methadone opioid usage, confirmed that lubiprostone is effective for treatment of OIC in patients taking nonmethadone opioids; no safety concerns were identified based on the type of opioid used.

14 CFR Appendix A to Subpart B of... - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-01-01

... suspected or reported violations to the NASA. 4. Contract Work Hours and Safety Standards Act (40 U.S.C. 327... laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work week is... pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable...

14 CFR Appendix to Part 1274 - Listing of Exhibits

Code of Federal Regulations, 2010 CFR

2010-01-01

... laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work week is... pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable... Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where applicable, all contracts awarded by...

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

PubMed Central

Cariou, Bertrand; Müller‐Wieland, Dirk; Colhoun, Helen M.; Del Prato, Stefano; Tinahones, Francisco J.; Ray, Kausik K.; Bujas‐Bobanovic, Maja; Domenger, Catherine; Mandel, Jonas; Samuel, Rita; Henry, Robert R.

2017-01-01

Aims To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy. Methods Participants at high cardiovascular risk with T2D (n = 441) or T1D (n = 76) and LDL cholesterol levels ≥1.8 mmol/L (≥70 mg/dL) were randomized 2:1 to alirocumab:placebo administered subcutaneously every 2 weeks, for 24 weeks' double‐blind treatment. Alirocumab‐treated participants received 75 mg every 2 weeks, with blinded dose increase to 150 mg every 2 weeks at week 12 if week 8 LDL cholesterol levels were ≥1.8 mmol/L. Primary endpoints were percentage change in calculated LDL cholesterol from baseline to week 24, and safety assessments. Results Alirocumab reduced LDL cholesterol from baseline to week 24 by a mean ± standard error of 49.0% ± 2.7% and 47.8% ± 6.5% vs placebo (both P < .0001) in participants with T2D and T1D, respectively. Significant reductions were observed in non‐HDL cholesterol (P < .0001), apolipoprotein B (P < .0001) and lipoprotein (a) (P ≤ .0039). At week 24, 76.4% and 70.2% of the alirocumab group achieved LDL cholesterol <1.8 mmol/L in the T2D and T1D populations (P < .0001), respectively. Glycated haemoglobin and fasting plasma glucose levels remained stable for the study duration. Treatment‐emergent adverse events were observed in 64.5% of alirocumab‐ vs 64.1% of placebo‐treated individuals (overall population). Conclusions Alirocumab produced significant LDL cholesterol reductions in participants with insulin‐treated diabetes regardless of diabetes type, and was generally well tolerated. Concomitant administration of alirocumab and insulin did not raise any safety concerns (NCT02585778). PMID:28905478

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.

PubMed

Li, Huafang; Li, Yan; Feng, Yu; Zhuo, Jianmin; Turkoz, Ibrahim; Mathews, Maju; Tan, Wilson

2018-01-01

To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. PREVAIL was a multicenter, single-arm, open-label, prospective Phase IV study in hospitalized Asian patients (either sex, aged 18-65 years) diagnosed with schizophrenia ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition). Change from baseline to week 13 in primary (Positive and Negative Syndrome Scale [PANSS] total score), secondary endpoints (PANSS responder rate, PANSS subscale, PANSS Marder factor, Clinical Global Impression-Severity, and Personal and Social Performance scale scores, readiness for hospital discharge questionnaire) and safety were assessed in this post hoc analysis. Significant mean reduction from baseline to week 13 in the PANSS total score, 30% PANSS responder rates ( P ≤0.01), PANSS subscales (positive and general psychopathology; all P ≤0.01), PANSS Marder factor (positive symptoms, uncontrolled hostility, and excitement and anxiety/depression; all P ≤0.01), Personal and Social Performance scale scores ( P ≤0.05) and Clinical Global Impression-Severity categorical summary ( P ≤0.05) were significantly greater in the ≤1 week subgroup versus >1 week subgroup ( P ≤0.05). The readiness for hospital discharge questionnaire improved over time for the overall study population, but remained similar between subgroups at all-time points. Treatment-emergent adverse events were similar between the subgroups. Early initiation of once-monthly paliperidone palmitate in hospitalized patients with acute exacerbation of schizophrenia led to greater improvements in psychotic symptoms with comparable safety than treatment initiation following 1 week of hospitalization.

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.

PubMed

Wei, James C-C; Baeten, Dominique; Sieper, Joachim; Deodhar, Atul; Bhosekar, Vaishali; Martin, Ruvie; Porter, Brian

2017-05-01

To evaluate efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis (AS) via a pooled subgroup analysis from two phase 3 studies, MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375). In MEASURE 1, patients were randomized to intravenous secukinumab 10 mg/kg or placebo at baseline, Weeks 2 and 4, followed by subcutaneous (s.c.) secukinumab 150 mg, 75 mg or placebo every 4 weeks (q4w) at Week 8. In MEASURE 2, patients were randomized to s.c. secukinumab 150 mg, 75 mg or placebo at baseline, Weeks 1, 2 and 3, and q4w starting at Week 4. Efficacy outcomes were SpondyloArthritis International Society (ASAS) 20/40, high-sensitivity C-reactive protein (hsCRP), ASAS5/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form-36 physical component summary, AS quality of life (QoL), ASAS partial remission, and Ankylosing Spondylitis Disease Activity Score - CRP at Weeks 16 and 52. Due to lack of efficacy, the secukinumab 75 mg dose in MEASURE 2 was excluded from this pooled Asian subgroup analysis. Safety analysis included patients who received ≥ 1 dose of study treatment. Of 517 patients enrolled into the MEASURE studies, 69 (13.3%) were Asians: 46 in pooled secukinumab and 23 in placebo. At Week 16, ASAS20/40 responses in Asian patients were 69.6%/43.5% with pooled secukinumab versus 26.1%/17.4% with placebo, which were comparable with rates reported in the overall study population. Secukinumab improved predefined efficacy endpoints at Week 16, with responses sustained through Week 52. Secukinumab was well tolerated in Asian patients, with a safety profile consistent with that reported in the overall study population. Secukinumab improved signs and symptoms, physical function, and disease-specific QoL in Asian patients with active AS. © 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

PubMed Central

Yoo, Dae Hyun; Hrycaj, Pawel; Miranda, Pedro; Ramiterre, Edgar; Piotrowski, Mariusz; Shevchuk, Sergii; Kovalenko, Volodymyr; Prodanovic, Nenad; Abello-Banfi, Mauricio; Gutierrez-Ureña, Sergio; Morales-Olazabal, Luis; Tee, Michael; Jimenez, Renato; Zamani, Omid; Lee, Sang Joon; Kim, HoUng; Park, Won; Müller-Ladner, Ulf

2013-01-01

Objectives To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. Methods Phase III randomised, double-blind, multicentre, multinational, parallel-group study. Patients with active disease despite MTX (12.5–25 mg/week) were randomised to receive 3 mg/kg of CT-P13 (n=302) or INX (n=304) with MTX and folic acid. The primary endpoint was the American College of Rheumatology 20% (ACR20) response at week 30. Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ±15%. Secondary endpoints included ACR response criteria, European League Against Rheumatism (EULAR) response criteria, change in Disease Activity Score 28 (DAS28), Medical Outcomes Study Short-Form Health Survey (SF-36), Simplified Disease Activity Index, Clinical Disease Activity Index, as well as pharmacokinetic (PK) and pharmacodynamic (PD) parameters, safety and immunogenicity. Results At week 30, ACR20 responses were 60.9% for CT-P13 and 58.6% for INX (95% CI −6% to 10%) in the intention-to-treat population. The proportions in CT-P13 and INX groups achieving good or moderate EULAR responses (C reactive protein (CRP)) at week 30 were 85.8% and 87.1%, respectively. Low disease activity or remission according to DAS28–CRP, ACR–EULAR remission rates, ACR50/ACR70 responses and all other PK and PD endpoints were highly similar at week 30. Incidence of drug-related adverse events (35.2% vs 35.9%) and detection of antidrug antibodies (48.4% vs 48.2%) were highly similar for CT-P13 and INX, respectively. Conclusions CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity. CT-P13 was well tolerated, with a safety profile comparable with that of INX. ClinicalTrials.gov Identifier NCT01217086 PMID:23687260

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

PubMed

Ashina, Messoud; Dodick, David; Goadsby, Peter J; Reuter, Uwe; Silberstein, Stephen; Zhang, Feng; Gage, Julia R; Cheng, Sunfa; Mikol, Daniel D; Lenz, Robert A

2017-09-19

To assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (EM). Patients enrolled in a 12-week, double-blind, placebo-controlled clinical trial (NCT01952574) who continued in an open-label extension (OLE) study will receive erenumab 70 mg every 4 weeks for up to 5 years. This preplanned interim analysis, conducted after all participants had completed the 1-year open-label follow-up, evaluated changes in monthly migraine days (MMD), achievement of ≥50%, ≥75%, and 100% reductions, Headache Impact Test (HIT-6) score, Migraine-Specific Quality of Life (MSQ), Migraine Disability Assessment (MIDAS), and safety. Data reported as observed without imputation for missing data. Of 472 patients enrolled in the parent study, 383 continued in the OLE with a median exposure to erenumab of 575 days (range 28-822 days). Mean (SD) MMD were 8.8 (2.6) at parent study baseline, 6.3 (4.2) at week 12 (beginning of OLE), and 3.7 (4.0) at week 64 (mean change from baseline [reduction] of 5.0 days). At week 64, 65%, 42%, and 26% achieved ≥50%, ≥75%, and 100% reduction in MMD, respectively. Mean HIT-6 scores were 60.2 (6.3) at baseline and 51.7 (9.2) at week 64. MSQ and MIDAS improvements from baseline were maintained through week 64. Safety profiles during the OLE were similar to those in the double-blind phase, which overall were similar to placebo. One-year efficacy, supported by functional improvements and favorable safety and tolerability profiles, supports further investigation of erenumab as a preventive treatment in patients with EM. NCT01952574. This study provides Class IV evidence that for patients with episodic migraine, erenumab reduces long-term MMD and improves headache-related disability and migraine-specific quality of life. © 2017 American Academy of Neurology.

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

PubMed

Pavel, Marianne; Gross, David J; Benavent, Marta; Perros, Petros; Srirajaskanthan, Raj; Warner, Richard R P; Kulke, Matthew H; Anthony, Lowell B; Kunz, Pamela L; Hörsch, Dieter; Weickert, Martin O; Lapuerta, Pablo; Jiang, Wenjun; Kassler-Taub, Kenneth; Wason, Suman; Fleming, Rosanna; Fleming, Douglas; Garcia-Carbonero, Rocio

2018-03-01

Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 12-week double-blind treatment period followed by a 36-week open-label extension (OLE). The primary safety and efficacy endpoints were incidence of treatment-emergent adverse events (TEAEs) and percent change from baseline in 24-h u5-HIAA at week 12. Patients ( N  = 76) were randomly assigned (1:1:1) to receive placebo or telotristat ethyl 250 mg or 500 mg 3 times per day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the OLE. Through week 12, TEAEs were generally mild to moderate in severity; 5 (placebo), 1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg) patients experienced serious events, and the rate of TEAEs in the OLE was comparable. At week 12, significant reductions in u5-HIAA from baseline were observed, with Hodges-Lehmann estimators of median treatment differences from placebo of -54.0% (95% confidence limits, -85.0%, -25.1%, P  < 0.001) and -89.7% (95% confidence limits, -113.1%, -63.9%, P  < 0.001) for telotristat ethyl 250 mg and 500 mg. These results support the safety and efficacy of telotristat ethyl when added to SSAs in patients with CS diarrhea (ClinicalTrials.gov identifier: Nbib2063659). © 2018 The authors.

Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.

PubMed

Weiden, Peter J; Du, Yangchun; Liu, Chih-Chin; Stanford, Arielle D

2018-06-26

Switching antipsychotic medications is common in patients with schizophrenia who are experiencing persistent symptoms or tolerability issues associated with their current drug regimen. This analysis assessed the safety of switching from an oral antipsychotic to the long-acting injectable antipsychotic aripiprazole lauroxil (AL). This was a post hoc analysis of outpatients with schizophrenia who were prescribed an oral antipsychotic and who enrolled in an international, open-label, long-term (52-week) safety study of AL. The analysis focused on the first 3 injections of AL 882 mg over 12 weeks, divided into the immediate 4-week crossover period between the first and second AL injections (initiation phase) and the subsequent 8 weeks (stabilization phase). Patients were grouped by preswitch oral antipsychotic medication, and safety and clinical symptoms were assessed. In total, 190 patients had switched from one of the following oral antipsychotic medications: aripiprazole, conventional antipsychotics, risperidone/paliperidone, olanzapine, or quetiapine. The 12-week completion rate was high (92.1%) and similar across the different preswitch oral antipsychotic groups. Overall, adverse event (AE) rates experienced over 12 weeks were modest; no AEs were considered serious. The most common AEs in the initiation phase were injection site pain (5.8%), insomnia (5.8%), and akathisia (3.2%). No apparent relationship was observed between preswitch medication and early-onset AEs. Mean Positive and Negative Syndrome Scale total scores remained stable during this period across preswitch antipsychotic groups. Switching from an oral antipsychotic to AL was feasible in an outpatient setting for patients with schizophrenia, and the 12-week retention rate was favorable.

Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.

PubMed

Rakugi, Hiromi; Tsuchihashi, Takuya; Shimada, Kazuyuki; Numaguchi, Hirotaka; Nishida, Chisato; Yamaguchi, Hiroya; Fujimoto, Go; Azuma, Kyoichi; Shirakawa, Masayoshi; Hanson, Mary E; Fujita, Kenji P

2014-12-01

Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose combination. In one study, subjects received losartan 50 mg (L50) plus H12.5 during an 8-week filter period. They were then randomized to either L100/H12.5 or L50/H12.5 for another 8 weeks, followed by L100/H12.5 for 44 weeks. The primary end point was safety of L100/H12.5 for 52 weeks. In the second study, subjects received L100 during an 8-week filter period. Subjects were then randomized to receive either L100/H12.5 or L100 for a further 8 weeks. The primary end point was change from baseline in sitting diastolic blood pressure (SiDBP) at week 8. Safety was assessed throughout both studies. L100/H12.5 reduced SiDBP and sitting systolic blood pressure (SiSBP) at 8 weeks, and when compared with L100, the differences were statistically significant for both measures (P<0.001). L100/H12.5 reductions SiDBP for 8 weeks were comparable to L50/H12.5. The efficacy of L100/H12.5 was maintained to week 52. Drug-related adverse events with an incidence ⩾ 2% in the L100/H12.5 group during the 52-week extension period were an increase in aspartate aminotransferase and in blood uric acid. Additionally, mean uric acid levels were reduced by 0.57 mg dl(-1) from baseline with long-term treatment with L100/H12.5 in subjects whose baseline uric acid level was >7.0 mg dl(-1). In conclusion, L100/H12.5 was shown to be more effective than L100 at reducing SiDBP and SiSBP and showed good tolerability in Japanese patients with essential hypertension.

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

PubMed Central

Rakugi, Hiromi; Enya, Kazuaki; Sugiura, Kenkichi; Ikeda, Yoshinori

2012-01-01

Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter, randomized, double-blind study compared the efficacy and safety of azilsartan (20–40 mg once daily by forced titration) and its ability to provide 24-h blood pressure (BP) control, with that of candesartan cilexetil (candesartan; 8–12 mg once daily by forced titration) in 622 Japanese patients with grade I–II essential hypertension. Efficacy was evaluated by clinic-measured sitting BP, and by ambulatory BP monitoring (ABPM) at week 14. Participants (mean age: 57 years, 61% males) had a mean baseline sitting BP of 159.8/100.4 mm Hg. The mean change from baseline in sitting diastolic BP at week 16 (primary endpoint) was −12.4 mm Hg in the azilsartan group and −9.8 mm Hg in the candesartan group, demonstrating a statistically significant greater reduction with azilsartan vs. candesartan (difference: −2.6 mm Hg, 95% confidence interval (CI): −4.08 to −1.22 mm Hg, P=0.0003). The week 16 (secondary endpoint) mean change from baseline in sitting systolic BP was −21.8 mm Hg and −17.5 mm Hg, respectively, a significant decrease with azilsartan vs. candesartan (difference: −4.4 mm Hg, 95% CI: −6.53 to −2.20 mm Hg, P<0.0001). On ABPM, the week 14 mean changes from baseline in diastolic and systolic BP were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning. Safety and tolerability were similar among the two groups. These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety. PMID:22278628

Introduction

NASA Astrophysics Data System (ADS)

2016-11-01

A year has passed since Raymond left us, but for many of us it seems like it was yesterday. Indeed, since his departure last July, not a week or even a day has gone by without his former collaborators, students, colleagues having a thought for him. Some initiatives have already been taken in order to celebrate Raymond's memory. The special day for Raymond organized at CERN last December was an opportunity to celebrate this exceptional man. In Annecy, with the implication of CERN and Marseille and thanks to a spontaneous and generous gift of Raymond's wife Marie-Françoise and their children Olivier and Thierry, the opening of a special room containing a huge collection of scientific books of Raymond is almost completed. It is in the same spirit that the present editors decided to dedicate a special issue of Nuclear Physics in memory of Raymond. In the following pages, some important problems Raymond was interested in are presented, discussed and sometimes solved. The diversity of topics in this issue reflects well the extent of Raymond's interests in Physics and Mathematics. Raymond was not only a gifted man for the so-called theoretical sciences, mathematics and physics, but he was also passionate about arts, music, drawing and of course literature, just as he was a leader always ready to bring his help and share his deep knowledge in physics and mathematics with others. Many people were deeply touched by Paul Sorba's tribute during Raymond's funeral. This is why we asked Paul to translate his speech, originally given in French, which seemed to us a perfect Prolegomena for this special volume of Nuclear Physics. The volume "Mathematical Foundations of Quantum Field Theory" is organized as follows: General and historical contributions

76 FR 18389 - Safety Zones; Charleston Race Week, Charleston Harbor, Charleston, SC

Federal Register 2010, 2011, 2012, 2013, 2014

2011-04-04

... South Carolina Maritime Foundation, will be hosting three sailboat races commencing on April 14, 2011... the hazards associated with the sailboat races. Discussion of Rule The three temporary safety zones...

DAMPE prototype and its beam test results at CERN

NASA Astrophysics Data System (ADS)

Wu, Jian; Hu, Yiming; Chang, Jin

The first Chinese high energy cosmic particle detector(DAMPE) aims to detect electron/gamma at the range between 5GeV and 10TeV in space. A prototype of this detector is made and tested using both cosmic muons and test beam at CERN. Energy and space resolution as well as strong separation power for electron and proton are shown in the results. The detector structure is illustrated as well.

About Separation of Hadron and Electromagnetic Cascades in the Pamela Calorimeter

NASA Astrophysics Data System (ADS)

Stozhkov, Yuri I.; Basili, A.; Bencardino, R.; Casolino, M.; de Pascale, M. P.; Furano, G.; Menicucci, A.; Minori, M.; Morselli, A.; Picozza, P.; Sparvoli, R.; Wischnewski, R.; Bakaldin, A.; Galper, A. M.; Koldashov, S. V.; Korotkov, M. G.; Mikhailov, V. V.; Voronov, S. A.; Yurkin, Y. T.; Adriani, O.; Bonechi, L.; Bongi, M.; Papini, P.; Ricciarini, S. B.; Spillantini, P.; Straulino, S.; Taccetti, F.; Vannuccini, E.; Castellini, G.; Boezio, M.; Bonvicini, M.; Mocchiutti, E.; Schiavon, P.; Vacchi, A.; Zampa, G.; Zampa, N.; Carlson, P.; Lund, J.; Lundquist, J.; Orsi, S.; Pearce, M.; Barbarino, G. C.; Campana, D.; Osteria, G.; Rossi, G.; Russo, S.; Boscherini, M.; Mennh, W.; Simonh, M.; Bongiorno, L.; Ricci, M.; Ambriola, M.; Bellotti, R.; Cafagna, F.; Circella, M.; de Marzo, C.; Giglietto, N.; Mirizzi, N.; Romita, M.; Spinelli, P.; Bogomolov, E.; Krutkov, S.; Vasiljev, G.; Bazilevskaya, G. A.; Kvashnin, A. N.; Logachev, V. I.; Makhmutov, V. S.; Maksumov, O. S.; Stozhkov, Yu. I.; Mitchell, J. W.; Streitmatter, R. E.; Stochaj, S. J.

Results of calibration of the PAMELA instrument at the CERN facilities are discussed. In September, 2003, the calibration of the Neutron Detector together with the Calorimeter was performed with the CERN beams of electrons and protons with energies of 20 - 180 GeV. The implementation of the Neutron Detector increases a rejection factor of hadrons from electrons about ten times. The results of calibration are in agreement with calculations.

Upper limits of the proton magnetic form factor in the time-like region from p¯p--> e+e- at the CERN-ISR

NASA Astrophysics Data System (ADS)

Baglin, C.; Baird, S.; Bassompierre, G.; Borreani, G.; Brient, J. C.; Broll, C.; Brom, J. M.; Bugge, L.; Buran, T.; Burq, J. P.; Bussière, A.; Buzzo, A.; Cester, R.; Chemarin, M.; Chevallier, M.; Escoubes, B.; Fay, J.; Ferroni, S.; Gracco, V.; Guillaud, J. P.; Khan-Aronsen, E.; Kirsebom, K.; Ille, B.; Lambert, M.; Leistam, L.; Lundby, A.; Macri, M.; Marchetto, F.; Mattera, L.; Menichetti, E.; Mouellic, B.; Pastrone, N.; Petrillo, L.; Pia, M. G.; Poulet, M.; Pozzo, A.; Rinaudo, G.; Santroni, A.; Severi, M.; Skjevling, G.; Stapnes, S.; Stugu, B.; Tomasini, F.; Valbusa, U.

1985-11-01

From the measurement of e+e- pairs from the reaction p¯p-->e+e- at the CERN-ISR, using an antiproton beam and a hydrogen jet target, we derived upper limits for the proton magnetic form factor in the time-like region at Q2⋍8.9(GeV/c)2 and Q2⋍12.5(GeV/c)2.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

PubMed

Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieslawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Lee, Younju; Rho, Young Hee

2018-02-01

Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those in patients who maintained treatment with INF or SB2. Patients with moderate to severe RA despite methotrexate treatment were randomised (1:1) to receive SB2 or INF at weeks 0, 2 and 6 and every 8 weeks thereafter until week 46. At week 54, patients previously receiving INF were rerandomised (1:1) to switch to SB2 (INF/SB2 (n=94)) or to continue on INF (INF/INF (n=101)) up to week 70. Patients previously receiving SB2 continued on SB2 (SB2/SB2 (n=201)) up to week 70. Efficacy, safety and immunogenicity were assessed up to week 78. Efficacy was sustained and comparable across treatment groups. American College of Rheumatology (ACR) 20 responses between weeks 54 and 78 ranged from 63.5% to 72.3% with INF/SB2, 66.3%%-69.4% with INF/INF and 65.6%-68.3% with SB2/SB2. Treatment-emergent adverse events during this time occurred in 36.2%, 35.6% and 40.3%, respectively, and infusion-related reactions in 3.2%, 2.0% and 3.5%. Among patients who were negative for antidrug antibodies (ADA) up to week 54, newly developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and SB2/SB2 groups, respectively. The efficacy, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2. NCT01936181; EudraCT number: 2012-005733-37. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study

PubMed Central

Liang, Ying; Cao, Changan; Zhu, Cheng; Wang, Chuanyue; Zhang, Congpei; Dong, Fang; Yang, Fude; Deng, Hong; Yu, Jingjie; Tang, Jisheng; Su, Lei; Xin, Limin; Hong, Ling; Gao, Minglong; Tang, Muni; Xie, Shiping; Lu, Shuiping; Liu, Tiebang; Xu, Xiaojin; Wang, Xijin; Li, Xuanzi; Wang, Xueyi; Li, Yi; Zhang, Yong; Chen, Zhiyu

2016-01-01

Abstract Introduction This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. Methods A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Results A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events. Discussion Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia. PMID:27020720

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.

PubMed

Seino, Yutaka; Terauchi, Yasuo; Wang, Xiangling; Watanabe, Daisuke; Niemoeller, Elisabeth

2018-01-01

To assess the overall safety of lixisenatide monotherapy in Japanese patients with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus, previously treated with ≤1 oral antidiabetic drug, were enrolled in an uncontrolled, open-label, single-arm study over 24 and 52 weeks. Any oral antidiabetic drug treatment was stopped at the start of the 6-week run-in period. From baseline, patients received once-daily lixisenatide monotherapy (10 μg for 1 week, 15 μg for 1 week, 20 μg thereafter) for 52 weeks (first 140 patients enrolled) or 24 weeks (subsequently enrolled patients). The primary end-point was safety over 24 and 52 weeks. Secondary efficacy end-points included absolute change in glycated hemoglobin, fasting plasma glucose and bodyweight from baseline. Of 428 patients screened, 361 and 140 were treated for 24 and 52 weeks, respectively; 88.4 and 90.0% completed treatment. During the 24- and 52-week treatment periods, 268/361 (74.2%) and 117/140 (83.6%) patients, respectively, had treatment-emergent adverse events; the most frequently reported was nausea (33.2 and 31.4%, respectively). The risk of severe hypoglycemia was low; only one case was reported. Lixisenatide treatment resulted in a decrease in mean glycated hemoglobin A1c (-0.98 and -0.86%), fasting plasma glucose (-1.05 and -0.85 mmol/L), and bodyweight (-1.33 and -1.48 kg) for the 24- and 52-week treatment periods, respectively. Once-daily lixisenatide monotherapy was associated with a safety profile in line with the glucagon-like peptide-1 receptor agonist class, and improved glycemic control in Japanese patients with type 2 diabetes mellitus. © 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

PubMed

Rakugi, Hiromi; Enya, Kazuaki; Sugiura, Kenkichi; Ikeda, Yoshinori

2012-05-01

Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter, randomized, double-blind study compared the efficacy and safety of azilsartan (20-40 mg once daily by forced titration) and its ability to provide 24-h blood pressure (BP) control, with that of candesartan cilexetil (candesartan; 8-12 mg once daily by forced titration) in 622 Japanese patients with grade I-II essential hypertension. Efficacy was evaluated by clinic-measured sitting BP, and by ambulatory BP monitoring (ABPM) at week 14. Participants (mean age: 57 years, 61% males) had a mean baseline sitting BP of 159.8/100.4 mm Hg. The mean change from baseline in sitting diastolic BP at week 16 (primary endpoint) was -12.4 mm Hg in the azilsartan group and -9.8 mm Hg in the candesartan group, demonstrating a statistically significant greater reduction with azilsartan vs. candesartan (difference: -2.6 mm Hg, 95% confidence interval (CI): -4.08 to -1.22 mm Hg, P=0.0003). The week 16 (secondary endpoint) mean change from baseline in sitting systolic BP was -21.8 mm Hg and -17.5 mm Hg, respectively, a significant decrease with azilsartan vs. candesartan (difference: -4.4 mm Hg, 95% CI: -6.53 to -2.20 mm Hg, P<0.0001). On ABPM, the week 14 mean changes from baseline in diastolic and systolic BP were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning. Safety and tolerability were similar among the two groups. These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

PubMed

Imafuku, Shinichi; Honma, Masaru; Okubo, Yukari; Komine, Mayumi; Ohtsuki, Mamitaro; Morita, Akimichi; Seko, Noriko; Kawashima, Naoko; Ito, Saori; Shima, Tomohiro; Nakagawa, Hidemi

2016-09-01

Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human-recombinant anti-interleukin-17A monoclonal antibody was indicated for psoriasis vulgaris and psoriatic arthritis in Japan but is not yet investigated for GPP. In this phase III, open-label multicenter single arm study, the efficacy and safety of secukinumab as monotherapy or with co-medication was evaluated in 12 Japanese patients with GPP. All the patients received secukinumab 150 mg s.c. at baseline, week 1, 2, 3 and 4, and then every 4 weeks. Two non-responders were up-titrated to 300 mg. Change in GPP severity from baseline was evaluated by clinical global impression (CGI) categorized as "worsened", "no change", "minimally improved", "much improved" or "very much improved". Treatment success was achieved by 83.3% (n = 10) of patients at week 16 (primary end-point) with CGI evaluated as "very much improved" (n = 9) and "much improved" (n = 1). Moreover, the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients. The improvements were sustained throughout 52 weeks. Over the 52-week treatment period, secukinumab was well tolerated with no unexpected safety signals. Nasopharyngitis, urticaria, diabetes mellitus and arthralgia were the frequent adverse events reported. The data from this study shows that secukinumab can become one of the potent treatment options for GPP. © 2016 Japanese Dermatological Association.

Safe Kids Week: Analysis of gender bias in a national child safety campaign, 1997-2016.

PubMed

Bauer, Michelle E E; Brussoni, Mariana; Giles, Audrey R; Fuselli, Pamela

2017-09-29

Background and Purpose Child safety campaigns play an important role in disseminating injury prevention information to families. A critical discourse analysis of gender bias in child safety campaign marketing materials can offer important insights into how families are represented and the potential influence that gender bias may have on uptake of injury prevention information. Methods Our approach was informed by poststructural feminist theory, and we used critical discourse analysis to identify discourses within the poster materials. We examined the national Safe Kids Canada Safe Kids Week campaign poster material spanning twenty years (1997-2016). Specifically, we analyzed the posters' typeface, colour, images, and language to identify gender bias in relation to discourses surrounding parenting, safety, and societal perceptions of gender. Results The findings show that there is gender bias present in the Safe Kids Week poster material. The posters represent gender as binary, mothers as primary caregivers, and showcase stereotypically masculine sporting equipment among boys and stereotypically feminine equipment among girls. Interestingly, we found that the colour and typeface of the text both challenge and perpetuate the feminization of safety. Discussion It is recommended that future child safety campaigns represent changing family dynamics, include representations of children with non-traditionally gendered sporting equipment, and avoid the representation of gender as binary. This analysis contributes to the discussion of the feminization of safety in injury prevention research and challenges the ways in which gender is represented in child safety campaigns. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris.

PubMed

Parish, Lawrence Charles; Parish, Jennifer L; Routh, Hirak B; Avakian, Edward; Olayinka, Babajide; Pappert, Eric J; Plaum, Stefan; Fleischer, Alan B; Hardas, Bhushan

2011-10-01

Naftifine HCl 2% cream (NAFT-2%) is a topical allylamine antifungal preparation under development in the U.S. The objective of this randomized, double-blind, vehicle-controlled study was to evaluate the efficacy and safety of a two-week course of once-daily NAFT-2% vs. vehicle in the treatment of Tinea cruris ("jock itch"). A total of 334 subjects with T. cruris were enrolled and randomly assigned to NAFT-2% (n=166) or vehicle (n=168), which was applied once daily for 14 days. Efficacy and safety were evaluated at week 2 (end of treatment) and week 4. Efficacy measures included complete cure, treatment effectiveness, mycological cure, clinical cure, and clinical success and were analyzed only in subjects with a positive potassium hydroxide (KOH) and dermatophyte culture at baseline (n=75, naftifine; n=71, vehicle). Safety was assessed by adverse events and changes from baseline in clinical status and laboratory studies. At week 4, 25 percent of naftifine-treated subjects achieved complete cure vs. three percent of vehicle subjects and 72 percent achieved mycological cure vs. 16 percent of vehicle treated subjects (one-sided, P<0.001). Treatment effectiveness was achieved in 60 percent of NAFT-2% subjects vs. 10 percent of vehicle subjects (one-sided, P<0.001). Clinical cure rate and clinical success rate were 33 percent and 84 percent in NAFT-2% subjects, respectively vs. 10 percent and 46 percent in vehicle subjects (both P is less than 0.001, 2-sided). Week 2 efficacy response rates in NAFT-2% subjects were all lower than at week 4 but were significantly higher than week 2 vehicle-treated counterparts (P<0.025). Treatment-related AE occurred in 11 subjects (7 NAFT-2%, 4 vehicle) during the study. The most common AE in both groups were contact dermatitis (2 NAFT-2%), pruritus (2 vehicle), and application site reaction (1 per group). NAFT-2% applied once daily for two weeks (one-half the treatment duration for naftifine 1% cream) is efficacious and safe for the treatment of T. cruris.

Determining the structure of Higgs couplings at the CERN LargeHadron Collider.

PubMed

Plehn, Tilman; Rainwater, David; Zeppenfeld, Dieter

2002-02-04

Higgs boson production via weak boson fusion at the CERN Large Hadron Collider has the capability to determine the dominant CP nature of a Higgs boson, via the tensor structure of its coupling to weak bosons. This information is contained in the azimuthal angle distribution of the two outgoing forward tagging jets. The technique is independent of both the Higgs boson mass and the observed decay channel.

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

PubMed Central

Takeuchi, Tsutomu; Yamanaka, Hisashi; Tanaka, Yoshiya; Sakurai, Takeo; Saito, Kazuyoshi; Ohtsubo, Hideo; Lee, Sang Joon; Nambu, Yoshihiro

2015-01-01

Objectives. To demonstrate the pharmacokinetic equivalence of CT-P13 and its innovator infliximab (IFX) in Japanese patients with rheumatoid arthritis (RA), and to compare the efficacy and safety of these drugs, administered for 54 weeks. Methods. In a randomized, double-blind, parallel-group, multicenter study, 3 mg/kg of CT-P13 or IFX, in combination with methotrexate (MTX) (6–16 mg/week), was administered for 54 weeks to Japanese active RA patients with an inadequate response to MTX, to demonstrate the pharmacokinetic equivalence, based on the area under the curve (AUCτ) (weeks 6–14) and Cmax (week 6) of these drugs, and to compare their efficacy and safety. Results. The CT-P13-to-IFX ratios (90% confidence intervals) of the geometric mean AUCτ and Cmax values in patients negative for antibodies to infliximab at week 14 were 111.62% (100.24–124.29%) and 104.09% (92.12–117.61%), respectively, demonstrating the pharmacokinetic equivalence of these drugs. In the full analysis set, CT-P13 and IFX showed comparable therapeutic effectiveness, as measured by the American College of Rheumatology, Disease Activity Score in 28 joints, the European League Against Rheumatism, and other efficacy criteria, at weeks 14 and 30. The incidence of adverse events was similar for these drugs. Conclusion. CT-P13 and IFX, administered at a dose of 3 mg/kg in combination with MTX to active RA patients, were pharmacokinetically equivalent and comparable in efficacy and safety. PMID:25736355

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.

PubMed

Viani, Rolando M; Alvero, Carmelita; Fenton, Terry; Acosta, Edward P; Hazra, Rohan; Townley, Ellen; Steimers, Debra; Min, Sherene; Wiznia, Andrew

2015-11-01

To assess the pharmacokinetics (PK), safety and efficacy of dolutegravir plus optimized background regimen in HIV-infected treatment-experienced adolescents. Children older than 12 to younger than 18 years received dolutegravir weight-based fixed doses at approximately 1.0 mg/kg once daily in a phase I/II multicenter open label 48-week study. Intensive PK evaluation was done at steady state after dolutegravir was added to a failing regimen or started at the end of a treatment interruption. Safety and HIV RNA and CD4 cell count assessments were performed through week 48. Twenty-three adolescents were enrolled and 22 (96%) completed the 48-week study visit. Median age and weight were 15 years and 52 kg, respectively. Median [interquartile range (IQR)] baseline CD4+ cell count was 466 cells/μL (297, 771). Median (IQR) baseline HIV-1 RNA log10 was 4.3 log10 copies/mL (3.9, 4.6). Dolutegravir geometric mean of the area under the plasma concentration-time curve from time of administration to 24 hours after dosing (AUC0-24) and 24 hour postdose concentration (C24) were 46.0 μg hours/mL and 0.90 μg/mL, respectively, which were within the study targets based on adult PK ranges. Virologic success with an HIV RNA <400 copies/mL was achieved in 74% [95% confidence interval (CI): 52-90%] at week 48. Additionally, 61% (95% CI: 39-80%) had an HIV RNA <50 copies/mL at week 48. Median (IQR) gain in CD4 cell count at week 48 was 84 cells/μL (-81, 238). Dolutegravir was well tolerated, with no grade 4 adverse events, serious adverse events or discontinuations because of serious adverse events. Dolutegravir achieved target PK exposures in adolescents. Dolutegravir was safe and well tolerated, providing good virologic efficacy through week 48.

Teaching safety at a summer camp: evaluation of a water safety curriculum in an urban community setting.

PubMed

Lawson, Karla A; Duzinski, Sarah V; Wheeler, Tareka; Yuma-Guerrero, Paula J; Johnson, Kelly M K; Maxson, R Todd; Schlechter, Robert

2012-11-01

The purpose of this project was to evaluate a water safety curriculum in a low-income, minority-focused, urban youth summer camp. The curriculum is available to Safe Kids Coalitions across the country; however, it has not previously been evaluated. Participants were pre-K to third-grade students (n = 166). Children watched a video and received the curriculum in a classroom setting. Each child was given a pre-, post-, and 3-week retention exam to assess knowledge change. Mean test scores and number of safety rules participants could list were analyzed using paired Student's t tests. Parents were given a baseline survey at the beginning (n = 140) and end of the weeklong curriculum (n = 118). The participants were 50% male, 27.5% Hispanic, 68.7% African American, and 3.8% biracial. Children were divided into three groups: pre-K/kindergarten, first and second grade, and third grade. Children in each of the groups received higher knowledge scores at the posttest (p = .0097, p < .0001, and p < .0001, respectively), with little decline in scores at the 3-week retention exam. Similar results were seen for the ability to list safety rules, though the number fell slightly between the posttest and retention test. The study demonstrates that children possessed more knowledge of water safety after receiving this curriculum. This knowledge increase was maintained through the 3-week retention exam. Further evaluation of the curriculum's content and its impact on water safety beliefs, attitudes, and behaviors are needed, as well as evaluation of additional settings, risk areas, and the role of parental involvement.

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.

PubMed

Vavricka, Stephan R; Schoepfer, Alain M; Bansky, Georg; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Scharl, Michael; Seibold, Frank; Straumann, Alex; Michetti, Pierre

2011-07-01

Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients. Evaluation questionnaires at baseline, week 6, and week 26 were completed by gastroenterologists in hospitals and private practices. Adverse events were evaluated according to World Health Organization (WHO) guidelines. Sixty patients (38F/22M) were included; 53% had complicated disease (stricturing or penetrating), 45% had undergone prior CD-related surgery. All patients had prior exposure to systemic steroids, 96% to immunomodulators, 73% to infliximab, and 43% to adalimumab. A significant decrease of the Harvey-Bradshaw Index (HBI) was observed under CZP therapy (12.2 ± 4.9 at week 0 versus 6.3 ± 4.7 at week 6 and 6.7 ± 5.3 at week 26, both P < 0.001). Response and remission rates were 70% and 40% (week 6) and 67% and 36%, respectively (week 26). The complete perianal fistula closure rate was 36% at week 6 and 55% at week 26. The frequency of adverse drug reactions attributed to CZP was 5%. CZP was continued in 88% of patients beyond week 6 and in 67% beyond week 26. In a population of CD patients with predominantly complicated disease behavior, CZP proved to be effective in induction and maintenance of response and remission. This series provides the first evidence of CZP's effectiveness in perianal fistulizing CD in clinical practice. Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

PubMed

Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee

2017-10-01

SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage. In this phase III, double-blind, parallel-group, multicentre study, patients with moderate to severe RA despite MTX were randomized (1:1) to receive 3 mg/kg of either SB2 or INF at 0, 2, 6 and every 8 weeks thereafter. Dose escalation by 1.5 mg/kg up to a maximum dose of 7.5 mg/kg was allowed after week 30. Efficacy, safety and immunogenicity were measured at each visit up to week 54. Radiographic damage evaluated by modified total Sharp score was measured at baseline and week 54. A total of 584 patients were randomized to receive SB2 (n = 291) or INF (n = 293). The rate of radiographic progression was comparable between SB2 and INF (mean modified total Sharp score difference: SB2, 0.38; INF, 0.37) at 1 year. ACR responses, 28-joint DAS, Clinical Disease Activity Index and Simplified Disease Activity Index were comparable between SB2 and INF up to week 54. The incidence of treatment-emergent adverse events and anti-drug antibodies were comparable between treatment groups. Such comparable trends of efficacy, safety and immunogenicity were consistent from baseline up to 54 weeks. The pattern of dose increment was also comparable between SB2 and INF. SB2 maintained similar efficacy, safety and immunogenicity with INF up to 54 weeks in patients with moderate to severe RA. Radiographic progression was comparable at 1 year. ClinicalTrials.gov (http://clinicaltrials.gov; NCT01936181) and EudraCT (https://www.clinicaltrialsregister.eu; 2012-005733-37). © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

PubMed Central

Smolen, Josef S.; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee

2017-01-01

Abstract Objectives SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage. Methods In this phase III, double-blind, parallel-group, multicentre study, patients with moderate to severe RA despite MTX were randomized (1:1) to receive 3 mg/kg of either SB2 or INF at 0, 2, 6 and every 8 weeks thereafter. Dose escalation by 1.5 mg/kg up to a maximum dose of 7.5 mg/kg was allowed after week 30. Efficacy, safety and immunogenicity were measured at each visit up to week 54. Radiographic damage evaluated by modified total Sharp score was measured at baseline and week 54. Results A total of 584 patients were randomized to receive SB2 (n = 291) or INF (n = 293). The rate of radiographic progression was comparable between SB2 and INF (mean modified total Sharp score difference: SB2, 0.38; INF, 0.37) at 1 year. ACR responses, 28-joint DAS, Clinical Disease Activity Index and Simplified Disease Activity Index were comparable between SB2 and INF up to week 54. The incidence of treatment-emergent adverse events and anti-drug antibodies were comparable between treatment groups. Such comparable trends of efficacy, safety and immunogenicity were consistent from baseline up to 54 weeks. The pattern of dose increment was also comparable between SB2 and INF. Conclusion SB2 maintained similar efficacy, safety and immunogenicity with INF up to 54 weeks in patients with moderate to severe RA. Radiographic progression was comparable at 1 year. Trial registration ClinicalTrials.gov (http://clinicaltrials.gov; NCT01936181) and EudraCT (https://www.clinicaltrialsregister.eu; 2012-005733-37) PMID:28957563

CERN data services for LHC computing

NASA Astrophysics Data System (ADS)

Espinal, X.; Bocchi, E.; Chan, B.; Fiorot, A.; Iven, J.; Lo Presti, G.; Lopez, J.; Gonzalez, H.; Lamanna, M.; Mascetti, L.; Moscicki, J.; Pace, A.; Peters, A.; Ponce, S.; Rousseau, H.; van der Ster, D.

2017-10-01

Dependability, resilience, adaptability and efficiency. Growing requirements require tailoring storage services and novel solutions. Unprecedented volumes of data coming from the broad number of experiments at CERN need to be quickly available in a highly scalable way for large-scale processing and data distribution while in parallel they are routed to tape for long-term archival. These activities are critical for the success of HEP experiments. Nowadays we operate at high incoming throughput (14GB/s during 2015 LHC Pb-Pb run and 11PB in July 2016) and with concurrent complex production work-loads. In parallel our systems provide the platform for the continuous user and experiment driven work-loads for large-scale data analysis, including end-user access and sharing. The storage services at CERN cover the needs of our community: EOS and CASTOR as a large-scale storage; CERNBox for end-user access and sharing; Ceph as data back-end for the CERN OpenStack infrastructure, NFS services and S3 functionality; AFS for legacy distributed-file-system services. In this paper we will summarise the experience in supporting LHC experiments and the transition of our infrastructure from static monolithic systems to flexible components providing a more coherent environment with pluggable protocols, tuneable QoS, sharing capabilities and fine grained ACLs management while continuing to guarantee dependable and robust services.

HIGH ENERGY PHYSICS: Bulgarians Sue CERN for Leniency.

PubMed

Koenig, R

2000-10-13

In cash-strapped Bulgaria, scientists are wondering whether a ticket for a front-row seat in high-energy physics is worth the price: Membership dues in CERN, the European particle physics lab, nearly equal the country's entire budget for competitive research grants. Faced with that grim statistic and a plea for leniency from Bulgaria's government, CERN's governing council is considering slashing the country's membership dues for the next 2 years.

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study

PubMed Central

Tanaka, Yoshiya; Yamamoto, Kazuhiko; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Eguchi, Katsumi; Watanabe, Akira; Origasa, Hideki; Shoji, Toshiharu; Miyasaka, Nobuyuki; Koike, Takao

2014-01-01

Abstract Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) plus methotrexate treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. Methods. J-RAPID double-blind patients were entered into an open-label extension (OLE) study. Patients withdrawn due to lack of efficacy at 16 weeks and double-blind completers without a week-24 American College of Rheumatology (ACR) 20 response received CZP 200 mg every other week (Q2W) plus methotrexate. Double-blind completers with week-24 ACR20 responses were randomized to CZP 200 mg Q2W plus methotrexate or CZP 400 mg every 4 weeks plus methotrexate. Results. The ACR20/ACR50/ACR70 response rates of double-blind completers (n = 204) were 89.7%/67.2%/36.3% at OLE entry and 95.6%/84.8%/58.3% at 52 weeks, respectively. Other clinical, functional and radiographic outcomes were sustained with long-term CZP plus methotrexate. Long-term treatment with CZP was well-tolerated with no new unexpected adverse events observed. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Continued CZP administration with methotrexate maintained efficacy over 52 weeks and was well-tolerated for Japanese RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules, giving flexibility in maintenance administration schedules. PMID:24593170

Wolfgang Kummer at CERN

NASA Astrophysics Data System (ADS)

Schopper, Herwig

Wolfgang Kummer was not only a great theorist but also a man with a noble spirit and extensive education, based on a fascinating long-term Austrian cultural tradition. As an experimentalist I am not sufficiently knowledgeable to evaluate his contributions to theoretical physics - this will certainly be done by more competent scientists. Nevertheless I admired him for not only being attached to fundamental and abstract problems like quantum field theory, quantum gravity or black holes, but for his interest in down to earth questions like electron-proton scattering or the toponium mass. I got to know Wolfgang Kummer very well and appreciate his human qualities during his long attachment to CERN, in particular when he served as president of the CERN Council, the highest decision taking authority of this international research centre, from 1985 to 1987 falling into my term as Director-General…

Database on Demand: insight how to build your own DBaaS

NASA Astrophysics Data System (ADS)

Gaspar Aparicio, Ruben; Coterillo Coz, Ignacio

2015-12-01

At CERN, a number of key database applications are running on user-managed MySQL, PostgreSQL and Oracle database services. The Database on Demand (DBoD) project was born out of an idea to provide CERN user community with an environment to develop and run database services as a complement to the central Oracle based database service. The Database on Demand empowers the user to perform certain actions that had been traditionally done by database administrators, providing an enterprise platform for database applications. It also allows the CERN user community to run different database engines, e.g. presently three major RDBMS (relational database management system) vendors are offered. In this article we show the actual status of the service after almost three years of operations, some insight of our new redesign software engineering and near future evolution.

Measurement of the inclusive jet cross section at the CERN pp collider

NASA Astrophysics Data System (ADS)

Arnison, G.; Albrow, M. G.; Allkofer, O. C.; Astbury, A.; Aubert, B.; Bacci, C.; Batley, J. R.; Bauer, G.; Bettini, A.; Bézaguet, A.; Bock, R. K.; Bos, K.; Buckley, E.; Bunn, J.; Busetto, G.; Catz, P.; Cennini, P.; Centro, S.; Ceradini, F.; Ciapetti, G.; Cittolin, S.; Clarke, D.; Cline, D.; Cochet, C.; Colas, J.; Colas, P.; Corden, M.; Cox, G.; Dallman, D.; Dau, D.; Debeer, M.; Debrion, J. P.; Degiorgi, M.; della Negra, M.; Demoulin, M.; Denby, B.; Denegri, D.; Diciaccio, A.; Dobrzynski, L.; Dorenbosch, J.; Dowell, J. D.; Duchovni, E.; Edgecock, R.; Eggert, K.; Eisenhandler, E.; Ellis, N.; Erhard, P.; Faissner, H.; Fince Keeler, M.; Flynn, P.; Fontaine, G.; Frey, R.; Frühwirth, R.; Garvey, J.; Gee, D.; Geer, S.; Ghesquière, C.; Ghez, P.; Ghio, F.; Giacomelli, P.; Gibson, W. R.; Giraud-Héraud, Y.; Givernaud, A.; Gonidec, A.; Goodman, M.; Grassmann, H.; Grayer, G.; Guryn, W.; Hansl-Kozanecka, T.; Haynes, W.; Haywood, S. J.; Hoffmann, H.; Holthuizen, D. J.; Homer, R. J.; Homer, R. J.; Honma, A.; Jank, W.; Jimack, M.; Jorat, G.; Kalmus, P. I. P.; Karimäri, V.; Keeler, R.; Kenyon, I.; Kernan, A.; Kienzle, W.; Kinnunen, R.; Kozanecki, W.; Kroll, J.; Kryn, D.; Kyberd, P.; Lacava, F.; Laugier, J. P.; Lees, J. P.; Leuchs, R.; Levegrun, S.; Lévêque, A.; Levi, M.; Linglin, D.; Locci, E.; Long, K.; Markiewicz, T.; Markytan, M.; Martin, T.; Maurin, F.; McMahon, T.; Mendiburu, J.-P.; Meneguzzo, A.; Meyer, O.; Meyer, T.; Minard, M.-N.; Mohammadi, M.; Morgan, K.; Moricca, M.; Moser, H.; Mours, B.; Muller, Th.; Nandi, A.; Naumann, L.; Norton, A.; Paoluzi, L.; Pascoli, D.; Pauss, F.; Perault, C.; Piano Mortari, G.; Pietarinen, E.; Pigot, C.; Pimiä, M.; Pitman, D.; Placci, A.; Porte, J.-P.; Radermacher, E.; Ransdell, J.; Redelberger, T.; Reithler, H.; Revol, J. P.; Richman, J.; Rijssenbeek, M.; Rohlf, J.; Rossi, P.; Roberts, C.; Ruhm, W.; Rubbia, C.; Sajot, G.; Salvini, G.; Sass, J.; Sadoulet, B.; Samyn, D.; Savoy-Navarro, A.; Schinzel, D.; Schwartz, A.; Scott, W.; Scott, W.; Shah, T. P.; Sheer, I.; Siotis, I.; Smith, D.; Sobie, R.; Sphicas, P.; Strauss, J.; Streets, J.; Stubenrauch, C.; Summers, D.; Sumorok, K.; Szonczo, F.; Tao, C.; Ten Have, I.; Thompson, G.; Tscheslog, E.; Tuominiemi, J.; van Eijk, B.; Verecchia, P.; Vialle, J. P.; Virdee, T. S.; von der Schmitt, H.; von Schlippe, W.; Vrana, J.; Vuillemin, V.; Wahl, H. D.; Watkins, P.; Wilke, R.; Wilson, J.; Wingerter, I.; Wimpenny, S. J.; Wulz, C.-E.; Wyatt, T.; Yvert, M.; Zacharov, I.; Zaganidis, N.; Zanello, L.; Zotto, P.

1986-05-01

The inclusive jet cross section has been measured in the UA1 experiment at the CERN pp Collider at centre-of-mass energies √s = 546 GeV and √s = 630 eV. The cross sections are found to be consistent with QCD predictions, The observed change in the cross section with the centre-of-mass energy √s is accounted for in terms of xT scaling.

Upgrade of the cryogenic CERN RF test facility

DOE Office of Scientific and Technical Information (OSTI.GOV)

Pirotte, O.; Benda, V.; Brunner, O.

2014-01-29

With the large number of superconducting radiofrequency (RF) cryomodules to be tested for the former LEP and the present LHC accelerator a RF test facility was erected early in the 1990’s in the largest cryogenic test facility at CERN located at Point 18. This facility consisted of four vertical test stands for single cavities and originally one and then two horizontal test benches for RF cryomodules operating at 4.5 K in saturated helium. CERN is presently working on the upgrade of its accelerator infrastructure, which requires new superconducting cavities operating below 2 K in saturated superfluid helium. Consequently, the RFmore » test facility has been renewed in order to allow efficient cavity and cryomodule tests in superfluid helium and to improve its thermal performances. The new RF test facility is described and its performances are presented.« less

Food Safety for Healthy Missouri Families: Evaluation of Program Effectiveness.

ERIC Educational Resources Information Center

Comer, Marcus M.

2002-01-01

The food safety knowledge of 22 inner-city Missouri youth from low-income families was assessed before and after a 4-week summer program. Posttest results showed dramatic changes in beliefs. However, topics such as irradiation, eating raw cookie dough, and safety of produce in grocery stores showed little change. (SK)

Commissioning results of CERN HIE-ISOLDE and INFN ALPI cryogenic control systems

NASA Astrophysics Data System (ADS)

Inglese, V.; Pezzetti, M.; Calore, A.; Modanese, P.; Pengo, R.

2017-02-01

The cryogenic systems of both accelerators, namely HIE ISOLDE (High Intensity and Energy Isotope Separator On Line DEvice) at CERN and ALPI (Acceleratore Lineare Per Ioni) at LNL, have been refurbished. HIE ISOLDE is a major upgrade of the existing ISOLDE facilities, which required the construction of a superconducting linear accelerator consisting of six cryomodules, each containing five superconductive RF cavities and superconducting solenoids. The ALPI linear accelerator, similar to HIE ISOLDE, is located at Legnaro National Laboratories (LNL) and became operational in the early 90’s. It is composed of 74 superconducting RF cavities, assembled inside 22 cryostats. The new control systems are equipped with PLC, developed on the CERN UNICOS framework, which include Schneider and Siemens PLCs and various fieldbuses (Profibus DP and PA, WorldFIP). The control systems were developed in synergy between CERN and LNL in order to build, effectively and with an optimized use of resources, control systems allowing to enhance ease of operation, maintainability, and long-term availability. This paper describes (i) the cryogenic systems, with special focus on the design of the control systems hardware and software, (ii) the strategy adopted in order to achieve a synergic approach, and (iii) the commissioning results after the cool-down to 4.5 K of the cryomodules.

Experience with procuring, deploying and maintaining hardware at remote co-location centre

NASA Astrophysics Data System (ADS)

Bärring, O.; Bonfillou, E.; Clement, B.; Coelho Dos Santos, M.; Dore, V.; Gentit, A.; Grossir, A.; Salter, W.; Valsan, L.; Xafi, A.

2014-05-01

In May 2012 CERN signed a contract with the Wigner Data Centre in Budapest for an extension to CERN's central computing facility beyond its current boundaries set by electrical power and cooling available for computing. The centre is operated as a remote co-location site providing rack-space, electrical power and cooling for server, storage and networking equipment acquired by CERN. The contract includes a 'remote-hands' services for physical handling of hardware (rack mounting, cabling, pushing power buttons, ...) and maintenance repairs (swapping disks, memory modules, ...). However, only CERN personnel have network and console access to the equipment for system administration. This report gives an insight to adaptations of hardware architecture, procurement and delivery procedures undertaken enabling remote physical handling of the hardware. We will also describe tools and procedures developed for automating the registration, burn-in testing, acceptance and maintenance of the equipment as well as an independent but important change to the IT assets management (ITAM) developed in parallel as part of the CERN IT Agile Infrastructure project. Finally, we will report on experience from the first large delivery of 400 servers and 80 SAS JBOD expansion units (24 drive bays) to Wigner in March 2013. Changes were made to the abstract file on 13/06/2014 to correct errors, the pdf file was unchanged.

DOE-EM Science of Safety Robotics Challenge

DOE Office of Scientific and Technical Information (OSTI.GOV)

Rimando, Rodrigo; Watts, Alex; Bobbitt, John

During the week of August 22nd, 2016, over 150 technologists, stakeholders, and Department of Energy, Office of Environmental Management workers, met at DOE’s Portsmouth Gaseous Diffusion Plant in Ohio, for the EM Science of Safety Robotics Challenge.

Let's Resolve Conflicts Together: Elementary School Classroom Activities. Conflict Management Week, May 1-7, 2000.

ERIC Educational Resources Information Center

Ohio Commission on Dispute Resolution and Conflict Management, Columbus.

With heightened awareness to issues of school safety, it is important for elementary schools to take an active role in promoting constructive responses to conflict. The week of May 1-7, 2000 has been designated as Conflict Management Week by the Governor of Ohio. Conflict is a natural and inevitable part of living; however, managing conflict is…

Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study.

PubMed

Hwang, Jin Soon; Lee, Hae Sang; Lee, Kee-Hyoung; Yoo, Han-Wook; Lee, Dae-Yeol; Suh, Byung-Kyu; Ko, Cheol Woo; Chung, Woo Yeong; Jin, Dong-Kyu; Shin, Choong Ho; Han, Heon-Seok; Han, Song; Kim, Ho-Seong

2018-06-20

To determine the optimal dose of LB03002, a sustained-release, once-weekly formulation of recombinant human growth hormone (rhGH), and to compare its efficacy and safety with daily rhGH in children with idiopathic short stature (ISS). This multicenter, randomized, open-label, phase II study included GH-naïve, prepubertal children with ISS, randomized to receive daily rhGH 0.37 mg/kg/week (control, n = 16), LB03002 0.5 mg/kg/week (n = 14), or LB03002 0.7 mg/kg/week (n = 16). The primary endpoint was height velocity (HV) change at week 26. At week 26, the least square (LS) means for HV change (cm/year) with control, LB03002 0.5 mg/kg/week, and LB03002 0.7 mg/kg/week were 5.08, 3.65, and 4.38, and the LS means for the change in height standard deviation score were 0.65, 0.49, and 0.58, respectively. The lower bound of the 90% confidence interval for the difference between LB03002 0.7 mg/kg/week and the control in the LS mean for HV change (-1.72) satisfied the noninferiority margin (-1.75). Adverse events were generally mild and short-lived. A once-weekly regimen of LB03002 0.7 mg/kg demonstrated noninferiority to the daily regimen of rhGH 0.37 mg/kg/week in terms of HV increments. LB03002 was well tolerated and its safety profile was comparable with that of daily rhGH. © 2018 S. Karger AG, Basel.

Highlights from High Energy Neutrino Experiments at CERN

NASA Astrophysics Data System (ADS)

Schlatter, W.-D.

2015-07-01

Experiments with high energy neutrino beams at CERN provided early quantitative tests of the Standard Model. This article describes results from studies of the nucleon quark structure and of the weak current, together with the precise measurement of the weak mixing angle. These results have established a new quality for tests of the electroweak model. In addition, the measurements of the nucleon structure functions in deep inelastic neutrino scattering allowed first quantitative tests of QCD.

Integrating Containers in the CERN Private Cloud

NASA Astrophysics Data System (ADS)

Noel, Bertrand; Michelino, Davide; Velten, Mathieu; Rocha, Ricardo; Trigazis, Spyridon

2017-10-01

Containers remain a hot topic in computing, with new use cases and tools appearing every day. Basic functionality such as spawning containers seems to have settled, but topics like volume support or networking are still evolving. Solutions like Docker Swarm, Kubernetes or Mesos provide similar functionality but target different use cases, exposing distinct interfaces and APIs. The CERN private cloud is made of thousands of nodes and users, with many different use cases. A single solution for container deployment would not cover every one of them, and supporting multiple solutions involves repeating the same process multiple times for integration with authentication services, storage services or networking. In this paper we describe OpenStack Magnum as the solution to offer container management in the CERN cloud. We will cover its main functionality and some advanced use cases using Docker Swarm and Kubernetes, highlighting some relevant differences between the two. We will describe the most common use cases in HEP and how we integrated popular services like CVMFS or AFS in the most transparent way possible, along with some limitations found. Finally we will look into ongoing work on advanced scheduling for both Swarm and Kubernetes, support for running batch like workloads and integration of container networking technologies with the CERN infrastructure.

Let's Resolve Conflicts Together: High School Classroom Activities. Conflict Management Week, May 1-7, 2000.

ERIC Educational Resources Information Center

Ohio Commission on Dispute Resolution and Conflict Management, Columbus.

The week of May 1-7, 2000 has been designated by the Governor of Ohio to be Conflict Management Week With heightened awareness to issues of school safety, it is important for high schools to take an active role in promoting constructive responses to conflict. Conflict is a natural and inevitable part of living, but managing conflict is difficult…

ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.

ClinicalTrials.gov

2012-04-28

The Primary Study Objective is to Assess the Efficacy and; Safety of Extended 4-week Heparin Prophylaxis Compared to; Prophylaxis Given for 8±2 Days After Planned Laparoscopic; Surgery for Colorectal Cancer.; The Clinical Benefit Will be Evaluated as the Difference in; the Incidence of VTE or VTE-related Death Occurring Within 30 Days; From Surgery in the Two Study Groups.

CERN@school: demonstrating physics with the Timepix detector

NASA Astrophysics Data System (ADS)

Whyntie, T.; Bithray, H.; Cook, J.; Coupe, A.; Eddy, D.; Fickling, R. L.; McKenna, J.; Parker, B.; Paul, A.; Shearer, N.

2015-10-01

This article shows how the Timepix hybrid silicon pixel detector, developed by the Medipix2 Collaboration, can be used by students and teachers alike to demonstrate some key aspects of any well-rounded physics curriculum with CERN@school. After an overview of the programme, the detector's capabilities for measuring and visualising ionising radiation are examined. The classification of clusters - groups of adjacent pixels - is discussed with respect to identifying the different types of particles. Three demonstration experiments - background radiation measurements, radiation profiles and the attenuation of radiation - are described; these can used as part of lessons or as inspiration for independent research projects. Results for exemplar data-sets are presented for reference, as well as details of ongoing research projects inspired by these experiments. Interested readers are encouraged to join the CERN@school Collaboration and so contribute to achieving the programme's aim of inspiring the next generation of scientists and engineers.

DOE-EM Science of Safety Robotics Challenge

ScienceCinema

Rimando, Rodrigo; Watts, Alex; Bobbitt, John; McLaughlin, Doug; Quigley, Morgan; Gladwell, Scott; McLoughlin, Mike; Kinnamon, Tony; Garcia, Joe; Ansari, Alex; Voyles, Richard; Chambers, David; Pryor, Mitch; Workman, Theresa; Mehling, Joshua; Browning, Kimberly; Deuel, Jake; Profitt, Bryan; Reibold, Marty

2018-06-12

During the week of August 22nd, 2016, over 150 technologists, stakeholders, and Department of Energy, Office of Environmental Management workers, met at DOE’s Portsmouth Gaseous Diffusion Plant in Ohio, for the EM Science of Safety Robotics Challenge.

International Workshop on Linear Colliders 2010

ScienceCinema

Yamada, Sakue

2018-05-24

IWLC2010 International Workshop on Linear Colliders 2010ECFA-CLIC-ILC joint meeting: Monday 18 October - Friday 22 October 2010Venue: CERN and CICG (International Conference Centre Geneva, Switzerland) This year, the International Workshop on Linear Colliders organized by the European Committee for Future Accelerators (ECFA) will study the physics, detectors and accelerator complex of a linear collider covering both CLIC and ILC options. Contact Workshop Secretariat  IWLC2010 is hosted by CERN

International Workshop on Linear Colliders 2010

ScienceCinema

Lebrun, Ph.

2018-06-20

IWLC2010 International Workshop on Linear Colliders 2010ECFA-CLIC-ILC joint meeting: Monday 18 October - Friday 22 October 2010Venue: CERN and CICG (International Conference Centre Geneva, Switzerland). This year, the International Workshop on Linear Colliders organized by the European Committee for Future Accelerators (ECFA) will study the physics, detectors and accelerator complex of a linear collider covering both CLIC and ILC options. Contact Workshop Secretariat  IWLC2010 is hosted by CERN.

33 CFR 165.941 - Safety Zones; Annual Fireworks Events in the Captain of the Port Detroit Zone.

Code of Federal Regulations, 2010 CFR

2010-07-01

... times for this event will be determined annually. (5) Alpena Fireworks, Alpena, MI: (i) Location: All... Alpena, MI. (ii) Expected date: One evening during the last week in of June or the first week of July...

Healdsburg High School's Course on the Automobile.

ERIC Educational Resources Information Center

Attwood, Philip B.

1995-01-01

Reprints an article originally published in 1937. Discusses the need for some kind of training in automobile safety. Discusses an eight-week high school course on the automobile that covers engine operation, safety, auxiliary systems, and actual driving practice. (RS)

Efficacy of Slimming Cream Containing 3.5% Water-Soluble Caffeine and Xanthenes for the Treatment of Cellulite: Clinical Study and Literature Review

PubMed Central

Byun, Sang-Young; Kwon, Soon-Hyo; Heo, Su-Hak; Shim, Jae-Seong; Du, Mi-Hee

2015-01-01

Background Cellulite is a 'cottage cheese-like' cutaneous change caused by subcutaneous fat bulging into the dermis that usually leads to cosmetic problems. Slimming cream containing 3.5% water-soluble caffeine and xanthenes exhibits a lipolytic effect with penetration into the dermis. Objective To evaluate the efficacy and safety of slimming cream for the treatment of cellulite. Methods Fifteen subjects with cellulite applied slimming cream to the thighs and inner side of the upper arms twice daily for 6 weeks. Efficacy was assessed using a standard visual scale, changes in the circumferences of the thighs and upper arms, and patient satisfaction by a questionnaire at baseline, week 3, and week 6. Safety was assessed by inquiring about adverse events through questionnaires. Results The standard visual scale score improved significantly by 0.49 points (19.8%) at week 6. Thigh and upper-arm circumferences decreased by 0.7 cm (1.7%) and 0.8 cm (2.3%), respectively, at week 6. Slight itching and transient flushing were commonly reported, but no serious adverse event occurred. Conclusion The slimming cream tested appears to be effective for the treatment of cellulitis without serious adverse effects. However, additional large clinical trials are required to confirm the efficacy and safety of slimming cream for the treatment of cellulitis. PMID:26082579

The management of large cabling campaigns during the Long Shutdown 1 of LHC

NASA Astrophysics Data System (ADS)

Meroli, S.; Machado, S.; Formenti, F.; Frans, M.; Guillaume, J. C.; Ricci, D.

2014-03-01

The Large Hadron Collider at CERN entered into its first 18 month-long shutdown period in February 2013. During this period the entire CERN accelerator complex will undergo major consolidation and upgrade works, preparing the machines for LHC operation at nominal energy (7 TeV/beam). One of the most challenging activities concerns the cabling infrastructure (copper and optical fibre cables) serving the CERN data acquisition, networking and control systems. About 1000 kilometres of cables, distributed in different machine areas, will be installed, representing an investment of about 15 MCHF. This implies an extraordinary challenge in terms of project management, including resource and activity planning, work execution and quality control. The preparation phase of this project started well before its implementation, by defining technical solutions and setting financial plans for staff recruitment and material supply. Enhanced task coordination was further implemented by deploying selected competences to form a central support team.

Protocols for Scholarly Communication

NASA Astrophysics Data System (ADS)

Pepe, A.; Yeomans, J.

2007-10-01

CERN, the European Organization for Nuclear Research, has operated an institutional preprint repository for more than 10 years. The repository contains over 850,000 records of which more than 450,000 are full-text OA preprints, mostly in the field of particle physics, and it is integrated with the library's holdings of books, conference proceedings, journals and other grey literature. In order to encourage effective propagation and open access to scholarly material, CERN is implementing a range of innovative library services into its document repository: automatic keywording, reference extraction, collaborative management tools and bibliometric tools. Some of these services, such as user reviewing and automatic metadata extraction, could make up an interesting testbed for future publishing solutions and certainly provide an exciting environment for e-science possibilities. The future protocol for scientific communication should guide authors naturally towards OA publication, and CERN wants to help reach a full open access publishing environment for the particle physics community and related sciences in the next few years.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

PubMed

van der Heijde, Désirée; Gladman, Dafna D; Kishimoto, Mitsumasa; Okada, Masato; Rathmann, Suchitrita S; Moriarty, Susan R; Shuler, Catherine L; Carlier, Hilde; Benichou, Olivier; Mease, Philip J

2018-03-01

To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A antagonist, in patients with psoriatic arthritis (PsA) after 52 weeks in a phase III study. Patients were initially randomly assigned to IXE 80 mg every 2 weeks (IXEQ2W) or every 4 weeks (IXEQ4W) after a 160-mg starting dose, placebo (PBO), or adalimumab (ADA) 40 mg Q2W. At Week 24 (Week 16 for inadequate responders), ADA (8-week washout before starting IXE) and PBO patients were rerandomized to IXEQ2W or IXEQ4W. Six treatment groups were evaluated in the extension period (weeks 24-52): IXEQ2W/IXEQ2W, IXEQ4W/IXEQ4W, ADA/IXEQ2W, ADA/IXEQ4W, PBO/IXEQ2W, and PBO/IXEQ4W. The extension period population (EPP) included patients who received ≥ 1 dose of study medication during the extension period. There were 381/417 (91.4%) patients who entered the extension period. In the IXEQ4W/IXEQ4W and IXEQ2W/IXEQ2W groups (EPP), respectively, American College of Rheumatology (ACR)20 (69.1% and 68.8%), ACR50 (54.6% and 53.1%), and ACR70 (39.2% and 39.6%) response rates were sustained at Week 52. Patients rerandomized to IXE also demonstrated efficacy measured by ACR response rates at Week 52. A similar pattern was observed for Psoriasis Area and Severity Index outcomes. Radiographic progression in all 6 groups was minimal. The most frequently reported treatment-emergent adverse events (≥ 4%) were nasopharyngitis, injection site reaction, injection site erythema, upper respiratory tract infection, and back pain. No deaths were reported, and serious adverse event frequency was 0-4% with IXE. During the extension period, IXEQ4W or IXEQ2W treatment demonstrated sustained efficacy in key PsA domains with a safety profile consistent with other studies investigating IXE. Clinical trial number: NCT01695239; EudraCT 2011-002326-49.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

PubMed Central

Park, Won; Yoo, Dae Hyun; Miranda, Pedro; Brzosko, Marek; Wiland, Piotr; Gutierrez-Ureña, Sergio; Mikazane, Helena; Lee, Yeon-Ah; Smiyan, Svitlana; Lim, Mie-Jin; Kadinov, Vladimir; Abud-Mendoza, Carlos; Kim, HoUng; Lee, Sang Joon; Bae, YunJu; Kim, SuYeon; Braun, Jürgen

2017-01-01

Objectives To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). Methods This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg) was administered intravenously every 8 weeks from week 62 to week 102. Efficacy end points included the proportion of patients achieving Assessment of SpondyloArthritis international Society (ASAS)20. Antidrug antibodies (ADAs) were measured using an electrochemiluminescent method. Data were analysed for patients treated with CT-P13 in the main PLANETAS study and the extension (maintenance group) and those who were switched to CT-P13 during the extension study (switch group). Results Overall, 174 (82.9%) of 210 patients who completed the first 54 weeks of PLANETAS and agreed to participate in the extension were enrolled. Among these, 88 were maintained on CT-P13 and 86 were switched to CT-P13 from RP. In these maintenance and switch groups, respectively, ASAS20 response rates at week 102 were 80.7% and 76.9%. ASAS40 and ASAS partial remission were also similar between groups. ADA positivity rates were comparable (week 102: 23.3% vs 27.4%). Adverse events led to treatment discontinuation during the extension study in 3 (3.3%) and 4 (4.8%) patients, respectively. Conclusions This is the first study to show that switching from RP to its biosimilar CT-P13 is possible without negative effects on safety or efficacy in patients with AS. In the maintenance group, CT-P13 was effective and well tolerated over 2 years of treatment. Trial registration number NCT01571206; Results. PMID:27117698

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

PubMed

DeJesus, Edwin; Haas, Bernard; Segal-Maurer, Sorana; Ramgopal, Moti N; Mills, Anthony; Margot, Nicolas; Liu, Ya-Pei; Makadzange, Tariro; McCallister, Scott

2018-04-01

We previously demonstrated superior efficacy and safety advantages in HIV-infected, virologically suppressed adults switched to a regimen containing tenofovir alafenamide (TAF) as compared with those remaining on a tenofovir disoproxil fumarate (TDF) regimen through week 48. We now report long-term data through week 96. In this randomized, active-controlled, multicenter, open-label, noninferiority trial (ClinicalTrials.gov No. NCT01815736), we randomized virologically suppressed (HIV-1 RNA <50 copies/ml) adults (2:1) to receive a once-daily, single-tablet regimen containing elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), and TAF group or to continue one of four TDF-containing regimens (TDF group) for 96 weeks. We evaluated efficacy (HIV-1 RNA <50 copies/ml using the FDA snapshot algorithm) and prespecified bone and renal endpoints at week 96. We randomized and treated 1,436 participants in this study (TAF n = 959, TDF n = 477). At week 96, TAF was superior to TDF in virologic efficacy, with 93% on TAF and 89% on TDF having HIV-1 RNA <50 copies/ml (difference 3.7%, 95% confidence interval: 0.4%-7.0%). Improvements in hip and spine bone mineral density for those assigned to TAF versus TDF continued through week 96 (p < .001). Significant improvements in urine protein or albumin to creatinine ratios were also seen among those in the TAF group versus TDF through week 96 (p < .001). There were no cases of investigator-reported proximal renal tubulopathy in the TAF group as compared with one case in the TDF group. Switching to EVG/COBI/FTC/TAF (E/C/F/TAF) was associated with statistically significant efficacy and safety advantages over remaining on a standard-of-care TDF-based regimen.

76 FR 388 - Sunshine Act Notice

Federal Register 2010, 2011, 2012, 2013, 2014

2011-01-04

... Commission. DATES: Weeks of January 3, 10, 17, 24, 31, February 7, 2011. PLACE: Commissioners' Conference..., 2011--Tentative There are no meetings scheduled for the week of January 17, 2011. Week of January 24, 2011--Tentative Monday, January 24, 2011 1 p.m. Briefing on Safety Culture Policy Statement (Public...

75 FR 13215 - National Poison Prevention Week, 2010

Federal Register 2010, 2011, 2012, 2013, 2014

2010-03-19

... reported poisonings involve children under the age of six, and the vast majority take place in the home. Parents should keep household chemicals and medicines in child-proof containers, beyond the reach of their children. Thanks to safety regulations and awareness campaigns like National Poison Prevention Week...

Diffractive Higgs boson production at the Fermilab Tevatron and the CERN Large Hadron Collider.

PubMed

Enberg, R; Ingelman, G; Kissavos, A; Tîmneanu, N

2002-08-19

Improved possibilities to find the Higgs boson in diffractive events, having less hadronic activity, depend on whether the cross section is large enough. Based on the soft color interaction models that successfully describe diffractive hard scattering at DESY HERA and the Fermilab Tevatron, we find that only a few diffractive Higgs events may be produced at the Tevatron, but we predict a substantial rate at the CERN Large Hadron Collider.

Safety Plan for Schools: No Guns

ERIC Educational Resources Information Center

Shah, Nirvi

2013-01-01

In a pre-emptive move against a school safety proposal from the National Rifle Association that is expected to include a call for more people trained and approved to carry guns at schools, a coalition of civil rights and education groups unveiled its own safety plan last week. It seeks the creation of positive school climates, thoughtful and…

ARC-2008-ACD08-0201-006

NASA Image and Video Library

2008-09-04

Safety Day Events 2008 Keynote speaker at the !0th Annual Safety Awareness Week Lt Col Wes Sharp shares his reveting account of an F-18 midair collision, his insight into the root cause, lessons he learned and how to excell under pressure to perform.

Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis.

PubMed

Allanore, Yannick; Distler, Oliver; Jagerschmidt, Alexandre; Illiano, Stephane; Ledein, Laetitia; Boitier, Eric; Agueusop, Inoncent; Denton, Christopher P; Khanna, Dinesh

2018-05-06

Preclinical studies suggest a role for lysophosphatidic acid (LPA) in the pathogenesis of systemic sclerosis (SSc). SAR100842, a potent selective oral antagonist of LPA1 receptor, was assessed for safety, biomarkers and clinical efficacy in patients with diffuse cutaneous SSc (dcSSc). An 8-week double-blind, randomized, placebo-controlled study followed by a 16-week open label extension with SAR100842 was performed in patients with early dcSSc and a baseline Rodnan skin score (mRSS) of at least 15. The primary endpoint was safety during the double-blind phase of the trial. Exploratory endpoints included the identification of a LPA-induced gene signature in patients 'skin. 17 of 32 subjects were randomized to placebo and 15 to SAR100842; 30 patients participated in the extension study. The most frequent adverse events reported for SAR100842 during the blinded phase were headache, diarrhea, nausea and fall and the safety profile was acceptable during the extension part. At Week 8, mean reduction in mRSS was numerically greater in the SAR100842 compared to placebo (mean change [SD]: -3.57 [4.18] versus -2.76 [4.85]; difference [95% CI]: -1.2 [-4.37 to 2.02], p=0.46). A greater reduction of LPA related genes was observed in skin of SAR100842 group at Week 8, indicating LPA 1 target engagement. SAR100842, a selective orally available LPA 1 receptor antagonist, was well tolerated in patients with dcSSc. MRSS improved during the study although not reaching significance, and additional gene signature analysis suggested target engagement. These results need to be confirmed in a larger controlled trial. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

CERN: A global project

NASA Astrophysics Data System (ADS)

Voss, Rüdiger

2017-07-01

In the most important shift of paradigm of its membership rules in 60 years, CERN in 2010 introduced a policy of “Geographical Enlargement” which for the first time opened the door for membership of non-European States in the Organization. This short article reviews briefly the history of CERN’s membership rules, discusses the rationale behind the new policy, its relationship with the emerging global roadmap of particle physics, and gives a short overview of the status of the enlargement process.

High Energy Electron Detection with ATIC

NASA Technical Reports Server (NTRS)

Chang, J.; Schmidt, W. K. H.; Adams, James H., Jr.; Ahn, H.; Ampe, J.; Whitaker, Ann F. (Technical Monitor)

2001-01-01

The ATIC (Advanced Thin Ionization Calorimeter) balloon-borne ionization calorimeter is well suited to record and identify high energy cosmic ray electrons. The instrument was exposed to high-energy beams at CERN H2 bean-dine in September of 1999. We have simulated the performance of the instrument, and compare the simulations with actual high energy electron exposures at the CERN accelerator. Simulations and measurements do not compare exactly, in detail, but overall the simulations have predicted actual measured behavior quite well.

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

PubMed

Agarwal, Kosh; Brunetto, Maurizia; Seto, Wai Kay; Lim, Young-Suk; Fung, Scott; Marcellin, Patrick; Ahn, Sang Hoon; Izumi, Namiki; Chuang, Wan-Long; Bae, Ho; Sharma, Manoj; Janssen, Harry L A; Pan, Calvin Q; Çelen, Mustafa Kemal; Furusyo, Norihiro; Shalimar, Dr; Yoon, Ki Tae; Trinh, Huy; Flaherty, John F; Gaggar, Anuj; Lau, Audrey H; Cathcart, Andrea L; Lin, Lanjia; Bhardwaj, Neeru; Suri, Vithika; Mani Subramanian, G; Gane, Edward J; Buti, Maria; Chan, Henry L Y

2018-04-01

Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to TDF in efficacy with improved renal and bone safety. We report 96-week outcomes for both trials. In two international trials, patients with chronic HBV infection were randomized 2:1 to receive 25 mg TAF or 300 mg TDF in a double-blinded fashion. One study enrolled HBeAg-positive patients and the other HBeAg-negative patients. We assessed efficacy in each study, and safety in the pooled population. At week 96, the differences in the rates of viral suppression were similar in HBeAg-positive patients receiving TAF and TDF (73% vs. 75%, respectively, adjusted difference -2.2% (95% CI -8.3 to 3.9%; p = 0.47), and in HBeAg-negative patients receiving TAF and TDF (90% vs. 91%, respectively, adjusted difference -0.6% (95% CI -7.0 to 5.8%; p = 0.84). In both studies the proportions of patients with alanine aminotransferase above the upper limit of normal at baseline, who had normal alanine aminotransferase at week 96 of treatment, were significantly higher in patients receiving TAF than in those receiving TDF. In the pooled safety population, patients receiving TAF had significantly smaller decreases in bone mineral density than those receiving TDF in the hip (mean % change -0.33% vs. -2.51%; p <0.001) and lumbar spine (mean % change -0.75% vs. -2.57%; p <0.001), as well as a significantly smaller median change in estimated glomerular filtration rate by Cockcroft-Gault method (-1.2 vs. -4.8 mg/dl; p <0.001). In patients with HBV infection, TAF remained as effective as TDF, with continued improved renal and bone safety, two years after the initiation of treatment. Clinicaltrials.gov number: NCT01940471 and NCT01940341. At week 96 of two ongoing studies comparing the efficacy and safety of tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B patients, TAF continues to be as effective as TDF with continued improved renal and bone safety. Registration: Clinicaltrials.gov number: NCT01940471 and NCT01940341. Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

x509-free access to WLCG resources

NASA Astrophysics Data System (ADS)

Short, H.; Manzi, A.; De Notaris, V.; Keeble, O.; Kiryanov, A.; Mikkonen, H.; Tedesco, P.; Wartel, R.

2017-10-01

Access to WLCG resources is authenticated using an x509 and PKI infrastructure. Even though HEP users have always been exposed to certificates directly, the development of modern Web Applications by the LHC experiments calls for simplified authentication processes keeping the underlying software unmodified. In this work we will show a solution with the goal of providing access to WLCG resources using the user’s home organisations credentials, without the need for user-acquired x509 certificates. In particular, we focus on identity providers within eduGAIN, which interconnects research and education organisations worldwide, and enables the trustworthy exchange of identity-related information. eduGAIN has been integrated at CERN in the SSO infrastructure so that users can authenticate without the need of a CERN account. This solution achieves x509-free access to Grid resources with the help of two services: STS and an online CA. The STS (Security Token Service) allows credential translation from the SAML2 format used by Identity Federations to the VOMS-enabled x509 used by most of the Grid. The IOTA CA (Identifier-Only Trust Assurance Certification Authority) is responsible for the automatic issuing of short-lived x509 certificates. The IOTA CA deployed at CERN has been accepted by EUGridPMA as the CERN LCG IOTA CA, included in the IGTF trust anchor distribution and installed by the sites in WLCG. We will also describe the first pilot projects which are integrating the solution.

CERN at 60: giant magnet journeys through Geneva

NASA Astrophysics Data System (ADS)

Banks, Michael

2014-07-01

More than 30,000 people descended onto Geneva's harbour last month to celebrate the bicentenary of the city's integration into Switzerland with a parade through the city. Joining the 1200 participants at the Genève200 celebrations were staff from the CERN particle-physics lab, which is located on the outskirts of Geneva, who paraded a superconducting dipole magnet - similar to the thousands used in the Large Hadron Collider - through the city's narrow streets on a 20 m lorry.

Retirement Kjell Johnsen

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2007-12-05

A l'occasion de son 65me anniversaire plusieurs orateurs (aussi l'ambassadeur de Norvège) remercient Kjell Johnsen, né en juin 1921 en Norvège, pour ses 34 ans de service au Cern et retracent sa vie et son travail. K.Johnsen a pris part aux premières études sur les accélérateurs du futur centre de physique et fut aussi le père et le premier directeur de l'Ecole du Cern sur les accélérateurs (CAS)

Measurement of the antiproton-nucleus annihilation cross-section at low energy

NASA Astrophysics Data System (ADS)

Aghai-Khozani, H.; Bianconi, A.; Corradini, M.; Hayano, R.; Hori, M.; Leali, M.; Lodi Rizzini, E.; Mascagna, V.; Murakami, Y.; Prest, M.; Vallazza, E.; Venturelli, L.; Yamada, H.

2018-02-01

Systematic measurements of the annihilation cross sections of low energy antinucleons were performed at CERN in the 80's and 90's. However the antiproton data on medium-heavy and heavy nuclear targets are scarce. The ASACUSA Collaboration at CERN has measured the antiproton annihilation cross section on carbon at 5.3 MeV: the value is (1.73 ± 0.25) barn. The result is compared with the antineutron experimental data and with the theoretical previsions.

Neutron-induced fission cross section measurement of 233U, 241Am and 243Am in the energy range 0.5 MeV En 20 MeV at n TOF at CERN

DOE Office of Scientific and Technical Information (OSTI.GOV)

Belloni, F.; Milazzo, P. M.; Calviani, M.

2012-01-01

Neutron-induced fission cross section measurements of 233U, 243Am and 241Am relative to 235U have been carried out at the neutron time-of-flight facility n TOF at CERN. A fast ionization chamber has been employed. All samples were located in the same detector; therefore the studied elements and the reference 235U target are subject to the same neutron beam.

Performance of a liquid argon time projection chamber exposed to the CERN West Area Neutrino Facility neutrino beam

DOE Office of Scientific and Technical Information (OSTI.GOV)

Arneodo, F.; Cavanna, F.; Mitri, I. De

2006-12-01

We present the results of the first exposure of a Liquid Argon TPC to a multi-GeV neutrino beam. The data have been collected with a 50 liters ICARUS-like chamber located between the CHORUS and NOMAD experiments at the CERN West Area Neutrino Facility (WANF). We discuss both the instrumental performance of the detector and its capability to identify and reconstruct low-multiplicity neutrino interactions.

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.

PubMed

Göke, Burkhard; Gallwitz, Baptist; Eriksson, Johan G; Hellqvist, Åsa; Gause-Nilsson, Ingrid

2013-04-01

To compare the long-term safety, tolerability and efficacy of saxagliptin vs. glipizide as add-on therapy to metformin. Adults with glycated haemoglobin (HbA1c) > 6.5-10% (on stable metformin ≥ 1500 mg/day) were randomised to saxagliptin 5 mg/day (n = 428) or glipizide titrated from 5 to 20 mg/day (mean dose 15 mg/day; n = 430) for 52 weeks with a 52-week extension (NCT00575588). Assessment of the long-term safety, tolerability and efficacy of add-on saxagliptin vs. glipizide after 104 weeks was a tertiary objective of the initial 52-week study. Saxagliptin was well tolerated during the 104-week period; 67.1% of patients receiving saxagliptin vs. 72.6% receiving glipizide had ≥ 1 adverse event (AE), and few patients (4.9% vs. 5.6%) discontinued owing to AEs. Fewer patients treated with saxagliptin experienced hypoglycaemia (3.5% vs. 38.4% with glipizide; difference, -34.9%, 95% CI, -39.8 to -30.0) or confirmed hypoglycaemia (0 vs. 9.1% with glipizide). Weight loss was observed with saxagliptin (-1.5 kg) vs. weight gain with glipizide (+1.3 kg; between-group difference, -2.8 kg, 95% CI, -3.32 kg to -2.20 kg). Change from baseline in HbA1c was -0.41 ± 0.04% with saxagliptin and -0.35 ± 0.04% with glipizide (between-group difference, -0.05%, 95% CI, -0.17 to 0.06%). A post hoc analysis showed that the proportion of patients with baseline HbA1c ≥ 7% who achieved HbA1c < 7% (observed data) at week 104 was 23.1% for saxagliptin + metformin and 22.7% for glipizide + metformin. A lower risk of hypoglycaemia and reduced body weight were observed with saxagliptin vs. glipizide. No other clinically significant differences were observed between groups in safety profile. No significant between-group differences were observed for reductions in glycaemic parameters. After week 24, a smaller weekly rise in HbA1c was observed with saxagliptin vs. glipizide as add-on therapy to metformin.

Viewpoint: the End of the World at the Large Hadron Collider?

DOE Office of Scientific and Technical Information (OSTI.GOV)

Peskin, Michael E.; /SLAC

New arguments based on astrophysical phenomena constrain the possibility that dangerous black holes will be produced at the CERN Large Hadron Collider. On 8 August, the Large Hadron Collider (LHC) at CERN injected its first beams, beginning an experimental program that will produce proton-proton collisions at an energy of 14 TeV. Particle physicists are waiting expectantly. The reason is that the Standard Model of strong, weak, and electromagnetic interactions, despite its many successes, is clearly incomplete. Theory says that the holes in the model should be filled by new physics in the energy region that will be studied by themore » LHC. Some candidate theories are simple quick fixes, but the most interesting ones involve new concepts of spacetime waiting to be discovered. Look up the LHC on Wikipedia, however, and you will find considerable space devoted to safety concerns. At the LHC, we will probe energies beyond those explored at any previous accelerator, and we hope to create particles that have never been observed. Couldn't we, then, create particles that would actually be dangerous, for example, ones that would eat normal matter and eventually turn the earth into a blob of unpleasantness? It is morbid fun to speculate about such things, and candidates for such dangerous particles have been suggested. These suggestions have been analyzed in an article in Reviews of Modern Physics by Jaffe, Busza, Wilczek, and Sandweiss and excluded on the basis of constraints from observation and from the known laws of physics. These conclusions have been upheld by subsequent studies conducted at CERN.« less

Integrating new Storage Technologies into EOS

NASA Astrophysics Data System (ADS)

Peters, Andreas J.; van der Ster, Dan C.; Rocha, Joaquim; Lensing, Paul

2015-12-01

The EOS[1] storage software was designed to cover CERN disk-only storage use cases in the medium-term trading scalability against latency. To cover and prepare for long-term requirements the CERN IT data and storage services group (DSS) is actively conducting R&D and open source contributions to experiment with a next generation storage software based on CEPH[3] and ethernet enabled disk drives. CEPH provides a scale-out object storage system RADOS and additionally various optional high-level services like S3 gateway, RADOS block devices and a POSIX compliant file system CephFS. The acquisition of CEPH by Redhat underlines the promising role of CEPH as the open source storage platform of the future. CERN IT is running a CEPH service in the context of OpenStack on a moderate scale of 1 PB replicated storage. Building a 100+PB storage system based on CEPH will require software and hardware tuning. It is of capital importance to demonstrate the feasibility and possibly iron out bottlenecks and blocking issues beforehand. The main idea behind this R&D is to leverage and contribute to existing building blocks in the CEPH storage stack and implement a few CERN specific requirements in a thin, customisable storage layer. A second research topic is the integration of ethernet enabled disks. This paper introduces various ongoing open source developments, their status and applicability.

A possible biomedical facility at the European Organization for Nuclear Research (CERN)

PubMed Central

Dosanjh, M; Myers, S

2013-01-01

A well-attended meeting, called “Brainstorming discussion for a possible biomedical facility at CERN”, was held by the European Organization for Nuclear Research (CERN) at the European Laboratory for Particle Physics on 25 June 2012. This was concerned with adapting an existing, but little used, 78-m circumference CERN synchrotron to deliver a wide range of ion species, preferably from protons to at least neon ions, with beam specifications that match existing clinical facilities. The potential extensive research portfolio discussed included beam ballistics in humanoid phantoms, advanced dosimetry, remote imaging techniques and technical developments in beam delivery, including gantry design. In addition, a modern laboratory for biomedical characterisation of these beams would allow important radiobiological studies, such as relative biological effectiveness, in a dedicated facility with standardisation of experimental conditions and biological end points. A control photon and electron beam would be required nearby for relative biological effectiveness comparisons. Research beam time availability would far exceed that at other facilities throughout the world. This would allow more rapid progress in several biomedical areas, such as in charged hadron therapy of cancer, radioisotope production and radioprotection. The ethos of CERN, in terms of open access, peer-reviewed projects and governance has been so successful for High Energy Physics that application of the same to biomedicine would attract high-quality research, with possible contributions from Europe and beyond, along with potential new funding streams. PMID:23549990

Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

PubMed

Fein, Henry G; Vaughan, T Brooks; Kushner, Harvey; Cram, David; Nguyen, Dat

2015-10-27

Overweight and obesity are common among patients with Cushing's syndrome (CS) and may persist in some patients even after ostensibly curative surgery, contributing to cardiometabolic dysfunction and increased cardiovascular risk. Mifepristone, a selective glucocorticoid receptor antagonist, was effective in controlling hyperglycemia in a 24-week trial of adults (N = 50) with endogenous CS and associated type 2 diabetes mellitus/impaired glucose tolerance or hypertension who had failed or were not candidates for surgery (SEISMIC, Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome). This analysis examines long-term weight change among patients who received mifepristone in SEISMIC and enrolled in a long-term safety extension (LTE) study. Patients completing the 24-week SEISMIC study and subsequent 6-week off-drug safety evaluation were invited to enroll in the LTE study. Mifepristone doses at the end of SEISMIC were the LTE starting doses. Body weight measures were reviewed at baseline and week 24 of SEISMIC and at LTE month 6, 12, 18, 24, and final visit (last observation collected during the LTE study). Of the 30 patients enrolled in the LTE, evaluable weight data were available for 29 (20/29 female; mean age of 44.7 ± 11.2 years). These patients received mifepristone for a median of 29.2 months (range 8.4-41.9). Mean ± SD weight from SEISMIC baseline to LTE final visit decreased by 10.3 ± 16.3 kg (mean 105.4 ± 34.3 kg to 95.1 ± 32.9 kg), a 9.3 % decrease from baseline weight (P = 0.0008). Of the 29 LTE patients, 18 (62.1 %) lost ≥ 5 % of body weight by the end of the initial 24-week treatment period; this ≥5 % weight loss persisted in 83.3 % (15/18) at LTE final visit. Ten patients (34.5 %) lost ≥ 10 % of initial body weight by week 24 of SEISMIC, which persisted in 80 % at LTE final visit. No new safety signals were detected with long-term mifepristone use. Clinically meaningful weight loss achieved during a 24-week study of mifepristone for CS persisted for two additional years in patients who remained on therapy. Long-term treatment with mifepristone appears to have a beneficial effect on weight in patients with endogenous CS. NCT00569582 (SEISMIC); NCT00936741 (Long-Term Extension).

Assessment of safety and interferon gamma responses of Mycobacterium bovis BCG vaccine in goat kids and milking goats.

PubMed

Pérez de Val, Bernat; Vidal, Enric; López-Soria, Sergio; Marco, Alberto; Cervera, Zoraida; Martín, Maite; Mercader, Irene; Singh, Mahavir; Raeber, Alex; Domingo, Mariano

2016-02-10

Vaccination of domestic animals has emerged as an alternative long-term strategy for the control of tuberculosis (TB). A trial under field conditions was conducted in a TB-free goat herd to assess the safety of the Mycobacterium bovis BCG vaccine. Eleven kids and 10 milking goats were vaccinated with BCG. Bacterial shedding and interferon gamma (IFN-γ) responses were monitored throughout the study. Comprehensive pathological examination and mycobacterial culture of target tissues were performed. BCG vaccine strain was only isolated from the draining lymph node of the injection site of a kid euthanized at week 8 post-vaccination. The remaining animals were euthanized at week 24. Six out of 20 showed small granulomas at the injection site. BCG shedding was not detected in either faeces or in milk throughout the study. All vaccinated kids showed BCG-induced IFN-γ responses at week 8 post-vaccination. BCG vaccination of goats showed no lack of biological safety for the animals, environment and public health, and local adverse reactions were negligible. Copyright © 2016 Elsevier Ltd. All rights reserved.

Fermilab Today | Tip of the Week Archive

Science.gov Websites

flood safety tips June 15, 2015 Why are there so many species? June 8, 2015 Cybersecurity in the 11, 2015 May is Electrical Safety Month May 4, 2015 The last line of defense is you April 27, 2015 A ? Fire! April 6, 2015 What could possibly go wrong? March 30, 2015 Improving traffic safety at Fermilab

Ceremony 25th birthday Cern

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

2006-05-08

Célébration du 25ème anniversaire du Cern (jour par jour) avec discours de L.Van Hove et J.B.Adams, des interludes musicals offerts par Mme Mey et ses collègues (au debut 1.mouvement du quatuor avec piano no 3 de L.van Beethoven) Les directeurs généraux procéderont à la remise du souvenir aux membres de personnel ayant 25 années de service dans l'organisation. Un témoignage de reconnaissance est auss fait à l'interprète Mme Zwerner

News UK public libraries offer walk-in access to research Atoms for Peace? The Atomic Weapons Establishment and UK universities Students present their research to academics: CERN@school Science in a suitcase: Marvin and Milo visit Ethiopia Inspiring telescopes A day for everyone teaching physics 2014 Forthcoming Events

NASA Astrophysics Data System (ADS)

2014-05-01

UK public libraries offer walk-in access to research Atoms for Peace? The Atomic Weapons Establishment and UK universities Students present their research to academics: CERN@school Science in a suitcase: Marvin and Milo visit Ethiopia Inspiring telescopes A day for everyone teaching physics 2014 Forthcoming Events

An On-Line Acoustic Fluorocarbon Coolant Mixture Analyzer for the ATLAS Silicon Tracker

NASA Astrophysics Data System (ADS)

Bates, R.; Battistin, M.; Berry, S.; Bitadze, A.; Bonneau, P.; Bousson, N.; Boyd, G.; Botelho-Direito, J.; DiGirolamo, B.; Doubek, M.; Egorov, K.; Godlewski, J.; Hallewell, G.; Katunin, S.; Mathieu, M.; McMahon, S.; Nagai, K.; Perez-Rodriguez, E.; Rozanov, A.; Vacek, V.; Vitek, M.

2012-10-01

The ATLAS silicon tracker community foresees an upgrade from the present octafluoropropane (C3F8) evaporative cooling fluid to a composite fluid with a probable 10-20% admixture of hexafluoroethane (C2F6). Such a fluid will allow a lower evaporation temperature and will afford the tracker silicon substrates a better safety margin against leakage current-induced thermal runaway caused by cumulative radiation damage as the luminosity profile at the CERN Large Hadron Collider increases. Central to the use of this new fluid is a new custom-developed speed-of-sound instrument for continuous real-time measurement of the C3F8/C2F6 mixture ratio and flow. An acoustic vapour mixture analyzer/flow meter with new custom electronics allowing ultrasonic frequency transmission through gas mixtures has been developed for this application. Synchronous with the emission of an ultrasound `chirp' from an acoustic transmitter, a fast readout clock (40 MHz) is started. The clock is stopped on receipt of an above threshold sound pulse at the receiver. Sound is alternately transmitted parallel and anti-parallel with the vapour flow for volume flow measurement from transducers that can serve as acoustic transmitters or receivers. In the development version, continuous real-time measurement of C3F8/C2F6 flow and calculation of the mixture ratio is performed within a graphical user interface developed in PVSS-II, the Supervisory, Control and Data Acquisition standard chosen for LHC and its experiments at CERN. The described instrument has numerous potential applications - including refrigerant leak detection, the analysis of hydrocarbons, vapour mixtures for semi-conductor manufacture and anesthetic gas mixtures.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

PubMed

Cohen, Stanley; Genovese, Mark C; Choy, Ernest; Perez-Ruiz, Fernando; Matsumoto, Alan; Pavelka, Karel; Pablos, Jose L; Rizzo, Warren; Hrycaj, Pawel; Zhang, Nan; Shergy, William; Kaur, Primal

2017-10-01

ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab. Secondary endpoints included Disease Activity Score 28-joint count-C reactive protein (DAS28-CRP). Safety was assessed via adverse events (AEs) and laboratory evaluations. Antidrug antibodies were assessed to determine immunogenicity. A total of 526 patients were randomised (n=264, ABP 501; n=262 adalimumab) and 494 completed the study. ACR20 response at week 24 was 74.6% (ABP 501) and 72.4% (adalimumab). At week 24, the RR of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133), confirming the primary hypothesis. Changes from baseline in DAS28-CRP, ACR50 and ACR70 were similar. There were no clinically meaningful differences in AEs and laboratory abnormalities. A total of 38.3% (ABP 501) and 38.2% (adalimumab) of patients tested positive for binding antidrug antibodies. Results from this study demonstrate that ABP 501 is similar to adalimumab in clinical efficacy, safety and immunogenicity in patients with moderate to severe RA. NCT01970475; Results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

PubMed

Sandborn, W J; Rutgeerts, P; Gasink, C; Jacobstein, D; Zou, B; Johanns, J; Sands, B E; Hanauer, S B; Targan, S; Ghosh, S; de Villiers, W J S; Colombel, J-F; Feagan, B G

2018-05-24

In Phase 3 studies of ustekinumab, a fully human monoclonal IL-12/23p40 antibody approved for moderate-to-severe Crohn's disease, patients entered a long-term extension after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy through 92 weeks and safety through 96 weeks of IM-UNITI maintenance are reported. UNITI-1 (TNF-antagonist failures) and UNITI-2 (conventional therapy failures) patients (N = 1281) entered IM-UNITI, including 397 ustekinumab intravenous induction responders randomised to subcutaneous ustekinumab 90 mg every 12 weeks, every 8 weeks, or placebo and 884 nonrandomised patients. Dose-adjustment to 90 mg every 8 weeks occurred in patients randomised to 90 mg every 12 weeks and placebo patients with loss of response (Weeks 8-32). All Week 44 completers could enter the long-term extension without further dose adjustment. Placebo patients discontinued following study unblinding. A total of 718 patients (all treated) entered the long-term extension (298 randomised and 420 not randomised). Overall, 86.5% (621/718) completed Week 96. The proportions of randomised patients in clinical remission were generally maintained from Week 44 through 92 in ustekinumab 90 mg every 12 weeks (77.4% to 72.6%), every 8 weeks (84.1% to 74.4%), and prior dose adjustment groups (63.4% to 53.5%). At Week 92, the proportions of patients in clinical remission were similar in the ustekinumab 90 mg every 12 weeks and every 8 weeks groups and lower in patients with prior dose adjustment. Proportions of patients in clinical remission at Week 92 for all treated every 8 weeks (64.4%) and every 12 weeks (64.3%) groups were lower than randomised every 8 weeks (74.4%) and every 12 weeks (72.6%) groups, but similarly maintained. Safety events (per hundred patient-years) were similar among all placebo and ustekinumab patients (Week 0-96), including adverse events (484.39 vs 447.76), serious adverse events (19.24 vs 18.82), and serious infections (4.09 vs 4.02). No dose effect was observed. Subcutaneous ustekinumab maintained clinical response and remission through Week 92. No new safety signals were observed. ClinicalTrials.gov number NCT01369355. © 2018 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

PubMed

Nash, Peter; Mease, Philip J; McInnes, Iain B; Rahman, Proton; Ritchlin, Christopher T; Blanco, Ricardo; Dokoupilova, Eva; Andersson, Mats; Kajekar, Radhika; Mpofu, Shephard; Pricop, Luminita

2018-03-15

The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study ( ClinicalTrials.gov NCT01989468). Patients (≥ 18 years of age; N = 414) with active PsA were randomized 1:1:1 to subcutaneous (s.c.) secukinumab 300 mg, 150 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. Per clinical response, placebo-treated patients were re-randomized to s.c. secukinumab 300 or 150 mg at week 16 (nonresponders) or week 24 (responders) and stratified at randomization by prior anti-tumor necrosis factor (TNF) therapy (anti-TNF-naïve, 68.1%; intolerant/inadequate response (anti-TNF-IR), 31.9%). The primary endpoint was the proportion of patients achieving at least 20% improvement in American College of Rheumatology response criteria (ACR20) at week 24. Autoinjector usability was evaluated by Self-Injection Assessment Questionnaire (SIAQ). Overall, 92.1% (300 mg), 91.3% (150 mg), and 93.4% (placebo) of patients completed 24 weeks, and 84.9% (300 mg) and 79.7% (150 mg) completed 52 weeks. In the overall population (combined anti-TNF-naïve and anti-TNF-IR), ACR20 response rate at week 24 was significantly higher in secukinumab groups (300 mg, 48.2% (p < 0.0001); 150 mg, 42% (p < 0.0001); placebo, 16.1%) and was sustained through 52 weeks. SIAQ results showed that more than 93% of patients were satisfied/very satisfied with autoinjector usage. Secukinumab was well tolerated with no new or unexpected safety signals reported. Secukinumab provided sustained improvements in signs and symptoms in active PsA patients through 52 weeks. High acceptability of autoinjector was observed. The safety profile was consistent with that reported previously. ClinicalTrials.gov NCT01989468 . Registered 21 November 2013. EudraCT 2013-004002-25 . Registered 17 December 2013.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

PubMed Central

Cohen, Stanley; Genovese, Mark C; Choy, Ernest; Perez-Ruiz, Fernando; Matsumoto, Alan; Pavelka, Karel; Pablos, Jose L; Rizzo, Warren; Hrycaj, Pawel; Zhang, Nan; Shergy, William; Kaur, Primal

2017-01-01

Objectives ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. Methods In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab. Secondary endpoints included Disease Activity Score 28-joint count-C reactive protein (DAS28-CRP). Safety was assessed via adverse events (AEs) and laboratory evaluations. Antidrug antibodies were assessed to determine immunogenicity. Results A total of 526 patients were randomised (n=264, ABP 501; n=262 adalimumab) and 494 completed the study. ACR20 response at week 24 was 74.6% (ABP 501) and 72.4% (adalimumab). At week 24, the RR of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133), confirming the primary hypothesis. Changes from baseline in DAS28-CRP, ACR50 and ACR70 were similar. There were no clinically meaningful differences in AEs and laboratory abnormalities. A total of 38.3% (ABP 501) and 38.2% (adalimumab) of patients tested positive for binding antidrug antibodies. Conclusions Results from this study demonstrate that ABP 501 is similar to adalimumab in clinical efficacy, safety and immunogenicity in patients with moderate to severe RA. Trial registration number NCT01970475; Results. PMID:28584187

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).

PubMed

Langley, R G; Papp, K; Gooderham, M; Zhang, L; Mallinckrodt, C; Agada, N; Blauvelt, A; Foley, P; Polzer, P

2018-06-01

Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter. To evaluate continuous Q2W dosing over 52 weeks. In this phase III, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2 : 1 : 1 ratio to continuous Q2W (n = 611), continuous Q4W (n = 310) or dose adjustment per protocol (Q4W/Q2W, n = 306), each with a 160-mg starting dose. Dose adjustment was determined by predefined criteria to which investigators were blinded; 72 (23?5%) patients in the Q4W/Q2W group adjusted dose. Efficacy outcomes were evaluated using logistic regression. Co-primary end points were met at week 52: Psoriasis Area and Severity Index 75 responses for Q2W and Q4W dose groups were 85·9% and 79·0%, respectively (P = 0·006), and static patient global assessment 0/1 responses for Q2W and Q4W dose groups were 78·6% and 70·6%, respectively (P = 0·005). Treatment-emergent and serious adverse events were comparable across dose groups. Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events. © 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

PubMed

Isenberg, D A; Petri, M; Kalunian, K; Tanaka, Y; Urowitz, M B; Hoffman, R W; Morgan-Cox, M; Iikuni, N; Silk, M; Wallace, D J

2016-02-01

Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds and neutralises membrane and soluble B-cell activating factor (BAFF) versus placebo plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE). This phase III, 52-week study randomised 1164 patients with moderate-to-severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index ≥6 at baseline). Patients received SoC plus subcutaneous injections of tabalumab or placebo, starting with a loading dose (240 mg) at week 0 and followed by 120 mg every two weeks (120 Q2W, n=387), 120 mg every four weeks (120 Q4W, n=389) or placebo Q2W (n=388). proportion of patients achieving SLE Responder Index 5 (SRI-5) response at week 52. Similar proportions of patients in each group achieved SRI-5 response at week 52 (120 Q2W: 31.8%; 120 Q4W: 35.2% and placebo: 29.3%). Key secondary endpoints were not met. In a sensitivity analysis not excluding patients who decreased antimalarials or immunosuppressants, SRI-5 response was achieved with 120 Q4W (37.0% vs 29.8% placebo; p=0.021), but not 120 Q2W (34.1%; p=0.171). Significant reductions in anti-dsDNA antibodies, increases in C3 and C4, and reductions in total B cells and immunoglobulins were observed with tabalumab. No differences were observed between treatment groups in percentage of deaths (120 Q2W: 0.8%; 120 Q4W: 0.5%; placebo: 0.5%), serious adverse events (AEs) (range 11.1-14.4%) or treatment-emergent AEs (range 81.1-82.3%). Tabalumab had biological activity-changes in anti-dsDNA, complement, B cells and immunoglobulins-consistent with BAFF pathway inhibition. Key clinical efficacy endpoints did not achieve statistical significance. Safety profiles were similar with tabalumab and placebo. NCT01196091. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

PubMed

Haneda, Masakazu; Seino, Yutaka; Inagaki, Nobuya; Kaku, Kohei; Sasaki, Takashi; Fukatsu, Atsushi; Kakiuchi, Haruka; Sato, Yuri; Sakai, Soichi; Samukawa, Yoshishige

2016-01-01

To evaluate the influence of renal function on the efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin (TS-071) in Japanese patients with type 2 diabetes mellitus (T2DM). Study 1 was a 52-week, Phase III study to evaluate the efficacy and safety of 2.5 mg/d luseogliflozin (or increased to 5 mg/d) in patients with T2DM with moderate renal impairment. During the initial 24 weeks, efficacy and safety of luseogliflozin were compared with placebo. Study 2 was a pooled analysis of four 52-week, Phase III studies of luseogliflozin, including Study 1, to evaluate the efficacy and safety of luseogliflozin in patients with various degrees of renal function. Patients were stratified into 3 groups by baseline estimated glomerular filtration rate (eGFR): normal renal function (≥90 mL/min/1.73 m(2)), mild impairment (≥60 to <90 mL/min/1.73 m(2)), and moderate impairment (≥30 to <60 mL/min/1.73 m(2)). Patients with moderate impairment were further divided into those with mild-moderate (≥45 to <60 mL/min/1.73 m(2)) and moderate-severe (≥30 to <45 mL/min/1.73 m(2)). In both studies, efficacy end points included changes in glycated hemoglobin (HbA1c) level, fasting plasma glucose (FPG) level, and body weight. The safety end points included adverse events (AEs) and laboratory parameters. In Study 1, HbA1c, FPG, and body weight significantly decreased at Week 24 in patients treated with luseogliflozin compared with patients treated with placebo, with the decrease in these parameters also observed with luseogliflozin at Week 52. The incidence of AEs was similar between groups. In Study 2, 1030 patients were included (normal, 275; mildly impaired, 598; and moderately impaired, 157). At Week 52, HbA1c, FPG, and body weight were significantly decreased from baseline in all groups. In between-group comparisons, the decreases in HbA1c and body weight were significantly smaller in patients with moderate impairment than in those with normal function; however, the HbA1c-lowering efficacy was reduced by nearly half, whereas the efficacy of body weight lowering was not so much diminished in the moderate impairment group. Furthermore, a scatter plot showed that changes in HbA1c were more influenced by baseline HbA1c than by baseline eGFR. The incidence of AEs during 52 weeks was similar among all groups, with the majority being mild. Luseogliflozin improved glycemic control and reduced body weight in all eGFR groups, and its efficacy on HbA1c lowering was reduced in those with moderate renal impairment. Luseogliflozin was well tolerated and safe, with no significant safety issues identified, regardless of baseline eGFR. The study is registered with Clinical Trials Information/JapicCTI of the Japan Pharmaceutical Information Center, and the study registry identification numbers are JapicCTI-111507, JapicCTI-111508, JapicCTI-111509, and JapicCTI-111543. Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Two-particle correlations in azimuthal angle and pseudorapidity in inelastic p + p interactions at the CERN Super Proton Synchrotron

DOE PAGES

Aduszkiewicz, A.; Ali, Y.; Andronov, E.; ...

2017-01-30

Results on two-particle ΔηΔΦ correlations in inelastic p + p interactions at 20, 31, 40, 80, and 158 GeV/c are presented. The measurements were performed using the large acceptance NA61/SHINE hadron spectrometer at the CERN Super Proton Synchrotron. The data show structures which can be attributed mainly to effects of resonance decays, momentum conservation, and quantum statistics. Furthermore, the results are compared with the Epos and UrQMD models.

CERN: A European laboratory for a global project

NASA Astrophysics Data System (ADS)

Voss, Rüdiger

2015-06-01

In the most important shift of paradigm of its membership rules in 60 years, CERN in 2010 introduced a policy of “Geographical Enlargement” which for the first time opened the door for membership of non-European States in the Organization. This short article reviews briefly the history of CERN's membership rules, discusses the rationale behind the new policy, its relationship with the emerging global roadmap of particle physics, and gives a short overview of the status of the enlargement process.

Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.

PubMed

Josiassen, Richard C; Kane, John M; Liang, Grace S; Burke, Joshua; O'Brien, Christopher F

2017-08-01

The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD. The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up). Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-Åsberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively. The LTE population included 430 subjects (KINECT, n = 46; KINECT 3, n = 220; KINECT 4, n = 164), 71.7% with SCHZ and 28.3% with a mood disorder; 85.5% were taking an antipsychotic (atypical only, 69.8%; typical only or typical + atypical, 15.7%). In the LTE population, treatment-emergent AEs (TEAEs) and discontinuations due to AEs were reported in 66.5% and 14.7% of subjects, respectively. The TEAE incidence was lower in the SCHZ subgroup (64.4%) than in the mood subgroup (71.9%). The 3 most common TEAEs in the SCHZ subgroup were urinary tract infection (UTI, 6.1%), headache (5.8%), and somnolence (5.2%). The 3 most common TEAEs in the mood subgroup were headache (12.4%), UTI (10.7%), and somnolence (9.1%). Mean score changes from baseline to end of treatment (Week 48) indicated that psychiatric stability was maintained in the SCHZ subgroup (PANSS Total, -3.4; PANSS Positive, -1.1; PANSS Negative, -0.1; PANSS General Psychopathology, -2.2; CDSS total, -0.4) and the mood subgroup (MADRS Total, 0.0; YMRS Total, -1.2). These scores remained generally stable during the 4-week drug-free follow-up periods. In the LTE population, mean changes in laboratory parameters, vital signs, ECG, and EPS scales were generally minimal and not clinically significant. Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results (presented separately), these results suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder).

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.

PubMed

Ogata, Atsushi; Atsumi, Tatsuya; Fukuda, Takaaki; Hirabayashi, Yasuhiko; Inaba, Masaaki; Ishiguro, Naoki; Kai, Motokazu; Kawabata, Daisuke; Kida, Daihei; Kohsaka, Hitoshi; Matsumura, Ryutaro; Minota, Seiji; Mukai, Masaya; Sumida, Takayuki; Takasugi, Kiyoshi; Tamaki, Shigenori; Takeuchi, Tsutomu; Ueda, Atsuhisa; Yamamoto, Kazuhiko; Yamanaka, Hisashi; Yoshifuji, Hajime; Nomura, Akira

2015-10-01

To evaluate the efficacy and safety of switching from intravenous (IV) tocilizumab (TCZ) to subcutaneous (SC) TCZ monotherapy in rheumatoid arthritis patients. Patients who had completed 24 weeks of TCZ-SC (162 mg/2 weeks) or TCZ-IV (8 mg/kg/4 weeks) monotherapy in the double-blind period of the MUSASHI study were enrolled in an 84-week open-label extension period. All received TCZ-SC (162 mg/2 weeks) monotherapy. Effects of the IV to SC switch were evaluated at week 36 (12 weeks after switching). Overall, 319 patients received ≥1 dose of TCZ-SC during the open-label extension period; 160 switched from TCZ-IV to TCZ-SC (TCZ IV/SC) and 159 continued TCZ-SC (TCZ SC/SC). Disease Activity Score in 28 joints using the erythrocyte sedimentation rate clinical remission rates were 62.5% (100 of 160) for TCZ IV/SC and 50.0% (79 of 158) for TCZ SC/SC at week 24, and were maintained at 62.5% (100 of 160) and 57.0% (90 of 158), respectively, at week 36. In the TCZ IV/SC group, 9% of patients (9 of 100) who had achieved remission at week 24 could not maintain remission at week 36. In TCZ IV/SC patients weighing ≥70 kg, the percentage with a sufficient serum TCZ concentration (≥1 μg/ml) decreased from 90.9% (10 of 11) at week 24 to 45.5% (5 of 11) at week 36. Overall safety profiles were similar in TCZ IV/SC and TCZ SC/SC except for mild injection site reactions in TCZ IV/SC. Efficacy is adequately maintained in most patients switching from TCZ-IV (8 mg/kg/4 weeks) to TCZ-SC (162 mg/2 weeks) monotherapy. Patients receiving TCZ-IV can switch to TCZ-SC without serious safety concerns. Clinical efficacy may be reduced after switching in some patients with high body weight. © 2015 The Authors. Arthritis Care & Research is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

News Conference: Physics brings the community together Training: CERN trains physics teachers Education: World conference fosters physics collaborations Lecture: Physics education live at ASE Prize: Physics teacher wins first Moore medal Festival: European presidents patronize Science on Stage festival Videoconference: Videoconference brings Durban closer to the classroom

NASA Astrophysics Data System (ADS)

2012-03-01

Conference: Physics brings the community together Training: CERN trains physics teachers Education: World conference fosters physics collaborations Lecture: Physics education live at ASE Prize: Physics teacher wins first Moore medal Festival: European presidents patronize Science on Stage festival Videoconference: Videoconference brings Durban closer to the classroom

News Festival: Science on stage deadline approaches Conference: Welsh conference attracts teachers Data: New phase of CERN openlab tackles exascale IT challenges for science Meeting: German Physical Society holds its physics education spring meeting Conference: Association offers golden opportunity in Norway Competition: So what's the right answer then?

NASA Astrophysics Data System (ADS)

2012-07-01

Festival: Science on stage deadline approaches Conference: Welsh conference attracts teachers Data: New phase of CERN openlab tackles exascale IT challenges for science Meeting: German Physical Society holds its physics education spring meeting Conference: Association offers golden opportunity in Norway Competition: So what's the right answer then?

Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder

PubMed Central

Josiassen, Richard C.; Kane, John M.; Liang, Grace S.; Burke, Joshua; O’Brien, Christopher F.

2017-01-01

Background The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD. Methods The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up). Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-Åsberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively. Results The LTE population included 430 subjects (KINECT, n = 46; KINECT 3, n = 220; KINECT 4, n = 164), 71.7% with SCHZ and 28.3% with a mood disorder; 85.5% were taking an antipsychotic (atypical only, 69.8%; typical only or typical + atypical, 15.7%). In the LTE population, treatment-emergent AEs (TEAEs) and discontinuations due to AEs were reported in 66.5% and 14.7% of subjects, respectively. The TEAE incidence was lower in the SCHZ subgroup (64.4%) than in the mood subgroup (71.9%). The 3 most common TEAEs in the SCHZ subgroup were urinary tract infection (UTI, 6.1%), headache (5.8%), and somnolence (5.2%). The 3 most common TEAEs in the mood subgroup were headache (12.4%), UTI (10.7%), and somnolence (9.1%). Mean score changes from baseline to end of treatment (Week 48) indicated that psychiatric stability was maintained in the SCHZ subgroup (PANSS Total, -3.4; PANSS Positive, -1.1; PANSS Negative, -0.1; PANSS General Psychopathology, -2.2; CDSS total, -0.4) and the mood subgroup (MADRS Total, 0.0; YMRS Total, -1.2). These scores remained generally stable during the 4-week drug-free follow-up periods. In the LTE population, mean changes in laboratory parameters, vital signs, ECG, and EPS scales were generally minimal and not clinically significant. Conclusion Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results (presented separately), these results suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder). PMID:28839341

Measurements and FLUKA Simulations of Bismuth, Aluminium and Indium Activation at the upgraded CERN Shielding Benchmark Facility (CSBF)

NASA Astrophysics Data System (ADS)

Iliopoulou, E.; Bamidis, P.; Brugger, M.; Froeschl, R.; Infantino, A.; Kajimoto, T.; Nakao, N.; Roesler, S.; Sanami, T.; Siountas, A.; Yashima, H.

2018-06-01

The CERN High energy AcceleRator Mixed field (CHARM) facility is situated in the CERN Proton Synchrotron (PS) East Experimental Area. The facility receives a pulsed proton beam from the CERN PS with a beam momentum of 24 GeV/c with 5·1011 protons per pulse with a pulse length of 350 ms and with a maximum average beam intensity of 6.7·1010 protons per second. The extracted proton beam impacts on a cylindrical copper target. The shielding of the CHARM facility includes the CERN Shielding Benchmark Facility (CSBF) situated laterally above the target that allows deep shielding penetration benchmark studies of various shielding materials. This facility has been significantly upgraded during the extended technical stop at the beginning of 2016. It consists now of 40 cm of cast iron shielding, a 200 cm long removable sample holder concrete block with 3 inserts for activation samples, a material test location that is used for the measurement of the attenuation length for different shielding materials as well as for sample activation at different thicknesses of the shielding materials. Activation samples of bismuth, aluminium and indium were placed in the CSBF in September 2016 to characterize the upgraded version of the CSBF. Monte Carlo simulations with the FLUKA code have been performed to estimate the specific production yields of bismuth isotopes (206 Bi, 205 Bi, 204 Bi, 203 Bi, 202 Bi, 201 Bi) from 209 Bi, 24 Na from 27 Al and 115 m I from 115 I for these samples. The production yields estimated by FLUKA Monte Carlo simulations are compared to the production yields obtained from γ-spectroscopy measurements of the samples taking the beam intensity profile into account. The agreement between FLUKA predictions and γ-spectroscopy measurements for the production yields is at a level of a factor of 2.

A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.

PubMed

Rakugi, Hiromi; Shimizu, Kohei; Nishiyama, Yuya; Sano, Yuhei; Umeda, Yuusuke

2018-06-01

Patients with essential hypertension who are receiving treatment with an angiotensin II receptor blocker and a calcium channel blocker often develop inadequate blood pressure (BP) control and require the addition of a diuretic. This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ). The phase III, open-label, multicenter study (NCT02277691) comprised a 4-week run-in period and 52-week treatment period. Patients with inadequate BP control despite AZL/AML therapy (n = 341) received 4 weeks' treatment with AZL/AML (combination tablet) + HCTZ (tablet) and 4 weeks' treatment with AZL/AML/HCTZ (combination tablet) in a crossover manner, followed by AZL/AML/HCTZ (combination tablet) from Week 8 of the treatment period up to Week 52. The primary and secondary endpoints were long-term safety and BP (office and home), respectively. Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported. The triple therapy provided consistent BP-lowering effects in both office and home measurements. The triple combination therapy with AZL/AML/HCTZ was well tolerated and effective for 52 weeks in Japanese patients with essential hypertension.

Fermilab Today

Science.gov Websites

Fundamental Physics in the Non-Linear Regime 3:30 p.m. Director's Coffee Break - 2nd Flr X-Over 4:00 p.m. All Week archive Fermilab Safety Tip of the Week archive Linear Collider News archive Fermilab Today Committee ECFA Study of Physics and Detectors for a Linear Collider" and GDE member, explained the

Three big differences in safety rules for U.S. and European truckers

DOT National Transportation Integrated Search

1999-06-01

The article discusses the differences in safety rules for U.S. and European truckers. Some of the specific differences include: European Union rules restrict truckers to 9 hours of driving per day, with two 10-hour days permitted each week; whereas U...

Safe RESIDential Environments? A longitudinal analysis of the influence of crime-related safety on walking.

PubMed

Foster, Sarah; Hooper, Paula; Knuiman, Matthew; Christian, Hayley; Bull, Fiona; Giles-Corti, Billie

2016-02-16

Numerous cross-sectional studies have investigated the premise that the perception of crime will cause residents to constrain their walking; however the findings to date are inconclusive. In contrast, few longitudinal or prospective studies have examined the impact of crime-related safety on residents walking behaviours. This study used longitudinal data to test whether there is a causal relationship between crime-related safety and walking in the local neighbourhood. Participants in the RESIDential Environments Project (RESIDE) in Perth, Australia, completed a questionnaire before moving to their new neighbourhood (n = 1813) and again approximately one (n = 1467), three (n = 1230) and seven years (n = 531) after relocating. Self-report measures included neighbourhood perceptions (modified NEWS items) and walking inside the neighbourhood (min/week). Objective built environmental measures were generated for each participant's 1600 m neighbourhood at each time-point, and the count of crimes reported to police were generated at the suburb-level for the first three time-points only. The impact of crime-related safety on walking was examined in SAS using the Proc Mixed procedure (marginal repeated measures model with unrestricted variance pattern). Initial models controlled for demographics, time and self-selection, and subsequent models progressively adjusted for other built and social environment factors based on a social ecological model. For every increase of one level on a five-point Likert scale in perceived safety from crime, total walking within the local neighbourhood increased by 18.0 min/week (p = 0.000). This relationship attenuated to an increase of 10.5 min/week after accounting for other built and social environment factors, but remained significant (p = 0.008). Further analyses examined transport and recreational walking separately. In the fully adjusted models, each increase in safety from crime was associated with a 7.0 min/week increase in recreational walking (p = 0.009), however findings for transport walking were non-significant. All associations between suburb-level crime and walking were non-significant. This study provides longitudinal evidence of a potential causal relationship between residents' perceptions of safety from crime and recreational walking. Safety perceptions appeared to influence recreational walking, rather than transport-related walking. Given the popularity of recreational walking and the need to increase levels of physical activity, community social and physical environmental interventions that foster residents' feelings of safety are likely to increase recreational walking and produce public health gains.

First experimental evidence of hydrodynamic tunneling of ultra–relativistic protons in extended solid copper target at the CERN HiRadMat facility

DOE Office of Scientific and Technical Information (OSTI.GOV)

Schmidt, R.; Grenier, D.; Wollmann, D.

2014-08-15

A novel experiment has been performed at the CERN HiRadMat test facility to study the impact of the 440 GeV proton beam generated by the Super Proton Synchrotron on extended solid copper cylindrical targets. Substantial hydrodynamic tunneling of the protons in the target material has been observed that leads to significant lengthening of the projectile range, which confirms our previous theoretical predictions [N. A. Tahir et al., Phys. Rev. Spec. Top.-Accel. Beams 15, 051003 (2012)]. Simulation results show very good agreement with the experimental measurements. These results have very important implications on the machine protection design for powerful machines like themore » Large Hadron Collider (LHC), the future High Luminosity LHC, and the proposed huge 80 km circumference Future Circular Collider, which is currently being discussed at CERN. Another very interesting outcome of this work is that one may also study the field of High Energy Density Physics at this test facility.« less

COMMITTEES: SQM 2007 - International Conference On Strangeness In Quark Matter SQM 2007 - International Conference On Strangeness In Quark Matter

NASA Astrophysics Data System (ADS)

2008-04-01

Local Organising Committee Ivan Králik (IEP SAS, Košice) Vojtěch Petráček (Czechoslovakia Technical University, Prague) Ján Pišút (Comenius University, Bratislava) Emanuele Quercigh (CERN) Karel Šafařík (CERN), Co-chair Ladislav v Sándor (IEP SAS, Košice), Co-chair Boris Tomášik (Mateja Bela University, Banská Bystrica) Jozef Urbán (UPJŠ Košice) International Advisory Committee Jörg Aichelin, Nantes Federico Antinori, Padova Tamás Biró, Budapest Peter Braun-Munzinger, GSI Jean Cleymans, Cape Town László Csernai, Bergen Timothy Hallman, BNL Huan Zhong Huang, UCLA Sonja Kabana, Nantes Roy A Lacey, Stony Brook Carlos Lourenço, CERN Yu-Gang Ma, Shanghai Jes Masden, Aarhus Yasuo Miake, Tsukuba Berndt Müller, Duke Grazyna Odyniec, LBNL Helmut Oeschler, Darmstadt Jan Rafelski, Arizona Hans Georg Ritter, LBNL Jack Sandweiss, Yale George S F Stephans, MIT Horst Stöcker, Frankfurt Thomas Ullrich, BNL Orlando Villalobos-Baillie, Birmingham William A Zajc, Columbia

Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.

PubMed

Tsuru, Tomomi; Tanaka, Yoshiya; Kishimoto, Mitsumasa; Saito, Kazuyoshi; Yoshizawa, Seiji; Takasaki, Yoshinari; Miyamura, Tomoya; Niiro, Hiroaki; Morimoto, Shinji; Yamamoto, Junichi; Lledo-Garcia, Rocio; Shao, Jing; Tatematsu, Shuichiro; Togo, Osamu; Koike, Takao

2016-01-01

This 12-week, randomized, double-blind, placebo-controlled, multicenter phase 1/2 study (NCT01449071) assessed the safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus despite standard of care. Twenty patients were randomized 1:1:1:1:1 to placebo or one of four epratuzumab dose regimens (100 mg every other week [Q2W], 400 mg Q2W, 600 mg every week [QW], or 1200 mg Q2W) administered during an initial 4-week dosing period. Adverse events (AEs), pharmacokinetics and pharmacodynamics were assessed. Nineteen of 20 patients completed the study. All placebo patients and 13 of 16 epratuzumab patients reported ≥1 AE, 2 of 16 epratuzumab patients reported a serious AE. C(max) and AUC(τ) increased proportionally with dose after first and last infusion, t(1/2) was similar across groups (∼13 days). Epratuzumab treatment was associated with decreased CD22 mean fluorescence intensity in total B cells (CD19(+)CD22(+)) and unswitched memory B cells (CD19(+)IgD(+)CD27(+)). Small-to-moderate decreases were observed in total B cell (CD20(+)) count. Epratuzumab was well-tolerated, with no new safety signals identified. The pharmacokinetics appeared linear after first and last infusions. Treatment with epratuzumab was associated with CD22 downregulation and with small-to-moderate decreases in total B cell count.

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.

PubMed

Hong, S; Park, C-Y; Han, K A; Chung, C H; Ku, B J; Jang, H C; Ahn, C W; Lee, M-K; Moon, M K; Son, H S; Lee, C B; Cho, Y-W; Park, S-W

2016-05-01

We assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n = 142) were randomized 2 : 1 into two different treatment groups as follows: 99 received teneligliptin (20 mg) and 43 received placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) level from baseline to week 24. Teneligliptin significantly reduced the HbA1c level from baseline compared with placebo after 24 weeks. At week 24, the differences between changes in HbA1c and fasting plasma glucose (FBG) in the teneligliptin and placebo groups were -0.94% [least-squares (LS) mean -1.22, -0.65] and -1.21 mmol/l (-1.72, -0.70), respectively (all p < 0.001). The incidence of hypoglycaemia and adverse events were not significantly different between the two groups. This phase III, randomized, placebo-controlled study provides evidence of the safety and efficacy of 24 weeks of treatment with teneligliptin as a monotherapy in Korean patients with T2DM. © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2 CFR Appendix A to Part 215 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-01-01

... hours. Work in excess of the standard work week is permissible provided that the worker is compensated... hours in the work week. Section 107 of the Act is applicable to construction work and provides that no.... Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where applicable, all contracts awarded by...

32 CFR Appendix A to Part 32 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

... Federal awarding agency. 4. Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where... hours. Work in excess of the standard work week is permissible provided that the worker is compensated... hours in the work week. Section 107 of the Act is applicable to construction work and provides that no...

45 CFR Appendix A to Part 74 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-10-01

... hours. Work in excess of the standard work week is permissible provided that the worker is compensated... hours in the work week. Section 107 of the Act is applicable to construction work and provides that no.... Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)— Where applicable, all contracts awarded...

75 FR 2467 - Hours of Service

Federal Register 2010, 2011, 2012, 2013, 2014

2010-01-15

... many hours per day and per week would be safe and healthy for a truck driver to work? 4. Would an hours... given scheduling flexibility--the ability to borrow an hour from another driving day once a week, for... No. FMCSA-2004-19608] RIN 2126-AB26 Hours of Service AGENCY: Federal Motor Carrier Safety...

Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial.

PubMed

Kanti, V; Hillmann, K; Kottner, J; Stroux, A; Canfield, D; Blume-Peytavi, U

2016-07-01

Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia (AGA) for 12 months. Efficacy and safety in both frontotemporal and vertex regions over longer application periods have not been studied so far. To evaluate the effect of 5% minoxidil topical foam (5% MTF) in the frontotemporal and vertex areas in patients with moderate AGA over 104 weeks. An 80-week, open-label extension phase was performed, following a 24-week randomized, double-blind, placebo-controlled study in men with AGA grade IIIvertex to VI. Group 1 (n = 22) received ongoing 5% MTF for 104 weeks, Group 2 (n = 23) received placebo topical foam (plaTF) until week 24, followed by 5% MTF until week 104 during the extension phase. Frontotemporal and vertex target area non-vellus hair counts (f-TAHC, v-TAHC) and cumulative hair width (f-TAHW, v-TAHW) were assessed at baseline and at weeks 24, 52, 76 and 104. In Group 1, f-TAHW and f-TAHC showed a statistically significant increase from baseline to week 52 and week 76, respectively, returning to values comparable to baseline at week 104. No significant differences were found between baseline and week 104 in v-TAHC in Group 1 as well as f-TAHC, v-TAHC, f-TAHW and v-TAHW values in Group 2. 5% MTF is effective in stabilizing hair density, hair width and scalp coverage in both frontotemporal and vertex areas over an application period of 104 weeks, while showing a good safety and tolerability profile with a low rate of irritant contact dermatitis. © 2015 European Academy of Dermatology and Venereology.

Nation, Districts Step up Safety

ERIC Educational Resources Information Center

Shah, Nirvi

2013-01-01

President Barack Obama's announcement last week of a wide-ranging anti-violence plan in response to the Newtown, Connecticut, school shootings comes as many districts are adopting new and sometimes dramatic measures--including arming teachers and volunteers--intended to prevent similar tragedies in their own schools. School safety experts warn…

Effects of safety belt laws on safety belt use by American High School Seniors, 1986-2000.

PubMed

O'Malley, Patrick M; Wagenaar, Alexander C

2004-01-01

This manuscript evaluates the effects of enactment of state laws that required safety belt use in various U.S. states between 1986 and 2000. Safety belt use was assessed using nationally representative cross-sectional samples of high school seniors; evaluation of the effects of laws used data from over 2,000 high school seniors before and about 3,300 after the laws took effect in 20 states. Belt use was found to increase significantly between 1986 and 2000, and the laws contributed significantly to that increase. Increases were similar for students differing by gender, race/ethnicity, parent education, grades, truancy, evenings out per week, miles driven per week, and an index of illicit drug use. The data show that although the laws have increased belt use, use is not universal and continued efforts are needed. This study shows that many teenagers fail to use belts when there is a secondary use law; an implication is that primary laws would be more efficacious in increasing use among this vulnerable population.

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

PubMed Central

Ito, Sadayoshi; Satoh, Minoru; Tamaki, Yuko; Gotou, Hiromi; Charney, Alan; Okino, Naoko; Akahori, Mizuki; Zhang, Jack

2015-01-01

This 8-week, multi-center, open-label study assessed the safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Patients (n=32) with mean sitting systolic blood pressure (msSBP) ⩾140 mm Hg (after a 2–5-week washout of previous antihypertensive medications) and estimated glomerular filtration rate (eGFR) ⩾15 and <60 ml min−1 1.73 m−2 received LCZ696 100 mg with an optional titration to 200 and 400 mg in a sequential manner starting from Week 2 in patients with inadequate BP control (msSBP ⩾130 mm Hg and mean sitting diastolic blood pressure (msDBP) ⩾80 mm Hg) and without safety concerns. Safety was assessed by monitoring and recording all adverse events (AEs) and change in potassium and creatinine. Efficacy was assessed as change from baseline in msSBP/msDBP. The mean baseline BP was 151.6/86.9 mm Hg, urinary albumin/creatinine ratio (UACR) geometric mean was 7.3 mg mmol−1 and eGFR was ⩾30 and <60 in 25 (78.1%) patients and was ⩾15 and <30 in 7 (21.9%) patients. Fourteen (43.8%) patients reported at least one AE, which were mild in severity. No severe AEs or deaths were reported. There were no clinically meaningful changes in creatinine, potassium, blood urea nitrogen and eGFR. The geometric mean reduction in UACR was 15.1%, and the mean reduction in msSBP and msDBP was 20.5±11.3 and 8.3±6.3 mm Hg, respectively, from baseline to Week 8 end point. LCZ696 was generally safe and well tolerated and showed effective BP reduction in Japanese patients with hypertension and renal dysfunction without a decline in renal function. PMID:25693859

A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.

PubMed

Parish, Lawrence Charles; Parish, Jennifer L; Routh, Hirak B; Fleischer, Alan B; Avakian, Edward V; Plaum, Stefan; Hardas, Bhushan

2011-11-01

Naftifine HCl 2% cream (NAFT-2) is a topical allylamine antifungal agent under development in the United States. This randomized, double-blind, vehicle-controlled, phase 3 trial evaluated the efficacy and safety of two weeks of NAFT-2 treatment in subjects with tinea pedis. Naftifine 1% cream (NAFT-1) treatment for four weeks and vehicle were also evaluated as a positive control. 709 subjects were randomly assigned 2:1:2:1 to one of four treatment groups: (i) NAFT-2 (n= 235), (ii) two-week vehicle (n=118), (iii) NAFT-1 (n=237), or (iv) four-week vehicle (n=119). Efficacy was evaluated at baseline, week 2, week 4, and week 6 and consisted of mycology determination (KOH and dermatophyte culture) and scoring of clinical symptom severity (erythema, scaling, and pruritus). Efficacy was only analyzed in 425 subjects with positive baseline dermatophyte culture. Safety was evaluated by adverse events (AE) and laboratory values in 707 subjects. At week 6, NAFT-2 subjects achieved 18 percent complete cure rate, 67 percent mycological cure rate, 57 percent treatment effectiveness, 22 percent clinical cure rate, and 78 percent clinical success rate compared to respective vehicle rates of seven percent (one-sided, P<0.01), 21 percent (P<0.001), 20 percent (P<0.001), 11 percent (P=0.04) and 49 percent (P<0.001). Week 6 efficacy responses in NAFT-1-treated subjects were significantly higher than vehicle subjects and almost identical to NAFT-2 subjects. Mycological cure and clinical response rates in both NAFT-2 and NAFT-1 increased from week 2 to week 6. Treatment-related AEs occurred in five percent of NAFT-2 subjects, seven percent of vehicle subjects, four percent of NAFT-1 subjects and eight percent of vehicle subjects. The most common AEs for all groups were application site pruritus and skin irritation. Topical NAFT-2 for two weeks is safe and provides significantly superior antifungal treatment than vehicle in tinea pedis subjects. NAFT-2 produces equivalent efficacy responses to four weeks of NAFT-1 treatment. The fungicidal activity of naftifine continues to increase for at least one month after treatment is completed. (Clinical Trials Identification Numbe=NCT00750139). J Drugs Dermatol. 2011;10(11):1282-1288.

First experimental evidence of hydrodynamic tunneling of ultra-relativistic protons in extended solid copper target at the CERN HiRadMat facility

NASA Astrophysics Data System (ADS)

Schmidt, R.; Blanco Sancho, J.; Burkart, F.; Grenier, D.; Wollmann, D.; Tahir, N. A.; Shutov, A.; Piriz, A. R.

2014-08-01

A novel experiment has been performed at the CERN HiRadMat test facility to study the impact of the 440 GeV proton beam generated by the Super Proton Synchrotron on extended solid copper cylindrical targets. Substantial hydrodynamic tunneling of the protons in the target material has been observed that leads to significant lengthening of the projectile range, which confirms our previous theoretical predictions [N. A. Tahir et al., Phys. Rev. Spec. Top.-Accel. Beams 15, 051003 (2012)]. Simulation results show very good agreement with the experimental measurements. These results have very important implications on the machine protection design for powerful machines like the Large Hadron Collider (LHC), the future High Luminosity LHC, and the proposed huge 80 km circumference Future Circular Collider, which is currently being discussed at CERN. Another very interesting outcome of this work is that one may also study the field of High Energy Density Physics at this test facility.

First test of BNL electron beam ion source with high current density electron beam

DOE Office of Scientific and Technical Information (OSTI.GOV)

Pikin, Alexander, E-mail: pikin@bnl.gov; Alessi, James G., E-mail: pikin@bnl.gov; Beebe, Edward N., E-mail: pikin@bnl.gov

A new electron gun with electrostatic compression has been installed at the Electron Beam Ion Source (EBIS) Test Stand at BNL. This is a collaborative effort by BNL and CERN teams with a common goal to study an EBIS with electron beam current up to 10 A, current density up to 10,000 A/cm{sup 2} and energy more than 50 keV. Intensive and pure beams of heavy highly charged ions with mass-to-charge ratio < 4.5 are requested by many heavy ion research facilities including NASA Space Radiation Laboratory (NSRL) at BNL and HIE-ISOLDE at CERN. With a multiampere electron gun, themore » EBIS should be capable of delivering highly charged ions for both RHIC facility applications at BNL and for ISOLDE experiments at CERN. Details of the electron gun simulations and design, and the Test EBIS electrostatic and magnetostatic structures with the new electron gun are presented. The experimental results of the electron beam transmission are given.« less

LHC, le Big Bang en éprouvette

DOE Office of Scientific and Technical Information (OSTI.GOV)

None

Notre compréhension de l’Univers est en train de changer… Bar des Sciences - Tout public Débat modéré par Marie-Odile Montchicourt, journaliste de France Info. Evenement en vidéoconférence entre le Globe de la science et de l’innovation, le bar le Baloard de Montpellier et la Maison des Métallos à Paris. Intervenants au CERN : Philippe Charpentier et Daniel Froideveaux, physiciens au CERN. Intervenants à Paris : Vincent Bontemps, philosophe et chercheur au CEA ; Jacques Arnould, philosophe, historien des sciences et théologien, Jean-Jacques Beineix, réalisateur, producteur, scénariste de cinéma. Intervenants à Montpellier (LPTA) : André Neveu, physicien théoricien et directeur demore » recherche au CNRS ; Gilbert Moultaka, physicien théoricien et chargé de recherche au CNRS. Partenariat : CERN, CEA, IN2P3, Université MPL2 (LPTA) Dans le cadre de la Fête de la science 2008.« less

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

PubMed Central

Vivio, Emily E.; Kanuri, Navya; Gilbertsen, Joanna J.; Monroe, Kelly; Dey, Neelendu; Chen, Chien-Huan; Gutierrez, Alexandra M.

2016-01-01

Background and aims: Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an inflammatory bowel disease (IBD) clinical practice. Methods: Patients beginning vedolizumab were enrolled with informed consent. A prospective cohort was followed with laboratory, disease activity and quality-of-life assessments made during infusion visits up to week 14. Duration of vedolizumab use, mucosal healing and safety were analysed retrospectively for all patients not captured in the prospective component of this study. Results: One hundred and two patients started vedolizumab, with 51 patients (30 CD, 21 UC) followed prospectively. The CD patients exhibited a significant decrease in Crohn’s Disease Activity Index (p = 0.04) and Harvey–Bradshaw index (p < 0.01) by week 14. The UC patients demonstrated improved partial Mayo scores at weeks 6 (p < 0.01) and 14 (p < 0.001). Ninety percent of all CD and UC patients remained on vedolizumab up to week 14. IBD-related quality of life was improved by week 6 in CD and UC cohorts (p = 0.02 and p < 0.01 respectively). Colectomy for lack of response and systemic histoplamosis were notable reasons for early discontinuation of vedolizumab, which was otherwise well tolerated. Conclusions: Vedolizumab was efficacious and a high percentage of patients continued this therapy beyond induction dosing. Observed safety signals may be attributed to the refractory IBD disease state of this early-adopting clinical cohort. PMID:26681763

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.

PubMed

Vivio, Emily E; Kanuri, Navya; Gilbertsen, Joanna J; Monroe, Kelly; Dey, Neelendu; Chen, Chien-Huan; Gutierrez, Alexandra M; Ciorba, Matthew A

2016-04-01

Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn's disease (CD) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an inflammatory bowel disease (IBD) clinical practice. Patients beginning vedolizumab were enrolled with informed consent. A prospective cohort was followed with laboratory, disease activity and quality-of-life assessments made during infusion visits up to week 14. Duration of vedolizumab use, mucosal healing and safety were analysed retrospectively for all patients not captured in the prospective component of this study. One hundred and two patients started vedolizumab, with 51 patients (30 CD, 21 UC) followed prospectively. The CD patients exhibited a significant decrease in Crohn's Disease Activity Index (p = 0.04) and Harvey-Bradshaw index (p < 0.01) by week 14. The UC patients demonstrated improved partial Mayo scores at weeks 6 (p < 0.01) and 14 (p < 0.001). Ninety percent of all CD and UC patients remained on vedolizumab up to week 14. IBD-related quality of life was improved by week 6 in CD and UC cohorts (p = 0.02 and p < 0.01 respectively). Colectomy for lack of response and systemic histoplamosis were notable reasons for early discontinuation of vedolizumab, which was otherwise well tolerated. Vedolizumab was efficacious and a high percentage of patients continued this therapy beyond induction dosing. Observed safety signals may be attributed to the refractory IBD disease state of this early-adopting clinical cohort. Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Industrial Education. Electricity/Electronics Curriculum Guide, Phase II. Instructional Modules, Level I (9 Week).

ERIC Educational Resources Information Center

Lillo, Robert E.; Soffiotto, Nicholas S.

Designed for students in grades 7 and 8, this electricity/electronics curriculum guide contains instructional modules for ten units of instruction (nine-week class): (1) orientation; (2) understanding electricity; (3) safety; (4) methods to generate electricity; (5) wiring tools and wire; (6) soldering; (7) magnetism and electromagnetism; (8)…

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

ERIC Educational Resources Information Center

Erickson, Craig A.; Veenstra-Vanderweele, Jeremy M.; Melmed, Raun D.; McCracken, James T.; Ginsberg, Lawrence D.; Sikich, Linmarie; Scahill, Lawrence; Cherubini, Maryann; Zarevics, Peter; Walton-Bowen, Karen; Carpenter, Randall L.; Bear, Mark F.; Wang, Paul P.; King, Bryan H.

2014-01-01

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32…

Disk storage at CERN

NASA Astrophysics Data System (ADS)

Mascetti, L.; Cano, E.; Chan, B.; Espinal, X.; Fiorot, A.; González Labrador, H.; Iven, J.; Lamanna, M.; Lo Presti, G.; Mościcki, JT; Peters, AJ; Ponce, S.; Rousseau, H.; van der Ster, D.

2015-12-01

CERN IT DSS operates the main storage resources for data taking and physics analysis mainly via three system: AFS, CASTOR and EOS. The total usable space available on disk for users is about 100 PB (with relative ratios 1:20:120). EOS actively uses the two CERN Tier0 centres (Meyrin and Wigner) with 50:50 ratio. IT DSS also provide sizeable on-demand resources for IT services most notably OpenStack and NFS-based clients: this is provided by a Ceph infrastructure (3 PB) and few proprietary servers (NetApp). We will describe our operational experience and recent changes to these systems with special emphasis to the present usages for LHC data taking, the convergence to commodity hardware (nodes with 200-TB each with optional SSD) shared across all services. We also describe our experience in coupling commodity and home-grown solution (e.g. CERNBox integration in EOS, Ceph disk pools for AFS, CASTOR and NFS) and finally the future evolution of these systems for WLCG and beyond.

First experience with carbon stripping foils for the 160 MeV H- injection into the CERN PSB

NASA Astrophysics Data System (ADS)

Weterings, Wim; Bracco, Chiara; Jorat, Louise; Noulibos, Remy; van Trappen, Pieter

2018-05-01

160 MeV H- beam will be delivered from the new CERN linear accelerator (Linac4) to the Proton Synchrotron Booster (PSB), using a H- charge-exchange injection system. A 200 µg/cm2 carbon stripping foil will convert H- into protons by stripping off the electrons. The H- charge-exchange injection principle will be used for the first time in the CERN accelerator complex and involves many challenges. In order to gain experience with the foil changing mechanism and the very fragile foils, in 2016, prior to the installation in the PSB, a stripping foil test stand has been installed in the Linac4 transfer line. In addition, parts of the future PSB injection equipment are also temporarily installed in the Linac4 transfer line for tests with a 160 MeV H- commissioning proton beam. This paper describes the foil changing mechanism and control system, summarizes the practical experience of gluing and handling these foils and reports on the first results with beam.

Chicago Ebola Response Network (CERN): A Citywide Cross-hospital Collaborative for Infectious Disease Preparedness.

PubMed

Lateef, Omar; Hota, Bala; Landon, Emily; Kociolek, Larry K; Morita, Julie; Black, Stephanie; Noskin, Gary; Kelleher, Michael; Curell, Krista; Galat, Amy; Ansell, David; Segreti, John; Weber, Stephen G

2015-11-15

The 2014-2015 Ebola virus disease (EVD) epidemic and international public health emergency has been referred to as a "black swan" event, or an event that is unlikely, hard to predict, and highly impactful once it occurs. The Chicago Ebola Response Network (CERN) was formed in response to EVD and is capable of receiving and managing new cases of EVD, while also laying the foundation for a public health network that can anticipate, manage, and prevent the next black swan public health event. By sharing expertise, risk, and resources among 4 major academic centers, Chicago created a sustainable network to respond to the latest in a series of public health emergencies. In this respect, CERN is a roadmap for how a region can prepare to respond to public health emergencies, thereby preventing negative impacts through planning and implementation. © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

PubMed

Nash, Peter; Ohson, Kamal; Walsh, Jessica; Delev, Nikolay; Nguyen, Dianne; Teng, Lichen; Gómez-Reino, Juan J; Aelion, Jacob A

2018-05-01

Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10% were eligible for early escape. At week 24, all patients received apremilast through week 52. Among 219 randomised patients (apremilast: n=110; placebo: n=109), a significantly greater American College of Rheumatology 20 response at week 16 (primary outcome) was observed with apremilast versus placebo (38.2% (42/110) vs 20.2% (22/109); P=0.004); response rates at week 2 (first assessment) were 16.4% (18/110) versus 6.4% (7/109) (P=0.025). Improvements in other efficacy outcomes, including 28-joint count Disease Activity Score (DAS-28) using C reactive protein (CRP), swollen joint count, Health Assessment Questionnaire-Disability Index (HAQ-DI), enthesitis and morning stiffness severity, were observed with apremilast at week 2. At week 16, apremilast significantly reduced PsA disease activity versus placebo, with changes in DAS-28 (CRP) (P<0.0001), HAQ-DI (P=0.023) and Gladman Enthesitis Index (P=0.001). Improvements were maintained with continued treatment through week 52. Over 52 weeks, apremilast's safety profile was consistent with prior phase 3 studies in psoriasis and PsA. During weeks 0-24, the incidence of protocol-defined diarrhoea was 11.0% (apremilast) and 8.3% (placebo); serious adverse event rates were 2.8% (apremilast) and 4.6% (placebo). In biological-naïve patients with PsA, onset of effect with apremilast was observed at week 2 and continued through week 52. The safety profile was consistent with previous reports. NCT01925768; Results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study.

PubMed

Sane, Rohit; Aklujkar, Abhijeet; Patil, Atul; Mandole, Rahul

The present study was designed to evaluate effect of heart failure reversal therapy (HFRT) using herbal procedure (panchakarma) and allied therapies, as add-on to standard CHF treatment (SCT) in chronic heart failure (CHF) patients. This open-label, randomized study conducted in CHF patients (aged: 25-65 years, ejection fraction: 30-65%), had 3-phases: 1-week screening, 6-week treatment (randomized [1:1] to HFRT+SCT or SCT-alone) and follow-up (12-week). Twice weekly HFRT (60-75min) consisting of snehana (external oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti (enema) was administered. Primary endpoints included evaluation of change in metabolic equivalents of task (MET) and peak oxygen uptake (VO 2peak ) from baseline, at end of 6-week treatment and follow-up at week-18 (non-parametric rank ANCOVA analysis). Safety and quality of life (QoL) was assessed. Seventy CHF patients (n=35, each treatment-arm; mean [SD] age: 53.0 [8.6], 80% men) were enrolled in the study. All patients completed treatment phase. Add-on HFRT caused a significant increase in METs (least square mean difference [LSMD], 6-week: 1.536, p=0.0002; 18-week: -1.254, p=0.0089) and VO 2peak (LSMD, 6-week: -5.52, p=0.0002; 18-week: -4.517, p=0.0089) as compared with SCT-alone. Results were suggestive of improved functional capacity in patients with HFRT (QoL; Mean [SD] HFRT+SCT vs. SCT-alone; 6-week: -0.44 [0.34] vs. -0.06 [0.25], p<0.0001 and 18-week: -0.53 [0.35] vs. -0.29 [0.26], p=0.0013). Seven treatment-emergent adverse events (mild severity) were reported in HFRT-arm. Findings of this study highlight therapeutic efficacy of add-on HFRT vs. SCT-alone in CHF patients. The non-invasive HFRT showed no safety concerns. Copyright © 2016. Published by Elsevier B.V.

Hair removal for Fitzpatrick skin types V and VI using light and heat energy technology.

PubMed

Sadick, Neil S; Krespi, Yoseph

2006-09-01

To determine the safety and efficacy of a light and heat energy (LHE)-based system (SkinStaion system; Radiancy Inc, Orangeburg, NY, USA) for hair removal in subjects with skin types V and VI. Thirty-one subjects with Fitzpatrick skin types V and VI were consented for treatment with the system. Twenty-six subjects completed the 12-week follow-up. Safety was evaluated at each visit and efficacy was evaluated at both follow-up visits. An average hair clearance of 41.7% from 57 treatment sites was reported at the 6-week follow-up visit and a 35.5% average hair clearance was reported at the 12-week follow-up. Edema was only reported in 2 cases (7.7%) of the study population. Eleven cases of erythema were reported following treatment. Treatment with the modified LHE system was safe and effective for hair removal in patients with skin types V and VI.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

PubMed

Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan; Blanco, Ricardo; Cohen, Martin; Delicha, Evie-Maria; Rohrer, Susanne; Richards, Hanno

2017-01-01

Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3 years) efficacy and safety of secukinumab in the MEASURE 2 study. MEASURE 2 (NCT01649375) is a 5-year phase III, randomised, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of subcutaneous loading and maintenance dosing of secukinumab in adult subjects with active AS. Subjects were randomised to receive subcutaneous secukinumab 150 mg, 75 mg or placebo at baseline, weeks 1, 2 and 3 and every 4 weeks from week 4. At week 16, placebo-treated subjects were rerandomised to receive secukinumab 150/75 mg. Retention rates were high during weeks 16-156 and were 86% and 76% for secukinumab 150 and 75 mg, respectively. Secukinumab 150 mg provided sustained improvements in the Assessment of Spondyloarthritis International Society ASAS 20/40 response rates at week 156 (70.1%/60.9%) compared with week 52 (74.2%/57.0%); however, there was a slight decrease for secukinumab 75 mg (54.3%/37.0% vs 62.5%/43.2%, respectively). Sustained improvements were observed in all other end points, including Bath Ankylosing Spondylitis Disease Activity Index, AS Disease Activity Score with C reactive protein inactive disease, ASAS 5/6, Short Form-36 Physical Component Summary and ASAS partial remission. Clinical benefits were observed regardless of prior exposure to anti-tumour necrosis factor agents. The safety profile remained favourable and was consistent with previous reports. This study showed sustained improvement through 3 years in signs, symptoms and physical function in subjects with AS. Retention rates were high and secukinumab was well tolerated, with a favourable safety profile.

Open-label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long-term use in patients with acne vulgaris: A secondary publication.

PubMed

Kawashima, Makoto; Nagare, Toshitaka; Katsuramaki, Tsuneo

2017-06-01

An open-label, randomized, multicenter study was conducted to evaluate the safety and efficacy of long-term use of 2.5% and 5% benzoyl peroxide (BPO) gels administrated once daily for 52 weeks to Japanese patients with acne vulgaris. The efficacy of the study drugs was evaluated by counting inflammatory lesions and non-inflammatory lesions. Safety was evaluated based on adverse events, local skin tolerability scores and laboratory test values. In total, 458 subjects were included in the efficacy and safety analyses. The total lesion count, the efficacy end-point, was similarly changed both in the 2.5% and 5% BPO groups over the course of the study. The median rates of reduction from baseline to week 12 were approximately 65%. Thereafter, the counts were maintained at a reduced level without increasing until week 52. The median rates at week 52 were approximately 80%. Similar trends were observed for inflammatory and non-inflammatory lesion counts. Bacteriological evaluation indicated similar distribution of the minimum inhibitory concentration of each of the antibacterial drugs against Propionibacterium acnes between the values at baseline and at week 52, suggesting that long-term use did not result in changes in the drug sensitivity. The incidence of adverse events was 84.0% in the 2.5% BPO group and 87.2% in the 5% BPO group. Many of the adverse events occurred within the first month and were mild or moderate in severity and transient. The results suggest that both 2.5% and 5% BPO gels are effective and safe for long-term treatment of patients with acne vulgaris. © 2017 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.

Commissioning the CERN IT Agile Infrastructure with experiment workloads

NASA Astrophysics Data System (ADS)

Medrano Llamas, Ramón; Harald Barreiro Megino, Fernando; Kucharczyk, Katarzyna; Kamil Denis, Marek; Cinquilli, Mattia

2014-06-01

In order to ease the management of their infrastructure, most of the WLCG sites are adopting cloud based strategies. In the case of CERN, the Tier 0 of the WLCG, is completely restructuring the resource and configuration management of their computing center under the codename Agile Infrastructure. Its goal is to manage 15,000 Virtual Machines by means of an OpenStack middleware in order to unify all the resources in CERN's two datacenters: the one placed in Meyrin and the new on in Wigner, Hungary. During the commissioning of this infrastructure, CERN IT is offering an attractive amount of computing resources to the experiments (800 cores for ATLAS and CMS) through a private cloud interface. ATLAS and CMS have joined forces to exploit them by running stress tests and simulation workloads since November 2012. This work will describe the experience of the first deployments of the current experiment workloads on the CERN private cloud testbed. The paper is organized as follows: the first section will explain the integration of the experiment workload management systems (WMS) with the cloud resources. The second section will revisit the performance and stress testing performed with HammerCloud in order to evaluate and compare the suitability for the experiment workloads. The third section will go deeper into the dynamic provisioning techniques, such as the use of the cloud APIs directly by the WMS. The paper finishes with a review of the conclusions and the challenges ahead.

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe.

PubMed

Harada-Shiba, Mariko; Kastelein, John J P; Hovingh, G Kees; Ray, Kausik K; Ohtake, Akira; Arisaka, Osamu; Ohta, Takao; Okada, Tomoo; Suganami, Hideki; Wiegman, Albert

2018-05-01

Children with Familial Hypercholesterolemia (FH) are widely prescribed statins, and it has been suggested that the effects of statins differ among ethnicities. We compared the efficacy and safety of pitavastatin in children and adolescents with FH in clinical trials conducted in Japan and Europe. Low-density lipoprotein cholesterol (LDL-C) reductions, adjusted for confounding factors, and safety were compared between the studies in Japan and Europe. In the Japanese study, 14 males with heterozygous FH, aged 11.8±1.6 years, were randomized to 52-week double-blind treatment with 1 or 2 mg/day pitavastatin. In the European study, 106 children and adolescents with high risk hyperlipidemia (103 heterozygous FH), aged 10.6±2.9 years, were randomized to 12-week double-blind treatment with 1, 2 or 4 mg/day pitavastatin or placebo; 84 of these patients and 29 new patients participated in a 52-week open-label extension study. Age, body weight and baseline LDL-C were identified as factors influencing LDL-C reduction. There were no significant differences in the adjusted mean percentage reduction in LDL-C in Japanese and European children by pitavastatin (24.5% and 23.6%, respectively at 1 mg/day and 33.5% and 30.8%, respectively at 2 mg/day). Pitavastatin was well tolerated without any difference in the frequency or nature of adverse events between the treatment groups, or between the studies. There were no significant differences between the efficacy or safety of pitavastatin in Japanese and European children and adolescents with FH, suggesting no relevant ethnic differences in the safety or efficacy of pitavastatin.

EOS developments

NASA Astrophysics Data System (ADS)

Sindrilaru, Elvin A.; Peters, Andreas J.; Adde, Geoffray M.; Duellmann, Dirk

2017-10-01

CERN has been developing and operating EOS as a disk storage solution successfully for over 6 years. The CERN deployment provides 135 PB and stores 1.2 billion replicas distributed over two computer centres. Deployment includes four LHC instances, a shared instance for smaller experiments and since last year an instance for individual user data as well. The user instance represents the backbone of the CERNBOX service for file sharing. New use cases like synchronisation and sharing, the planned migration to reduce AFS usage at CERN and the continuous growth has brought EOS to new challenges. Recent developments include the integration and evaluation of various technologies to do the transition from a single active in-memory namespace to a scale-out implementation distributed over many meta-data servers. The new architecture aims to separate the data from the application logic and user interface code, thus providing flexibility and scalability to the namespace component. Another important goal is to provide EOS as a CERN-wide mounted filesystem with strong authentication making it a single storage repository accessible via various services and front- ends (/eos initiative). This required new developments in the security infrastructure of the EOS FUSE implementation. Furthermore, there were a series of improvements targeting the end-user experience like tighter consistency and latency optimisations. In collaboration with Seagate as Openlab partner, EOS has a complete integration of OpenKinetic object drive cluster as a high-throughput, high-availability, low-cost storage solution. This contribution will discuss these three main development projects and present new performance metrics.

College Students and Awareness of Food Safety

ERIC Educational Resources Information Center

McArthur, Laura H.; Holbert, Donald; Forsythe, William A., III

2007-01-01

Microbial foodborne illnesses are a public health problem in the United States. Americans are patronizing restaurants three or more times a week and college students are frequently employed in food service; therefore, this study assessed compliance with and awareness of food safety recommendations among 460 college students. Compliance was…

78 FR 6725 - Airworthiness Directives; Turbomeca S.A. Turboshaft Engines

Federal Register 2010, 2011, 2012, 2013, 2014

2013-01-31

...;Prices of new books are listed in the first FEDERAL REGISTER issue of each #0;week. #0; #0; #0; #0;#0..., February 26, 1979); and 3. Will not have a significant economic impact, positive or negative, on a... CFR Part 39 Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety...

78 FR 42677 - Airworthiness Directives; Austro Engine GmbH Engines

Federal Register 2010, 2011, 2012, 2013, 2014

2013-07-17

...;Prices of new books are listed in the first FEDERAL REGISTER issue of each #0;week. #0; #0; #0; #0;#0... making a regulatory distinction, and (4) Will not have a significant economic impact, positive or..., Aviation safety, Incorporation by reference, Safety. Adoption of the Amendment Accordingly, under the...

Changing Safety Culture, One Step at a Time: The Value of the DOE-VPP Program at PNNL

DOE Office of Scientific and Technical Information (OSTI.GOV)

Wright, Patrick A.; Isern, Nancy G.

2005-02-01

The primary value of the Pacific Northwest National Laboratory (PNNL) Voluntary Protection Program (VPP) is the ongoing partnership between management and staff committed to change Laboratory safety culture one step at a time. VPP enables PNNL's safety and health program to transcend a top-down, by-the-book approach to safety, and it also raises grassroots safety consciousness by promoting a commitment to safety and health 24 hours a day, 7 days a week. PNNL VPP is a dynamic, evolving program that fosters innovative approaches to continuous improvement in safety and health performance at the Laboratory.

Safety assessment of 4-week oral intake of proanthocyanidin-rich grape seed extract in healthy subjects.

PubMed

Sano, Atsushi

2017-10-01

A clinical study was conducted to assess the safety and tolerability of oral doses of proanthocyanidin-rich grape seed extract (GSE) in healthy Japanese adult volunteers. In an open-label, 4-week toxicity test, 29 subjects daily received 1000, 1500, or 2500 mg GSE orally. Serum Fe levels of two subjects in the 2500 mg GSE group decreased to 61 and 60 μg/100 mL from 205 and 182 μg/100 mL at baseline respectively, at second week of GSE consumption; these values are low but within the normal range for the Japanese population. Two weeks after completing the 4-week course of GSE ingestion, the serum Fe levels of both subjects returned to near baseline levels (210 and 189 μg/100 mL). No subject discontinued the study. Oral intake of GSE up to 2500 mg for 4 weeks was found to be generally safe and well tolerated in humans. Research with a larger number of subjects is required to confirm these findings. Copyright © 2016. Published by Elsevier Ltd.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

PubMed

Keystone, Edward C; Genovese, Mark C; Schlichting, Douglas E; de la Torre, Inmaculada; Beattie, Scott D; Rooney, Terence P; Taylor, Peter C

2018-01-01

To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) up to 128 weeks in a phase IIb study (NCT01185353). After a 24-week blinded period, eligible patients entered an initial 52-week open-label extension (OLE); patients receiving 8 mg once daily (QD) continued with that dose and all others received 4 mg QD. Doses could be escalated to 8 mg QD at 28 or 32 weeks at investigator discretion when ≥ 6 tender and ≥ 6 swollen joints were present. Patients completing the first OLE were eligible to enter a second 52-week OLE and receive 4 mg QD regardless of previous dose. In the 4-mg (n = 108) and 8-mg (n = 93) groups, treatment-emergent adverse events (AE) occurred in 63% and 67%, serious AE in 16% and 13%, infections in 35% and 40%, and serious infections in 5% and 3% of patients, respectively. Exposure-adjusted incidence rates for AE for all baricitinib groups in the second OLE were similar to or lower than rates observed in the first OLE. No opportunistic infections, tuberculosis cases, or lymphomas were observed through 128 weeks; 1 death occurred during the first OLE. Among all patients in both OLE, the proportions who achieved disease improvement at Week 24 were similar or increased at weeks 76 and 128. In a phase IIb study in RA, the safety and tolerability profile of baricitinib, up to 128 weeks, remained consistent with earlier observations, without unexpected late signals. Clinical improvements seen in the 24-week blinded period were maintained during the OLE.

Evaluation results of xTCA equipment for HEP experiments at CERN

NASA Astrophysics Data System (ADS)

Di Cosmo, M.; Bobillier, V.; Haas, S.; Joos, M.; Mico, S.; Vasey, F.; Vichoudis, P.

2013-12-01

The MicroTCA and AdvancedTCA industry standards are candidate modular electronic platforms for the upgrade of the current generation of high energy physics experiments. The PH-ESE group at CERN launched in 2011 the xTCA evaluation project with the aim of performing technical evaluations and eventually providing support for commercially available components. Different devices from different vendors have been acquired, evaluated and interoperability tests have been performed. This paper presents the test procedures and facilities that have been developed and focuses on the evaluation results including electrical, thermal and interoperability aspects.

The ISOLDE LEGO® robot: building interest in frontier research

NASA Astrophysics Data System (ADS)

Elias Cocolios, Thomas; Lynch, Kara M.; Nichols, Emma

2017-07-01

An outreach programme centred around nuclear physics making use of a LEGO® Mindstorm® kit is presented. It consists of a presentation given by trained undergraduate students as science ambassadors followed by a workshop where the target audience programs the LEGO® Mindstorm® robots to familiarise themselves with the concepts in an interactive and exciting way. This programme has been coupled with the CERN-ISOLDE 50th anniversary and the launch of the CERN-MEDICIS facility in Geneva, Switzerland. The modular aspect of the programme readily allows its application to other topics.

Retirement Kjell Johnsen

ScienceCinema

None

2017-12-09

A l'occasion de son 65me anniversaire plusieurs orateurs (aussi l'ambassadeur de Norvège) remercient Kjell Johnsen, né en juin 1921 en Norvège, pour ses 34 ans de service au Cern et retracent sa vie et son travail. K.Johnsen a pris part aux premières études sur les accélérateurs du futur centre de physique et fut aussi le père et le premier directeur de l'Ecole du Cern sur les accélérateurs (CAS)

Experience in running relational databases on clustered storage

NASA Astrophysics Data System (ADS)

Gaspar Aparicio, Ruben; Potocky, Miroslav

2015-12-01

For past eight years, CERN IT Database group has based its backend storage on NAS (Network-Attached Storage) architecture, providing database access via NFS (Network File System) protocol. In last two and half years, our storage has evolved from a scale-up architecture to a scale-out one. This paper describes our setup and a set of functionalities providing key features to other services like Database on Demand [1] or CERN Oracle backup and recovery service. It also outlines possible trend of evolution that, storage for databases could follow.

Unified Monitoring Architecture for IT and Grid Services

NASA Astrophysics Data System (ADS)

Aimar, A.; Aguado Corman, A.; Andrade, P.; Belov, S.; Delgado Fernandez, J.; Garrido Bear, B.; Georgiou, M.; Karavakis, E.; Magnoni, L.; Rama Ballesteros, R.; Riahi, H.; Rodriguez Martinez, J.; Saiz, P.; Zolnai, D.

2017-10-01

This paper provides a detailed overview of the Unified Monitoring Architecture (UMA) that aims at merging the monitoring of the CERN IT data centres and the WLCG monitoring using common and widely-adopted open source technologies such as Flume, Elasticsearch, Hadoop, Spark, Kibana, Grafana and Zeppelin. It provides insights and details on the lessons learned, explaining the work performed in order to monitor the CERN IT data centres and the WLCG computing activities such as the job processing, data access and transfers, and the status of sites and services.

Windows Terminal Servers Orchestration

NASA Astrophysics Data System (ADS)

Bukowiec, Sebastian; Gaspar, Ricardo; Smith, Tim

2017-10-01

Windows Terminal Servers provide application gateways for various parts of the CERN accelerator complex, used by hundreds of CERN users every day. The combination of new tools such as Puppet, HAProxy and Microsoft System Center suite enable automation of provisioning workflows to provide a terminal server infrastructure that can scale up and down in an automated manner. The orchestration does not only reduce the time and effort necessary to deploy new instances, but also facilitates operations such as patching, analysis and recreation of compromised nodes as well as catering for workload peaks.

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.

PubMed

Araki, Eiichi; Onishi, Yukiko; Asano, Michiko; Kim, Hyosung; Ekholm, Ella; Johnsson, Eva; Yajima, Toshitaka

2016-07-01

Dapagliflozin treatment when added to insulin therapy in Japanese patients with type 2 diabetes remains to be evaluated. This was a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy (at 16 weeks) and long-term safety (at 52 weeks) of dapagliflozin in addition to insulin therapy. The interim analysis was carried out at week 16 to assess the efficacy and safety profiles. The patients receiving insulin (n = 182) were randomized to either dapagliflozin 5 mg or a placebo at a 2:1 ratio. The primary efficacy end-point was the change in hemoglobin A1c (HbA1c) from baseline at week 16. Patients in the dapagliflozin group showed an adjusted decrease in HbA1c of -0.55% from baseline, whereas the placebo showed a marginal increase of 0.05%. The placebo-corrected mean change of HbA1c from baseline to week 16 in dapagliflozin was -0.60% (P < 0.0001). In addition, the placebo-corrected mean change of fasting plasma glucose and bodyweight from baseline to week 16 in the dapagliflozin group was -22.7 mg/dL (P < 0.0001) and -1.21 kg (P < 0.0001), respectively. The placebo-corrected mean daily insulin dose in the dapagliflozin group was numerically decreased (treatment difference: -0.72 IU/day; P = 0.0743). No major episodes or discontinuations as a result of hypoglycemia were reported during the study period. Dapagliflozin used as add-on treatment to insulin therapy showed significantly greater reduction of HbA1c, fasting plasma glucose and bodyweight without severe hypoglycemia compared with the placebo at week 16. These results show the clinical benefit of prescribing dapagliflozin for Japanese patients with insufficient glycemic control even with insulin therapy. © 2015 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

PubMed Central

Hou, Ling; Liang, Li; Dong, Guanping; Shen, Shuixian; Zhao, Zhuhui; Gong, Chun Xiu; Li, Yuchuan; Du, Min-lian; Su, Zhe; Du, Hongwei; Yan, Chaoying

2017-01-01

Objective We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). Design Phase II and III, multicenter, open-label, randomized controlled trials. Methods 108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively. Patients in the phase II study were randomized 1:1:1 to weekly Jintrolong (0.1 mg/kg/week PEG-rhGH complex), weekly Jintrolong (0.2 mg/kg/week PEG-rhGH complex) or daily rhGH (0.25 mg/kg/week) for 25 weeks. Patients in the phase III study were randomized in a 2:1 ratio to weekly Jintrolong (0.2 mg/kg/week) or daily rhGH (0.25 mg/kg/week) for 25 weeks. The primary endpoint for both studies was height velocity (HV) increase at the end of treatment. Other growth-related parameters, safety and compliance were also monitored. Results The phase II study established the preliminary efficacy, safety and recommended dose of Jintrolong PEG-rhGH. In the phase III study, we demonstrated significantly greater HV increases in patients receiving Jintrolong treatment (from 2.26 ± 0.87 cm/year to 13.41 ± 3.72 cm/year) vs daily rhGH (from 2.25 ± 0.82 cm/year to 12.55 ± 2.99 cm/year) at the end of treatment (P < 0.05). Additionally, significantly greater improvement in the height standard deviation scores was associated with Jintrolong throughout the treatment (P < 0.05). Adverse event rates and treatment compliance were comparable between the two groups. Conclusion Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH. PMID:28566441

Where's the Fire?

ERIC Educational Resources Information Center

Needham, Dorothy

1977-01-01

National Fire Protection Week is a perfect time for launching a fire safety learning center. The activities described here are intended to help children recognize fire hazards in their homes, play areas and public buildings; learn how to act intelligently in fire emergencies; be able to share their knowledge of fire safety with others and…

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis

PubMed Central

Hewett, Karen; Sanders, Donald B.; Grove, Richard A.; Broderick, Christine L.; Rudo, Todd J.; Bassiri, Ashlyn; Zvartau-Hind, Marina

2018-01-01

Objective To investigate the efficacy and safety of belimumab, a fully human immunoglobulin G1λ monoclonal antibody against B-lymphocyte stimulator, in participants with generalized myasthenia gravis (MG) who remained symptomatic despite standard of care (SoC) therapy. Methods Eligible participants with MG were randomized 1:1 to receive IV belimumab 10 mg/kg or placebo in this phase II, placebo-controlled, multicenter, double-blind study (NCT01480596; BEL115123). Participants received SoC therapies throughout the 24-week treatment phase and 12-week follow-up period. The primary efficacy endpoint was mean change from baseline in the Quantitative Myasthenia Gravis (QMG) scale at week 24; safety assessments included the frequency and severity of adverse events (AEs) and serious AEs. Results Forty participants were randomized (placebo n = 22; belimumab n = 18). The mean change in QMG score from baseline at week 24 was not significantly different for belimumab vs placebo (p = 0.256). There were no statistically significant differences between treatment groups for secondary endpoints, including the MG Composite and MG–Activity of Daily Living scores. Acetylcholine receptor antibody levels decreased over time in both treatment groups. No unexpected AEs were identified and occurrence was similar in the belimumab (78%) and placebo (91%) groups. One participant receiving placebo died (severe sepsis) during the treatment phase. Conclusions The primary endpoint was not met for belimumab in participants with generalized MG receiving SoC. There was no significant difference in mean change in the QMG score at week 24 for belimumab vs placebo. The safety profile of belimumab was consistent with previous systemic lupus erythematosus studies. Classification of evidence This study provides Class I evidence that for participants with generalized MG, belimumab did not significantly improve QMG score compared with placebo. PMID:29661905

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

PubMed

Gecse, Krisztina B; Lovász, Barbara D; Farkas, Klaudia; Banai, János; Bene, László; Gasztonyi, Beáta; Golovics, Petra Anna; Kristóf, Tünde; Lakatos, László; Csontos, Ágnes Anna; Juhász, Márk; Nagy, Ferenc; Palatka, Károly; Papp, Mária; Patai, Árpád; Lakner, Lilla; Salamon, Ágnes; Szamosi, Tamás; Szepes, Zoltán; Tóth, Gábor T; Vincze, Áron; Szalay, Balázs; Molnár, Tamás; Lakatos, Péter L

2016-02-01

Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking. A prospective, nationwide, multicentre, observational cohort was designed to examine the efficacy, safety, and immunogenicity of CT-P13 infliximab biosimilar in the induction treatment of Crohn's disease [CD] and ulcerative colitis [UC]. Demographic data were collected and a harmonised monitoring strategy was applied. Early clinical remission, response, and early biochemical response were evaluated at Week 14, steroid-free clinical remission was evaluated at Week 30. Therapeutic drug level was monitored using a conventional enzyme-linked immunosorbent assay. In all, 210 consecutive inflammatory bowel disease [126 CD and 84 UC] patients were included in the present cohort. At Week 14, 81.4% of CD and 77.6% of UC patients showed clinical response and 53.6% of CD and 58.6% of UC patients were in clinical remission. Clinical remission rates at Week 14 were significantly higher in CD and UC patients who were infliximab naïve, compared with those with previous exposure to the originator compound [p < 0.05]. Until Week 30, adverse events were experienced in 17.1% of all patients. Infusion reactions and infectious adverse events occurred in 6.6% and 5.7% of all patients, respectively. This prospective multicentre cohort shows that CT-P13 is safe and effective in the induction of clinical remission and response in both CD and UC. Patients with previous infliximab exposure exhibited decreased response rates and were more likely to develop allergic reactions. Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results

PubMed Central

Akbar, Ayesha; Hart, Ailsa; Subramanian, Sreedhar; Bommelaer, Gilles; Baumgart, Daniel C.; Grimaud, Jean-Charles; Cadiot, Guillaume; Makins, Richard; Hoque, Syed; Bouguen, Guillaume; Bonaz, Bruno

2016-01-01

Background and Aims: Patients with active, steroid-dependent ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologic therapies have limited treatment options. Adacolumn, a granulocyte/monocyte adsorptive apheresis device, has shown clinical benefit in these patients. This study aimed to provide additional clinical data regarding the safety and efficacy of Adacolumn in this patient subgroup. Methods: This single-arm, open-label, multicentre trial [ART] was conducted at 18 centres across the UK, France, and Germany. Eligible patients were 18–75 years old with moderate-to-severe, steroid-dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologics. Patients received ≥ 5 weekly apheresis sessions with Adacolumn. The primary endpoint was clinical remission rate [clinical activity index ≤ 4] at Week 12. Results: In all, 86 patients were enrolled. At Week 12, 33/84 [39.3%] of patients in the intention-to-treat population achieved clinical remission, with 47/84 [56.0%] achieving a clinical response [clinical activity index reduction of ≥ 3]. Clinical remission was achieved in 30.0% of patients with previous immunosuppressant and biologic failure; steroid-free clinical remission and response were observed in 22.6% and 35.7% of these patients, respectively. Quality of life [Short Health Scale] significantly improved at Week 12 [p < 0.0001]. The majority of adverse events were of mild/moderate intensity. Conclusions: At Week 12, Adacolumn provided significant clinical benefit in a large cohort of steroid-dependent ulcerative colitis patients with previous failure to immunosuppressant and/or biologic treatment, with a favourable safety profile. These results are consistent with previous studies and support Adacolumn use in this difficult-to-treat patient subgroup. PMID:26818659

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

PubMed

Bissonnette, R; Papp, K A; Poulin, Y; Gooderham, M; Raman, M; Mallbris, L; Wang, C; Purohit, V; Mamolo, C; Papacharalambous, J; Ports, W C

2016-11-01

Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown. Tofacitinib, a small-molecule JAK inhibitor, was investigated for the topical treatment of AD. In this 4-week, phase IIa, randomized, double-blind, vehicle-controlled study (NCT02001181), 69 adults with mild-to-moderate AD were randomized 1:1 to 2% tofacitinib or vehicle ointment twice daily. Percentage change from baseline (CFB) in Eczema Area and Severity Index (EASI) score at week 4 was the primary end point. Secondary efficacy end points included percentage CFB in body surface area (BSA), CFB in EASI Clinical Signs Severity Sum Score, proportion of patients with Physician's Global Assessment (PGA) response and CFB in patient-reported pruritus. Safety, local tolerability and pharmacokinetics were monitored. The mean percentage CFB at week 4 in EASI score was significantly greater (P < 0·001) for tofacitinib (-81·7%) vs. vehicle (-29·9%). Patients treated with tofacitinib showed significant (P < 0·001) improvements vs. vehicle across all prespecified efficacy end points and for pruritus at week 4. Significant improvements in EASI, PGA and BSA were observed by week 1 and improvements in pruritus were observed by day 2. Safety/local tolerability were generally similar for both treatments, although more adverse events were observed for vehicle vs. tofacitinib. Tofacitinib ointment showed significantly greater efficacy vs. vehicle across end points, with early onset of effect and comparable safety/local tolerability to vehicle. JAK inhibition through topical delivery is potentially a promising therapeutic target for AD. © 2016 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

3 CFR 8432 - Proclamation 8432 of October 2, 2009. Fire Prevention Week, 2009

Code of Federal Regulations, 2010 CFR

2010-01-01

.... Fire Prevention Week is a time to learn about important fire safety issues and empower our communities... in their homes and workplaces. We can greatly reduce these tragedies by taking a few, very simple... of fire, we honor the brave men and women who protect us from it, and we recommit ourselves to its...

Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial.

PubMed

Zhang, Zhe; Zhang, Fan; Wang, Yang; Du, Yi; Zhang, Huiyong; Kong, Dezhao; Liu, Yue; Yang, Guanlin

2014-10-30

Stable angina pectoris is experienced as trans-sternal or retro-sternal pressure or pain that may radiate to the left arm, neck or back. Although available evidence relating to its effectiveness and mechanism are weak, traditional Chinese medicine is used as an alternative therapy for stable angina pectoris. We report a protocol of a randomized controlled trial using traditional Chinese medicine to investigate the effectiveness, mechanism and safety for patients with stable angina pectoris. This is a north-east Chinese, multi-center, multi-blinded, placebo-controlled and superiority randomized trail. A total of 240 patients with stable angina pectoris will be randomly assigned to three groups: two treatment groups and a control group. The treatment groups will receive Chinese herbal medicine consisting of Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granule and Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu granule, respectively, and conventional medicine. The control group will receive placebo medicine in addition to conventional medicine. All 3 groups will undergo a 12-week treatment and 2-week follow-up. Four visits in sum will be scheduled for each subject: 1 visit each in week 0, week 4, week 12 and week 14. The primary outcomes include: the frequency of angina pectoris attack; the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire. The secondary outcomes include: except for the body limited dimension of SAQ, traditional Chinese medicine pattern questionnaire and so on. Therapeutic mechanism outcomes, safety outcomes and endpoint outcomes will be also assessed. The primary aim of this trial is to develop a standard protocol to utilize high-quality EBM evidence for assessing the effectiveness and safety of SAP via TCM pattern differentiation as well as exploring the efficacy mechanism and regulation with the molecular biology and systems biology. ChiCTR-TRC-13003608, registered 18 June 2013.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

PubMed

Park, Won; Yoo, Dae Hyun; Miranda, Pedro; Brzosko, Marek; Wiland, Piotr; Gutierrez-Ureña, Sergio; Mikazane, Helena; Lee, Yeon-Ah; Smiyan, Svitlana; Lim, Mie-Jin; Kadinov, Vladimir; Abud-Mendoza, Carlos; Kim, HoUng; Lee, Sang Joon; Bae, YunJu; Kim, SuYeon; Braun, Jürgen

2017-02-01

To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg) was administered intravenously every 8 weeks from week 62 to week 102. Efficacy end points included the proportion of patients achieving Assessment of SpondyloArthritis international Society (ASAS)20. Antidrug antibodies (ADAs) were measured using an electrochemiluminescent method. Data were analysed for patients treated with CT-P13 in the main PLANETAS study and the extension (maintenance group) and those who were switched to CT-P13 during the extension study (switch group). Overall, 174 (82.9%) of 210 patients who completed the first 54 weeks of PLANETAS and agreed to participate in the extension were enrolled. Among these, 88 were maintained on CT-P13 and 86 were switched to CT-P13 from RP. In these maintenance and switch groups, respectively, ASAS20 response rates at week 102 were 80.7% and 76.9%. ASAS40 and ASAS partial remission were also similar between groups. ADA positivity rates were comparable (week 102: 23.3% vs 27.4%). Adverse events led to treatment discontinuation during the extension study in 3 (3.3%) and 4 (4.8%) patients, respectively. This is the first study to show that switching from RP to its biosimilar CT-P13 is possible without negative effects on safety or efficacy in patients with AS. In the maintenance group, CT-P13 was effective and well tolerated over 2 years of treatment. NCT01571206; Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

CERN Computing in Commercial Clouds

NASA Astrophysics Data System (ADS)

Cordeiro, C.; Field, L.; Garrido Bear, B.; Giordano, D.; Jones, B.; Keeble, O.; Manzi, A.; Martelli, E.; McCance, G.; Moreno-García, D.; Traylen, S.

2017-10-01

By the end of 2016 more than 10 Million core-hours of computing resources have been delivered by several commercial cloud providers to the four LHC experiments to run their production workloads, from simulation to full chain processing. In this paper we describe the experience gained at CERN in procuring and exploiting commercial cloud resources for the computing needs of the LHC experiments. The mechanisms used for provisioning, monitoring, accounting, alarming and benchmarking will be discussed, as well as the involvement of the LHC collaborations in terms of managing the workflows of the experiments within a multicloud environment.

AMS data production facilities at science operations center at CERN

NASA Astrophysics Data System (ADS)

Choutko, V.; Egorov, A.; Eline, A.; Shan, B.

2017-10-01

The Alpha Magnetic Spectrometer (AMS) is a high energy physics experiment on the board of the International Space Station (ISS). This paper presents the hardware and software facilities of Science Operation Center (SOC) at CERN. Data Production is built around production server - a scalable distributed service which links together a set of different programming modules for science data transformation and reconstruction. The server has the capacity to manage 1000 paralleled job producers, i.e. up to 32K logical processors. Monitoring and management tool with Production GUI is also described.

The CERN-EU high-energy Reference Field (CERF) facility: applications and latest developments

NASA Astrophysics Data System (ADS)

Silari, Marco; Pozzi, Fabio

2017-09-01

The CERF facility at CERN provides an almost unique high-energy workplace reference radiation field for the calibration and test of radiation protection instrumentation employed at high-energy accelerator facilities and for aircraft and space dosimetry. This paper describes the main features of the facility and supplies a non-exhaustive list of recent (as of 2005) applications for which CERF is used. Upgrade work started in 2015 to provide the scientific and industrial communities with a state-of-the-art reference facility is also discussed.

Media Training

ScienceCinema

None

2017-12-09

With the LHC starting up soon, the world's media are again turning their attention to CERN. We're all likely to be called upon to explain what is happening at CERN to media, friends and neighbours. The seminar will be given by BBC television news journalists Liz Pike and Nadia Marchant, and will deal with the kind of questions we're likely to be confronted with through the restart period. The training is open for everybody. Make sure you arrive early enough to get a seat - there are only 200 seats in the Globe. The session will also be webcast: http://webcast.cern.ch/

News Music: Here comes science that rocks Student trip: Two views of the future of CERN Classroom: Researchers can motivate pupils Appointment: AstraZeneca trust appoints new director Multimedia: Physics Education comes to YouTube Competition: Students compete in European Union Science Olympiad 2010 Physics roadshow: Pupils see wonders of physics

NASA Astrophysics Data System (ADS)

2010-07-01

Music: Here comes science that rocks Student trip: Two views of the future of CERN Classroom: Researchers can motivate pupils Appointment: AstraZeneca trust appoints new director Multimedia: Physics Education comes to YouTube Competition: Students compete in European Union Science Olympiad 2010 Physics roadshow: Pupils see wonders of physics

Lower limit on dark matter production at the CERN Large Hadron Collider.

PubMed

Feng, Jonathan L; Su, Shufang; Takayama, Fumihiro

2006-04-21

We evaluate the prospects for finding evidence of dark matter production at the CERN Large Hadron Collider. We consider weakly interacting massive particles (WIMPs) and superWIMPs and characterize their properties through model-independent parametrizations. The observed relic density then implies lower bounds on dark matter production rates as functions of a few parameters. For WIMPs, the resulting signal is indistinguishable from background. For superWIMPs, however, this analysis implies significant production of metastable charged particles. For natural parameters, these rates may far exceed Drell-Yan cross sections and yield spectacular signals.

Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.

PubMed

Standaert, David G; Rodriguez, Ramon L; Slevin, John T; Lobatz, Michael; Eaton, Susan; Chatamra, Krai; Facheris, Maurizio F; Hall, Coleen; Sail, Kavita; Jalundhwala, Yash J; Benesh, Janet

2017-01-01

Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the United States), delivered via percutaneous gastrojejunostomy (PEG-J) and titrated in the inpatient setting, is an established treatment option for advanced Parkinson's disease (PD) patients with motor fluctuations. However, long-term prospective data on the efficacy of LCIG on non-motor symptoms and the safety of outpatient titration are limited. In this 60-week, open-label phase 3b study, LCIG titration was initiated in an outpatient setting following PEG-J placement in PD patients. The efficacy of LCIG on motor and non-motor symptoms, quality of life, and safety was assessed. Thirty-nine patients were enrolled in the study and 28 patients completed the treatment. A majority of patients (54%) completed outpatient titration within the first week of LCIG infusion. LCIG led to significant reductions from baseline in Non-Motor Symptom Scale (NMSS) total score (least squares mean ± SE = -17.6 ± 3.6, P < 0.001) and 6 of the NMSS domain scores (sleep/fatigue, attention/memory, gastrointestinal tract, urinary, sexual function, miscellaneous) at week 12. These reductions were maintained at week 60 with the exception of the urinary domain. "Off" time (-4.9 ± 0.5 hours/day, P < 0.001) and "On" time without troublesome dyskinesia (-4.3 ± 0.6 hours/day, P < 0.001) were improved at week 60. Adverse events (AEs) were reported in 37 (95%) patients. LCIG treatment led to reductions in non-motor symptom burden and motor fluctuations in advanced PD patients. The safety profile was consistent with previous studies that used inpatient titration and outpatient titration did not appear to pose additional risk.

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

PubMed

Rodríguez, P C; Prada, D M; Moreno, E; Aira, L E; Molinero, C; López, A M; Gómez, J A; Hernández, I M; Martínez, J P; Reyes, Y; Milera, J M; Hernández, M V; Torres, R; Avila, Y; Barrese, Y; Viada, C; Montero, E; Hernández, P

2018-02-01

Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6-week monotherapy clinical trial conducted in rheumatoid arthritis (RA) patients. The current Phase I study evaluated the safety and clinical response for a longer treatment of 12 itolizumab intravenous doses in subjects with active RA despite previous disease-modifying anti-rheumatic drug (DMARD) therapy. Twenty-one subjects were enrolled into four dosage groups (0·1, 0·2, 0·4 and 0·8 mg/kg). Efficacy end-points including American College of Rheumatology (ACR)20, ACR50 and ACR70 response rates and disease activity score in 28 joints (DAS28) were monitored at baseline and at specific time-points during a 10-week follow-up period. Itolizumab was well tolerated up to the highest tested dose. No related serious adverse events were reported and most adverse events were mild. Remarkably, itolizumab treatment did not produce lymphopenia and, therefore, was not associated with infections. All patients achieved a clinical response (ACR20) at least once during the study. Eleven subjects (55%) achieved at least a 20% improvement in ACR just 1 week after the first itolizumab administration. The clinical response was observed from the beginning of the treatment and was sustained during 24 weeks. The efficacy profile of this 12-week treatment was similar to that of the previous study (6-week treatment). These results reinforce the safety profile of itolizumab and provide further evidence on the clinical benefit from the use of this anti-CD6 mAb in RA patients. © 2017 British Society for Immunology.

Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

PubMed Central

Zhao, Jingyuan; Song, Xueqin; Ai, Xiaoqing; Gu, Xiaojing; Huang, Guangbiao; Li, Xue; Pang, Lijuan; Ding, Minli; Ding, Shuang; Lv, Luxian

2015-01-01

Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS). Rating scales and safety assessments (RSESE, BARS, UKU) were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8. Results One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group). PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusions Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia. Trial Registration chictr.org ChiCTR-IOR-15006278 PMID:26448615

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.

PubMed

Aman, Michael G; Findling, Robert L; Hardan, Antonio Y; Hendren, Robert L; Melmed, Raun D; Kehinde-Nelson, Ola; Hsu, Hai-An; Trugman, Joel M; Palmer, Robert H; Graham, Stephen M; Gage, Allyson T; Perhach, James L; Katz, Ephraim

2017-06-01

Abnormal glutamatergic neurotransmission is implicated in the pathophysiology of autism spectrum disorder (ASD). In this study, the safety, tolerability, and efficacy of the glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist memantine (once-daily extended-release [ER]) were investigated in children with autism in a randomized, placebo-controlled, 12 week trial and a 48 week open-label extension. A total of 121 children 6-12 years of age with Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR)-defined autistic disorder were randomized (1:1) to placebo or memantine ER for 12 weeks; 104 children entered the subsequent extension trial. Maximum memantine doses were determined by body weight and ranged from 3 to 15 mg/day. There was one serious adverse event (SAE) (affective disorder, with memantine) in the 12 week study and one SAE (lobar pneumonia) in the 48 week extension; both were deemed unrelated to treatment. Other AEs were considered mild or moderate and most were deemed not related to treatment. No clinically significant changes occurred in clinical laboratory values, vital signs, or electrocardiogram (ECG). There was no significant between-group difference on the primary efficacy outcome of caregiver/parent ratings on the Social Responsiveness Scale (SRS), although an improvement over baseline at Week 12 was observed in both groups. A trend for improvement at the end of the 48 week extension was observed. No improvements in the active group were observed on any of the secondary end-points, with one communication measure showing significant worsening with memantine compared with placebo (p = 0.02) after 12 weeks. This trial did not demonstrate clinical efficacy of memantine ER in autism; however, the tolerability and safety data were reassuring. Our results could inform future trial design in this population and may facilitate the investigation of memantine ER for other clinical applications.

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.

PubMed

Luo, Xiaoping; Hou, Ling; Liang, Li; Dong, Guanping; Shen, Shuixian; Zhao, Zhuhui; Gong, Chun Xiu; Li, Yuchuan; Du, Min-Lian; Su, Zhe; Du, Hongwei; Yan, Chaoying

2017-08-01

We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). Phase II and III, multicenter, open-label, randomized controlled trials. 108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively. Patients in the phase II study were randomized 1:1:1 to weekly Jintrolong (0.1 mg/kg/week PEG-rhGH complex), weekly Jintrolong (0.2 mg/kg/week PEG-rhGH complex) or daily rhGH (0.25 mg/kg/week) for 25 weeks. Patients in the phase III study were randomized in a 2:1 ratio to weekly Jintrolong (0.2 mg/kg/week) or daily rhGH (0.25 mg/kg/week) for 25 weeks. The primary endpoint for both studies was height velocity (HV) increase at the end of treatment. Other growth-related parameters, safety and compliance were also monitored. The phase II study established the preliminary efficacy, safety and recommended dose of Jintrolong PEG-rhGH. In the phase III study, we demonstrated significantly greater HV increases in patients receiving Jintrolong treatment (from 2.26 ± 0.87 cm/year to 13.41 ± 3.72 cm/year) vs daily rhGH (from 2.25 ± 0.82 cm/year to 12.55 ± 2.99 cm/year) at the end of treatment ( P  < 0.05). Additionally, significantly greater improvement in the height standard deviation scores was associated with Jintrolong throughout the treatment ( P  < 0.05). Adverse event rates and treatment compliance were comparable between the two groups. Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH. © 2017 The authors.

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension

PubMed Central

Findling, Robert L.; Hardan, Antonio Y.; Hendren, Robert L.; Melmed, Raun D.; Kehinde-Nelson, Ola; Hsu, Hai-An; Trugman, Joel M.; Palmer, Robert H.; Graham, Stephen M.; Gage, Allyson T.; Perhach, James L.; Katz, Ephraim

2017-01-01

Abstract Objective: Abnormal glutamatergic neurotransmission is implicated in the pathophysiology of autism spectrum disorder (ASD). In this study, the safety, tolerability, and efficacy of the glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist memantine (once-daily extended-release [ER]) were investigated in children with autism in a randomized, placebo-controlled, 12 week trial and a 48 week open-label extension. Methods: A total of 121 children 6–12 years of age with Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR)-defined autistic disorder were randomized (1:1) to placebo or memantine ER for 12 weeks; 104 children entered the subsequent extension trial. Maximum memantine doses were determined by body weight and ranged from 3 to 15 mg/day. Results: There was one serious adverse event (SAE) (affective disorder, with memantine) in the 12 week study and one SAE (lobar pneumonia) in the 48 week extension; both were deemed unrelated to treatment. Other AEs were considered mild or moderate and most were deemed not related to treatment. No clinically significant changes occurred in clinical laboratory values, vital signs, or electrocardiogram (ECG). There was no significant between-group difference on the primary efficacy outcome of caregiver/parent ratings on the Social Responsiveness Scale (SRS), although an improvement over baseline at Week 12 was observed in both groups. A trend for improvement at the end of the 48 week extension was observed. No improvements in the active group were observed on any of the secondary end-points, with one communication measure showing significant worsening with memantine compared with placebo (p = 0.02) after 12 weeks. Conclusions: This trial did not demonstrate clinical efficacy of memantine ER in autism; however, the tolerability and safety data were reassuring. Our results could inform future trial design in this population and may facilitate the investigation of memantine ER for other clinical applications. PMID:26978327

Trial of Tocilizumab in Giant-Cell Arteritis.

PubMed

Stone, John H; Tuckwell, Katie; Dimonaco, Sophie; Klearman, Micki; Aringer, Martin; Blockmans, Daniel; Brouwer, Elisabeth; Cid, Maria C; Dasgupta, Bhaskar; Rech, Juergen; Salvarani, Carlo; Schett, Georg; Schulze-Koops, Hendrik; Spiera, Robert; Unizony, Sebastian H; Collinson, Neil

2017-07-27

Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis. In this 1-year trial, we randomly assigned 251 patients, in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52 weeks. The primary outcome was the rate of sustained glucocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the placebo group that underwent the 26-week prednisone taper. The key secondary outcome was the rate of remission in each tocilizumab group as compared with the placebo group that underwent the 52-week prednisone taper. Dosing of prednisone and safety were also assessed. Sustained remission at week 52 occurred in 56% of the patients treated with tocilizumab weekly and in 53% of those treated with tocilizumab every other week, as compared with 14% of those in the placebo group that underwent the 26-week prednisone taper and 18% of those in the placebo group that underwent the 52-week prednisone taper (P<0.001 for the comparisons of either active treatment with placebo). The cumulative median prednisone dose over the 52-week period was 1862 mg in each tocilizumab group, as compared with 3296 mg in the placebo group that underwent the 26-week taper (P<0.001 for both comparisons) and 3818 mg in the placebo group that underwent the 52-week taper (P<0.001 for both comparisons). Serious adverse events occurred in 15% of the patients in the group that received tocilizumab weekly, 14% of those in the group that received tocilizumab every other week, 22% of those in the placebo group that underwent the 26-week taper, and 25% of those in the placebo group that underwent the 52-week taper. Anterior ischemic optic neuropathy developed in one patient in the group that received tocilizumab every other week. Tocilizumab, received weekly or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustained glucocorticoid-free remission in patients with giant-cell arteritis. Longer follow-up is necessary to determine the durability of remission and safety of tocilizumab. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01791153 .).

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

PubMed

Abe, Koji; Itoyama, Yasuto; Sobue, Gen; Tsuji, Shoji; Aoki, Masashi; Doyu, Manabu; Hamada, Chikuma; Kondo, Kazuoki; Yoneoka, Takatomo; Akimoto, Makoto; Yoshino, Hiide

2014-12-01

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.v. infusion over 60 min for the first 14 days in cycle 1, and for 10 of the first 14 days during cycles 2 to 6. The efficacy primary endpoint was changed in the revised ALS functional rating scale (ALSFRS-R) scores during the 24-week treatment. Patients were treated with placebo (n = 104) and edaravone (n = 102). Changes in ALSFRS-R during the 24-week treatment were -6.35 ± 0.84 in the placebo group (n = 99) and -5.70 ± 0.85 in the edaravone group (n = 100), with a difference of 0.65 ± 0.78 (p = 0.411). Adverse events amounted to 88.5% (92/104) in the placebo group and 89.2% (91/102) in the edaravone group. In conclusion, the reduction of ALSFRS-R was smaller in the edaravone group than in the placebo group, but efficacy of edaravone for treatment of ALS was not demonstrated. Levels and frequencies of reported adverse events were similar in the two groups.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

PubMed

Schoepfer, Alain M; Vavricka, Stephan R; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Seibold, Frank; Straumann, Alex; Michetti, Pierre

2010-06-01

Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients. Baseline and Week 6 evaluation questionnaires were sent to all Swiss gastroenterologists in hospitals and private practices. Disease activity was assessed with the Harvey-Bradshaw Index (HBI) and adverse events were evaluated according to WHO guidelines. Fifty patients (31 women, 19 men) were included; 56% had complicated disease (stricture or fistula) and 52% had undergone prior CD-related surgery. All patients had prior exposure to systemic steroids, 96% to immunomodulators, 78% to infliximab, and 50% to adalimumab. A significant decrease in HBI was observed at Week 6 (versus Week 0) following induction therapy with CZP 400 mg subcutaneously at Weeks 0, 2, and 4 (12.6 +/- 4.7 Week 0 versus 6.2 +/- 4.4 Week 6, P < 0.001). Response and remission rates at Week 6 were 54% and 40%, respectively. We identified 8/11 CD patients undergoing a 50% fistula response (P = 0.021). The frequency of adverse drug reactions attributed to CZP was 6%. CZP was continued in 80% of patients beyond Week 6. In a population of CD patients with complicated disease behavior, CZP induced a response and remission in 54% and 40% of patients, respectively. This series provides the first evidence of the effectiveness of CZP in perianal fistulizing CD.

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

PubMed Central

Maksymowych, Walter P; Dougados, Maxime; Sieper, Joachim; Braun, Jürgen; Citera, Gustavo; Van den Bosch, Filip; Logeart, Isabelle; Wajdula, Joseph; Jones, Heather; Marshall, Lisa; Bonin, Randi; Pedersen, Ron; Vlahos, Bonnie; Kotak, Sameer; Bukowski, Jack F

2016-01-01

Objective To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA). Methods Patients meeting Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, received double-blind ETN 50 mg/week or placebo (PBO) for 12 weeks, then open-label ETN (ETN/ETN or PBO/ETN). Clinical, health, productivity, MRI and safety outcomes were assessed and the 48-week data are presented here. Results 208/225 patients (92%) entered the open-label phase at week 12 (ETN, n=102; PBO, n=106). The percentage of patients achieving ASAS40 increased from 33% to 52% between weeks 12 and 48 for ETN/ETN and from 15% to 53% for PBO/ETN (within-group p value <0.001 for both). For ETN/ETN and PBO/ETN, the EuroQol 5 Dimensions utility score improved by 0.14 and 0.08, respectively, between baseline and week 12 and by 0.23 and 0.22 between baseline and week 48. Between weeks 12 and 48, MRI Spondyloarthritis Research Consortium of Canada sacroiliac joint (SIJ) scores decreased by −1.1 for ETN/ETN and by −3.0 for PBO/ETN, p<0.001 for both. Decreases in MRI SIJ inflammation and C-reactive protein correlated with several clinical outcomes at weeks 12 and 48. Conclusions Patients with early active nr-axSpA demonstrated improvement from week 12 in clinical, health, productivity and MRI outcomes that was sustained to 48 weeks. Trial registration number NCT01258738. PMID:26269397

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

PubMed

Williams, Kathryn E; Reeves, Karen R; Billing, Clare B; Pennington, Ann M; Gong, Jason

2007-04-01

We assessed the safety of long-term varenicline administration for smoking cessation. In this randomized, double-blind, multicenter trial, eligible adult smokers (18-75 years) who smoked an average of > or =10 cigarettes/day were randomized to either varenicline 1 mg twice daily (BID) or placebo for 52 weeks. Subjects made weekly clinic visits until week 8, and then every 4 weeks until week 52, with a follow-up visit at week 53. The target quit date was the morning of the week 1 clinic visit. Brief counseling was provided at each visit, and vital signs, adverse events (AEs), and smoking status were documented. Other laboratory measures were collected at specified visits. A total of 251 subjects were randomized to varenicline and 126 to placebo. Approximately half of the subjects in each arm completed the study (53.8% varenicline; 46.8% placebo). Treatment-emergent AEs were observed in 96.4% of varenicline- and 82.5% of placebo-treated subjects during the study. Common varenicline-associated AEs were nausea (40.2%), abnormal dreams (22.7%), and insomnia (19.1%). Most AEs were considered mild or moderate in intensity. AEs leading to discontinuation of varenicline treatment included nausea (7.6%), insomnia (3.2%), and abnormal dreams (2.4%). A single varenicline-related serious AE, bilateral subcapsular cataracts, was observed. At week 52, 7-day point prevalence abstinence rates were 36.7% (varenicline) and 7.9% (placebo). Varenicline 1 mg BID can be safely administered for up to 1 year. Varenicline was also a more effective smoking cessation aid than placebo throughout the study, supporting both its short- (12-week) and long-term (52-week) efficacy.

Use of Active-Play Video Games to Enhance Aerobic Fitness in Schizophrenia: Feasibility, Safety, and Adherence.

PubMed

Kimhy, David; Khan, Samira; Ayanrouh, Lindsey; Chang, Rachel W; Hansen, Marie C; Lister, Amanda; Ballon, Jacob S; Vakhrusheva, Julia; Armstrong, Hilary F; Bartels, Matthew N; Sloan, Richard P

2016-02-01

Active-play video games have been used to enhance aerobic fitness in various clinical populations, but their use among individuals with schizophrenia has been limited. Feasibility, acceptability, safety, and adherence data were obtained for use of aerobic exercise (AE) equipment by 16 individuals with schizophrenia during a 12-week AE program consisting of three one-hour exercise sessions per week. Equipment included exercise video games for Xbox 360 with Kinect motion sensing devices and traditional exercise equipment. Most participants (81%) completed the training, attending an average of 79% of sessions. The proportion of time spent playing Xbox (39%) exceeded time spent on any other type of equipment. When using Xbox, participants played 2.24±1.59 games per session and reported high acceptability and enjoyment ratings, with no adverse events. Measures of feasibility, acceptability, adherence, and safety support the integration of active-play video games into AE training for people with schizophrenia.

openSE: a Systems Engineering Framework Particularly Suited to Particle Accelerator Studies and Development Projects

DOE Office of Scientific and Technical Information (OSTI.GOV)

Bonnal, P.; Féral, B.; Kershaw, K.

Particle accelerator projects share many characteristics with industrial projects. However, experience has shown that best practice of industrial project management is not always well suited to particle accelerator projects. Major differences include the number and complexity of technologies involved, the importance of collaborative work, development phases that can last more than a decade, and the importance of telerobotics and remote handling to address future preventive and corrective maintenance requirements due to induced radioactivity, to cite just a few. The openSE framework it is a systems engineering and project management framework specifically designed for scientific facilities’ systems and equipment studies andmore » development projects. Best practices in project management, in systems and requirements engineering, in telerobotics and remote handling and in radiation safety management were used as sources of inspiration, together with analysis of current practices surveyed at CERN, GSI and ESS.« less

78 FR 74048 - Eleventh Coast Guard District Annual Fireworks Events

Federal Register 2010, 2011, 2012, 2013, 2014

2013-12-10

.... The first proposed safety zone is for the ``Big Bay Boom Fourth of July Fireworks'' event occurring one evening during the first week of July in San Diego Bay. This event requires four 1,000 foot radius... events. The first proposed safety zone is for the ``Colorado Belle & Edgewater Hotel/Casino Thanksgiving...

An on-line acoustic fluorocarbon coolant mixture analyzer for the ATLAS silicon tracker

DOE Office of Scientific and Technical Information (OSTI.GOV)

Bates, R.; Battistin, M.; Berry, S.

2011-07-01

The ATLAS silicon tracker community foresees an upgrade from the present octafluoro-propane (C{sub 3}F{sub 8}) evaporative cooling fluid - to a composite fluid with a probable 10-20% admixture of hexafluoro-ethane (C{sub 2}F{sub 6}). Such a fluid will allow a lower evaporation temperature and will afford the tracker silicon substrates a better safety margin against leakage current-induced thermal runaway caused by cumulative radiation damage as the luminosity profile at the CERN Large Hadron Collider increases. Central to the use of this new fluid is a new custom-developed speed-of-sound instrument for continuous real-time measurement of the C{sub 3}F{sub 8}/C{sub 2}F{sub 6} mixturemore » ratio and flow. An acoustic vapour mixture analyzer/flow meter with new custom electronics allowing ultrasonic frequency transmission through gas mixtures has been developed for this application. Synchronous with the emission of an ultrasound 'chirp' from an acoustic transmitter, a fast readout clock (40 MHz) is started. The clock is stopped on receipt of an above threshold sound pulse at the receiver. Sound is alternately transmitted parallel and anti-parallel with the vapour flow for volume flow measurement from transducers that can serve as acoustic transmitters or receivers. In the development version, continuous real-time measurement of C{sub 3}F{sub 8}/C{sub 2}F{sub 6} flow and calculation of the mixture ratio is performed within a graphical user interface developed in PVSS-II, the Supervisory, Control and Data Acquisition standard chosen for LHC and its experiments at CERN. The described instrument has numerous potential applications - including refrigerant leak detection, the analysis of hydrocarbons, vapour mixtures for semiconductor manufacture and anesthetic gas mixtures. (authors)« less

Feasibility and Safety of Intra-Dialysis Yoga and Education in Maintenance Hemodialysis Patients

PubMed Central

Birdee, Gurjeet S.; Rothman, Russell L.; Sohl, Stephanie J.; Wertenbaker, Dolphi; Wheeler, Amy; Bossart, Chase; Balasire, Oluwaseyi; Ikizler, T. Alp

2016-01-01

Objective Patients with end-stage renal disease on maintenance hemodialysis are much more sedentary than healthy individuals. The purpose of this study was to assess the feasibility and safety of a 12-week intra-dialysis yoga intervention versus a kidney education intervention on the promotion of physical activity. Design and Methods We randomized participants by dialysis shift to either 12-week intra-dialysis yoga or an educational intervention. Intra-dialysis yoga was provided by yoga teachers to participants while receiving hemodialysis. Participants receiving the 12-week educational intervention received a modification of a previously developed comprehensive educational program for patients with kidney disease (“Kidney School”). The primary outcome for this study was feasibility based on recruitment and adherence to the interventions, and safety of intra-dialysis yoga. Secondary outcomes were to determine the feasibility of administering questionnaires at baseline and 12-weeks including the Kidney Disease-Related Quality of Life-36. Results Among 56 eligible patients approached for the study, 55% (n=31) were interested and consented to participation with 18 assigned to intra-dialysis yoga and 13 to the educational program. A total of 5 participants withdrew from the pilot study, all from the intra-dialysis yoga group. Two of these participants reported no further interest in participation. Three withdrawn participants switched dialysis times and therefore could no longer receive intra-dialysis yoga. As a result, 72% (13 of 18) and 100% (13 of 13) of participants completed 12-week intra-dialysis yoga and educational programs, respectively. There were no adverse events related to intra-dialysis yoga. Intervention participants practiced yoga a median of 21 sessions (70% participation frequency), with 60% of participants practicing at least 2 times a week. Participants in the educational program completed a median of 30 sessions (83% participation frequency). Of participants who completed the study (n=26), baseline and 12-week questionnaires were obtained from 85%. Conclusions Our pilot study of a 12-week intra-dialysis yoga and 12-week educational intervention reached recruitment goals, but less than targeted completion and adherence to intervention rates. This study provided valuable feasibility data to increase follow-up and adherence for future clinical trials to compare efficacy. PMID:25869658

Campaign Safe & Sober. Youth & Generation X Planner.

ERIC Educational Resources Information Center

National Highway Traffic Safety Administration (DOT), Washington, DC.

This packet contains information on safe and sober driving for members of Generation X. The packet includes information on "Buckle Up America! Week 1998," which was designed to encourage everyone on the road to use seat belts and child safety seats and to use them properly. It also offers a safety city brochure and multiple program…

Safety of Lumbar Puncture Procedures in Patients with Alzheimer's Disease

PubMed Central

Peskind, E.; Nordberg, A.; Darreh-Shori, T.; Soininen, H.

2014-01-01

Changes in cerebrospinal fluid (CSF) biomarkers are representative of biochemical changes in the brain. Collection of CSF by lumbar puncture (LP) is essential for biomarker analysis, which is important for research in neurodegenerative disorders. However, LP for research purposes has been controversial due to a reported high incidence of severe LP headache when using standard 18g or 20g Quincke needles with a beveled cutting tip. A procedural safety analysis was performed using the database of a multicenter, 13-week study of CSF cholinesterase activity. A 24g Sprotte atraumatic needle was used to collect CSF at baseline and at Week 13 from 63 older patients with mild to moderate Alzheimer's disease. There was a < 2% LP headache incidence, and a favorable safety profile was reported. In conclusion, LP performed with a 24g Sprotte atraumatic needle (blunt, “bullet” tip) was a well-tolerated procedure, with good acceptability. PMID:19519311

College Rampage Renews School Safety Concerns

ERIC Educational Resources Information Center

Maxwell, Lesli A.

2007-01-01

Coming just four days before the anniversary of the Columbine school shootings, the mass slayings by a student gunman at Virginia Polytechnic Institute last week revived vexing questions and raised familiar fears for educators across the country who grapple daily with ensuring the safety of their students and staffs. The April 16 killings provoked…

10 CFR Appendix A to Subpart B of... - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-01-01

... suspected or reported violations to the Federal awarding agency. 4. Contract Work Hours and Safety Standards... mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work... basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is...

33 CFR 165.1315 - Safety Zones: Fireworks displays in the Captain of the Port Columbia River Zone.

Code of Federal Regulations, 2011 CFR

2011-07-01

... seconds North, 119 degrees 08 minutes 52 seconds West. (ii) Enforcement date. Every July 4th. (4) Cedco...) Enforcement period. One day in early July. (5) Astoria 4th of July Fireworks, Astoria, OR (i) Location. All... the third week of August and the third week of September. (8) Florence Chamber 4th of July Fireworks...

33 CFR 165.1315 - Safety Zones: Fireworks displays in the Captain of the Port Columbia River Zone.

Code of Federal Regulations, 2012 CFR

2012-07-01

... seconds North, 119 degrees 08 minutes 52 seconds West. (ii) Enforcement date. Every July 4th. (4) Cedco...) Enforcement period. One day in early July. (5) Astoria 4th of July Fireworks, Astoria, OR (i) Location. All... the third week of August and the third week of September. (8) Florence Chamber 4th of July Fireworks...

33 CFR 165.1315 - Safety Zones: Fireworks displays in the Captain of the Port Columbia River Zone.

Code of Federal Regulations, 2013 CFR

2013-07-01

... seconds North, 119 degrees 08 minutes 52 seconds West. (ii) Enforcement date. Every July 4th. (4) Cedco...) Enforcement period. One day in early July. (5) Astoria 4th of July Fireworks, Astoria, OR (i) Location. All... the third week of August and the third week of September. (8) Florence Chamber 4th of July Fireworks...

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.

PubMed

Bagel, Jerry; Duffin, Kristina Callis; Moore, Angela; Ferris, Laura K; Siu, Kimberly; Steadman, Jennifer; Kianifard, Farid; Nyirady, Judit; Lebwohl, Mark

2017-10-01

Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis. Evaluate the efficacy and safety of secukinumab in moderate-to-severe scalp psoriasis. In this 24-week, double-blind, phase 3b study, 102 patients were randomized 1:1 to subcutaneous secukinumab 300 mg or placebo at baseline, weeks 1, 2, and 3, and then every 4 weeks from week 4 to 20. The primary efficacy variable was 90% improvement of Psoriasis Scalp Severity Index (PSSI 90) score from baseline to week 12. At week 12, PSSI 90 (secukinumab 300 mg vs placebo, 52.9% vs 2.0%) and Investigator's Global Assessment modified 2011 scalp responses of 0 or 1 (secukinumab 300 mg vs placebo, 56.9% vs 5.9%) were significantly greater with secukinumab 300 mg than placebo (P < .001 for both). In addition, significantly more patients achieved complete clearance of scalp psoriasis at week 12 with secukinumab 300 mg than placebo (35.3% vs 0%; P < .001). The median time to 50% reduction in PSSI score was 3.29 weeks with secukinumab 300 mg. The safety profile of secukinumab was consistent with previous phase 3 studies. There was no active comparator arm. Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe scalp psoriasis. Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients

PubMed Central

Pichholiya, Meenu; Yadav, Arvind Kumar; Luhadia, S. K.; Tahashildar, Jameela; Aseri, M. L.

2016-01-01

Objectives: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). Methods: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0th, 2nd, 4th, 6th, and 8th week of ATT. Patients whose uric acid level was found to be increased at 2nd week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t-test and ANOVA. Results: Mean serum uric acid level decreased from 10.698 mg/dl (at 2nd week) to 7.846 mg/dl (at 8th week) in Group A and from 11.34 mg/dl (at 2nd week) to 7.280 mg/dl (at 8th week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. Conclusion: Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA. PMID:27721537

Laser resonance ionization spectroscopy on lutetium for the MEDICIS project

NASA Astrophysics Data System (ADS)

Gadelshin, V.; Cocolios, T.; Fedoseev, V.; Heinke, R.; Kieck, T.; Marsh, B.; Naubereit, P.; Rothe, S.; Stora, T.; Studer, D.; Van Duppen, P.; Wendt, K.

2017-11-01

The MEDICIS-PROMED Innovative Training Network under the Horizon 2020 EU program aims to establish a network of early stage researchers, involving scientific exchange and active cooperation between leading European research institutions, universities, hospitals, and industry. Primary scientific goal is the purpose of providing and testing novel radioisotopes for nuclear medical imaging and radionuclide therapy. Within a closely linked project at CERN, a dedicated electromagnetic mass separator system is presently under installation for production of innovative radiopharmaceutical isotopes at the new CERN-MEDICIS laboratory, directly adjacent to the existing CERN-ISOLDE radioactive ion beam facility. It is planned to implement a resonance ionization laser ion source (RILIS) to ensure high efficiency and unrivaled purity in the production of radioactive ions. To provide a highly efficient ionization process, identification and characterization of a specific multi-step laser ionization scheme for each individual element with isotopes of interest is required. The element lutetium is of primary relevance, and therefore was considered as first candidate. Three two-step excitation schemes for lutetium atoms are presented in this work, and spectroscopic results are compared with data of other authors.

Life in the Universe? Is anybody out there?

NASA Astrophysics Data System (ADS)

2001-07-01

What is our understanding at the beginning of the 21st century? Is there any scientific evidence for other forms of life? How can you define life? What signs are we looking for? What would the reaction be if other forms of life were discovered? The European Organization for Nuclear Research (CERN), the European Space Agency and the European Southern Observatory, in cooperation with the European Association for Astronomy Education, have organised a competition to find out what young people in Europe think. The European Molecular Biology Laboratory and the European Synchrotron Radiation Facility are also involved. This "Life in the Universe" project is being mounted in collaboration with the research directorate of the European Commission for the European Week of Science and Technology in November this year. Competitions are already under way in 23 European countries to find the best projects from school students aged between 14 and 19. Entries can be in one of two categories: scientific or artistic. The projects can therefore be essays, newspapers, websites, artworks, poetry or even a theatrical or musical performance. Two winning teams (one in each category) from each country will be invited to a final event at CERN in Geneva on 8-11 November to present their projects to an international panel of experts at a special event devoting three days to enquiring into the possibility of other life forms existing in our Universe. This final event will be broadcast all over the world via the Internet. The home base of the "Life in the Universe" project is a vibrant website www.lifeinuniverse.org where details of the programme can be found. It is still under development but already has a wealth of information and links to the national websites, where all entries are posted. Is there other life in the Universe? We do not know - but the search is on!

Antiproton Trapping for Advanced Space Propulsion Applications

NASA Technical Reports Server (NTRS)

Smith, Gerald A.

1998-01-01

The Summary of Research parallels the Statement of Work (Appendix I) submitted with the proposal, and funded effective Feb. 1, 1997 for one year. A proposal was submitted to CERN in October, 1996 to carry out an experiment on the synthesis and study of fundamental properties of atomic antihydrogen. Since confined atomic antihydrogen is potentially the most powerful and elegant source of propulsion energy known, its confinement and properties are of great interest to the space propulsion community. Appendix II includes an article published in the technical magazine Compressed Air, June 1997, which describes CERN antiproton facilities, and ATHENA. During the period of this grant, Prof. Michael Holzscheiter served as spokesman for ATHENA and, in collaboration with Prof. Gerald Smith, worked on the development of the antiproton confinement trap, which is an important part of the ATHENA experiment. Appendix III includes a progress report submitted to CERN on March 12, 1997 concerning development of the ATHENA detector. Section 4.1 reviews technical responsibilities within the ATHENA collaboration, including the Antiproton System, headed by Prof. Holzscheiter. The collaboration was advised (see Appendix IV) on June 13, 1997 that the CERN Research Board had approved ATHENA for operation at the new Antiproton Decelerator (AD), presently under construction. First antiproton beams are expected to be delivered to experiments in about one year. Progress toward assembly of the ATHENA detector and initial testing expected in 1999 has been excellent. Appendix V includes a copy of the minutes of the most recently documented collaboration meeting held at CERN of October 24, 1997, which provides more information on development of systems, including the antiproton trapping apparatus. On February 10, 1998 Prof. Smith gave a 3 hour lecture on the Physics of Antimatter, as part of the Physics for the Third Millennium Lecture Series held at MSFC. Included in Appendix VI are notes and graphs presented on the ATHENA experiment. Portable antiproton trap has been under development. The goal is to store and transport antiprotons from a production site, such as Fermilab near Chicago, to a distant site, such as Huntsville, AL, thus demonstrating the portability of antiprotons.

15 CFR Appendix A to Part 14 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-01-01

... wages of every mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of... than 11/2 times the basic rate of pay for all hours worked in excess of 40 hours in the work week.... Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333)—Where applicable, all contracts awarded by...

33 CFR 165.1315 - Safety Zones: Fireworks displays in the Captain of the Port Columbia River Zone.

Code of Federal Regulations, 2014 CFR

2014-07-01

... seconds North, 119 degrees 08 minutes 52 seconds West. (ii) Enforcement date. Every July 4th. (4) Cedco...) Enforcement period. One day in early July. (5) Astoria 4th of July Fireworks, Astoria, OR (i) Location. All... the third week of August and the third week of September. (8) Florence Chamber 4th of July Fireworks...

34 CFR Appendix A to Part 74 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

... suspected or reported violations to the Federal awarding agency. 4. Contract Work Hours and Safety Standards... mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work... basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is...

36 CFR Appendix A to Part 1210 - Contract Provisions

Code of Federal Regulations, 2010 CFR

2010-07-01

... suspected or reported violations to the Federal awarding agency. 4. Contract Work Hours and Safety Standards... mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work... basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is...

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.

PubMed

Pichholiya, Meenu; Yadav, Arvind Kumar; Luhadia, S K; Tahashildar, Jameela; Aseri, M L

2016-01-01

To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0 th , 2 nd , 4 th , 6 th , and 8 th week of ATT. Patients whose uric acid level was found to be increased at 2 nd week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t -test and ANOVA. Mean serum uric acid level decreased from 10.698 mg/dl (at 2 nd week) to 7.846 mg/dl (at 8 th week) in Group A and from 11.34 mg/dl (at 2 nd week) to 7.280 mg/dl (at 8 th week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA.

[The Big Data Game : On the Ludic Constitution of the Collaborative Production of Knowledge in High-Energy Physics at CERN].

PubMed

Dippel, Anne

2017-12-01

This article looks at how games and play contribute to the big data-driven production of knowledge in High-Energy Physics, with a particular focus on the Large Hadron Collider (LHC) at the European Organization for Nuclear Research (CERN), where the author has been conducting anthropological fieldwork since 2014. The ludic (playful) aspect of knowledge production is analyzed here in three different dimensions: the Symbolic, the Ontological, and the Epistemic. The first one points towards CERN as place where a cosmological game of probability is played with the help of Monte-Carlo simulations. The second one can be seen in the agonistic infrastructures of competing experimental collaborations. The third dimension unfolds in ludic platforms, such as online Challenges and citizen science games, which contribute to the development of machine learning algorithms, whose function is necessary in order to process the huge amount of data gathered from experimental events. Following Clifford Geertz, CERN itself is characterized as a site of deep play, a concept that contributes to understanding wider social and cultural orders through the analysis of ludic collective phenomena. The article also engages with Peter Galison's idea of the trading zone, proposing to comprehend it in the age of big data as a Playground. Thus the author hopes to contribute to a wider discussion in the historiographical and social study of science and technology, as well as in cultural anthropology, by recognizing the ludic in science as a central element of understanding collaborative knowledge production.

Role of the law in ensuring work related road safety.

PubMed

Griffith, Richard; Tengnah, Cassam

2007-12-01

Some 150 deaths and serious injuries are caused each week by people who were driving in the course of their work. The police, health and safety executive and government are seeking to improve this startling statistic by ensuring that organizations, including NHS Trusts, comply with health and safety law and fulfil their duty to carry out an assessment of risks associated with work related driving and implement a policy to minimize those risks. Failing to comply could result in prosecution by the police and health and safety executive.

Data acquisition using the 168/E. [CERN ISR

DOE Office of Scientific and Technical Information (OSTI.GOV)

Carroll, J.T.; Cittolin, S.; Demoulin, M.

1983-03-01

Event sizes and data rates at the CERN anti p p collider compose a formidable environment for a high level trigger. A system using three 168/E processors for experiment UA1 real-time event selection is described. With 168/E data memory expanded to 512K bytes, each processor holds a complete event allowing a FORTRAN trigger algorithm access to data from the entire detector. A smart CAMAC interface reads five Remus branches in parallel transferring one word to the target processor every 0.5 ..mu..s. The NORD host computer can simultaneously read an accepted event from another processor.

The evolution of the ISOLDE control system

NASA Astrophysics Data System (ADS)

Jonsson, O. C.; Catherall, R.; Deloose, I.; Evensen, A. H. M.; Gase, K.; Focker, G. J.; Fowler, A.; Kugler, E.; Lettry, J.; Olesen, G.; Ravn, H. L.; Drumm, P.

1996-04-01

The ISOLDE on-line mass separator facility is operating on a Personal Computer based control system since spring 1992. Front End Computers accessing the hardware are controlled from consoles running Microsoft Windows® through a Novell NetWare4® local area network. The control system is transparently integrated in the CERN wide office network and makes heavy use of the CERN standard office application programs to control and to document the running of the ISOLDE isotope separators. This paper recalls the architecture of the control system, shows its recent developments and gives some examples of its graphical user interface.

Enhancing moral agency: clinical ethics residency for nurses.

PubMed

Robinson, Ellen M; Lee, Susan M; Zollfrank, Angelika; Jurchak, Martha; Frost, Debra; Grace, Pamela

2014-09-01

One antidote to moral distress is stronger moral agency-that is, an enhanced ability to act to bring about change. The Clinical Ethics Residency for Nurses, an educational program developed and run in two large northeastern academic medical centers with funding from the Health Resources and Services Administration, intended to strengthen nurses' moral agency. Drawing on Improving Competencies in Clinical Ethics Consultation: An Education Guide, by the American Society for Bioethics and Humanities, and on the goals of the nursing profession, CERN sought to change attitudes, increase knowledge, and develop skills to act on one's knowledge. One of the key insights the faculty members brought to the design of this program is that knowledge of clinical ethics is not enough to develop moral agency. In addition to lecture-style classes, CERN employed a variety of methods based in adult learning theory, such as active application of ethics knowledge to patient scenarios in classroom discussion, simulation, and the clinical practicum. Overwhelmingly, the feedback from the participants (sixty-seven over three years of the program) indicated that CERN achieved transformative learning. © 2014 by The Hastings Center.

Novel approaches for inspiring students and electrifying the public

NASA Astrophysics Data System (ADS)

Lidström, Suzy; Read, Alex; Parke, Stephen; Allen, Roland; Goldfarb, Steven; Mehlhase, Sascha; Ekelöf, Tord; Walker, Alan

2014-03-01

We will briefly summarize a wide variety of innovative approaches for inspiring students and stimulating broad public interest in fundamental physics research, as exemplified by recent activities related to the Higgs boson discovery and Higgs-Englert Nobel Prize on behalf of the Swedish Academy, CERN, Fermilab, and the Niels Bohr Institute. Personal interactions with the scientists themselves can be particularly electrifying, and these were encouraged by the wearing of ``Higgs Boson? Ask Me!'' badges, which will be made available to those attending this talk. At CERN, activities include Virtual Visits, (Google) Hangout with CERN, initiatives to grab attention (LEGO models, music videos, art programs, pins, etc.), substantive communication (lab visits and events, museum exhibits, traveling exhibits, local visits, Masterclasses, etc.), and educational activities (summer student programs, semester abroad programs, internships, graduate programs, etc.). For serious students and their teachers, or scientists in other areas, tutorial articles are appropriate. These are most effective if they also incorporate innovative approaches - for example, attractive figures that immediately illustrate the concepts, analogies that will resonate with the reader, and a broadening of perspective. Physica Scripta, Royal Swedish Academy of Sciences.

Techniques for hazard analysis and their use at CERN.

PubMed

Nuttall, C; Schönbacher, H

2001-01-01

CERN, The European Organisation for Nuclear Research is situated near Geneva and has its accelerators and experimental facilities astride the Swiss and French frontiers attracting physicists from all over the world to this unique laboratory. The main accelerator is situated in a 27 km underground ring and the experiments take place in huge underground caverns in order to detect the fragments resulting from the collision of subatomic particles at speeds approaching that of light. These detectors contain many hundreds of tons of flammable materials, mainly plastics in cables and structural components, flammable gases in the detectors themselves, and cryogenic fluids such as helium and argon. The experiments consume high amounts of electrical power, thus the dangers involved have necessitated the use of analytical techniques to identify the hazards and quantify the risks to personnel and the infrastructure. The techniques described in the paper have been developed in the process industries where they have been to be of great value. They have been successfully applied to CERN industrial and experimental installations and, in some cases, have been instrumental in changing the philosophy of the experimentalists and their detectors.

Discussion map and cooking classes: testing the effectiveness of teaching food safety to immigrants and refugees.

PubMed

Gold, Abby; Yu, Nan; Buro, Brandy; Garden-Robinson, Julie

2014-01-01

To evaluate the effectiveness of a food safety map as an educational method with English language learners. English language learner community members (n = 73) were assigned randomly to participate in 1 of 3 experimental conditions: food safety map, cooking class, and control. Participants in the food safety map and cooking class conditions completed a pre-education demographic and cooking history questionnaire, a post-education knowledge and intention questionnaire, and a 2-week post-cooking and food safety habits assessment. Participants in the control group received no educational training but completed the pre- and 2-week post-education assessments. The cooking class and the map class were both effective in increasing food safety knowledge. Specifically, by comparing with the control group, they significantly increased participants' knowledge of safely cooking large meat (χ² [df = 2, n = 66] = 40.87; P < .001; V* = .79) and correctly refrigerating cooked food (χ² [df = 2, n = 73] = 24.87, P < .001; V* = .58). The two class types generated similar positive educational effects on boosting food safety behavioral intention (measured right after the class). The data collected 2 weeks after the classes suggested that individuals who took the classes followed the suggested food behaviors more closely than those in the control group (P < .01). The food safety map is simple to use and prepare, beneficial for oral and visual learners, and inexpensive. Compared with a food safety cooking class, the map produces similar learning and behavioral outcomes. Copyright © 2014 Society for Nutrition Education and Behavior. Published by Elsevier Inc. All rights reserved.

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.

PubMed

Adkinson, N Franklin; Strauss, William E; Macdougall, Iain C; Bernard, Kristine E; Auerbach, Michael; Kaper, Robert F; Chertow, Glenn M; Krop, Julie S

2018-05-01

Few trials have examined rates of hypersensitivity reactions (HSRs) with intravenous iron formulations used to treat iron deficiency anemia (IDA). This randomized, multicenter, double-blind clinical trial compared the safety, and efficacy of ferumoxytol versus ferric carboxymaltose (FCM), focusing on rates of HSRs and hypotension as the primary end point. Patients with IDA of any etiology in whom oral iron was unsatisfactory or intolerable received ferumoxytol (n = 997) or FCM (n = 1000) intravenously over ≥15 minutes on days 1 and 8 or 9 for total respective doses of 1.02 g and 1.50 g. Composite incidences of moderate-to-severe HSRs, including anaphylaxis, or moderate-to-severe hypotension from baseline to week 5 (primary safety end point) were 0.6% and 0.7% in the ferumoxytol and FCM groups, respectively, with ferumoxytol noninferior to FCM. No anaphylaxis was reported in either group. The secondary safety end point of incidences of moderate-to-severe HSRs, including anaphylaxis, serious cardiovascular events, and death from baseline to week 5 were 1.3% and 2.0% in the ferumoxytol and FCM groups, respectively (noninferiority test P < .0001). Least-squares mean changes in hemoglobin at week 5 were 1.4 g/dL and 1.6 g/dL in the ferumoxytol and FCM groups, respectively (noninferiority test P < .0001). Incidence of hypophosphatemia was 0.4% for ferumoxytol and 38.7% for FCM. © 2018 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.

PubMed

Yataba, Ikuko; Otsuka, Noboru; Matsushita, Isao; Matsumoto, Hideo; Hoshino, Yuichi

2016-08-01

The newly developed S-flurbiprofen plaster (SFPP) is a tape-type patch that shows innovative percutaneous absorption. This study was designed to evaluate the safety of a long-term 52-week SFPP application to osteoarthritis (OA) patients. This was a multi-center, open-label, uncontrolled prospective study that included 201 OA patients. SFPP at 40 mg/day was applied to the site of pain in 101 patients and at 80 mg/day (2 patches) in 100 patients at a total of 301 sites for 52 weeks. The affected sites assessed included the knee (192), lumbar spine (66), cervical spine (26), and others (17). Drug safety was evaluated by medical examination, laboratory tests, and examination of vital signs. Efficacy was evaluated by the patient's and clinician's global assessments and clinical symptoms. Most patients (80.1 %) completed the 52-week SFPP application. The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46.8 % of the sites. No photosensitive dermatitis was observed. Systemic AEs occurred in 9.0 % of the patients; a serious AE (gastric ulcer hemorrhage) occurred in one patient. No clinically significant changes in the laboratory tests and vital signs were observed. The efficacy evaluation showed an improvement from 2 weeks after the SFPP application, which continued during the 52 weeks' treatment. No apparent safety concerns were observed, even during the long-term SFPP application. Therefore, SFPP could be an additional pharmacotherapy in OA treatment.

Helix Nebula and CERN: A Symbiotic approach to exploiting commercial clouds

NASA Astrophysics Data System (ADS)

Barreiro Megino, Fernando H.; Jones, Robert; Kucharczyk, Katarzyna; Medrano Llamas, Ramón; van der Ster, Daniel

2014-06-01

The recent paradigm shift toward cloud computing in IT, and general interest in "Big Data" in particular, have demonstrated that the computing requirements of HEP are no longer globally unique. Indeed, the CERN IT department and LHC experiments have already made significant R&D investments in delivering and exploiting cloud computing resources. While a number of technical evaluations of interesting commercial offerings from global IT enterprises have been performed by various physics labs, further technical, security, sociological, and legal issues need to be address before their large-scale adoption by the research community can be envisaged. Helix Nebula - the Science Cloud is an initiative that explores these questions by joining the forces of three European research institutes (CERN, ESA and EMBL) with leading European commercial IT enterprises. The goals of Helix Nebula are to establish a cloud platform federating multiple commercial cloud providers, along with new business models, which can sustain the cloud marketplace for years to come. This contribution will summarize the participation of CERN in Helix Nebula. We will explain CERN's flagship use-case and the model used to integrate several cloud providers with an LHC experiment's workload management system. During the first proof of concept, this project contributed over 40.000 CPU-days of Monte Carlo production throughput to the ATLAS experiment with marginal manpower required. CERN's experience, together with that of ESA and EMBL, is providing a great insight into the cloud computing industry and highlighted several challenges that are being tackled in order to ease the export of the scientific workloads to the cloud environments.

Comparison of electromagnetic and hadronic models generated using Geant 4 with antiproton dose measured in CERN.

PubMed

Tavakoli, Mohammad Bagher; Reiazi, Reza; Mohammadi, Mohammad Mehdi; Jabbari, Keyvan

2015-01-01

After proposing the idea of antiproton cancer treatment in 1984 many experiments were launched to investigate different aspects of physical and radiobiological properties of antiproton, which came from its annihilation reactions. One of these experiments has been done at the European Organization for Nuclear Research known as CERN using the antiproton decelerator. The ultimate goal of this experiment was to assess the dosimetric and radiobiological properties of beams of antiprotons in order to estimate the suitability of antiprotons for radiotherapy. One difficulty on this way was the unavailability of antiproton beam in CERN for a long time, so the verification of Monte Carlo codes to simulate antiproton depth dose could be useful. Among available simulation codes, Geant4 provides acceptable flexibility and extensibility, which progressively lead to the development of novel Geant4 applications in research domains, especially modeling the biological effects of ionizing radiation at the sub-cellular scale. In this study, the depth dose corresponding to CERN antiproton beam energy by Geant4 recruiting all the standard physics lists currently available and benchmarked for other use cases were calculated. Overall, none of the standard physics lists was able to draw the antiproton percentage depth dose. Although, with some models our results were promising, the Bragg peak level remained as the point of concern for our study. It is concluded that the Bertini model with high precision neutron tracking (QGSP_BERT_HP) is the best to match the experimental data though it is also the slowest model to simulate events among the physics lists.

The impact of nurse working hours on patient safety culture: a cross-national survey including Japan, the United States and Chinese Taiwan using the Hospital Survey on Patient Safety Culture.

PubMed

Wu, Yinghui; Fujita, Shigeru; Seto, Kanako; Ito, Shinya; Matsumoto, Kunichika; Huang, Chiu-Chin; Hasegawa, Tomonori

2013-10-07

A positive patient safety culture (PSC) is one of the most critical components to improve healthcare quality and safety. The Hospital Survey on Patient Safety Culture (HSOPS), developed by the US Agency for Healthcare Research and Quality, has been used to assess PSC in 31 countries. However, little is known about the impact of nurse working hours on PSC. We hypothesized that long nurse working hours would deteriorate PSC, and that the deterioration patterns would vary between countries. Moreover, the common trends observed in Japan, the US and Chinese Taiwan may be useful to improve PSC in other countries. The purpose of this study was to clarify the impact of long nurse working hours on PSC in Japan, the US, and Chinese Taiwan using HSOPS. The HSOPS questionnaire measures 12 sub-dimensions of PSC, with higher scores indicating a more positive PSC. Odds ratios (ORs) were calculated using a generalized linear mixed model to evaluate the impact of working hours on PSC outcome measures (patient safety grade and number of events reported). Tukey's test and Cohen's d values were used to verify the relationships between nurse working hours and the 12 sub-dimensions of PSC. Nurses working ≥60 h/week in Japan and the US had a significantly lower OR for patient safety grade than those working <40 h/week. In the three countries, nurses working ≥40 h/week had a significantly higher OR for the number of events reported. The mean score on 'staffing' was significantly lower in the ≥60-h group than in the <40-h group in all the three countries. The mean score for 'teamwork within units' was significantly lower in the ≥60-h group than in the <40-h group in Japan and Chinese Taiwan. Patient safety grade deteriorated and the number of events reported increased with long working hours. Among the 12 sub-dimensions of PSC, long working hours had an impact on 'staffing' and 'teamwork within units' in Japan, the US and Chinese Taiwan.

Outsourcing strategy and tendering methodology for the operation and maintenance of CERN’s cryogenic facilities

NASA Astrophysics Data System (ADS)

Serio, L.; Bremer, J.; Claudet, S.; Delikaris, D.; Ferlin, G.; Ferrand, F.; Pezzetti, M.; Pirotte, O.

2017-12-01

CERN operates and maintains the world largest cryogenic infrastructure ranging from ageing but well maintained installations feeding detectors, test facilities and general services, to the state-of-the-art cryogenic system serving the flagship LHC machine complex. A study was conducted and a methodology proposed to outsource to industry the operation and maintenance of the whole cryogenic infrastructure. The cryogenic installations coupled to non LHC-detectors, test facilities and general services infrastructure have been fully outsourced for operation and maintenance on the basis of performance obligations. The contractor is responsible for the operational performance of the installations based on a yearly operation schedule provided by CERN. The maintenance of the cryogenic system serving the LHC machine and its detectors has been outsourced on the basis of tasks oriented obligations, monitored by key performance indicators. CERN operation team, with the support of the contractor operation team, remains responsible for the operational strategy and performances. We report the analysis, strategy, definition of the requirements and technical specifications as well as the achieved technical and economic performances after one year of operation.

Analysis of SEL on Commercial SRAM Memories and Mixed-Field Characterization of a Latchup Detection Circuit for LEO Space Applications

NASA Astrophysics Data System (ADS)

Secondo, R.; Alía, R. Garcia; Peronnard, P.; Brugger, M.; Masi, A.; Danzeca, S.; Merlenghi, A.; Vaillé, J.-R.; Dusseau, L.

2017-08-01

A single event latchup (SEL) experiment based on commercial static random access memory (SRAM) memories has recently been proposed in the framework of the European Organization for Nuclear Research (CERN) Latchup Experiment and Student Satellite nanosatellite low Earth orbit (LEO) space mission. SEL characterization of three commercial SRAM memories has been carried out at the Paul Scherrer Institut (PSI) facility, using monoenergetic focused proton beams and different acquisition setups. The best target candidate was selected and a circuit for SEL detection has been proposed and tested at CERN, in the CERN High Energy AcceleRator Mixed-field facility (CHARM). Experimental results were carried out at test locations representative of the LEO environment, thus providing a full characterization of the SRAM cross sections, together with the analysis of the single-event effect and total ionizing dose of the latchup detection circuit in relation to the particle spectra expected during mission. The setups used for SEL monitoring are described, and details of the proposed circuit components and topology are presented. Experimental results obtained both at PSI and at CHARM facilities are discussed.

Novel apparatus and methods for performing remotely controlled particle-solid interaction experiments at CERN

NASA Astrophysics Data System (ADS)

Krause, H. F.; Deveney, E. F.; Jones, N. L.; Vane, C. R.; Datz, S.; Knudsen, H.; Grafström, P.; Schuch, R.

1997-04-01

Recent atomic physics studies involving ultrarelativistic Pb ions required solid target positioners, scintillators, and a sophisticated data acquisition and control system placed in a remote location at the CERN Super Proton Synchrotron near Geneva, Switzerland. The apparatus, installed in a high-radiation zone underground, had to (i) function for months, (ii) automatically respond to failures such as power outages and particle-induced computer upsets, and (iii) communicate with the outside world via a telephone line. The heart of the apparatus developed was an Apple Macintosh-based CAMAC system that answered the telephone and interpreted and executed remote control commands that (i) sensed and set targets, (ii) controlled voltages and discriminator levels for scintillators, (iii) modified data acquisition hardware logic, (iv) reported control information, and (v) automatically synchronized data acquisition to the CERN spill cycle via a modem signal and transmitted experimental data to a remote computer. No problems were experienced using intercontinental telephone connections at 1200 baud. Our successful "virtual laboratory" approach that uses off-the-shelf electronics is generally adaptable to more conventional bench-type experiments.

Monitoring Evolution at CERN

NASA Astrophysics Data System (ADS)

Andrade, P.; Fiorini, B.; Murphy, S.; Pigueiras, L.; Santos, M.

2015-12-01

Over the past two years, the operation of the CERN Data Centres went through significant changes with the introduction of new mechanisms for hardware procurement, new services for cloud provisioning and configuration management, among other improvements. These changes resulted in an increase of resources being operated in a more dynamic environment. Today, the CERN Data Centres provide over 11000 multi-core processor servers, 130 PB disk servers, 100 PB tape robots, and 150 high performance tape drives. To cope with these developments, an evolution of the data centre monitoring tools was also required. This modernisation was based on a number of guiding rules: sustain the increase of resources, adapt to the new dynamic nature of the data centres, make monitoring data easier to share, give more flexibility to Service Managers on how they publish and consume monitoring metrics and logs, establish a common repository of monitoring data, optimise the handling of monitoring notifications, and replace the previous toolset by new open source technologies with large adoption and community support. This contribution describes how these improvements were delivered, present the architecture and technologies of the new monitoring tools, and review the experience of its production deployment.

LHC, le Big Bang en éprouvette

ScienceCinema

None

2017-12-09

Notre compréhension de l’Univers est en train de changer… Bar des Sciences - Tout public Débat modéré par Marie-Odile Montchicourt, journaliste de France Info. Evenement en vidéoconférence entre le Globe de la science et de l’innovation, le bar le Baloard de Montpellier et la Maison des Métallos à Paris. Intervenants au CERN : Philippe Charpentier et Daniel Froideveaux, physiciens au CERN. Intervenants à Paris : Vincent Bontemps, philosophe et chercheur au CEA ; Jacques Arnould, philosophe, historien des sciences et théologien, Jean-Jacques Beineix, réalisateur, producteur, scénariste de cinéma. Intervenants à Montpellier (LPTA) : André Neveu, physicien théoricien et directeur de recherche au CNRS ; Gilbert Moultaka, physicien théoricien et chargé de recherche au CNRS. Partenariat : CERN, CEA, IN2P3, Université MPL2 (LPTA) Dans le cadre de la Fête de la science 2008

ALICE inner tracking system readout electronics prototype testing with the CERN "Giga Bit Transceiver''

DOE Office of Scientific and Technical Information (OSTI.GOV)

Schambach, Joachim; Rossewij, M. J.; Sielewicz, K. M.

The ALICE Collaboration is preparing a major detector upgrade for the LHC Run 3, which includes the construction of a new silicon pixel based Inner Tracking System (ITS). The ITS readout system consists of 192 readout boards to control the sensors and their power system, receive triggers, and deliver sensor data to the DAQ. To prototype various aspects of this readout system, an FPGA based carrier board and an associated FMC daughter card containing the CERN Gigabit Transceiver (GBT) chipset have been developed. Furthermore, this contribution describes laboratory and radiation testing results with this prototype board set.

New radiation protection calibration facility at CERN.

PubMed

Brugger, Markus; Carbonez, Pierre; Pozzi, Fabio; Silari, Marco; Vincke, Helmut

2014-10-01

The CERN radiation protection group has designed a new state-of-the-art calibration laboratory to replace the present facility, which is >20 y old. The new laboratory, presently under construction, will be equipped with neutron and gamma sources, as well as an X-ray generator and a beta irradiator. The present work describes the project to design the facility, including the facility placement criteria, the 'point-zero' measurements and the shielding study performed via FLUKA Monte Carlo simulations. © The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

ALICE inner tracking system readout electronics prototype testing with the CERN ``Giga Bit Transceiver''

NASA Astrophysics Data System (ADS)

Schambach, J.; Rossewij, M. J.; Sielewicz, K. M.; Aglieri Rinella, G.; Bonora, M.; Ferencei, J.; Giubilato, P.; Vanat, T.

2016-12-01

The ALICE Collaboration is preparing a major detector upgrade for the LHC Run 3, which includes the construction of a new silicon pixel based Inner Tracking System (ITS). The ITS readout system consists of 192 readout boards to control the sensors and their power system, receive triggers, and deliver sensor data to the DAQ. To prototype various aspects of this readout system, an FPGA based carrier board and an associated FMC daughter card containing the CERN Gigabit Transceiver (GBT) chipset have been developed. This contribution describes laboratory and radiation testing results with this prototype board set.

Search for the 1P 1 charmonium state in overlinepp annihilations at the CERN intersecting storage rings

NASA Astrophysics Data System (ADS)

Baglin, C.; Baird, S.; Bassompierre, G.; Borreani, G.; Brient, J.-C.; Broll, C.; Brom, J.-M.; Bugge, L.; Buran, T.; Burq, J.-P.; Bussière, A.; Buzzo, A.; Cester, R.; Chemarin, M.; Chevallier, M.; Escoubes, B.; Fay, J.; Ferroni, S.; Gracco, V.; Guillaud, J.-P.; Khan-Aronsen, E.; Kirsebom, K.; Kylling, A.; Ille, B.; Lambert, M.; Leistam, L.; Lundby, A.; Macri, M.; Marchetto, F.; Menichetti, E.; Mörch, Ch.; Mouellic, B.; Olsen, D.; Pastrone, N.; Petrillo, L.; Pia, M. G.; Poole, J.; Poulet, M.; Rinaudo, G.; Santroni, A.; Severi, M.; Skjevling, G.; Stapnes, S.; Stugu, B.; R704 Collaboration

1986-04-01

This experiment has been performed at the CERN Intersecting Storage Rings to study the direct formation of charmonium states in antiproton-proton annihilations. The experimental program has partly been devoted to an inclusive scan for overlinepp → J/ψ + X in the range 3520-3530 MeV/ c2. A cluster of five events has been observed in a narrow energy band, centred on the centre of gravity of the 3P J states where the 1P 1 is expected to be. When interpreted as a new resonace, these data yield a mass m = 3525.4±0.8 MeV/ c2.

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study

PubMed Central

Handley, Alison; Lloyd, Eric; Roberts, Andrew; Barger, Bruce

2016-01-01

Abstract This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). All subjects (n = 669) initiated AZL-M 40 mg QD, force-titrated to 80 mg QD at week 4, if tolerated. From week 8, subjects could receive additional medications, starting with chlorthalidone (CLD) 25 mg QD (Cohort 1) or hydrochlorothiazide (HCTZ) 12.5–25 mg QD (Cohort 2), if required, to reach BP targets. Adverse events (AEs) were reported in 75.9% of subjects overall in the two cohorts (73.8% Cohort 1, 78.5% Cohort 2). The most common AEs were dizziness (14.3%), headache (9.9%) and fatigue (7.2%). Transient serum creatinine elevations were more frequent with add-on CLD. Clinic systolic/diastolic BP (observed cases at week 56) decreased by 25.2/18.4 mmHg (Cohort 1) and 24.2/17.9 mmHg (Cohort 2). These results demonstrate that AZL-M is well tolerated over the long term and provides stable BP improvements when used in a treat-to-target BP approach with thiazide-type diuretics. PMID:26817604

Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.

PubMed

Hasanzadeh, Hournaz; Nasrollahi, Saman Ahmad; Halavati, Nader; Saberi, Maryam; Firooz, Alireza

2016-09-01

Male pattern hair loss is widespread around the world. Its prevalence indicates the importance of finding the best treatment modalities. This study evaluates the efficacy and safety of minoxidil 5% topical foam in male pattern hair loss treatment and patient satisfaction. This study was a before-and-after trial on 17 male patients with male pattern hair loss. Subjects were instructed to apply one capful (1 ml) of minoxidil 5% topical foam on the scalp daily for 6 months. Efficacy was assessed through hair counts, subject assessment, and global photographic review. Seventeen male volunteers were recruited, and three volunteers were withdrawn; 14 participated in the trial for 16 weeks, and 12 continued up to 24 weeks. The average hair count with a camera at week 16 (181.87 ± 52.42) and week 24 (194.58 ± 62.82) and with an eye count at week 16 (62.57 ± 15.28) and week 24 (69.91 ± 15.61) increased significantly compared to the baseline after intervention. This study confirmed that minoxidil 5% topical foam is a safe and effective treatment for MPHL. The effect of it is evident after 24 weeks of use.

Future Approach to tier-0 extension

NASA Astrophysics Data System (ADS)

Jones, B.; McCance, G.; Cordeiro, C.; Giordano, D.; Traylen, S.; Moreno García, D.

2017-10-01

The current tier-0 processing at CERN is done on two managed sites, the CERN computer centre and the Wigner computer centre. With the proliferation of public cloud resources at increasingly competitive prices, we have been investigating how to transparently increase our compute capacity to include these providers. The approach taken has been to integrate these resources using our existing deployment and computer management tools and to provide them in a way that exposes them to users as part of the same site. The paper will describe the architecture, the toolset and the current production experiences of this model.

W production at large transverse momentum at the CERN Large Hadron Collider.

PubMed

Gonsalves, Richard J; Kidonakis, Nikolaos; Sabio Vera, Agustín

2005-11-25

We study the production of W bosons at large transverse momentum in pp collisions at the CERN Large Hadron Collider. We calculate the complete next-to-leading order (NLO) corrections to the differential cross section. We find that the NLO corrections provide a large increase to the cross section but, surprisingly, do not reduce the scale dependence relative to leading order (LO). We also calculate next-to-next-to-leading-order (NNLO) soft-gluon corrections and find that, although they are small, they significantly reduce the scale dependence thus providing a more stable result.

The evolution of the ISOLDE control system

NASA Astrophysics Data System (ADS)

Jonsson, O. C.; Catherall, R.; Deloose, I.; Drumm, P.; Evensen, A. H. M.; Gase, K.; Focker, G. J.; Fowler, A.; Kugler, E.; Lettry, J.; Olesen, G.; Ravn, H. L.; Isolde Collaboration

The ISOLDE on-line mass separator facility is operating on a Personal Computer based control system since spring 1992. Front End Computers accessing the hardware are controlled from consoles running Microsoft Windows ™ through a Novell NetWare4 ™ local area network. The control system is transparently integrated in the CERN wide office network and makes heavy use of the CERN standard office application programs to control and to document the running of the ISOLDE isotope separators. This paper recalls the architecture of the control system, shows its recent developments and gives some examples of its graphical user interface.

Anomalous single production of the fourth generation quarks at the CERN LHC

DOE Office of Scientific and Technical Information (OSTI.GOV)

Ciftci, R.

Possible anomalous single productions of the fourth standard model generation up and down type quarks at CERN Large Hadron Collider are studied. Namely, pp{yields}u{sub 4}(d{sub 4})X with subsequent u{sub 4}{yields}bW{sup +} process followed by the leptonic decay of the W boson and d{sub 4}{yields}b{gamma} (and its H.c.) decay channel are considered. Signatures of these processes and corresponding standard model backgrounds are discussed in detail. Discovery limits for the quark mass and achievable values of the anomalous coupling strength are determined.

ALICE inner tracking system readout electronics prototype testing with the CERN "Giga Bit Transceiver''

DOE PAGES

Schambach, Joachim; Rossewij, M. J.; Sielewicz, K. M.; ...

2016-12-28

The ALICE Collaboration is preparing a major detector upgrade for the LHC Run 3, which includes the construction of a new silicon pixel based Inner Tracking System (ITS). The ITS readout system consists of 192 readout boards to control the sensors and their power system, receive triggers, and deliver sensor data to the DAQ. To prototype various aspects of this readout system, an FPGA based carrier board and an associated FMC daughter card containing the CERN Gigabit Transceiver (GBT) chipset have been developed. Furthermore, this contribution describes laboratory and radiation testing results with this prototype board set.

HIGH ENERGY PHYSICS: CERN Link Breathes Life Into Russian Physics.

PubMed

Stone, R

2000-10-13

Without fanfare, 600 Russian scientists here at CERN, the European particle physics laboratory, are playing key roles in building the Large Hadron Collider (LHC), a machine that will explore fundamental questions such as why particles have mass, as well as search for exotic new particles whose existence would confirm supersymmetry, a popular theory that aims to unify the four forces of nature. In fact, even though Russia is not one of CERN's 20 member states, most top high-energy physicists in Russia are working on the LHC. Some say their work could prove the salvation of high-energy physics back home.

33 CFR 165.1330 - Safety Zone; Fleet Week Maritime Festival, Pier 66, Elliott Bay, Seattle, Washington.

Code of Federal Regulations, 2014 CFR

2014-07-01

..., Seattle, Washington. (a) Location. The following area is a safety zone: All waters extending 100 yards... minutes following the conclusion of the Parade of Ships. For the purpose of this rule, the Parade of Ships includes both the pass and review of the ships near Pier 66 and the aerial demonstrations immediately...

A Pilot Study of Safety and Efficacy of Cranial Electrotherapy Stimulation in Treatment of Bipolar II Depression.

PubMed

McClure, Deimante; Greenman, Samantha C; Koppolu, Siva Sundeep; Varvara, Maria; Yaseen, Zimri S; Galynker, Igor I

2015-11-01

This double-blind, sham-controlled study sought to investigate the effectiveness of cranial electrotherapy stimulation (CES) for the treatment of bipolar II depression (BD II). After randomization, the active group participants (n = 7) received 2 mA CES treatment for 20 minutes five days a week for 2 weeks, whereas the sham group (n = 9) had the CES device turned on and off. Symptom non-remitters from both groups received an additional 2 weeks of open-label active treatment. Active CES treatment but not sham treatment was associated with a significant decrease in the Beck Depression Inventory (BDI) scores from baseline to the second week (p = 0.003) maintaining significance until week 4 (p = 0.002). There was no difference between the groups in side effects frequency. The results of this small study indicate that CES may be a safe and effective treatment for BD II suggesting that further studies on safety and efficacy of CES may be warranted.

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.

PubMed

Handley, Alison; Lloyd, Eric; Roberts, Andrew; Barger, Bruce

2016-01-01

This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). All subjects (n = 669) initiated AZL-M 40 mg QD, force-titrated to 80 mg QD at week 4, if tolerated. From week 8, subjects could receive additional medications, starting with chlorthalidone (CLD) 25 mg QD (Cohort 1) or hydrochlorothiazide (HCTZ) 12.5-25 mg QD (Cohort 2), if required, to reach BP targets. Adverse events (AEs) were reported in 75.9% of subjects overall in the two cohorts (73.8% Cohort 1, 78.5% Cohort 2). The most common AEs were dizziness (14.3%), headache (9.9%) and fatigue (7.2%). Transient serum creatinine elevations were more frequent with add-on CLD. Clinic systolic/diastolic BP (observed cases at week 56) decreased by 25.2/18.4 mmHg (Cohort 1) and 24.2/17.9 mmHg (Cohort 2). These results demonstrate that AZL-M is well tolerated over the long term and provides stable BP improvements when used in a treat-to-target BP approach with thiazide-type diuretics.

Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance.

PubMed

Kameda, Hideto; Nishida, Keiichiro; Nannki, Toshihiro; Watanabe, Akira; Oshima, Yukiya; Momohara, Shigaki

2017-01-01

Objective: To evaluate the safety and effectiveness of certolizumab pegol (CZP) in a real-world setting among Japanese patients with rheumatoid arthritis. Post-marketing surveillance data from 2,579 patients treated with CZP were analyzed. Adverse events (AEs) observed during the 24-week CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR and DAS28-CRP at baseline, Week 12, Week 24, or at withdrawal. The total period of exposure to CZP was 1313.8 patient-years (PY). AEs were reported in 658 (25.5%) patients, at an event rate (ER) of 73.68/100 PY. The most frequent serious AEs were pneumonia, herpes zoster, and interstitial lung disease, at ER per 100 PY of 2.06, 1.29, and 1.22, respectively. Mean disease activity scores at baseline, as measured by DAS28-ESR and DAS28-CRP, were 4.77 ± 1.34 and 4.21 ± 1.27, respectively. Mean changes from baseline at the last observation were -1.29 ± 1.46 and -1.30 ± 1.42, respectively. EULAR good or moderate responses were achieved in 65% of patients. Longer disease duration, prior biologics use, and treatment without MTX co-therapy were associated with EULAR no response. In this interim analysis, no new safety signals were observed. Clinical response to CZP was observed in approximately two thirds of patients.

A Pilot Study of Safety and Efficacy of Cranial Electrotherapy Stimulation in Treatment of Bipolar II Depression

PubMed Central

McClure, Deimante; Greenman, Samantha C.; Koppolu, Siva Sundeep; Varvara, Maria; Yaseen, Zimri S.; Galynker, Igor I.

2015-01-01

Abstract This double-blind, sham-controlled study sought to investigate the effectiveness of cranial electrotherapy stimulation (CES) for the treatment of bipolar II depression (BD II). After randomization, the active group participants (n = 7) received 2 mA CES treatment for 20 minutes five days a week for 2 weeks, whereas the sham group (n = 9) had the CES device turned on and off. Symptom non-remitters from both groups received an additional 2 weeks of open-label active treatment. Active CES treatment but not sham treatment was associated with a significant decrease in the Beck Depression Inventory (BDI) scores from baseline to the second week (p = 0.003) maintaining significance until week 4 (p = 0.002). There was no difference between the groups in side effects frequency. The results of this small study indicate that CES may be a safe and effective treatment for BD II suggesting that further studies on safety and efficacy of CES may be warranted. PMID:26414234

A 52-week safety study in cynomolgus macaques for genetically modified rice expressing Cry1Ab/1Ac protein.

PubMed

Mao, Jie; Sun, Xing; Cheng, Jian-Hua; Shi, Yong-Jie; Wang, Xin-Zheng; Qin, Jun-Jie; Sang, Zhi-Hong; He, Kun; Xia, Qing

2016-09-01

A 52-week feeding study in cynomolgus macaques was carried out to evaluate the safety of Bt rice Huahui 1 (HH1), a transgenic rice line expressing Cry1Ab/1Ac protein. Monkeys were fed a diet with 20% or 60% HH1 rice, 20% or 60% parental rice (Minghui 63, MH63), normal diet, normal diet spiked with purified recombinant Cry1Ab/1Ac fusion protein or bovine serum albumin (BSA) respectively. During the feeding trail, clinical observations were conducted daily, and multiple parameters, including body weight, body temperature, electrocardiogram, hematology, blood biochemistry, serum metabolome and gut microbiome were examined at regular intervals. Upon sacrifice, the organs were weighted, and the macroscopic, microscopic and electron microscopic examinations were performed. The results show no adverse or toxic effects of Bt rice HH1 or Cry1Ab/1Ac fusion protein on monkeys. Therefore, the present 52-week primate feeding study suggests that the transgenic rice containing Cry 1Ab/1Ac is equivalent to its parental rice line MH63. Copyright © 2016 Elsevier Ltd. All rights reserved.

33 CFR 165.1330 - Safety Zone; Fleet Week Maritime Festival, Pier 66, Elliott Bay, Seattle, Washington.

Code of Federal Regulations, 2011 CFR

2011-07-01

..., Seattle, Washington. (a) Location. The following area is a safety zone: All waters extending 100 yards... minutes following the conclusion of the Parade of Ships. For the purpose of this rule, the Parade of Ships includes both the pass and review of the ships near Pier 66 and the aerial demonstrations immediately...

Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD

ERIC Educational Resources Information Center

Greenhill, Laurence; Kollins, Scott; Abikoff, Howard; McCracken, James; Riddle, Mark; Swanson, James; McGough, James; Wigal, Sharon; Wigal, Tim; Vitiello, Benedetto; Skrobala, Anne; Posner, Kelly; Ghuman, Jaswinder; Cunningham, Charles; Davies, Mark; Chuang, Shirley; Cooper, Tom

2006-01-01

Objective: The Preschool ADHD Treatment Study (PATS) was a NIMH-funded, six-center, randomized, controlled trial to determine the efficacy and safety of immediate-release methylphenidate (MPH-IR), given t.i.d. to children ages 3 to 5.5 years with attention-deficit/hyperactivity disorder (ADHD). Method: The 8-phase, 70-week PATS protocol included…

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.

PubMed

Colonna, Lucien; Andersen, Henning Friis; Reines, Elin Heldbo

2005-10-01

A randomized, double-blind, 24-week-fixed-dose study comparing the efficacy and safety of escitalopram to that of citalopram was safety was conducted in primary care patients with moderate to severe major depressive disorder (MDD). This was a randomized, double-blind, 24-week fixeddose study. Patients were randomly assigned to treatment with escitalopram 10 mg/day (n = 175) or citalopram 20 mg/day (n = 182). Clinical response was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) and Clinical Global Impression-Severity (CGI-S) scale. The prospectively defined primary parameter of antidepressant efficacy was the change from baseline in the mean MADRS total score during the 24 weeks of double-blind treatment, using a repeated measures analysis of variance to compare the treatment groups over all assessment points simultaneously. Based on the primary parameter, escitalopram was at least as efficacious as citalopram. Based on the prospectively defined secondary parameter, mean change from baseline in the CGI-S score, escitalopram was statistically significantly superior to citalopram at Week 24. The importance of long-term treatment could be demonstrated, in that more than half (55% and 51%) of the patients who had not responded by Week 8 achieved remission by Week 24. Both escitalopram and citalopram were safe and well tolerated in acute and long-term treatment, and the overall adverse event profiles for the two drugs were similar. For the intent-to-treat population, there were statistically significantly fewer withdrawals in the escitalopram group than in the citalopram group, particularly after Week 8. Patients with MDD responded well to long-term treatment with either escitalopram or citalopram. This study demonstrated the importance of extending treatment of depression beyond 8 weeks.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

PubMed

Tanaka, Yoshiya; Takeuchi, Tsutomu; Yamanaka, Hisashi; Nakamura, Hiroyuki; Toyoizumi, Shigeyuki; Zwillich, Samuel

2015-07-01

To evaluate oral tofacitinib versus placebo for treatment of active rheumatoid arthritis in Japanese patients with inadequate response to disease-modifying antirheumatic drugs. In this double-blind, placebo-controlled, randomized, parallel-group, 12-week, phase 2 study (clinicaltrials.gov NCT00687193), 317 patients received tofacitinib: 1, 3, 5, 10, or 15 mg as monotherapy or placebo twice daily (BID). response rate by American College of Rheumatology (ACR) ≥ 20% improvement criteria (ACR20) at week 12. ACR20 response rates: 37.7% (20/53), 67.9% (36/53), 73.1% (38/52), 84.9% (45/53), and 90.7% (49/54) with tofacitinib: 1, 3, 5, 10, and 15 mg BID, respectively, versus 15.4% (8/52) with placebo (p < 0.01; all doses). Dose-dependent ACR20 responses with tofacitinib versus placebo occurred from week 2 onward (p < 0.05). Changes from baseline in 28-joint disease activity score using erythrocyte sedimentation rate improved with tofacitinib versus placebo from week 4 (p < 0.01; all doses). Six tofacitinib patients experienced treatment-related serious adverse events (AEs). Most common treatment-emergent AEs: nasopharyngitis (10% vs 12%) and hyperlipidemia (5% vs 0%). Serum creatinine, hemoglobin, and total-, low-, and high-density lipoprotein-cholesterol levels increased with tofacitinib. Tofacitinib produced dose-dependent ACR20 responses and reduced disease activity. The safety profile was consistent with that reported from global monotherapy trials.

Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.

PubMed

Ishigooka, Jun; Iwashita, Shuichi; Tadori, Yoshihiro

2018-06-01

This study assessed the long-term safety, tolerability, and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia. This 52-week, open-label, flexible-dose (1-4 mg/day) study included patients with schizophrenia who continued treatment from a short-term randomized placebo-controlled fixed-dose (1, 2, or 4 mg/day) trial and de novo patients who switched from other antipsychotics. A total of 282 patients (184 de novo and 98 rolled over from short-term trial) entered the 52-week treatment with brexpiprazole, and 150 (53.2%) patients completed the week-52 assessment. Treatment-emergent adverse events (TEAE) were experienced by 235/281 patients (83.6%), and TEAE reported by ≥10% of all patients were nasopharyngitis (23.1%) and worsening of schizophrenia (22.4%). During the study, most of the TEAE were mild or moderate in severity, and there were no deaths, and no clinically meaningful mean changes in laboratory values, vital signs, or electrocardiogram parameters. Mean scores for the Positive and Negative Syndrome Scale total and Clinical Global Impression-Severity remained stable until week 52. Brexpiprazole was generally safe and well tolerated and maintained therapeutic effects in the long-term treatment of Japanese patients with schizophrenia. © 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.

Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials

PubMed Central

Zhang, Zong Mei; Li, Wei; Jiang, Xue Liang

2016-01-01

Background/Aims To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. Methods Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. UC-related randomized controlled trials (RCTs) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. Results This meta-analysis included three RCTs. ADA was considerably more effective compared with a placebo, and it increased the ratio of patients with clinical remission, clinical responses, mucosal healing and inflammatory bowel disease questionnaire responses in the induction and maintenance phases (p<0.05), as well as patients with steroid-free remission (p<0.05) during the maintenance phase. Clinical remission was achieved in a greater number of UC cases in the ADA 160/80/40 mg groups (0/2/4 week, every other week) compared with the placebo group at week 8 (p=0.006) and week 52 (p=0.0002), whereas the week 8 clinical remission rate was equivalent between the ADA 80/40 mg groups and the placebo group. Among the patients who received immunomodulators (IMM) at baseline, ADA was superior to the placebo in terms of inducing clinical remission (p=0.01). Between-group differences were not observed in terms of serious adverse events (p=0.61). Conclusions ADA, particularly at doses of 160/80/40 mg (0/2/4 week, every other week), is effective and safe in patients with moderate-to-severe UC who are unresponsive to traditional treatment. Concomitant IMM therapy may improve the short-term therapeutic efficacy of ADA. PMID:26780088

Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.

PubMed

Jafarinia, Morteza; Afarideh, Mohsen; Tafakhori, Abbas; Arbabi, Mohammad; Ghajar, Alireza; Noorbala, Ahmad Ali; Saravi, Maryam Alamdar; Agah, Elmira; Akhondzadeh, Shahin

2016-11-01

Ketamine is a glutamate N-methyl-d-aspartate receptor antagonist capable of exerting antidepressive effects in single or repeated intravenous infusions. The objective of this study was to investigate the safety and the efficacy of oral ketamine vs. diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain. This study is a 6-week, randomized, double-blind, controlled, parallel-group trial with two intervention arms (ketamine, fixed daily dosage of 150mg vs. diclofenac, fixed daily dosage of 150mg). Twenty participants in each arm completed the trial program all of whom had two post-baseline measurements at week 3 and week 6. Reduction in depression symptoms was assessed using the Hamilton Depression Rating Scale (HDRS) and the hospital anxiety and depression subscale for depression (HADSDepression) scores at baseline and week 3 and week 6 post-intervention. Significantly lower HDRS scores were observed in the ketamine treatment group as early as 6 weeks post-intervention (P=0.008). By comparison, mean (±standard deviation) HADS depression subscale scores were significantly lower for individuals receiving ketamine compared to diclofenac for both post-baseline measures at week 3 (6.95±1.47 vs. 8.40±1.6, P=0.005) and week 6 (6.20±1.15 vs. 7.35±1.18, p=0.003). The limitations of the present study were its small sample size and the short-term follow-up period. Oral ketamine appears to be a safe and effective option in improving depressive symptoms of patients with chronic pain with mild-to-moderate depression. Copyright © 2016 Elsevier B.V. All rights reserved.

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.

PubMed

Maksymowych, Walter P; Dougados, Maxime; van der Heijde, Désirée; Sieper, Joachim; Braun, Jürgen; Citera, Gustavo; Van den Bosch, Filip; Logeart, Isabelle; Wajdula, Joseph; Jones, Heather; Marshall, Lisa; Bonin, Randi; Pedersen, Ron; Vlahos, Bonnie; Kotak, Sameer; Bukowski, Jack F

2016-07-01

To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA). Patients meeting Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, received double-blind ETN 50 mg/week or placebo (PBO) for 12 weeks, then open-label ETN (ETN/ETN or PBO/ETN). Clinical, health, productivity, MRI and safety outcomes were assessed and the 48-week data are presented here. 208/225 patients (92%) entered the open-label phase at week 12 (ETN, n=102; PBO, n=106). The percentage of patients achieving ASAS40 increased from 33% to 52% between weeks 12 and 48 for ETN/ETN and from 15% to 53% for PBO/ETN (within-group p value <0.001 for both). For ETN/ETN and PBO/ETN, the EuroQol 5 Dimensions utility score improved by 0.14 and 0.08, respectively, between baseline and week 12 and by 0.23 and 0.22 between baseline and week 48. Between weeks 12 and 48, MRI Spondyloarthritis Research Consortium of Canada sacroiliac joint (SIJ) scores decreased by -1.1 for ETN/ETN and by -3.0 for PBO/ETN, p<0.001 for both. Decreases in MRI SIJ inflammation and C-reactive protein correlated with several clinical outcomes at weeks 12 and 48. Patients with early active nr-axSpA demonstrated improvement from week 12 in clinical, health, productivity and MRI outcomes that was sustained to 48 weeks. NCT01258738. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.

PubMed

Supasyndh, Ouppatham; Wang, Jian'an; Hafeez, Kudsia; Zhang, Ying; Zhang, Jack; Rakugi, Hiromi

2017-11-06

Systolic hypertension is common in elderly patients and remains a challenge to treat effectively. The efficacy and safety of sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (≥65 years) with systolic hypertension. In this randomized, double-blind, 14-week study, patients initially received once-daily sacubitril/valsartan 100 mg or olmesartan 10 mg, increased to sacubitril/valsartan 200 mg or olmesartan 20 mg at week 4. At week 10, for patients with blood pressure (BP) >140/90 mm Hg, the doses were up-titrated to sacubitril/valsartan 400 mg or olmesartan 40 mg. The primary assessment was superiority of sacubitril/valsartan vs. olmesartan in reducing office mean sitting (ms) systolic BP (msSBP) from baseline at week 10. Secondary efficacy assessments included changes from baseline in ms diastolic BP (msDBP), ms pulse pressure (msPP), 24-hour mean ambulatory (ma) BP (maBP), and maPP at week 10; msBP and msPP at weeks 4 and 14. Overall, 588 patients were randomized (mean age, 70.7 years; baseline msBP, 160.3/84.9 mm Hg; msPP, 75.4 mm Hg). At week 10, sacubitril/valsartan provided superior msSBP reductions vs. olmesartan (22.71 vs. 16.11 mm Hg, respectively; P < 0.001); similarly, reductions from baseline in other BP and PP assessments were significantly greater with sacubitril/valsartan. At week 14, despite more patients requiring up-titration in the olmesartan group, msBP and msPP reductions from baseline were significantly greater with sacubitril/valsartan. Both treatments were generally well-tolerated. Sacubitril/valsartan is more effective than olmesartan in reducing BP in elderly Asian patients with systolic hypertension. © American Journal of Hypertension, Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

PubMed

Semvua, Hadija H; Mtabho, Charles M; Fillekes, Quirine; van den Boogaard, Jossy; Kisonga, Riziki M; Mleoh, Liberate; Ndaro, Arnold; Kisanga, Elton R; van der Ven, Andre; Aarnoutse, Rob E; Kibiki, Gibson S; Boeree, Martin J; Burger, David M

2013-01-01

To evaluate the effect of rifampicin-based tuberculosis (TB) treatment on the pharmacokinetics of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet, and vice versa, in Tanzanian TB-HIV-coinfected patients. This was a Phase II open-label multiple dose pharmacokinetic and safety study. This study was conducted in TB-HIV-coinfected Tanzanian patients who started TB treatment (rifampicin/isoniazid/pyrazinamide/ethambutol) at week 1 to week 8 and continued with rifampicin and isoniazid for another 16 weeks. Antiretroviral treatment (ART) of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet was started at week 4 after initiation of TB treatment. A 24-h pharmacokinetic sampling curve was recorded at week 8 (with TB treatment) and week 28 (ART alone). For TB drugs, blood samples at 2 and 5 h post-dose were taken at week 3 (TB treatment alone) and week 8 (with ART). A total of 25 patients (56% male) completed the study; 21 had evaluable pharmacokinetic profiles. The area under the concentration-time curve 0-24 h post-dose of efavirenz, tenofovir and emtricitabine were slightly higher when these drugs were coadministered with TB drugs; geometric mean ratios (90% CI) were 1.08 (0.90, 1.30), 1.13 (0.93, 1.38) and 1.05 (0.85, 1.29), respectively. For TB drugs, equivalence was suggested for peak plasma concentrations when administered with and without efavirenz/tenofovir/emtricitabine. Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported. Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV.

Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.

PubMed

Morgentaler, Abraham; Dobs, Adrian S; Kaufman, Joel M; Miner, Martin M; Shabsigh, Ridwan; Swerdloff, Ronald S; Wang, Christina

2008-12-01

We determined the pharmacokinetics and safety of 750 mg long acting testosterone undecanoate given intramuscularly at 0, 4 and 14 weeks to men with hypogonadism. A 24-week, single arm, open label, multicenter trial in 130 hypogonadal men 18 years or older who were screened for serum total testosterone less than 300 ng/dl was performed at 31 research sites in the United States between March and November 2007. Testosterone undecanoate (750 mg) was administered at baseline, and at weeks 4 and 14. Serum testosterone samples were collected on days 4, 7, 11, 14, 21, 28, 42, 56 and 70 following injection 3. Safety was assessed, eg biochemical markers and adverse events, secondary to testosterone undecanoate treatment. Of the 130 patients 116 with a mean +/- SE age of 54.2 +/- 0.90 years completed the 24-week trial. Following the week 14 injection mean +/- SD average serum testosterone was 494.9 +/- 141.46 ng/dl during the 70-day dosing interval and mean +/- SD maximum serum testosterone was 890.6 +/- 345.11 ng/dl with a mean concentration within the young healthy adult male range (300 to 1,000 ng/dl) in 94% of patients and a mean maximum concentration of below 1,500 ng/dl in 92%. Mean +/- SE hematocrit and hemoglobin increased from baseline to week 24 (43.3% +/- 0.32% to 45.7% +/- 0.35% and 14.6 +/- 0.11 to 15.5 +/- 0.13 gm/dl, respectively). Mean +/- SE prostate specific antigen increased from baseline to 24 weeks (1.0 +/- 0.08 to 1.3 +/- 0.10 ng/ml). No prostate cancer or gynecomastia was observed during this 24-week study. This 24-week clinical study demonstrated that 750 mg testosterone undecanoate depot injection administered intramuscularly at 0, 4 and 14 weeks achieves serum testosterone levels in the normal range during a 10-week dosing interval.

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.

PubMed

Papp, K; Bachelez, H; Costanzo, A; Foley, P; Gooderham, M; Kaur, P; Philipp, S; Spelman, L; Zhang, N; Strober, B

2017-12-01

ABP 501, a U.S.A. Food and Drug Administration- and European Medicines Agency-approved biosimilar, is highly similar to adalimumab in structure, function and pharmacokinetics. To demonstrate similarity in efficacy, safety and immunogenicity of ABP 501 vs. adalimumab for moderate-to-severe plaque psoriasis (clinical trial: NCT01970488). Patients were randomized (1 : 1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At week 16, patients with ≥ 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score were eligible to continue to week 52. Patients receiving ABP 501 continued; adalimumab patients were rerandomized (1 : 1) to continue adalimumab or undergo a single transition to ABP 501. Key efficacy assessments included percentage PASI improvement from baseline, PASI responders and mean change in affected body surface area from baseline to weeks 16, 32 and 50. Safety was monitored via adverse events (AEs) and antidrug antibodies (ADAs) were assessed. A total of 308 patients were rerandomized at week 16 (ABP 501/ABP 501, n = 152; adalimumab/adalimumab, n = 79; adalimumab/ABP 501, n = 77). PASI percentage improvements from baseline were similar across groups for weeks 16, 32 and 50 (range: 85·8-88·2%), with no significant differences detected across groups in percentages of PASI 50, 75, 90 and 100 responders. Changes from baseline in percentage body surface area affected were similar across groups and time points. No new safety signals were detected. AEs were balanced between groups. Percentages of patients with binding and neutralizing ADAs were similar across treatments. ABP 501 and adalimumab have similar clinical efficacy, safety and immunogenicity profiles over 52 weeks, including after single transition, in this patient population. © 2017 British Association of Dermatologists.

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.

PubMed

Dokoupilová, E; Aelion, J; Takeuchi, T; Malavolta, N; Sfikakis, P P; Wang, Y; Rohrer, S; Richards, H B

2018-02-20

To assess the efficacy and safety of secukinumab in patients with rheumatoid arthritis (RA) who failed to respond to tumour necrosis factor- α (TNF-α) inhibitors. This phase III double-blind, double-dummy, placebo-controlled study (NCT01770379) randomized (1:1:1) patients to subcutaneous secukinumab 150 mg, secukinumab 75 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and then every 4 weeks. American College of Rheumatology (ACR) 20 response at week 24 was the primary endpoint. Secondary outcomes included the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP), Health Assessment Questionnaire Disability Index (HAQ-DI), and ACR50 at week 24. Long-term treatment was planned for 5 years. ACR20 response rates at week 24 for the secukinumab 150 mg and 75 mg groups were not statistically superior to placebo. None of the secondary endpoints was met for either secukinumab dose. Although not statistically significant, compared with placebo, numerically greater differences in least squares mean changes from baseline in HAQ-DI score and numerically higher ACR50 response rates were observed at week 24 in both secukinumab treatment groups. No new or unexpected adverse events were observed in this study compared with the large secukinumab safety database across psoriasis, psoriatic arthritis, ankylosing spondylitis, and other RA studies. Given that other second-line therapies have demonstrated efficacy in RA patients who failed to respond to TNF-α inhibitors, these findings may suggest that interleukin-17A inhibition with secukinumab does not provide additional benefit to these patients. This study further confirms the well-characterized safety profile of secukinumab.

Efficacy and safety of lubiprostone in patients with chronic constipation.

PubMed

Barish, Charles F; Drossman, Douglas; Johanson, John F; Ueno, Ryuji

2010-04-01

The aim of this study is to assess the efficacy and safety of lubiprostone in adults with chronic constipation. This multicenter, parallel-group trial enrolled 237 patients with chronic constipation and randomized them to 4 weeks of double-blind treatment with oral lubiprostone 24 mcg or placebo twice daily. The primary efficacy endpoint was the number of spontaneous bowel movements (SBMs) after 1 week of treatment. Secondary evaluations included SBMs at weeks 2, 3, and 4; percentage of patients with a SBM within 24 h of first study dose; stool consistency; degree of straining; constipation severity; abdominal bloating and discomfort; global treatment effectiveness; and safety assessments. Lubiprostone-treated patients experienced greater mean numbers of SBMs at week 1 compared with placebo (5.89 versus 3.99, P = 0.0001), with significantly greater percentages having SBMs within 24 h of the first dose (61.3% versus 31.4%, P < 0.0001). At each assessment, SBM frequency and percentages of full responders (> or =4 SBM per week) were significantly greater among lubiprostone-treated patients compared with placebo (P < or = 0.0171). Lubiprostone-treated patients reported significant improvements in stool consistency, straining, and constipation severity at all weeks, and in abdominal bloating at week 1. Patient assessments of treatment effectiveness were significantly greater with lubiprostone compared with placebo at all weeks (P < 0.0004). Gastrointestinal-related disorders were the most common adverse events in both treatment groups. In patients with chronic constipation, lubiprostone produced a bowel movement in the majority of individuals within 24 h of initial dosing, with sustained improvement in frequency as well as other constipation symptoms over 4 weeks of treatment.

33 CFR 165.1330 - Safety Zone; Fleet Week Maritime Festival, Pier 66, Elliott Bay, Seattle, Washington.

Code of Federal Regulations, 2012 CFR

2012-07-01

..., Seattle, Washington. (a) Location. The following area is a safety zone: All waters extending 100 yards... minutes following the conclusion of the Parade of Ships. For the purpose of this rule, the Parade of Ships includes both the pass and review of the ships near Pier 66 and the aerial demonstrations immediately...

33 CFR 165.1330 - Safety Zone; Fleet Week Maritime Festival, Pier 66, Elliott Bay, Seattle, Washington.

Code of Federal Regulations, 2013 CFR

2013-07-01

..., Seattle, Washington. (a) Location. The following area is a safety zone: All waters extending 100 yards... minutes following the conclusion of the Parade of Ships. For the purpose of this rule, the Parade of Ships includes both the pass and review of the ships near Pier 66 and the aerial demonstrations immediately...

The safety and pharmacokinetics of cyanidin-3-glucoside after 2-week administration of black bean seed coat extract in healthy subjects.

PubMed

Jeon, Sangil; Han, Seunghoon; Lee, Jongtae; Hong, Taegon; Yim, Dong-Seok

2012-08-01

We analyzed the pharmacokinetics of C3G on data from twelve subjects, after 2-week multiple dosing of black bean (Phaseolus vulgaris, Cheongjakong-3-ho) seed coat extract, using the mixed effect analysis method (NONMEM, Ver. 6.2), as well as the conventional non-compartmental method. We also examined the safety and tolerability. The PK analysis used plasma concentrations of the C3G on day 1 and 14. There was no observed accumulation of C3G after 2-week multiple dosing of black bean seed coat extract. The typical point estimates of PK were CL (clearance)=3,420 l/h, V (volume)=7,280 L, Ka (absorption constant)=9.94 h(-1), ALAG (lag time)=0.217 h. The black bean seed coat extract was well tolerated and there were no serious adverse events. In this study, we confirmed that a significant amount of C3G was absorbed in human after given the black bean seed coat extract.

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

PubMed

Seto, Wai-Kay; Asahina, Yasuhiro; Brown, Todd T; Peng, Cheng-Yuan; Stanciu, Carol; Abdurakhmanov, Dzhamal; Tabak, Fehmi; Nguyen, Tuan T; Chuang, Wan-Long; Inokuma, Tetsuro; Ikeda, Fusao; Santantonio, Teresa Antonia; Habersetzer, François; Ramji, Alnoor; Lau, Audrey H; Suri, Vithika; Flaherty, John F; Wang, Hongyuan; Gaggar, Anuj; Subramanian, G Mani; Mukewar, Shrikant; Brunetto, Maurizia R; Fung, Scott; Chan, Henry Lik-Yuen

2018-06-19

Long-term use of tenofovir disoproxil fumarate (TDF) reduces bone mineral density (BMD). Tenofovir alafenamide (TAF), a new prodrug of tenofovir, has shown non-inferior efficacy to TDF in patients with chronic hepatitis B virus (HBV) infection, with improved bone effects at 48 weeks. We performed a randomized trial to evaluate the bone safety of TAF compared with TDF over 2 years, assessing baseline risk factors for bone loss, were evaluated after 2 years of treatment. In a double-blind study, hepatitis B e antigen (HBeAg)-positive patients (n=873) and HBeAg-negative patients (n=425) were randomly assigned (2:1) to groups given TAF (25 mg, n=866) or TDF (300 mg, n=432) once daily. We assessed bone safety, including hip and spine BMD, using dual-energy X-ray absorptiometry and measured changes in serum markers of bone turnover over 96 weeks. At baseline, treatment groups were well matched. At week 96, patients receiving TAF had significantly smaller decreases in hip BMD (mean reduction of 0.33%) than patients receiving TDF (mean reduction of 2.51%) (P<.001) and spine BMD (reduction of 0.75% in patients receiving patients receiving TAF vs reduction of 2.57% in patients receiving TDF) (P<.001). For hip BMD, the magnitude of difference in bone loss between the TAF and TDF groups increased at week 96 compared to week 48 (P<.001). The TAF group had minimal changes in markers of bone turnover by 12 weeks of treatment, but the TDF group had significant changes, compared to baseline. Risk factors for bone loss had fewer effects in patients receiving TAF than TDF at week 96. In double-blind randomized trials, we found that after 2 years of treatment, patients receiving TAF had continued improvements in bone safety compared with patients receiving TDF. Clinicaltrial.gov no: NCT01940471 and NCT01940341. Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

PubMed

Akdim, Fatima; Stroes, Erik S G; Sijbrands, Eric J G; Tribble, Diane L; Trip, Mieke D; Jukema, J Wouter; Flaim, Joann D; Su, John; Yu, Rosie; Baker, Brenda F; Wedel, Mark K; Kastelein, John J P

2010-04-13

The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy. Mipomersen is an apolipoprotein (apo) B synthesis inhibitor that has demonstrated significant reductions in apo B and low-density lipoprotein (LDL) cholesterol in Phase 1 clinical trials in healthy volunteers. A randomized, placebo-controlled, dose-escalation Phase 2 study was designed to evaluate the effects of mipomersen in hypercholesterolemic subjects taking stable statin therapy. Seventy-four subjects were enrolled sequentially into 1 of 6 dose cohorts at a 4:1 (active/placebo) ratio. Subjects received 7 doses of 30 to 400 mg over 5 weeks in the first 5 cohorts and 15 doses of 200 mg over 13 weeks in the sixth cohort. Pre-specified end points included percentage change from baseline in apo B and LDL cholesterol. Safety was assessed with laboratory test results and by the incidence and severity of adverse events. The apo B and LDL cholesterol were reduced by 19% to 54% and 21% to 52%, respectively, at doses of 100 mg/week mipomersen and higher in the 5-week treatment cohorts. Efficacy seemed to increase upon treatment for 13 weeks at a dose of 200 mg/week. Injection site reactions (mild to moderate erythema [90%]) and hepatic transaminase increases (17%) were the most common adverse events, leading to discontinuation in 2 subjects and 1 subject, respectively. In the 13-week treatment cohort, 5 of 10 subjects (50%) had elevations >or=3x the upper limit of normal, 4 of which persisted on 2 consecutive occasions. Mipomersen might hold promise for treatment of patients not reaching target LDL cholesterol levels on stable statin therapy. Further studies are needed to address the mechanisms and clinical relevance of transaminase changes after mipomersen administration. (Dose-Escalating Safety Study in Subjects on Stable Statin Therapy; NCT00231569). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

PubMed Central

Tanaka, Yoshiya; Takeuchi, Tsutomu; Yamanaka, Hisashi; Nakamura, Hiroyuki; Toyoizumi, Shigeyuki; Zwillich, Samuel

2015-01-01

Abstract Objectives. To evaluate oral tofacitinib versus placebo for treatment of active rheumatoid arthritis in Japanese patients with inadequate response to disease-modifying antirheumatic drugs. Methods. In this double-blind, placebo-controlled, randomized, parallel-group, 12-week, phase 2 study (clinicaltrials.gov NCT00687193), 317 patients received tofacitinib: 1, 3, 5, 10, or 15 mg as monotherapy or placebo twice daily (BID). Primary endpoint: response rate by American College of Rheumatology (ACR) ≥ 20% improvement criteria (ACR20) at week 12. Results. ACR20 response rates: 37.7% (20/53), 67.9% (36/53), 73.1% (38/52), 84.9% (45/53), and 90.7% (49/54) with tofacitinib: 1, 3, 5, 10, and 15 mg BID, respectively, versus 15.4% (8/52) with placebo (p < 0.01; all doses). Dose-dependent ACR20 responses with tofacitinib versus placebo occurred from week 2 onward (p < 0.05). Changes from baseline in 28-joint disease activity score using erythrocyte sedimentation rate improved with tofacitinib versus placebo from week 4 (p < 0.01; all doses). Six tofacitinib patients experienced treatment-related serious adverse events (AEs). Most common treatment-emergent AEs: nasopharyngitis (10% vs 12%) and hyperlipidemia (5% vs 0%). Serum creatinine, hemoglobin, and total-, low-, and high-density lipoprotein-cholesterol levels increased with tofacitinib. Conclusions. Tofacitinib produced dose-dependent ACR20 responses and reduced disease activity. The safety profile was consistent with that reported from global monotherapy trials. PMID:25496464

Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience.

PubMed

Kim, Yoshiharu; Asukai, Nozomu; Konishi, Takako; Kato, Hiroshi; Hirotsune, Hideto; Maeda, Masaharu; Inoue, Hirotaka; Narita, Hiroyasu; Iwasaki, Masaru

2008-12-01

The present study was a 52-week, non-comparative, open-label study of flexible dose paroxetine (20-40 mg) in 52 Japanese post-traumatic stress disorder (PTSD) patients in order to obtain clinical experience regarding efficacy and safety in regular clinical practice. Efficacy was measured using the Clinician-Administered PTSD Scale One Week Symptom Status Version (CAPS-SX). The mean change from baseline in CAPS-SX total score was -19.1, -22.8 and -32.3 at weeks 4, 12 and 52, respectively, and that in the Clinical Global Impression (CGI) Severity of Illness score was -1.1 at week 12 and -1.7 at week 52. A total of 46.9% were CGI responders at week 12, while 67.3% were improved on the CGI at week 52. Of 52 subjects who entered into the drug treatment, 25 completed the study. Only one patient withdrew from the study due to lack of efficacy. In patients who were rated as 'moderately ill' or less at baseline, the proportion of CGI responders at end-point was higher at a dose of 20 mg/day than at higher doses, whereas in patients rated as 'markedly ill' or more, it was higher at 30 and 40 mg/day, suggesting that severely ill patients could benefit from higher doses. Paroxetine appeared generally tolerated in short- and long-term use, and the safety profile in this study was consistent with international trials and other Japanese populations (i.e. patients suffering from depression, panic disorder or obsessive-compulsive disorder). Although the study was not conducted in double-blind fashion, the current findings suggest that paroxetine may contribute to clinically meaningful improvement that is maintained during long-term use and is generally well tolerated.

Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.

PubMed

Zhang, Zong Mei; Li, Wei; Jiang, Xue Liang

2016-03-01

To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. UC-related randomized controlled trials (RCTs) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. This meta-analysis included three RCTs. ADA was considerably more effective compared with a placebo, and it increased the ratio of patients with clinical remission, clinical responses, mucosal healing and inflammatory bowel disease questionnaire responses in the induction and maintenance phases (p<0.05), as well as patients with steroid-free remission (p<0.05) during the maintenance phase. Clinical remission was achieved in a greater number of UC cases in the ADA 160/80/40 mg groups (0/2/4 week, every other week) compared with the placebo group at week 8 (p=0.006) and week 52 (p=0.0002), whereas the week 8 clinical remission rate was equivalent between the ADA 80/40 mg groups and the placebo group. Among the patients who received immunomodulators (IMM) at baseline, ADA was superior to the placebo in terms of inducing clinical remission (p=0.01). Between-group differences were not observed in terms of serious adverse events (p=0.61). ADA, particularly at doses of 160/80/40 mg (0/2/4 week, every other week), is effective and safe in patients with moderate-to-severe UC who are unresponsive to traditional treatment. Concomitant IMM therapy may improve the short-term therapeutic efficacy of ADA.

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.

PubMed

Aronson, Ronnie; Frias, Juan; Goldman, Allison; Darekar, Amanda; Lauring, Brett; Terra, Steven G

2018-06-01

This phase III, multicentre, randomized study (ClinicalTrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53-91 mmol/mol]) despite diet and exercise. The 52-week study comprised a 26-week, double-blind, placebo-controlled period (Phase A) during which 461 participants received placebo, ertugliflozin 5 mg/d or ertugliflozin 15 mg/d. This was followed by a 26-week active-controlled period (Phase B) during which participants in the placebo group who had not received glycaemic rescue therapy had blinded metformin added. Results to Week 52 are reported. Because of the use of metformin in Phase B, no statistical comparisons of efficacy were made between the ertugliflozin and placebo/metformin groups at Week 52. The mean (standard error) change from baseline to Week 52 in HbA1c was -0.9% (0.1) and -1.0% (0.1) in the ertugliflozin 5 and 15 mg groups, respectively. The proportions of participants with HbA1c <7.0% at Week 52 were 25.6% and 28.5%, respectively. Ertugliflozin reduced fasting plasma glucose, body weight and systolic blood pressure (SBP). The incidence of genital mycotic infections (GMIs) in females was significantly higher in both ertugliflozin groups (5 mg, 26.9%; 15 mg, 29.0%) vs the placebo/metformin group (9.9%), and in males was significantly higher in the 15 mg group (7.8%) vs the placebo/metformin group (1.2%). Ertugliflozin was not associated with increased incidence of urinary tract infections, symptomatic hypoglycaemia or hypovolaemia adverse events compared with placebo/metformin. Ertugliflozin treatment over 52 weeks improved glycaemic control and reduced body weight and SBP, but increased GMIs. © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

ENLIGHT: European network for Light ion hadron therapy.

PubMed

Dosanjh, Manjit; Amaldi, Ugo; Mayer, Ramona; Poetter, Richard

2018-04-03

The European Network for Light Ion Hadron Therapy (ENLIGHT) was established in 2002 following various European particle therapy network initiatives during the 1980s and 1990s (e.g. EORTC task group, EULIMA/PIMMS accelerator design). ENLIGHT started its work on major topics related to hadron therapy (HT), such as patient selection, clinical trials, technology, radiobiology, imaging and health economics. It was initiated through CERN and ESTRO and dealt with various disciplines such as (medical) physics and engineering, radiation biology and radiation oncology. ENLIGHT was funded until 2005 through the EC FP5 programme. A regular annual meeting structure was started in 2002 and continues until today bringing together the various disciplines and projects and institutions in the field of HT at different European places for regular exchange of information on best practices and research and development. Starting in 2006 ENLIGHT coordination was continued through CERN in collaboration with ESTRO and other partners involved in HT. Major projects within the EC FP7 programme (2008-2014) were launched for R&D and transnational access (ULICE, ENVISION) and education and training networks (Marie Curie ITNs: PARTNER, ENTERVISION). These projects were instrumental for the strengthening of the field of hadron therapy. With the start of 4 European carbon ion and proton centres and the upcoming numerous European proton therapy centres, the future scope of ENLIGHT will focus on strengthening current and developing European particle therapy research, multidisciplinary education and training and general R&D in technology and biology with annual meetings and a continuously strong CERN support. Collaboration with the European Particle Therapy Network (EPTN) and other similar networks will be pursued. Copyright © 2018 CERN. Published by Elsevier B.V. All rights reserved.

Food Safety

MedlinePlus

... Price Tag Read the Food Label Kitchen Timesavers Cooking for Your Family Tasty & Low-Cost Recipes Sample 2-Week Menus Resources for Professionals MyPlate Tip Sheets Print Materials Infographics 5 Ways ...

Experience with ATLAS MySQL PanDA database service

NASA Astrophysics Data System (ADS)

Smirnov, Y.; Wlodek, T.; De, K.; Hover, J.; Ozturk, N.; Smith, J.; Wenaus, T.; Yu, D.

2010-04-01

The PanDA distributed production and analysis system has been in production use for ATLAS data processing and analysis since late 2005 in the US, and globally throughout ATLAS since early 2008. Its core architecture is based on a set of stateless web services served by Apache and backed by a suite of MySQL databases that are the repository for all PanDA information: active and archival job queues, dataset and file catalogs, site configuration information, monitoring information, system control parameters, and so on. This database system is one of the most critical components of PanDA, and has successfully delivered the functional and scaling performance required by PanDA, currently operating at a scale of half a million jobs per week, with much growth still to come. In this paper we describe the design and implementation of the PanDA database system, its architecture of MySQL servers deployed at BNL and CERN, backup strategy and monitoring tools. The system has been developed, thoroughly tested, and brought to production to provide highly reliable, scalable, flexible and available database services for ATLAS Monte Carlo production, reconstruction and physics analysis.

An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents.

PubMed

Park, Hyun Jun; Park, Nam Cheol; Shim, Hong Bang; Park, Jong Kwan; Lee, Sung Won; Park, Kwangsung; Kim, Sae Woong; Moon, Ki Hak; Lee, Dong Hyeon; Yoon, Sang Jin

2008-10-01

Erectile dysfunction (ED) is common among men taking antihypertensive agents to control blood pressure. We evaluated the efficacy and safety of sildenafil citrate in men with ED taking antihypertensive agents. A total of 198 male subjects, aged 20 years and older were enrolled. This study was conducted for 10 weeks as an open-label, multicenter and flexible dose trial with a 2-week screening period and an 8-week treatment phase. Subjects were asked to complete Event Log Worksheets, as well as the International Index of Erectile Function (IIEF) and the Global Efficacy Assessment Questions (GEAQ) questionnaires during the study period. The average age among the 167 subjects who completed the study was 55.8 (31.7 to 77.1). The scores for questions 3 and 4 of IIEF improved from 2.3 and 1.8 at baseline to 3.7 and 3.4 at week 4 and 3.8 and 3.4 at week 8, respectively. There were 86.3% of the patients reported improved erectile function at week 8; 88.3% of the patients reported improved ability to achieve sexual intercourse at week 8. There were no significant differences observed in the responses to questions 3 and 4 of IIEF and GEAQ by the number of antihypertensive agents taken. The adverse events were facial flushing (20.1%), headache (11.7%), palpitation (5.0%), rhinitis (2.8%), URI (2.8%), dizziness (2.2%), dyspnea (2.2%), and nausea (1.7%). Sildenafil citrate is an effective treatment for ED; it is safe and well tolerated by patients with ED taking multiple antihypertensive agents for arterial hypertension.

Using modeling and rehearsal to teach fire safety to children with autism.

PubMed

Garcia, David; Dukes, Charles; Brady, Michael P; Scott, Jack; Wilson, Cynthia L

2016-09-01

We evaluated the efficacy of an instructional procedure to teach young children with autism to evacuate settings and notify an adult during a fire alarm. A multiple baseline design across children showed that an intervention that included modeling, rehearsal, and praise was effective in teaching fire safety skills. Safety skills generalized to novel settings and maintained during a 5-week follow-up in both training and generalization settings. © 2016 Society for the Experimental Analysis of Behavior.

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

PubMed

Owen, Randall; Sikich, Linmarie; Marcus, Ronald N; Corey-Lisle, Patricia; Manos, George; McQuade, Robert D; Carson, William H; Findling, Robert L

2009-12-01

The objective of this study was to evaluate short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder who were manifesting behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these. This 8-week, double-blind, randomized, placebo-controlled, parallel-group study was conducted of children and adolescents (aged 6-17 years) with autistic disorder. Patients were randomly assigned (1:1) to flexibly dosed aripiprazole (target dosage: 5, 10, or 15 mg/day) or placebo. Efficacy outcome measures included the Aberrant Behavior Checklist irritability subscale and the Clinical Global Impression-Improvement score (CGI-I). Safety and tolerability were also assessed. Ninety-eight patients were randomly assigned to receive placebo (n = 51) or aripiprazole (n = 47). Mean improvement in Aberrant Behavior Checklist irritability subscale score was significantly greater with aripiprazole than with placebo from week 1 through week 8. Aripiprazole demonstrated significantly greater global improvements than placebo, as assessed by the mean CGI-I score from week 1 through week 8; however, clinically significant residual symptoms may still persist for some patients. Discontinuation rates as a result of adverse events (AEs) were 10.6% for aripiprazole and 5.9% for placebo. Extrapyramidal symptom-related AE rates were 14.9% for aripiprazole and 8.0% for placebo. No serious AEs were reported. Mean weight gain was 2.0 kg on aripiprazole and 0.8 kg on placebo at week 8. Aripiprazole was efficacious in children and adolescents with irritability associated with autistic disorder and was generally safe and well tolerated.

A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

PubMed

Hall, R P; Fairley, J; Woodley, D; Werth, V P; Hannah, D; Streilein, R D; McKillip, J; Okawa, J; Rose, M; Keyes-Elstein, L L; Pinckney, A; Overington, A; Wedgwood, J; Ding, L; Welch, B

2015-03-01

Pemphigus vulgaris (PV) is a blistering disease and tumour necrosis factor-α has a role in its pathogenesis. To evaluate the safety of infliximab (IFX) with prednisone compared with prednisone alone in the treatment of PV. In addition, treatment response was assessed and mechanistic studies were performed. Subjects with PV who had ongoing disease activity while being maintained on prednisone were randomized to receive either IFX or placebo in addition to prednisone. Response status and immunoglobulin (Ig) G anti-desmoglein (Dsg)1 and Dsg3 antibodies were assessed at 18 and 26 weeks. Ten subjects were randomized to each group. There were no safety signals during the course of the study. At week 18, one subject in each group had responded. At week 26, three IFX-treated subjects vs. none in the placebo group had responded (P = 0·21). At weeks 18 and 26, the median IgG anti-Dsg1 and anti-Dsg3 levels were lower in the IFX-treated patients [IgG anti-Dsg-1 (week 18, P = 0·035; week 26, P = 0·022); IgG anti-Dsg3 (week 18, P = 0·035; week, 26 P = 0·05)]. This study is limited by the relatively small sample size. There was no significant difference between study arms in the proportion of subjects with treatment-related adverse events > grade 3. IFX therapy was not shown to be effective for the treatment of patients with PV in this randomized, placebo-controlled trial, although IFX treatment may be associated with a decrease in anti-Dsg1 and Dsg3 antibodies. © 2014 British Association of Dermatologists.

A multi-centered randomized trial of the treatment of pemphigus vulgaris patients with infliximab and prednisone compared to prednisone alone

PubMed Central

Hall, R.P.; Fairley, J.; Woodley, D.; Werth, V.P.; Hannah, D.; Streilein, R.D.; McKillip, J.; Okawa, J.; Rose, M.; Keyes-Elstein, L.L.; Pinckney, A.; Overington, A.; Wedgwood, J.; Ding, L.; Welch, B.

2014-01-01

Background Pemphigus vulgaris (PV) is a blistering disease in which TNF-α has a role in the pathogenesis. Objectives The objective was to evaluate the safety of infliximab (IFX) with prednisone compared to prednisone alone in the treatment of PV. In addition, treatment response was assessed and mechanistic studies were performed. Methods PV subjects who had ongoing disease activity while maintained on prednisone were randomized to receive either IFX or placebo in addition to prednisone. Response status and IgG anti-DSG1 and DSG3 antibodies were assessed at 18 and 26 weeks. . Results 10 subjects were randomized to each group. There were no safety signals during the course of the study. At week 18, 1 subject in each group had responded. At week 26, 3 IFX treated subjects vs. none in the placebo group had responded (p =0 .21). At weeks 18 and 26, the median IgG anti-DSG1 and anti-DSG3 levels were lower in the IFX treated-patients (IgG anti DSG-1: week 18 p =0.035, week 26 p = 0.022; IgG anti-DSG3; week 18 p=0.035, week 26 p = 0.05)). Limitations This study is limited by the relative small sample size. Conclusions There was no significant difference between study arms in the proportion of subjects with treatment-related Adverse Events > Grade 3. IFX therapy was not shown to be effective for the treatment of patients with PV in this randomized, placebo-controlled trial, although IFX treatment may be associated with a decrease in anti-DSG1 and DSG3 antibodies. PMID:25123295

Safety and efficacy of bi-annual intra-articular LBSA0103 injections in patients with knee osteoarthritis.

PubMed

Lee, Jin Kyu; Choi, Chong-Hyuk; Oh, Kwang-Jun; Kyung, Hee-Soo; Yoo, Ju-Hyung; Ha, Chul-Won; Bin, Seong-Il; Kang, Seung-Baik; Kim, Myung Ku; Lee, Ju-Hong; Lee, Myung Chul

2017-11-01

The objective of this study is to assess the safety and efficacy of repeated intra-articular injection of high molecular weight hyaluronic acid (LBSA0103) at a 26-week interval, in patients with osteoarthritis of the knee. The study was an open-label, single arm, multicentre prospective trial conducted in patients with symptomatic knee osteoarthritis. The intervention consisted of two intra-articular injections of LBSA0103, with the second injection performed 26 weeks after the first injection. The primary outcome was the incidence of adverse drug reactions related to each injection. Assessment of efficacy of repeated injections in terms of maintenance of pain relief was a secondary objective of this study. Of the 185 patients screened, 174 patients received the first injection and 153 patients received both injections of LBSA0103. Nine adverse drug reactions occurred in seven patients (4.02%) after the first injection, while only one adverse drug reaction occurred (0.65%) after the second injection. As a secondary outcome measure, the improvements in the efficacy parameters including total WOMAC score and weight-bearing pain were all significant at both week 13 and 39 compared to the baseline value (P < 0.001), and improvements after the second injection were consistent with those after the initial injection of LBSA0103 (between week 26 and week 39, P < 0.001). Repeated intra-articular injection of LBSA0103 at a 26-week interval is safe without increased risk of adverse drug reactions. Additionally, LBSA0103 is effective in reduction of osteoarthritis knee pain and in maintenance of pain reduction for a 39-week period when a second injection is administered.

Optimising the Active Muon Shield for the SHiP Experiment at CERN

NASA Astrophysics Data System (ADS)

Baranov, A.; Burnaev, E.; Derkach, D.; Filatov, A.; Klyuchnikov, N.; Lantwin, O.; Ratnikov, F.; Ustyuzhanin, A.; Zaitsev, A.

2017-12-01

The SHiP experiment is designed to search for very weakly interacting particles beyond the Standard Model which are produced in a 400 GeV/c proton beam dump at the CERN SPS. The critical challenge for this experiment is to keep the Standard Model background level negligible. In the beam dump, around 1011 muons will be produced per second. The muon rate in the spectrometer has to be reduced by at least four orders of magnitude to avoid muoninduced backgrounds. It is demonstrated that new improved active muon shield may be used to magnetically deflect the muons out of the acceptance of the spectrometer.

CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.

PubMed

Zhang, Ka; Cao, Hong; Liang, Jiayi; Shu, Xin; Sun, Haixia; Li, Gang; Xu, Qihuan

2016-08-01

The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D). All patients were followed for 48 weeks. Efficacy and safety analyses were performed. Patients in group a received 135 μg of PEG-INF-α2a by subcutaneous injection once weekly for 48 weeks. Patients in the ADV add-on group received 135 μg of PEG-INF-α2a subcutaneously once weekly and received 10 mg of ADV administered once daily for 48 weeks. HBV DNA, HBsAg, HBeAg, and hepatitis B e antibody levels were determined. Responses were determined at week 12 (ADV add-on), the end of treatment for PEG-INF-α2a (48weeks) and ADV (EOT) and at the end of 96 weeks of follow-up (EOF). The rate of HBV DNA loss were higher in the combination groups than group A at the week 12, week 48, the EOT and EOF (P < 0.05). The rates of HBeAg seroconversion and HBsAg loss were similar among the treatment groups (P>0.05). The alanineaminotransferase (ALT) normalization rate was higher in the combination group than group A only at the EOT (P = 0.007). By the EOF, the patients with ADV added at week 12 achieved higher rates of HBV DNA loss (71.9%), HBeAg seroconversion (50.0%), HBsAg loss (15.6%), and ALT normalization (78.1%). PEG-INF-α2a plus ADV combination therapy is safe and superior to PEG-INF-α2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss. Adding ADV at week 12 may be an optimal combination strategy.

Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation.

PubMed

Davidson, M; Epstein, M; Burt, R; Schaefer, C; Whitworth, G; McDonald, A

1998-01-01

To evaluate the efficacy and safety of a transdermal nicotine patch as an aid for smoking cessation in an over-the-counter setting. Multicenter, double-blind, randomized, placebo-controlled trial of 6-week duration with 18 weeks of follow-up. Four shopping mall precincts. The randomized sample consisted of 802 adults (mean age, 39 years) and was 89% white and 54% female. A smoking history of at least 20 cigarettes per day for 1 year and a score of 5 (on a 10-point scale) on a motivational assessment questionnaire were required for enrollment. Poststudy follow-up was limited to those who had quit smoking at the end of 6 weeks. Nicotine patches were provided at the shopping mall. Guidance consisted only of package instructions and a smoking cessation self-help booklet. Quit rates were defined as total abstinence from smoking for 4 consecutive weeks (treatment weeks 3-6), point prevalence smoking status at week 6, or nonsmoker at week 6 and week 24 (6-month postquit date). Smoking status was assessed by diaries, and verification for the first 2 quit rates was obtained by confirmation of carbon monoxide of 8 ppm or less in expired breath. Safety was evaluated by self-reported adverse events. Quit rate was 12% for the active treatment group and 5.5% for the placebo group, based on total abstinence for 4 consecutive weeks (P = .001) compared with quit rates of 19.5% and 7.5% for active treatment and placebo groups, respectively, based on point prevalence data at week 6. At 24 weeks, 8.2% of nonsmokers in the active treatment group and 4.0% in the placebo group remained nonsmokers. At least 1 adverse event was reported by 57% receiving the nicotine patch and 39% receiving placebo (P<.001). When the nicotine patch was used in an over-the-counter setting, quit rates were comparable to those reported for medical settings. A 2:1 quit rate advantage was achieved at week 6 and was maintained at 24 weeks.

Radiation protection challenges in the management of radioactive waste from high-energy accelerators.

PubMed

Ulrici, Luisa; Algoet, Yvon; Bruno, Luca; Magistris, Matteo

2015-04-01

The European Laboratory for Particle Physics (CERN) has operated high-energy accelerators for fundamental physics research for nearly 60 y. The side-product of this activity is the radioactive waste, which is mainly generated as a result of preventive and corrective maintenance, upgrading activities and the dismantling of experiments or accelerator facilities. Prior to treatment and disposal, it is common practice to temporarily store radioactive waste on CERN's premises and it is a legal requirement that these storage facilities are safe and secure. Waste treatment typically includes sorting, segregation, volume and size reduction and packaging, which will depend on the type of component, its chemical composition, residual activity and possible surface contamination. At CERN, these activities are performed in a dedicated waste treatment centre under the supervision of the Radiation Protection Group. This paper gives an overview of the radiation protection challenges in the conception of a temporary storage and treatment centre for radioactive waste in an accelerator facility, based on the experience gained at CERN. The CERN approach consists of the classification of waste items into 'families' with similar radiological and physical-chemical properties. This classification allows the use of specific, family-dependent techniques for radiological characterisation and treatment, which are simultaneously efficient and compliant with best practices in radiation protection. The storage was planned on the basis of radiological and other possible hazards such as toxicity, pollution and fire load. Examples are given of technical choices for the treatment and radiological characterisation of selected waste families, which could be of interest to other accelerator facilities. © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.

PubMed

Bagel, J; Tyring, S; Rice, K C; Collier, D H; Kricorian, G; Chung, J; Iles, J; Stolshek, B S; Kaliyaperumal, A; Papp, K A

2017-08-01

Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy. To evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. This phase IV open-label single-arm estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static Physician's Global Assessment (sPGA) score 0/1 (clear/almost clear). Patients subsequently lost response, defined as sPGA ≥ 3 or loss of 50% improvement in Psoriasis Area and Severity Index (PASI 50). At baseline, patients had involved body surface area ≥ 10%, sPGA ≥ 3 and PASI ≥ 10. Antiadalimumab antibodies (ADAs) were measured at screening. Patients received etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly. The primary end point was sPGA 0/1 at week 12 (intention-to-treat analysis; no hypothesis tested). Additional outcomes included rates of sPGA 0/1, PASI responses, safety, PROs of itch, pain and flaking, Dermatology Life Quality Index, treatment satisfaction and Work Productivity and Activity Impairment questionnaire. Sixty-four patients enrolled; 67% had ADAs. sPGA 0/1 rates at week 12 were 39·7% [95% confidence interval (CI) 27·6-52·8; primary end point] and 45% (95% CI 29·3-61·5) for patients positive for ADAs and 35% (95% CI 15·4-59·2) for patients negative for ADAs. PASI 75 response rates at week 12 were 47·5% (95% CI 31·5-63·9) for patients who were positive for ADAs and 50% (95% CI 27·2-72·8) for patients negative for ADAs. No new safety signals were observed. PROs of itch, pain and flaking consistently improved at week 12 and were maintained through week 24. Patients with psoriasis who experienced secondary failure of adalimumab achieved satisfactory response to etanercept regardless of ADA status. © 2016 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

PubMed

Nadler, Jeffrey P; Berger, Daniel S; Blick, Gary; Cimoch, Paul J; Cohen, Calvin J; Greenberg, Richard N; Hicks, Charles B; Hoetelmans, Richard M W; Iveson, Kathy J; Jayaweera, Dushyantha S; Mills, Anthony M; Peeters, Monika P; Ruane, Peter J; Shalit, Peter; Schrader, Shannon R; Smith, Stephen M; Steinhart, Corklin R; Thompson, Melanie; Vingerhoets, Johan H; Voorspoels, Ellen; Ward, Douglas; Woodfall, Brian

2007-03-30

TMC125-C223 is an open-label, partially blinded, randomized clinical trial to evaluate the efficacy and safety of two dosages of etravirine (TMC125), a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant HIV-1. A total of 199 patients were randomly assigned 2: 2: 1 to twice-daily etravirine 400 mg, 800 mg and control groups, respectively. The primary endpoint was a change in viral load from baseline at week 24 in the intention-to-treat population. Patients had HIV-1 with genotypic resistance to approved NNRTIs and at least three primary protease inhibitor (PI) mutations. Etravirine groups received an optimized background of at least two approved antiretroviral agents [nucleoside reverse transcriptase inhibitors (NRTI) and/or lopinavir/ritonavir and/or enfuvirtide]. Control patients received optimized regimens of at least three antiretroviral agents (NRTIs or PIs and/or enfuvirtide). The mean change from baseline in HIV-1 RNA at week 24 was -1.04, -1.18 and -0.19 log10 copies/ml for etravirine 400 mg twice a day, 800 mg twice a day and the control group, respectively (P < 0.05 for both etravirine groups versus control). Etravirine showed no dose-related effects on safety and tolerability. No consistent pattern of neuropsychiatric symptoms was observed. There were few hepatic adverse events, and rashes were predominantly early onset and mild to moderate in severity. Etravirine plus an optimized background significantly reduced HIV-1-RNA levels from baseline after 24 weeks in patients with substantial NNRTI and PI resistance, and demonstrated a favorable safety profile compared with control.

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)

PubMed Central

Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei

2018-01-01

Aims To evaluate the long‐term safety and efficacy of tofogliflozin as an add‐on treatment to insulin over 52 weeks. Materials and methods This 52‐week, multicentre, Phase 4 study consisted of a 16‐week, randomized, double‐blind, placebo‐controlled phase and a 36‐week open label extension phase (NCT02201004). Japanese patients with type 2 diabetes mellitus, aged 20 to 75 years, with suboptimal glycaemic control (7.5%‐10.5%) receiving insulin monotherapy (basal‐bolus, bolus, premix [low and high] and basal) or receiving combination therapy with basal insulin and dipeptidyl peptidase‐4 inhibitor were eligible for participation. Patients who received tofogliflozin throughout the study (52 weeks) were referred to as the ‘tofo‐tofo group’ and patients who received placebo and tofogliflozin (36 weeks) were referred to as the ‘pla‐tofo group’. Results A total of 210 patients received treatment per randomization. Hypoglycaemia was the most common treatment‐emergent adverse event (AE) (42.9% in the tofo‐tofo group and 29.4% in the pla‐tofo group). Patients reported genital infection, urinary tract infection, excessive urination and AEs related to volume depletion (2.1%, 2.1%, 7.1% and 10.0% of patients in the tofo‐tofo group, and 0%, 1.5%, 2.9% and 7.4% of patients in the pla‐tofo group, respectively). Mean HbA1c and body weight at baseline (mean changes ± standard error from baseline to Week 52) in the tofo‐tofo and pla‐tofo groups were 8.53% (−0.76% ± 0.077) and 8.40% (−0.73% ± 0.102); 68.84 kg (−1.52 kg ± 0.207) and 72.24 kg (−2.13 kg ± 0.313), respectively. Conclusions This study demonstrates the safety and efficacy of tofogliflozin as add‐on to insulin therapy in type 2 diabetes mellitus patients, offering a new therapeutic solution to diabetes management. PMID:29316236

Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.

PubMed

Gold, Michael; Dhawan, Sunil; Verma, Amit; Kuligowski, Michael; Dobrowski, David

2016-06-01

Tinea corporis is fungal infection of body surfaces other than the feet, groin, scalp, or beard. Naftifine hydrochloride is a topical antifungal of the allylamine class used to treat tinea corporis, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects.
To evaluate the efficacy and safety of two-weeks once daily application of naftifine cream 2% in the treatment of tinea corporis among pediatric subjects.
At baseline, 231 subjects were randomly assigned 1:1 to naftifine cream 2% (n=116) and vehicle (n=115). Treatment effect consisting of mycologic determination (KOH and dermatophyte cultures) and scoring of clinical symptom severity was evaluated at baseline, week 2 (end of treatment) and week 3. Efficacy was analyzed in 181 subjects (n=88, naftifine; n=93, vehicle) with a positive baseline dermatophyte culture and KOH for whom week 3 assessments were available. Safety was evaluated by adverse events (AE) and laboratory values in 231 subjects (n=116, naftifine; n=115, vehicle).
Children with tinea corporis treated with naftifine cream 2% demonstrated significantly greater improvements from baseline over vehicle for mycological cure (P<0.0001) and treatment effectiveness (P=0.003) as early as 2 weeks (end of treatment). Response rates continued to increase post-treatment and were the highest 1-week after completion of the therapy (P=0.003 for complete cure; and P<0.001 for mycological cure and treatment effectiveness). Treatment related adverse events were minimal.
Treatment with naftifine cream 2% applied once daily for two weeks was well-tolerated and was effective in treating tinea corporis in children. Further improvement was observed 1-week after treatment completion for all key outcome measures (complete cure, mycological cure, treatment effectiveness, clinical cure, and clinical success) and clinical signs and symptoms (erythema, induration, and pruritus).

J Drugs Dermatol. 2016;15(6):743-748.

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).

PubMed

Terauchi, Yasuo; Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei

2018-05-01

To evaluate the long-term safety and efficacy of tofogliflozin as an add-on treatment to insulin over 52 weeks. This 52-week, multicentre, Phase 4 study consisted of a 16-week, randomized, double-blind, placebo-controlled phase and a 36-week open label extension phase (NCT02201004). Japanese patients with type 2 diabetes mellitus, aged 20 to 75 years, with suboptimal glycaemic control (7.5%-10.5%) receiving insulin monotherapy (basal-bolus, bolus, premix [low and high] and basal) or receiving combination therapy with basal insulin and dipeptidyl peptidase-4 inhibitor were eligible for participation. Patients who received tofogliflozin throughout the study (52 weeks) were referred to as the 'tofo-tofo group' and patients who received placebo and tofogliflozin (36 weeks) were referred to as the 'pla-tofo group'. A total of 210 patients received treatment per randomization. Hypoglycaemia was the most common treatment-emergent adverse event (AE) (42.9% in the tofo-tofo group and 29.4% in the pla-tofo group). Patients reported genital infection, urinary tract infection, excessive urination and AEs related to volume depletion (2.1%, 2.1%, 7.1% and 10.0% of patients in the tofo-tofo group, and 0%, 1.5%, 2.9% and 7.4% of patients in the pla-tofo group, respectively). Mean HbA1c and body weight at baseline (mean changes ± standard error from baseline to Week 52) in the tofo-tofo and pla-tofo groups were 8.53% (-0.76% ± 0.077) and 8.40% (-0.73% ± 0.102); 68.84 kg (-1.52 kg ± 0.207) and 72.24 kg (-2.13 kg ± 0.313), respectively. This study demonstrates the safety and efficacy of tofogliflozin as add-on to insulin therapy in type 2 diabetes mellitus patients, offering a new therapeutic solution to diabetes management. © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial.

PubMed

Lötvall, Jan; Bleecker, Eugene R; Busse, William W; O'Byrne, Paul M; Woodcock, Ashley; Kerwin, Edward M; Stone, Sally; Forth, Richard; Jacques, Loretta; Bateman, Eric D

2014-01-01

Inhaled corticosteroids (ICSs) improve asthma disease control; once-daily ICS administration may have advantages for patients. Our objective was to assess the efficacy and safety of the novel ICS fluticasone furoate (FF) over 24 weeks versus placebo. This was a 24-week double-blind, double-dummy, placebo- and active-controlled study (NCT01159912) of 343 asthma patients (≥12 years) not controlled by their current ICS. Patients were randomised (1:1:1) to FF100 μg, placebo (both administered once-daily [OD] via ELLIPTA™ dry powder inhaler in the evening) or fluticasone propionate (FP) 250 μg (administered twice-daily (BD) via DISKUS™/ACCUHALER™). Primary endpoint was change from baseline in pre-dose evening forced expiratory volume in 1s (FEV1) at Week 24; change from baseline in % rescue-free 24-h periods was a powered secondary endpoint. Adverse events (AEs) were assessed. FF100 μg OD and FP250 μg BD significantly improved pre-dose evening FEV1 compared with placebo at Week 24 (+146 ml [p = 0.009] and +145 ml [p = 0.011], respectively). Percentage of rescue-free 24-h periods was increased with FF100 μg OD (+14.8%) and FP250 μg BD (+17.9%) compared to placebo (both p < 0.001). On-treatment AEs were reported by 53% (FF100 μg OD), 42% (FP250 μg BD) and 40% (placebo) of patients. On-treatment severe asthma exacerbations were lower with FF100 μg OD (3%) and FP250 μg BD (2%) than placebo (7%). There was significant suppression of urinary cortisol at week 24 with FF100 μg OD (p = 0.030) and FP250 μg BD (p = 0.036) relative to placebo. FF100 μg OD, administered in the evening, achieves significant improvements in lung function and rescue inhaler use over 24 weeks, comparable to FP250 μg BD with similar safety profile. Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

HST at CERN an Amazing Adventure

NASA Astrophysics Data System (ADS)

Restivo, Evelyn

2009-04-01

The High School Teacher Program (HST) at the European Organization for Nuclear Research, CERN, in Geneva, Switzerland was initiated in 1998 by a group of scientists, as a multicultural international program designed to introduce high school physics teachers to high-energy physics. The goal of the program is to provide experiences and materials that will help teachers lead their students to a better understanding of the physical world. Interacting with physics teachers from around the world leads to new approaches for dealing with educational issues that all teachers encounter. The program includes a variety of tours, a series of lectures and classroom activities about the physics expected from the Large Hadron Collider.

Effects of bulk viscosity and hadronic rescattering in heavy ion collisions at energies available at the BNL Relativistic Heavy Ion Collider and at the CERN Large Hadron Collider

NASA Astrophysics Data System (ADS)

Ryu, Sangwook; Paquet, Jean-François; Shen, Chun; Denicol, Gabriel; Schenke, Björn; Jeon, Sangyong; Gale, Charles

2018-03-01

We describe ultrarelativistic heavy ion collisions at the BNL Relativistic Heavy Ion Collider and the CERN Large Hadron Collider with a hybrid model using the IP-Glasma model for the earliest stage and viscous hydrodynamics and microscopic transport for the later stages of the collision. We demonstrate that within this framework the bulk viscosity of the plasma plays an important role in describing the experimentally observed radial flow and azimuthal anisotropy simultaneously. We further investigate the dependence of observables on the temperature below which we employ the microscopic transport description.

PanDA for COMPASS at JINR

NASA Astrophysics Data System (ADS)

Petrosyan, A. Sh.

2016-09-01

PanDA (Production and Distributed Analysis System) is a workload management system, widely used for data processing at experiments on Large Hadron Collider and others. COMPASS is a high-energy physics experiment at the Super Proton Synchrotron. Data processing for COMPASS runs locally at CERN, on lxbatch, the data itself stored in CASTOR. In 2014 an idea to start running COMPASS production through PanDA arose. Such transformation in experiment's data processing will allow COMPASS community to use not only CERN resources, but also Grid resources worldwide. During the spring and summer of 2015 installation, validation and migration work is being performed at JINR. Details and results of this process are presented in this paper.

Final Scientific EFNUDAT Workshop

ScienceCinema

None

2017-12-09

The Final Scientific EFNUDAT Workshop - organized by the CERN/EN-STI group on behalf of n_TOF Collaboration - will be held at CERN, Geneva (Switzerland) from 30 August to 2 September 2010 inclusive.EFNUDAT website: http://www.efnudat.euTopics of interest include: Data evaluationCross section measurementsExperimental techniquesUncertainties and covariancesFission propertiesCurrent and future facilities  International Advisory Committee: C. Barreau (CENBG, France)T. Belgya (IKI KFKI, Hungary)E. Gonzalez (CIEMAT, Spain)F. Gunsing (CEA, France)F.-J. Hambsch (IRMM, Belgium)A. Junghans (FZD, Germany)R. Nolte (PTB, Germany)S. Pomp (TSL UU, Sweden) Workshop Organizing Committee: Enrico Chiaveri (Chairman)Marco CalvianiSamuel AndriamonjeEric BerthoumieuxCarlos GuerreroRoberto LositoVasilis Vlachoudis Workshop Assistant: Géraldine Jean

DOE Office of Scientific and Technical Information (OSTI.GOV)

Fernandez T, Arturo

The use of the sophisticated and large underground detectors at CERN for cosmic ray studies has been considered by several groups, e.g. UA1, LEP and LHC detectors. They offer the opportunity to provide large sensitivity area with magnetic analysis which allow a precise determination of the direction of cosmic ray muons as well as their momentum up to the order of some TeV. The aim of this article is to review the observation of high energy cosmic ray muons using precise spectrometers at CERN, mainly LEP detectors as well as the possibility of improve those measurements with LHC apparatus, givingmore » special emphasis to the ACORDE-ALICE cosmic ray physics program.« less

DOE Office of Scientific and Technical Information (OSTI.GOV)

Valerio-Lizarraga, Cristhian A., E-mail: cristhian.alfonso.valerio.lizarraga@cern.ch; Departamento de Investigación en Física, Universidad de Sonora, Hermosillo; Lallement, Jean-Baptiste

The space charge effect of low energy, unbunched ion beams can be compensated by the trapping of ions or electrons into the beam potential. This has been studied for the 45 keV negative hydrogen ion beam in the CERN Linac4 Low Energy Beam Transport using the package IBSimu [T. Kalvas et al., Rev. Sci. Instrum. 81, 02B703 (2010)], which allows the space charge calculation of the particle trajectories. The results of the beam simulations will be compared to emittance measurements of an H{sup −} beam at the CERN Linac4 3 MeV test stand, where the injection of hydrogen gas directlymore » into the beam transport region has been used to modify the space charge compensation degree.« less

The FLUKA Code: An Overview

NASA Technical Reports Server (NTRS)

Ballarini, F.; Battistoni, G.; Campanella, M.; Carboni, M.; Cerutti, F.; Empl, A.; Fasso, A.; Ferrari, A.; Gadioli, E.; Garzelli, M. V.;

Double-Blind Maintenance Safety and Effectiveness Findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study

ERIC Educational Resources Information Center

Findling, Robert L.; Johnson, Jacqueline L.; McClellan, Jon; Frazier, Jean A.; Vitiello, Benedetto; Hamer, Robert M.; Lieberman, Jeffrey A.; Ritz, Louise; McNamara, Nora K.; Lingler, Jacqui; Hlastala, Stefanie; Pierson, Leslie; Puglia, Madeline; Maloney, Ann E.; Kaufman, Emily Michael; Noyes, Nancy; Sikich, Linmarie

2010-01-01

Objective: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. Method: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication…

22 CFR Appendix A to Part 145 - Clauses for Contracts and Small Purchases Awarded by Recipient

Code of Federal Regulations, 2010 CFR

2010-04-01

... suspected or reported violations to the Department. 4. Contract Work Hours and Safety Standards Act (40 U.S... mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work... basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is...

Development of radiation tolerant components for the Quench Protection System at CERN

NASA Astrophysics Data System (ADS)

Bitterling, O.; Denz, R.; Steckert, J.; Uznanski, S.

2016-01-01

This paper describes the results of irradiation campaigns with the high resolution Analog to Digital Converter (ADC) ADS1281. This ADC will be used as part of a revised quench detection circuit for the 600 A corrector magnets at the CERN Large Hadron Collider (LHC) . To verify the radiation tolerance of the ADC an irradiation campaign using a proton beam, applying doses up to 3,4 kGy was conducted. The resulting data and an analysis of the found failure modes is discussed in this paper. Several mitigation measures are described that allow to reduce the error rate to levels acceptable for operation as part of the LHC QPS.

How to create successful Open Hardware projects — About White Rabbits and open fields

NASA Astrophysics Data System (ADS)

van der Bij, E.; Arruat, M.; Cattin, M.; Daniluk, G.; Gonzalez Cobas, J. D.; Gousiou, E.; Lewis, J.; Lipinski, M. M.; Serrano, J.; Stana, T.; Voumard, N.; Wlostowski, T.

2013-12-01

CERN's accelerator control group has embraced ''Open Hardware'' (OH) to facilitate peer review, avoid vendor lock-in and make support tasks scalable. A web-based tool for easing collaborative work was set up and the CERN OH Licence was created. New ADC, TDC, fine delay and carrier cards based on VITA and PCI-SIG standards were designed and drivers for Linux were written. Often industry was paid for developments, while quality and documentation was controlled by CERN. An innovative timing network was also developed with the OH paradigm. Industry now sells and supports these designs that find their way into new fields.

Open Media Training Session

ScienceCinema

None

2017-12-09

Have you ever wondered how the media work and why some topics make it into the news and other don't? Would you like to know how to (and how not to) give an interview to a journalist? With the LHC preparing for first collisions at high energies, the world's media are again turning their attention to CERN. We're all likely to be called upon to explain what is happening at CERN to media, friends and neighbours. The seminar will be given by BBC television news journalists Liz Pike and Nadia Marchant, and will deal with the kind of questions we're likely to be confronted with through the restart period. Follow the webcast: http://webcast.cern.ch/

Final Scientific EFNUDAT Workshop

ScienceCinema

None

2018-05-23

The Final Scientific EFNUDAT Workshop - organized by the CERN/EN-STI group on behalf of n_TOF Collaboration - will be held at CERN, Geneva (Switzerland) from 30 August to 2 September 2010 inclusive. EFNUDAT website: http://www.efnudat.euTopics of interest include: Data evaluation Cross section measurements Experimental techniques Uncertainties and covariances Fission properties Current and future facilities ; International Advisory Committee: C. Barreau (CENBG, France)T. Belgya (IKI KFKI, Hungary)E. Gonzalez (CIEMAT, Spain)F. Gunsing (CEA, France)F.-J. Hambsch (IRMM, Belgium)A. Junghans (FZD, Germany)R. Nolte (PTB, Germany)S. Pomp (TSL UU, Sweden) ;Workshop Organizing Committee: Enrico Chiaveri (Chairman)Marco Calviani Samuel Andriamonje Eric Berthoumieux Carlos Guerrero Roberto Losito Vasilis Vlachoudis;Workshop Assistant: Geraldine Jean

A Bonner Sphere Spectrometer with extended response matrix

NASA Astrophysics Data System (ADS)

Birattari, C.; Dimovasili, E.; Mitaroff, A.; Silari, M.

2010-08-01

This paper describes the design, calibration and applications at high-energy accelerators of an extended-range Bonner Sphere neutron Spectrometer (BSS). The BSS was designed by the FLUKA Monte Carlo code, investigating several combinations of materials and diameters of the moderators for the high-energy channels. The system was calibrated at PTB in Braunschweig, Germany, using monoenergetic neutron beams in the energy range 144 keV-19 MeV. It was subsequently tested with Am-Be source neutrons and in the simulated workplace neutron field at CERF (the CERN-EU high-energy reference field facility). Since 2002, it has been employed for neutron spectral measurements around CERN accelerators.

Hadron-collider limits on new electroweak interactions from the heterotic string

DOE Office of Scientific and Technical Information (OSTI.GOV)

del Aguila, F.; Moreno, J.M.; Quiros, M.

1990-01-01

We evaluate the {ital Z}{prime}{r arrow}{ital l}{sup +}l{sup {minus}} cross section at present and future hadron colliders, for the minimal (E{sub 6}) extended electroweak models inspired by superstrings (including renormalization effects on new gauge couplings and new mixing angles). Popular models are discussed for comparison. Analytical expressions for the bounds on the mass of a new gauge boson, {ital M}{sub {ital Z}{prime}}, as a function of the bound on the ratio {ital R}{equivalent to}{sigma}({ital Z}{prime}){ital B}(Z{prime}{r arrow}l{sup +}{ital l}{sup {minus}})/{sigma}({ital Z}){ital B} ({ital Z}{r arrow}{ital l}{sup +}{ital l}{sup {minus}}), are given for the CERN S{ital p {bar p}}S, Fermilab Teva-more » tron, Serpukhov UNK, CERN Large Hadron Collider, and Superconducting Super Collider for the different models. In particular, the {ital M}{sub {ital Z}{prime}} bounds from the present {ital R} limit at CERN, as well as from the eventually available {ital R} limits at Fermilab and at the future hadron colliders (after three months of running at the expected luminosity), are given explicitly.« less

A Simulation of the Front End Signal Digitization for the ATLAS Muon Spectrometer thin RPC trigger upgrade project

NASA Astrophysics Data System (ADS)

Meng, Xiangting; Chapman, John; Levin, Daniel; Dai, Tiesheng; Zhu, Junjie; Zhou, Bing; Um Atlas Group Team

2016-03-01

The ATLAS Muon Spectrometer Phase-I (and Phase-II) upgrade includes the BIS78 muon trigger detector project: two sets of eight very thin Resistive Place Chambers (tRPCs) combined with small Monitored Drift Tube (MDT) chambers in the pseudorapidity region 1<| η|<1.3. The tRPCs will be comprised of triplet readout layer in each of the eta and azimuthal phi coordinates, with about 400 readout strips per layer. The anticipated hit rate is 100-200 kHz per strip. Digitization of the strip signals will be done by 32-channel CERN HPTDC chips. The HPTDC is a highly configurable ASIC designed by the CERN Microelectronics group. It can work in both trigger and trigger-less modes, be readout in parallel or serially. For Phase-I operation, a stringent latency requirement of 43 bunch crossings (1075 ns) is imposed. The latency budget for the front end digitization must be kept to a minimal value, ideally less than 350 ns. We conducted detailed HPTDC latency simulations using the Behavioral Verilog code from the CERN group. We will report the results of these simulations run for the anticipated detector operating environment and for various HPTDC configurations.

Lecture archiving on a larger scale at the University of Michigan and CERN

NASA Astrophysics Data System (ADS)

Herr, Jeremy; Lougheed, Robert; Neal, Homer A.

2010-04-01

The ATLAS Collaboratory Project at the University of Michigan has been a leader in the area of collaborative tools since 1999. Its activities include the development of standards, software and hardware tools for lecture archiving, and making recommendations for videoconferencing and remote teaching facilities. Starting in 2006 our group became involved in classroom recordings, and in early 2008 we spawned CARMA, a University-wide recording service. This service uses a new portable recording system that we developed. Capture, archiving and dissemination of rich multimedia content from lectures, tutorials and classes are increasingly widespread activities among universities and research institutes. A growing array of related commercial and open source technologies is becoming available, with several new products introduced in the last couple years. As the result of a new close partnership between U-M and CERN IT, a market survey of these products was conducted and a summary of the results are presented here. It is informing an ambitious effort in 2009 to equip many CERN rooms with automated lecture archiving systems, on a much larger scale than before. This new technology is being integrated with CERN's existing webcast, CDS, and Indico applications.

Mechanical qualification of the support structure for MQXF, the Nb 3Sn low-β quadrupole for the high luminosity LHC

DOE PAGES

Juchno, M.; Ambrosio, G.; Anerella, M.; ...

2016-01-26

Within the scope of the High Luminosity LHC project, the collaboration between CERN and U.S. LARP is developing new low-β quadrupoles using the Nb 3Sn superconducting technology for the upgrade of the LHC interaction regions. The magnet support structure of the first short model was designed and two units were fabricated and tested at CERN and at LBNL. The structure provides the preload to the collars-coils subassembly by an arrangement of outer aluminum shells pre-tensioned with water-pressurized bladders. For the mechanical qualification of the structure and the assembly procedure, superconducting coils were replaced with solid aluminum “dummy coils”, the structuremore » was preloaded at room temperature, and then cooled-down to 77 K. Mechanical behavior of the magnet structure was monitored with the use of strain gauges installed on the aluminum shells, the dummy coils and the axial preload system. As a result, this paper reports on the outcome of the assembly and the cool-down tests with dummy coils, which were performed at CERN and at LBNL, and presents the strain gauge measurements compared to the 3D finite element model predictions.« less